Career Employer

Your FREE NAPLEX (North American Pharmacist Licensure Examination) Practice Questions 2026 – 460+ Q&A

Prepare with realistic, NAPLEX-style questions — take a full North American Pharmacist Licensure Examination practice test or drill one domain at a time.

How ready are you?

To find us again, just search “Career Employer NAPLEX”

By
NAPLEX exam by the numbersStandard mode

Where the NAPLEX exam's points come from

NABP's official outline weights, the exam rules and our 460 free practice questions mapped domain by domain. Use it to plan your study hours.

  • Question type:Computer-based, fixed form (multiple choice and other formats)
  • Result:Pass/fail; scaled score 0-150, passing score is 75
  • Administered by:NABP, delivered at Pearson VUE test centers
  • Eligibility:Pharmacy graduates and FPGEC-certified pharmacists seeking U.S. licensure
  • Cost:Approximately $575 administration fee (verify in the NABP Candidate Application Bulletin)
  • Retakes:45-day wait after a failure; up to 5 attempts unless a board allows more
Facts from NABP's official exam outline and rules
225
Questions
6 hrs
Time limit

Where the NAPLEX points are

NABP's official weight for each of the five domains. Hover or tap a domain to see how many questions that means on your exam.

See these numbers as a table
Weights from NABP's NAPLEX exam outline. Questions on your exam = weight × 225 questions, rounded. Practice questions: Career Employer's NAPLEX bank.
DomainOfficial weightQuestions on your examOur practice questions
Foundational Knowledge for Pharmacy Practice25%56115
Medication Use Process (Prescribing, Transcribing/Documenting, Dispensing, Administering, Monitoring)25%56115
Person-Centered Assessment and Treatment Planning40%90184
Professional Practice5%1123
Pharmacy Management and Leadership5%1123

What to do: Person-Centered Assessment and Treatment Planning is the biggest domain at 40%, which means 90 of your questions. Professional Practice and Pharmacy Management and Leadership are the smallest at 5% each. The other two domains are within a point of each other, so don't skip any.

Split your study time

Your hours, divided by NABP's domain weights.

Foundational Knowledge for Pharmacy Practice
15 hrs
Medication use process
15 hrs
Person-Centered Assessment and Treatment Planning
24 hrs
Professional Practice
3.0 hrs
Pharmacy Management and Leadership
3.0 hrs

Our NAPLEX student data is on its way

We’ve logged 2,926 first-try answers on our NAPLEX questions so far. This section switches to real NAPLEX student results by itself once each part has enough people behind it:

What switches onNeeds
Headline numbers150 studiers
Accuracy by domain300 answers + 50 people per domain
First full exam score100 full exams
Finish rate150 people starting

Then it shows points lost by domain, you vs everyone and question difficulty.

Weights and rules from NABP's published NAPLEX exam outline and certification pages. Practice-question counts from Career Employer's NAPLEX bank. Fees and requirements can change; check NABP before you register.

The North American Pharmacist Licensure Examination (NAPLEX) is the licensure exam used by boards of pharmacy across the United States to assess whether a candidate can practice pharmacy safely and competently.

It is administered by the National Association of Boards of Pharmacy (NABP) and delivered by computer at Pearson VUE test centers.[1] The NAPLEX measures clinical knowledge and judgment across five content domains.

These practice questions follow the published NAPLEX Content Outline, mirroring the content and blueprint weighting of the real exam so you can build readiness across every domain.[2] To build readiness across every domain, pair these with our free study guide, flashcards, and cheat sheet.

Prices, schedules, and policies change — always verify the current details in the NABP Candidate Application Bulletin at nabp.pharmacy before applying.

What Is on the NAPLEX Exam?

The NAPLEX exam covers five content domains totaling 225 questions: Person-Centered Assessment and Treatment Planning (40%), Foundational Knowledge for Pharmacy Practice (25%), the Medication Use Process (25%), Professional Practice (5%), and Pharmacy Management and Leadership (5%).[2]

These domains come from the NABP NAPLEX Content Outline, with Person-Centered Assessment and Treatment Planning by far the largest. Our full practice test mirrors these proportions.

NAPLEX practice test — practice questions by domain with answer explanations

Practice Questions by Domain

Use Start Test for a full weighted NAPLEX simulation, or open the hub and pick a single domain to drill your weak area. After each full exam, your results show a per-domain breakdown so you know exactly where to focus — most candidates need the most reps on Person-Centered Assessment and Treatment Planning, the largest part of the exam.

Who Is Eligible to Take the NAPLEX?

The NAPLEX is open to candidates who have graduated (or are about to graduate) from a pharmacy program and to FPGEC-certified foreign-educated pharmacists, in each case as authorized by the board of pharmacy where they seek licensure.[1]

You apply for the exam through your NABP e-Profile and submit the official documentation and transcripts your board requires; eligibility is ultimately granted by the board of pharmacy, not by candidates self-registering.

Because requirements vary by jurisdiction, confirm your board's specific eligibility rules and deadlines. Additional eligibility details are provided in the official NABP Candidate Application Bulletin.

How Do You Register for the NAPLEX?

You register for the NAPLEX through your NABP e-Profile, pay the approximately $575 administration fee, and after your board authorizes your eligibility you schedule your exam at a Pearson VUE test center.[3]

The NABP e-Profile is the account used for all NABP licensure programs. Verify the current fee in the Candidate Application Bulletin at nabp.pharmacy before applying, as fees change.

After your application is processed and your board grants eligibility, you receive an Authorization to Test and can schedule at a Pearson VUE professional testing center. Apply well ahead of when you intend to test, since processing and authorization take time.

Testing fees are non-refundable, and the name on your application must exactly match your government-issued ID.

How Is the NAPLEX Scored?

The NAPLEX is reported as pass or fail, with NABP calculating a scaled score on a 0 to 150 range; a scaled score of 75 or higher is passing.[5]

The passing standard is set by NABP through a formal standard-setting process rather than a fixed percentage of correct answers, so you must demonstrate minimum competency across the content domains.

Results are posted to your NABP e-Profile, typically within about seven business days, and are then released to your board of pharmacy. Candidates who do not pass receive domain-level feedback to help target their next attempt.

How Hard Is the NAPLEX?

The NAPLEX is demanding mainly because it tests applied clinical judgment — not just recall — across 225 questions in a 6-hour sitting.[1] The practical challenge is reasoning through patient cases accurately while sustaining focus over a long exam.

Person-Centered Assessment and Treatment Planning is the heaviest section at 40%, so the exam rewards candidates who can integrate pharmacology, therapeutics, and patient factors to choose the safest, most effective drug therapy.

Foundational Knowledge and the Medication Use Process reward solid science and dispensing accuracy, while Professional Practice and Pharmacy Management and Leadership test ethics, public health, and operations. Breadth plus clinical reasoning is what makes the NAPLEX hard.

75
Passing scaled score
on a 0-150 scale
40%
Largest domain
assessment & planning

The takeaway: drill until you’re consistently passing full-length, blueprint-weighted practice tests — especially Person-Centered Assessment and Treatment Planning — before you book your exam date.

What to Expect on Exam Day

Arrive at your Pearson VUE test center early to check in — bring a valid, unexpired government-issued photo ID whose name matches your NAPLEX registration.[3] You’ll store phones and personal items in a locker; no notes are allowed, but you’re given materials for scratch work and an on-screen calculator.

A short tutorial precedes the exam, then you work through 225 questions across five domains, with scheduled break time built into the roughly 6-hour appointment.

NABP processes your results and posts them to your NABP e-Profile, typically within about seven business days. Having simulated the full timing with practice tests makes that long clock feel routine.

How to Use This NAPLEX Practice Test

  • Recreate exam conditions. Take the full test timed, with no notes.[1]
  • Diagnose, then drill. Use a full NAPLEX simulation to find weak domains, then drill them.
  • Prioritize assessment and planning. It’s 40% of the exam and the biggest score-mover.
  • Learn the why. Read every explanation — clinical reasoning beats memorizing.
  • Answer everything. There’s no guessing penalty, so never leave a question blank.

Why the NAPLEX Matters

Passing the NAPLEX is a required step to becoming a licensed pharmacist in the United States — boards of pharmacy use it as the objective measure of your competence to practice safely.[1] Because the exam emphasizes clinical decision making across all five domains, strong, balanced preparation directly translates into both passing and being ready for real patient care. These free NAPLEX practice tests are the most efficient way to get there.

Conclusion

Performing well on the NAPLEX comes down to applied clinical judgment — pharmacology, therapeutics, the medication use process, and professional practice — and the stamina to sustain it across a long exam. Use this free NAPLEX practice test to find your weak domains, drill them to mastery, and pair it with our free study guide, flashcards, and cheat sheet. Start with one full-length practice test to find your weakest section, then drill that section first.

NAPLEX Practice Test FAQ

The NAPLEX (North American Pharmacist Licensure Examination) is the licensure exam administered by the National Association of Boards of Pharmacy (NABP). It measures a candidate's knowledge and ability to practice pharmacy safely and competently, and boards of pharmacy use the results as one component of the licensure process. It is intended for recent pharmacy graduates and FPGEC-certified foreign-educated pharmacists seeking licensure in the United States.

What changed on this page

Every real change, with the date.

  1. Interactive charts added. Built from the official outline and our question bank.
  2. 460 questions rewritten.

NAPLEX question bank

All 460 questions, by domain

A reference copy of every question in this practice test. Each answer stays hidden until you choose to show it. To practice with scoring, timing and your readiness score, use Start Test at the top of the page.

Foundational Knowledge for Pharmacy Practice (115)

  1. A drug exhibits first-order elimination kinetics. As the plasma concentration of the drug increases, what happens to the amount of drug eliminated per unit time?

    • A.Falls proportionally with concentration
    • B.Stays constant despite concentration
    • C.Rises proportionally with concentration
    • D.Plateaus quickly despite concentration
    Show answerHide answer

    Correct answer: Rises proportionally with concentration

    In first-order elimination a constant fraction of the drug is removed in each unit of time, so the amount removed "Rises proportionally with concentration". "Stays constant despite concentration" describes zero-order elimination, where a fixed amount is removed whatever the level. "Plateaus quickly despite concentration" describes saturable (Michaelis-Menten) elimination, which is not first-order. "Falls proportionally with concentration" has the relationship backwards: a higher concentration means more drug removed, not less.

  2. Which of the following best defines the volume of distribution (Vd) of a drug?

    • A.The actual physical volume of fluid and tissue that the drug in the body occupies
    • B.The proportionality constant relating total amount of drug in the body to plasma concentration
    • C.The volume of plasma completely cleared of the drug per unit of time
    • D.The fraction of an orally administered dose of drug reaching the systemic circulation unchanged
    Show answerHide answer

    Correct answer: The proportionality constant relating total amount of drug in the body to plasma concentration

    Volume of distribution is an apparent volume: "The proportionality constant relating total amount of drug in the body to plasma concentration" (Vd = amount in body / plasma concentration). It is not "The actual physical volume of fluid and tissue that the drug in the body occupies", because Vd is not an anatomic space and can exceed total body water many times over for tissue-bound drugs. "The volume of plasma completely cleared of the drug per unit of time" defines clearance, and "The fraction of an orally administered dose of drug reaching the systemic circulation unchanged" defines bioavailability.

  3. A loading dose is calculated for a patient using the equation: loading dose =Vd×CtargetF= \frac{V_d \times C_\text{target}}{F}. If the target plasma concentration is 15 mg/L, the volume of distribution is 40 L, and bioavailability is 1, what is the loading dose?

    • A.55 mg
    • B.375 mg
    • C.600 mg
    • D.6000 mg
    Show answerHide answer

    Correct answer: 600 mg

    Loading dose = Vd×target concentrationF=40 L×15 mg/L1=600 mg\frac{V_{d} \times \text{target concentration}}{F} = \frac{40\ \text{L} \times 15\ \text{mg/L}}{1} = 600\ \text{mg}, so the answer is 600 mg. 55 mg comes from adding 40 and 15 instead of multiplying. 375 mg comes from dividing the concentration by the volume (1540=0.375\frac{15}{40} = 0.375) and then mishandling the units. 6000 mg is a decimal-place slip in the multiplication.

  4. A drug has a half-life of 6 hours and follows first-order elimination. Approximately how long will it take to reach steady state with regular dosing?

    • A.Approximately 4 hours
    • B.Approximately 9 hours
    • C.Approximately 30 hours
    • D.Approximately 20 hours
    Show answerHide answer

    Correct answer: Approximately 30 hours

    Steady state is reached after about 4 to 5 half-lives, and 5 x 6 hours is approximately 30 hours. The answer "approximately 4 hours" multiplies the half-life by 0.693, a constant that belongs in the half-life equation, not here. "Approximately 9 hours" multiplies the half-life by 1.44, which gives the mean residence time, not the time to steady state. "Approximately 20 hours" is about 3.3 half-lives, when the drug is only about 90% of the way to steady state.

  5. Which property most directly describes the extent to which an orally administered drug reaches the systemic circulation unchanged?

    • A.Bioequivalence
    • B.Bioavailability
    • C.Extraction ratio
    • D.Dissolution rate
    Show answerHide answer

    Correct answer: Bioavailability

    Bioavailability (F) is the fraction of an administered dose that reaches the systemic circulation unchanged; an intravenous dose has F = 1 by definition. Bioequivalence is a comparison of the rate and extent of absorption between two products, not the property of one drug. Extraction ratio is the fraction of drug removed in one pass through an organ such as the liver; it lowers F but is not the term for the extent reaching the circulation. Dissolution rate describes how fast a solid dosage form goes into solution, which is a rate, not an extent of systemic exposure.

  6. A drug undergoes extensive first-pass metabolism after oral administration. What is the most likely consequence for this drug?

    • A.Reduced oral bioavailability, needing a larger oral dose
    • B.Reduced oral bioavailability, needing a smaller oral dose
    • C.Greater oral bioavailability, needing a larger oral dose
    • D.Greater oral bioavailability, needing a smaller oral dose
    Show answerHide answer

    Correct answer: Reduced oral bioavailability, needing a larger oral dose

    Drug absorbed from the gut passes through the portal vein to the liver, and extensive first-pass metabolism removes much of it before it reaches the systemic circulation: "Reduced oral bioavailability, needing a larger oral dose" than the parenteral dose. "Reduced oral bioavailability, needing a smaller oral dose" gets the bioavailability right but the dose adjustment wrong, since less drug arriving means more must be given. "Greater oral bioavailability, needing a larger oral dose" and "Greater oral bioavailability, needing a smaller oral dose" both wrongly state that first-pass metabolism raises oral bioavailability.

  7. A pharmacist is preparing a 1:50 epinephrine solution. What does this ratio strength represent?

    • A.1 gram of drug in 50 L of solution
    • B.1 milligram of drug in 50 mL of solution
    • C.1 gram of drug in 50 mL of solution
    • D.1 milligram of drug in 50 L of solution
    Show answerHide answer

    Correct answer: 1 gram of drug in 50 mL of solution

    For a solid dissolved in a liquid, ratio strength means grams of solute in milliliters of solution, so 1:50 is 1 gram of drug in 50 mL of solution, which equals 2% w/v. "1 milligram of drug in 50 mL of solution" uses the wrong weight unit and would be only 0.002% w/v. "1 gram of drug in 50 L of solution" uses the wrong volume unit, and "1 milligram of drug in 50 L of solution" makes both errors.

  8. Using alligation, a pharmacist mixes a 20% cream and a 5% cream to make a 10% cream. What is the ratio of parts of the 20% cream to parts of the 5% cream?

    • A.2 parts 20% to 1 part 5%
    • B.1 part 20% to 2 parts 5%
    • C.1 part 20% to 4 parts 5%
    • D.4 parts 20% to 1 part 5%
    Show answerHide answer

    Correct answer: 1 part 20% to 2 parts 5%

    By alligation, parts of the 20% cream = desired minus lower = 10 - 5 = 5, and parts of the 5% cream = higher minus desired = 20 - 10 = 10, so 5:10 simplifies to 1 part 20% to 2 parts 5%. "2 parts 20% to 1 part 5%" assigns the two differences to the wrong creams and would give 15%. "1 part 20% to 4 parts 5%" takes the ratio of the two strengths (5:20) as the ratio of parts and would give 8%. "4 parts 20% to 1 part 5%" does the same with the ratio the other way round and would give 17%.

  9. How many milliequivalents of potassium are in 1500 mg of potassium chloride? (Atomic weight K = 39, Cl = 35.5)

    • A.About 14 mEq
    • B.About 38 mEq
    • C.About 20 mEq
    • D.About 50 mEq
    Show answerHide answer

    Correct answer: About 20 mEq

    Potassium chloride has a formula weight of 39 + 35.5 = 74.5 and potassium is monovalent, so 1 mEq = 74.5 mg and 1500 / 74.5 is about 20 mEq. "About 38 mEq" divides by the atomic weight of potassium alone (1500 / 39). "About 14 mEq" counts two chlorides in the formula weight (1500 / 110). "About 50 mEq" inverts the division (74.5 / 1500) and shifts the decimal point.

  10. What is the primary purpose of calculating the osmolarity of a parenteral nutrition solution before peripheral administration?

    • A.To confirm whether the calcium can mix with the phosphate without precipitating
    • B.To judge whether the veins can tolerate the infusion without phlebitis
    • C.To check whether the lipid can join the admixture without cracking
    • D.To verify whether the patient can receive the dextrose without hyperglycemia
    Show answerHide answer

    Correct answer: To judge whether the veins can tolerate the infusion without phlebitis

    Osmolarity is calculated "To judge whether the veins can tolerate the infusion without phlebitis": solutions above roughly 900 mOsm/L irritate small veins and need central access. "To confirm whether the calcium can mix with the phosphate without precipitating" is answered by a calcium-phosphate solubility check, which depends on pH, amino acid content and concentrations, not osmolarity. "To check whether the lipid can join the admixture without cracking" is a question of emulsion stability, governed by pH and cation load. "To verify whether the patient can receive the dextrose without hyperglycemia" is assessed from the glucose infusion rate in mg/kg/min, not from osmolarity.

  11. Under USP Chapter 797, which ISO classification is required for the primary engineering control (such as a laminar airflow workbench) where sterile compounding manipulations occur?

    • A.ISO Class 4
    • B.ISO Class 7
    • C.ISO Class 8
    • D.ISO Class 5
    Show answerHide answer

    Correct answer: ISO Class 5

    USP 797 requires the primary engineering control, where the critical manipulations take place, to provide ISO Class 5 air (no more than 3,520 particles of 0.5 micron or larger per cubic meter). ISO Class 7 is the requirement for the buffer room that surrounds the hood, and ISO Class 8 is the minimum for an anteroom that opens into a positive-pressure buffer room. ISO Class 4 is cleaner than the standard asks for and is not the class USP 797 names.

  12. According to USP Chapter 797, what is the term for the date or time after which a compounded sterile preparation should not be used?

    • A.Beyond-use date
    • B.Expiration date
    • C.Retest date
    • D.Sell-by date
    Show answerHide answer

    Correct answer: Beyond-use date

    "Beyond-use date" is the USP term for the date or time after which a compounded preparation must not be used; the compounder assigns it from the compounding category and storage conditions. An "Expiration date" is set by a manufacturer from stability studies on its own product. A "Retest date" applies to a bulk drug substance: the date by which it must be re-examined before it is used in manufacturing. A "Sell-by date" is a retail stock-rotation date, not a term from USP 797.

  13. A compounded sterile preparation is assigned a beyond-use date. Which factor most directly determines the maximum beyond-use date permitted under USP standards?

    • A.The therapeutic class of the agent and the hazardous drug listing
    • B.The category of compounding and the conditions assuring sterility
    • C.The route of administration and the duration of the infusion ordered
    • D.The osmolarity of the admixture and the pH of the final solution
    Show answerHide answer

    Correct answer: The category of compounding and the conditions assuring sterility

    USP 797 caps the beyond-use date according to "The category of compounding and the conditions assuring sterility": whether the preparation is Category 1, 2 or 3, how it was sterilized, whether sterility testing was done, and the storage temperature. "The therapeutic class of the agent and the hazardous drug listing" decides which handling precautions apply under USP 800, not the dating limit. "The route of administration and the duration of the infusion ordered" and "The osmolarity of the admixture and the pH of the final solution" affect how and where the preparation can be given, but none of them appears in the USP tables that set the longest permitted date.

  14. Which USP chapter primarily governs the safe handling of hazardous drugs to protect healthcare personnel and the environment?

    • A.USP 790
    • B.USP 800
    • C.USP 797
    • D.USP 825
    Show answerHide answer

    Correct answer: USP 800

    USP 800 covers the handling of hazardous drugs from receipt through storage, compounding, dispensing, administration and disposal, with its engineering controls and protective equipment. USP 797 sets the standards for sterile compounding in general. USP 825 covers radiopharmaceuticals. USP 790 deals with visible particulates in injections.

  15. A clinical trial reports that a new drug reduces the absolute risk of a stroke from 8% to 4% over one year. What is the number needed to treat (NNT)?

    • A.2
    • B.9
    • C.25
    • D.13
    Show answerHide answer

    Correct answer: 25

    Absolute risk reduction = 8%−4%=4%=0.048\% - 4\% = 4\% = 0.04, and NNT = 10.04=25\frac{1}{0.04} = 25. The value 2 comes from using the relative risk reduction (48=0.5\frac{4}{8} = 0.5, and 10.5=2\frac{1}{0.5} = 2). The value 9 comes from adding the two risks instead of subtracting them (10.12=8.3\frac{1}{0.12} = 8.3, rounded up). The value 13 comes from dividing 1 by the control-group risk alone (10.08=12.5\frac{1}{0.08} = 12.5, rounded up).

  16. What does the number needed to treat (NNT) represent in the interpretation of a clinical trial?

    • A.How many patients must be treated for one more adverse reaction to be produced
    • B.How many patients must be enrolled for one real difference to be detected
    • C.How many patients must be screened for one hidden case to be detected
    • D.How many patients must be treated for one more adverse outcome to be prevented
    Show answerHide answer

    Correct answer: How many patients must be treated for one more adverse outcome to be prevented

    The NNT is the reciprocal of the absolute risk reduction: "How many patients must be treated for one more adverse outcome to be prevented". "How many patients must be treated for one more adverse reaction to be produced" defines the number needed to harm. "How many patients must be enrolled for one real difference to be detected" is a loose description of a sample-size (power) calculation. "How many patients must be screened for one hidden case to be detected" defines the number needed to screen.

  17. A study reports a 95% confidence interval for a relative risk that ranges from 0.65 to 0.92. What does this confidence interval indicate about statistical significance?

    • A.Statistically significant, as the interval excludes 0
    • B.Statistically significant, as the interval excludes 1
    • C.Not statistically significant, as the interval excludes 1
    • D.Not statistically significant, as the interval excludes 0
    Show answerHide answer

    Correct answer: Statistically significant, as the interval excludes 1

    For a ratio measure such as relative risk the value of no effect is 1, and the interval of 0.65 to 0.92 lies wholly below it, so the result is "Statistically significant, as the interval excludes 1". "Statistically significant, as the interval excludes 0" reaches the right conclusion from the wrong test: 0 is the no-effect value for a difference, and an interval for a ratio can never contain 0. "Not statistically significant, as the interval excludes 1" draws the opposite conclusion from the correct observation. "Not statistically significant, as the interval excludes 0" makes both mistakes.

  18. In a study comparing means between two groups, a 95% confidence interval for the difference in means is reported as -2.0 to 5.0. Which conclusion is most appropriate?

    • A.Not statistically significant, since the interval spans one
    • B.Statistically significant, since most of the interval is positive
    • C.Not statistically significant, since the interval spans zero
    • D.Statistically significant, since the midpoint of the interval is positive
    Show answerHide answer

    Correct answer: Not statistically significant, since the interval spans zero

    For a difference in means the value of no effect is zero, and -2.0 to 5.0 runs from below zero to above it, so the difference is "Not statistically significant, since the interval spans zero". "Not statistically significant, since the interval spans one" applies the test for a ratio; one is the no-effect value for relative risks and odds ratios, not for a difference. "Statistically significant, since most of the interval is positive" and "Statistically significant, since the midpoint of the interval is positive" both ignore that the interval still includes negative values and zero itself, so chance cannot be excluded however the interval is centered.

  19. A trial reports a p value of 0.03 for the primary outcome with an alpha set at 0.05. What is the correct interpretation?

    • A.The finding is clinically significant, as the p value is less than alpha
    • B.The null hypothesis is proven to be false, as the p value is less than alpha
    • C.The null hypothesis is retained, as the p value is less than alpha
    • D.The finding is statistically significant, as the p value is less than alpha
    Show answerHide answer

    Correct answer: The finding is statistically significant, as the p value is less than alpha

    A p value of 0.03 is below the preset alpha of 0.05, so "The finding is statistically significant, as the p value is less than alpha" and the null hypothesis is rejected. "The finding is clinically significant, as the p value is less than alpha" confuses statistical with clinical significance, which depends on the size of the effect. "The null hypothesis is proven to be false, as the p value is less than alpha" overstates the result: rejecting the null is a decision made with an accepted error rate, not proof. "The null hypothesis is retained, as the p value is less than alpha" reverses the decision rule; the null is retained when p is greater than alpha.

  20. A cohort study finds that patients exposed to a drug have a relative risk of 2.5 for developing a complication. How is this best interpreted?

    • A.Unexposed patients have 2.5 times the risk of exposed patients
    • B.Exposed patients have a 2.5% higher risk than unexposed patients
    • C.Unexposed patients have a 2.5% higher risk than exposed patients
    • D.Exposed patients have 2.5 times the risk of unexposed patients
    Show answerHide answer

    Correct answer: Exposed patients have 2.5 times the risk of unexposed patients

    Relative risk is the incidence in the exposed group divided by the incidence in the unexposed group, so a value of 2.5 means "Exposed patients have 2.5 times the risk of unexposed patients". "Unexposed patients have 2.5 times the risk of exposed patients" inverts the ratio. "Exposed patients have a 2.5% higher risk than unexposed patients" reads the ratio as a percentage difference; a relative risk of 2.5 is a 150% relative increase, and it says nothing by itself about the absolute difference. "Unexposed patients have a 2.5% higher risk than exposed patients" makes both errors.

  21. During which phase of clinical trials is a drug first administered to a small group of healthy volunteers primarily to evaluate safety, tolerability, and pharmacokinetics?

    • A.Phase 2
    • B.Phase 1
    • C.Phase 3
    • D.Phase 4
    Show answerHide answer

    Correct answer: Phase 1

    Phase 1 trials are the first studies in humans, usually in a small group of healthy volunteers, and look at safety, tolerability and pharmacokinetics. Phase 2 studies enroll patients with the disease to explore efficacy and dose. Phase 3 studies are the large confirmatory trials that support approval. Phase 4 is post-marketing surveillance.

  22. A pharmacogenomic test reveals a patient is a CYP2C19 poor metabolizer. What is the most likely clinical implication for a prodrug activated by CYP2C19, such as clopidogrel?

    • A.More of the active metabolite forms, so the antiplatelet effect is stronger
    • B.Less of the parent compound is cleared, so the antiplatelet effect is stronger
    • C.Less of the active metabolite forms, so the antiplatelet effect is weaker
    • D.More of the parent compound is cleared, so the antiplatelet effect is weaker
    Show answerHide answer

    Correct answer: Less of the active metabolite forms, so the antiplatelet effect is weaker

    Clopidogrel is inactive until CYP2C19 converts it, so in a poor metabolizer "Less of the active metabolite forms, so the antiplatelet effect is weaker" and the risk of thrombotic events rises. "More of the active metabolite forms, so the antiplatelet effect is stronger" describes an ultra-rapid metabolizer. "Less of the parent compound is cleared, so the antiplatelet effect is stronger" treats the parent compound as the active drug, which it is not. "More of the parent compound is cleared, so the antiplatelet effect is weaker" gets the direction of the effect right for the wrong reason: a poor metabolizer clears less parent compound, not more.

  23. Which pharmacokinetic parameter describes the volume of plasma cleared of drug per unit time?

    • A.Clearance
    • B.Bioavailability
    • C.Volume of distribution
    • D.Elimination rate constant
    Show answerHide answer

    Correct answer: Clearance

    Clearance is the volume of plasma from which drug is completely removed per unit of time (for example L/h), and it sets the maintenance dose rate. Bioavailability is the fraction of a dose that reaches the systemic circulation. Volume of distribution relates the amount of drug in the body to the plasma concentration and has units of volume only. The "Elimination rate constant" is the fraction of drug removed per unit of time, with units of 1/time, not a volume.

  24. A drug follows zero-order elimination at therapeutic concentrations. What is a key consequence of this kinetic pattern?

    • A.A fixed fraction of drug is removed in each unit of time regardless of the concentration
    • B.The steady-state concentration is directly proportional to the size of the drug dose
    • C.A fixed amount of drug is removed in each unit of time regardless of the concentration
    • D.The steady-state concentration is reached within five half-lives of starting the drug
    Show answerHide answer

    Correct answer: A fixed amount of drug is removed in each unit of time regardless of the concentration

    Zero-order elimination occurs when the eliminating enzymes are saturated: "A fixed amount of drug is removed in each unit of time regardless of the concentration". "A fixed fraction of drug is removed in each unit of time regardless of the concentration" defines first-order elimination. "The steady-state concentration is directly proportional to the size of the drug dose" is true only of first-order (linear) drugs; with saturated elimination a small dose increase gives a disproportionately large rise. "The steady-state concentration is reached within five half-lives of starting the drug" also assumes first-order behavior, because a zero-order drug has no constant half-life.

  25. A patient with a high body fat percentage is given a highly lipophilic drug. How is the volume of distribution of this drug most likely affected?

    • A.It increases, as the drug partitions widely into adipose tissue
    • B.It decreases, as the drug partitions widely into adipose tissue
    • C.It decreases, as the drug stays largely within the plasma water
    • D.It is unchanged, as the drug stays largely within the plasma water
    Show answerHide answer

    Correct answer: It increases, as the drug partitions widely into adipose tissue

    A lipophilic drug leaves the plasma for fat, so with more body fat less of the dose remains in plasma and the apparent volume is larger: "It increases, as the drug partitions widely into adipose tissue". "It decreases, as the drug partitions widely into adipose tissue" names the right process but the wrong direction; drug held in tissue lowers the plasma level and so raises Vd. "It decreases, as the drug stays largely within the plasma water" and "It is unchanged, as the drug stays largely within the plasma water" describe a polar, hydrophilic drug, not a highly lipophilic one.

  26. A pharmacist must compound 500 mL of a 3% solution from a 70% stock solution. How many milliliters of the 70% stock are needed?

    • A.About 21.4 mL
    • B.About 7.1 mL
    • C.About 10.5 mL
    • D.About 23.3 mL
    Show answerHide answer

    Correct answer: About 21.4 mL

    Stock strength x stock volume = final strength x final volume, so the stock volume = (3% x 500 mL) / 70% = 1500 / 70, which is about 21.4 mL; it is then diluted to 500 mL. "About 7.1 mL" divides 500 by 70 and leaves out the 3%. "About 10.5 mL" multiplies the 15 g of solute by 0.70 instead of dividing by it. "About 23.3 mL" divides 70 by 3, which is the dilution factor, not a volume.

  27. Which of the following best describes the goal of sterile compounding under USP standards?

    • A.To keep medications free of microbes, endotoxins, and particulate matter
    • B.To keep personnel free of hazardous drug residues, vapors, and aerosols
    • C.To keep ingredients free of moisture, oxidation, and photochemical damage
    • D.To keep orders free of dosing, labeling, and transcription errors
    Show answerHide answer

    Correct answer: To keep medications free of microbes, endotoxins, and particulate matter

    Preparations that are injected, instilled in the eye or inhaled bypass the body's barriers, so the aim of sterile compounding is "To keep medications free of microbes, endotoxins, and particulate matter". "To keep personnel free of hazardous drug residues, vapors, and aerosols" is the aim of the hazardous-drug standard, USP 800. "To keep ingredients free of moisture, oxidation, and photochemical damage" is a matter of storage and chemical stability, which applies to every dosage form. "To keep orders free of dosing, labeling, and transcription errors" describes order verification and medication-error prevention, not the compounding standard.

  28. A new biologic enters Phase III clinical trials. What is the primary objective of this phase?

    • A.To explore efficacy and refine dosing in a small group of patients
    • B.To assess safety and pharmacokinetics in a small group of healthy volunteers
    • C.To confirm efficacy and track adverse effects in a large group of patients
    • D.To follow safety and detect rare effects in a broad group of users after marketing
    Show answerHide answer

    Correct answer: To confirm efficacy and track adverse effects in a large group of patients

    Phase III trials are the large, usually randomized, studies that provide the pivotal evidence for approval; their aim is "To confirm efficacy and track adverse effects in a large group of patients". "To explore efficacy and refine dosing in a small group of patients" is the aim of Phase II. "To assess safety and pharmacokinetics in a small group of healthy volunteers" is the aim of Phase I. "To follow safety and detect rare effects in a broad group of users after marketing" is the aim of Phase IV post-marketing surveillance.

  29. A patient is started on a drug with a narrow therapeutic index that is metabolized by CYP2D6. The patient is a known ultra-rapid metabolizer at CYP2D6. For a drug that is inactivated by CYP2D6, what is the most likely effect?

    • A.Slower inactivation, with higher plasma levels and a risk of toxicity
    • B.Faster inactivation, with lower plasma levels and a weaker response
    • C.Faster activation, with higher plasma levels and a risk of toxicity
    • D.Slower activation, with lower plasma levels and a weaker response
    Show answerHide answer

    Correct answer: Faster inactivation, with lower plasma levels and a weaker response

    An ultra-rapid metabolizer has extra CYP2D6 activity, and this drug is inactivated by that enzyme, so the result is "Faster inactivation, with lower plasma levels and a weaker response"; standard doses may fail. "Slower inactivation, with higher plasma levels and a risk of toxicity" describes a poor metabolizer. "Faster activation, with higher plasma levels and a risk of toxicity" is what an ultra-rapid metabolizer experiences with a prodrug such as codeine, not with a drug the enzyme inactivates. "Slower activation, with lower plasma levels and a weaker response" describes a poor metabolizer given a prodrug.

  30. What is the milliequivalent weight of calcium (atomic weight 40, valence 2)?

    • A.20 mg/mEq
    • B.0.05 mg/mEq
    • C.40 mg/mEq
    • D.80 mg/mEq
    Show answerHide answer

    Correct answer: 20 mg/mEq

    Milliequivalent weight = atomic weight / valence = 402\frac{40}{2}, so the answer is 20 mg/mEq. 40 mg/mEq leaves out the valence, which is right only for a monovalent ion. 80 mg/mEq multiplies by the valence instead of dividing. 0.05 mg/mEq inverts the division (240\frac{2}{40}).

  31. A 95% confidence interval is calculated for the mean reduction in blood pressure produced by a drug. Increasing the sample size, while holding other factors constant, will most likely have which effect on the confidence interval?

    • A.Widen the interval
    • B.Shift the interval higher
    • C.Shift the interval lower
    • D.Narrow the interval
    Show answerHide answer

    Correct answer: Narrow the interval

    A larger sample reduces the standard error, so the estimate becomes more precise and the effect is to "Narrow the interval". "Widen the interval" is what a smaller sample, or a higher confidence level, would do. "Shift the interval higher" and "Shift the interval lower" are wrong because sample size affects the width of the interval, not the location of the point estimate in any predictable direction.

  32. A pharmacist evaluates a drug whose oral bioavailability is reported as 0.40. A patient receiving 100 mg orally absorbs approximately how much drug into the systemic circulation?

    • A.40 mg
    • B.60 mg
    • C.140 mg
    • D.250 mg
    Show answerHide answer

    Correct answer: 40 mg

    Bioavailability (F) is the fraction of the dose that reaches the systemic circulation: 100 mg×0.40100\ \text{mg} \times 0.40 gives 40 mg. 60 mg is the amount that does not reach the circulation (1−F1 - F). 140 mg adds 40% to the dose instead of taking 40% of it. 250 mg divides by F (1000.40\frac{100}{0.40}), which is how an oral dose is scaled up from an intravenous one.

  33. Which statement best characterizes how protein binding affects a drug's distribution and activity?

    • A.Only bound drug is active and able to distribute into tissues
    • B.Only bound drug is filtered and able to undergo renal clearance
    • C.Only unbound drug is retained and able to act as a plasma reservoir
    • D.Only unbound drug is active and able to distribute into tissues
    Show answerHide answer

    Correct answer: Only unbound drug is active and able to distribute into tissues

    Drug bound to albumin or alpha-1 acid glycoprotein is too large to leave the capillaries, so "Only unbound drug is active and able to distribute into tissues" and reach receptors. "Only bound drug is active and able to distribute into tissues" reverses the two fractions. "Only bound drug is filtered and able to undergo renal clearance" is wrong because the bound complex is not filtered at the glomerulus; the free drug is. "Only unbound drug is retained and able to act as a plasma reservoir" assigns the reservoir role to the wrong fraction: the bound drug is the inactive store in plasma.

  34. A drug's plasma concentration declines from 80 mg/L to 10 mg/L over 12 hours by first-order elimination. What is the approximate half-life?

    • A.4 hours
    • B.6 hours
    • C.8 hours
    • D.36 hours
    Show answerHide answer

    Correct answer: 4 hours

    Falling from 80 to 40 to 20 to 10 mg/L is three halvings, so 12 hours3\frac{12\ \text{hours}}{3} gives 4 hours. 6 hours counts only two halvings. 8 hours takes the ratio of the two concentrations (8010\frac{80}{10}) as the half-life. 36 hours multiplies 12 hours by the three halvings instead of dividing.

  35. In a randomized controlled trial, the investigators set alpha at 0.05. What does alpha represent?

    • A.The highest accepted probability of a type I error
    • B.The highest accepted probability of a type II error
    • C.The actual observed probability of a type I error
    • D.The actual observed probability of a type II error
    Show answerHide answer

    Correct answer: The highest accepted probability of a type I error

    Alpha is chosen before the trial as "The highest accepted probability of a type I error", that is, of rejecting a null hypothesis that is true. "The highest accepted probability of a type II error" defines beta. "The actual observed probability of a type I error" is wrong because alpha is a preset threshold, not something calculated from the data; the value calculated from the data is the p value. "The actual observed probability of a type II error" is wrong on both counts.

  36. A loading dose is most appropriately used in which clinical situation?

    • A.When a therapeutic level is needed quickly and the half-life is short
    • B.When a dose is being titrated slowly and the half-life is long
    • C.When a dose is being titrated slowly and the half-life is short
    • D.When a therapeutic level is needed quickly and the half-life is long
    Show answerHide answer

    Correct answer: When a therapeutic level is needed quickly and the half-life is long

    Without a loading dose a drug needs four to five half-lives to reach steady state, which is days for a long half-life drug, so a loading dose is most useful "When a therapeutic level is needed quickly and the half-life is long". "When a therapeutic level is needed quickly and the half-life is short" is not the situation that calls for one: with a short half-life the maintenance regimen alone reaches steady state within hours, so a loading dose adds little. "When a dose is being titrated slowly and the half-life is long" and "When a dose is being titrated slowly and the half-life is short" describe gradual titration, which is the opposite of loading.

  37. A total parenteral nutrition order is being prepared with a final osmolarity of 1100 mOsm/L. Based on osmolarity, what is the most appropriate route of administration?

    • A.Short peripheral catheter
    • B.Midline peripheral catheter
    • C.Radial arterial catheter
    • D.Central venous catheter
    Show answerHide answer

    Correct answer: Central venous catheter

    Parenteral nutrition above about 900 mOsm/L must go through a "Central venous catheter", where high blood flow dilutes it at once. A "Short peripheral catheter" would expose a small vein to a hypertonic solution and cause phlebitis. A "Midline peripheral catheter" is longer, but its tip still lies in a peripheral vein, so the same osmolarity limit applies. A "Radial arterial catheter" is used for pressure monitoring and blood sampling, not for infusing nutrition.

  38. Which of the following is a key pharmaceutical factor that can reduce the bioavailability of an orally administered drug?

    • A.Rapid complete dissolution in the stomach
    • B.High membrane permeability in the small intestine
    • C.Minimal enzymatic breakdown in the gut wall
    • D.Extensive first-pass metabolism in the liver
    Show answerHide answer

    Correct answer: Extensive first-pass metabolism in the liver

    After absorption a drug passes through the portal vein to the liver, and "Extensive first-pass metabolism in the liver" removes part of the dose before it reaches the systemic circulation. "Rapid complete dissolution in the stomach" makes the drug available for absorption, and "High membrane permeability in the small intestine" lets more of it cross the gut wall, so both favor bioavailability. "Minimal enzymatic breakdown in the gut wall" means less drug is lost before reaching the portal blood, which also raises bioavailability.

  39. A pharmacist reviews a study reporting an odds ratio of 0.80 with a 95% confidence interval of 0.55 to 1.15 for an adverse event. What is the correct interpretation?

    • A.Significant, because the interval spans less than 1
    • B.Not significant, because the interval includes 1
    • C.Significant, because the interval is mostly below 1
    • D.Not significant, because the interval is mostly below 1
    Show answerHide answer

    Correct answer: Not significant, because the interval includes 1

    For an odds ratio the value of no association is 1, and 0.55 to 1.15 runs across it, so the result is "Not significant, because the interval includes 1". "Significant, because the interval spans less than 1" confuses precision with significance; the width of an interval shows how precise the estimate is, not whether the no-effect value lies inside it. "Significant, because the interval is mostly below 1" treats the position of the bulk of the interval as the test, when any overlap with 1 means chance cannot be excluded. "Not significant, because the interval is mostly below 1" reaches the right conclusion for a wrong reason: an interval lying below 1 is what a significant reduction looks like, provided the whole of it is below 1.

  40. USP Chapter 800 requires that hazardous drugs identified as antineoplastic and requiring manipulation be compounded under which condition?

    • A.In a containment primary engineering control operated under positive pressure
    • B.In a horizontal laminar airflow workbench operated under negative pressure
    • C.In a horizontal laminar airflow workbench operated under positive pressure
    • D.In a containment primary engineering control operated under negative pressure
    Show answerHide answer

    Correct answer: In a containment primary engineering control operated under negative pressure

    USP 800 places manipulation of antineoplastic hazardous drugs In a containment primary engineering control operated under negative pressure, so that air moves inward and vapors and particles are kept away from the compounder and the surrounding rooms. In a containment primary engineering control operated under positive pressure names the right device with the airflow reversed: positive pressure pushes contaminated air out toward staff. In a horizontal laminar airflow workbench operated under negative pressure fails because that workbench protects the product only and sweeps air across the work surface toward the operator, whatever the pressure setting. In a horizontal laminar airflow workbench operated under positive pressure describes ordinary nonhazardous sterile compounding and gives the worker no containment at all.

  41. A medication is described as having linear (first-order) pharmacokinetics. What does this imply about the relationship between dose and steady-state concentration?

    • A.Doubling the dose more than doubles the steady-state concentration
    • B.Doubling the dose roughly doubles the steady-state concentration
    • C.Doubling the dose raises the steady-state concentration less than twofold
    • D.Doubling the dose barely raises the steady-state concentration
    Show answerHide answer

    Correct answer: Doubling the dose roughly doubles the steady-state concentration

    In linear, first-order kinetics clearance is constant, so exposure is proportional to dose: Doubling the dose roughly doubles the steady-state concentration. Doubling the dose more than doubles the steady-state concentration describes nonlinear, capacity-limited kinetics, in which saturated enzymes let levels climb out of proportion (phenytoin is the usual example). Doubling the dose raises the steady-state concentration less than twofold is the pattern of saturable absorption or of a drug that induces its own metabolism, which are also nonlinear. Doubling the dose barely raises the steady-state concentration confuses concentration with half-life and clearance, which are the quantities that stay constant when the dose of a linear drug is changed.

  42. A drug has a clearance of 6 L/hr and is being dosed to maintain a steady-state concentration of 5 mg/L. What maintenance infusion rate is required at steady state?

    • A.30 mg/hr
    • B.1.2 mg/hr
    • C.0.5 mg/hr
    • D.720 mg/hr
    Show answerHide answer

    Correct answer: 30 mg/hr

    At steady state the rate in equals the rate out, so the infusion rate is clearance times the target concentration: 6 L/hr×5 mg/L=30 mg/hr6\ \text{L/hr} \times 5\ \text{mg/L} = 30\ \text{mg/hr}. 1.2 mg/hr comes from dividing clearance by concentration (65\frac{6}{5}) instead of multiplying, which does not even leave units of mg/hr. 0.5 mg/hr is the correct rate expressed per minute (3060=0.5 mg/min\frac{30}{60} = 0.5\ \text{mg/min}) and then mislabeled as an hourly rate. 720 mg/hr is the amount needed over a full day (30×24=720 mg30 \times 24 = 720\ \text{mg} per day), not the hourly rate.

  43. A pharmacist must prepare 250 mL of a solution containing 4 mEq/mL of a monovalent electrolyte. How many total milliequivalents are in the final preparation?

    • A.254 mEq
    • B.62.5 mEq
    • C.1000 mEq
    • D.4000 mEq
    Show answerHide answer

    Correct answer: 1000 mEq

    Total milliequivalents are concentration times volume: 4 mEq/mL×250 mL=1000 mEq4\ \text{mEq/mL} \times 250\ \text{mL} = 1000\ \text{mEq}. Valence matters only when converting between milligrams, millimoles and milliequivalents; it plays no part here because the concentration is already given in mEq/mL. 254 mEq comes from adding the two figures instead of multiplying them. 62.5 mEq comes from dividing the volume by the concentration (2504\frac{250}{4}). 4000 mEq is what a full liter at this strength would contain (4×10004 \times 1000), not the 250 mL being prepared.

  44. Which definition best describes pharmacogenomics as applied in pharmacy practice?

    • A.How genetic variation shapes individual drug response
    • B.How organ function determines systemic drug clearance
    • C.How receptor binding produces measurable drug effects
    • D.How population exposure reveals infrequent drug harms
    Show answerHide answer

    Correct answer: How genetic variation shapes individual drug response

    Pharmacogenomics studies How genetic variation shapes individual drug response: inherited differences in metabolizing enzymes, transporters, receptors and immune genes explain why the same dose is effective in one patient and toxic or useless in another, and they support genotype-guided drug and dose selection. How organ function determines systemic drug clearance belongs to pharmacokinetics, the study of absorption, distribution, metabolism and excretion. How receptor binding produces measurable drug effects is pharmacodynamics, the relationship between drug at its site of action and the response. How population exposure reveals infrequent drug harms describes pharmacoepidemiology and pharmacovigilance.

  45. A pharmacist needs to determine the beyond-use date for a Category 1 compounded sterile preparation prepared in an unclassified segregated compounding area. Which of the following is the controlling reference standard?

    • A.USP Chapter 797
    • B.USP Chapter 795
    • C.USP Chapter 800
    • D.USP Chapter 825
    Show answerHide answer

    Correct answer: USP Chapter 797

    A compounded sterile preparation takes its beyond-use date from USP Chapter 797, which defines Category 1, 2 and 3 preparations and sets the maximum dating for each according to where the preparation is made and how it is stored; a Category 1 preparation from a segregated compounding area is limited to 12 hours at room temperature or 24 hours refrigerated. USP Chapter 795 covers nonsterile compounding and its own beyond-use dates. USP Chapter 800 covers the safe handling of hazardous drugs and assigns no dating. USP Chapter 825 covers radiopharmaceuticals.

  46. A drug given orally has a much lower potency than when given intravenously, requiring a roughly four-fold higher oral dose. This difference is most likely explained by which pharmacokinetic process?

    • A.Extensive plasma protein binding
    • B.Extensive enterohepatic cycling
    • C.Extensive adipose tissue storage
    • D.Extensive first-pass metabolism
    Show answerHide answer

    Correct answer: Extensive first-pass metabolism

    Extensive first-pass metabolism explains the gap: after absorption the drug travels through the gut wall and the portal vein to the liver, where much of it is metabolized before reaching the systemic circulation, so the oral dose must be several times the intravenous dose (propranolol and morphine are familiar examples). Extensive plasma protein binding applies equally to drug given by either route and does not create a route-dependent dose. Extensive enterohepatic cycling returns drug from bile to the gut and tends to prolong exposure, not reduce the fraction of an oral dose that arrives. Extensive adipose tissue storage enlarges the volume of distribution for intravenous and oral doses alike.

  47. A trial reports the primary endpoint with a p value of 0.20 when alpha was set at 0.05. What is the most appropriate conclusion?

    • A.The result rejects the null hypothesis
    • B.The result lacks statistical significance
    • C.The result proves therapeutic equivalence
    • D.The result demonstrates a type II error
    Show answerHide answer

    Correct answer: The result lacks statistical significance

    A p value of 0.20 is larger than the alpha of 0.05 chosen in advance, so The result lacks statistical significance and the null hypothesis is not rejected. The result rejects the null hypothesis would require a p value below 0.05. The result proves therapeutic equivalence overreaches: failing to show a difference is not evidence of no difference, and equivalence needs a trial designed and powered to test it. The result demonstrates a type II error also claims too much; an underpowered trial may have missed a real effect, but a single nonsignificant p value cannot tell a missed effect from a true absence of one.

  48. In a clinical trial, the control group event rate is 20% and the treatment group event rate is 12%. What is the relative risk?

    • A.0.40
    • B.0.60
    • C.0.55
    • D.1.10
    Show answerHide answer

    Correct answer: 0.60

    Relative risk is the event rate in the treatment group divided by the event rate in the control group: 0.12 / 0.20 = 0.60. A value below 1 means the event was less frequent with treatment. 0.40 is the relative risk reduction (1 - 0.60, or 0.08 / 0.20), a different measure. 0.55 is the odds ratio, (0.12 / 0.88) divided by (0.20 / 0.80), which uses odds in place of risks. 1.10 is the ratio of the event-free proportions (0.88 / 0.80), which describes patients who did not have the event.

  49. Which feature distinguishes a Phase IV (post-marketing surveillance) study from earlier phases?

    • A.It tests the drug in healthy volunteers for tolerability or dose limits
    • B.It monitors the drug in marketed use for rare or long-term adverse events
    • C.It explores the drug in selected patients for efficacy or dose response
    • D.It confirms the drug in large pivotal trials for efficacy or safety claims
    Show answerHide answer

    Correct answer: It monitors the drug in marketed use for rare or long-term adverse events

    A Phase IV study is post-marketing surveillance: It monitors the drug in marketed use for rare or long-term adverse events, because reactions that occur in one patient in several thousand, or only after years of use, cannot be seen in the few thousand patients studied before approval. It tests the drug in healthy volunteers for tolerability or dose limits describes Phase I. It explores the drug in selected patients for efficacy or dose response describes Phase II. It confirms the drug in large pivotal trials for efficacy or safety claims describes Phase III, the large trials that support the marketing application.

  50. A patient is being dosed with a drug that follows one-compartment first-order kinetics. After how many half-lives is approximately 94% of the drug eliminated from the body?

    • A.4 half-lives
    • B.5 half-lives
    • C.7 half-lives
    • D.9 half-lives
    Show answerHide answer

    Correct answer: 4 half-lives

    Each half-life removes half of what remains, leaving 50%, 25%, 12.5% and then 6.25%, so after 4 half-lives about 94% of the drug has been eliminated. 5 half-lives leaves about 3% (roughly 97% eliminated); it is the figure usually quoted for essentially complete elimination or for reaching steady state, not for 94%. 7 half-lives leaves less than 1%, which is more than 99% eliminated. 9 half-lives leaves about 0.2%, far past the 94% mark.

  51. A pharmacist must compound an isotonic ophthalmic solution. Why is matching the osmolarity (tonicity) to physiologic levels important?

    • A.To prevent osmotic shifts that irritate or harm the ocular tissue
    • B.To prevent microbial growth that spoils or contaminates the bottle
    • C.To prevent chemical degradation that weakens or discolors the drug
    • D.To prevent particle settling that clogs or misdoses the dropper
    Show answerHide answer

    Correct answer: To prevent osmotic shifts that irritate or harm the ocular tissue

    Tonicity is adjusted To prevent osmotic shifts that irritate or harm the ocular tissue: a hypotonic drop drives water into corneal and conjunctival cells and a hypertonic drop draws it out, causing stinging, tearing and possible injury, whereas a solution close to 0.9% sodium chloride is comfortable. To prevent microbial growth that spoils or contaminates the bottle is the job of sterile preparation and, in multidose containers, a preservative. To prevent chemical degradation that weakens or discolors the drug is the job of buffers, antioxidants and suitable storage. To prevent particle settling that clogs or misdoses the dropper concerns suspensions and their viscosity agents, not tonicity.

  52. A bioavailability study compares a generic tablet to the brand reference. Which parameter pair is most commonly used to assess the rate and extent of absorption?

    • A.Trough plasma levels (Cmin) and total body clearance (CL)
    • B.Mean residence time (MRT) and volume of distribution (Vd)
    • C.Peak plasma concentration (Cmax) and area under the curve (AUC)
    • D.Elimination rate constant (Ke) and lag time before absorption (Tlag)
    Show answerHide answer

    Correct answer: Peak plasma concentration (Cmax) and area under the curve (AUC)

    Bioavailability and bioequivalence studies compare Peak plasma concentration (Cmax) and area under the curve (AUC): Cmax reflects how fast the drug is absorbed and AUC reflects how much reaches the circulation, and the generic passes when the 90% confidence intervals for the ratios of both fall within 80% to 125%. Trough plasma levels (Cmin) and total body clearance (CL) describe accumulation and elimination, which belong to the drug and not to the tablet. Mean residence time (MRT) and volume of distribution (Vd) describe persistence and distribution in the body. Elimination rate constant (Ke) and lag time before absorption (Tlag) are not the criteria on which a generic is judged, although lag time is sometimes reported.

  53. A pharmacist reviews data showing a drug has a high hepatic extraction ratio. What effect does this typically have when the drug is given orally?

    • A.Low oral bioavailability from limited intestinal permeability
    • B.High oral bioavailability from efficient hepatic drug uptake
    • C.Low oral bioavailability from extensive first-pass metabolism
    • D.High oral bioavailability from complete portal vein delivery
    Show answerHide answer

    Correct answer: Low oral bioavailability from extensive first-pass metabolism

    Oral bioavailability cannot exceed 1 minus the hepatic extraction ratio, so a drug the liver removes efficiently shows Low oral bioavailability from extensive first-pass metabolism (lidocaine, propranolol and morphine are examples). Low oral bioavailability from limited intestinal permeability gives the right direction for the wrong reason: extraction ratio describes removal by the liver, not passage across the gut wall. High oral bioavailability from efficient hepatic drug uptake reverses the effect, because rapid uptake by the liver is exactly what removes drug before it reaches the systemic circulation. High oral bioavailability from complete portal vein delivery also reverses it: delivering the whole absorbed dose to the liver first is what exposes it to first-pass loss.

  54. A pharmacist mixes 200 g of a 10% ointment with 300 g of a 2% ointment. What is the final concentration of the mixture?

    • A.5.2%
    • B.6.0%
    • C.6.8%
    • D.8.7%
    Show answerHide answer

    Correct answer: 5.2%

    Find the total drug and divide by the total weight: 200 g×10%=20 g200\ \text{g} \times 10\% = 20\ \text{g} and 300 g×2%=6 g300\ \text{g} \times 2\% = 6\ \text{g}, giving 26 g of drug in 500 g of ointment, and 26500=5.2%\frac{26}{500} = 5.2\%. 6.0% is the simple average of 10% and 2%, which ignores the unequal weights. 6.8% comes from attaching the weights to the wrong strengths (300 g at 10% and 200 g at 2% gives 34 g in 500 g). 8.7% comes from dividing the 26 g of drug by 300 g instead of by the full 500 g.

  55. Which statement correctly distinguishes a manufacturer's expiration date from a compounded preparation's beyond-use date?

    • A.The expiration date reflects compounding and storage conditions; the beyond-use date reflects stability data
    • B.The expiration date reflects stability data; the beyond-use date reflects the same stability testing data
    • C.The expiration date reflects compounding and storage conditions; the beyond-use date reflects them as well
    • D.The expiration date reflects stability data; the beyond-use date reflects compounding and storage conditions
    Show answerHide answer

    Correct answer: The expiration date reflects stability data; the beyond-use date reflects compounding and storage conditions

    The expiration date reflects stability data; the beyond-use date reflects compounding and storage conditions. A manufacturer sets an expiration date from formal stability studies of the product in its original container, while a compounder assigns a beyond-use date from the USP limits for the type of preparation, the environment in which it was made and how it will be stored, because a compounded preparation has not been through that testing. The expiration date reflects compounding and storage conditions; the beyond-use date reflects stability data reverses the two. The expiration date reflects stability data; the beyond-use date reflects the same stability testing data is wrong because the manufacturer's studies stop applying once the product is opened and manipulated. The expiration date reflects compounding and storage conditions; the beyond-use date reflects them as well is wrong because a manufactured product is dated from its stability program, not from pharmacy compounding conditions.

  56. A drug is known to be a strong CYP3A4 inhibitor. When co-administered with a substrate metabolized by CYP3A4, what pharmacokinetic effect is expected on the substrate?

    • A.Lower substrate levels and a likely loss of therapeutic effect
    • B.Higher substrate clearance and a shorter elimination half-life
    • C.Lower substrate absorption and a delayed peak plasma effect
    • D.Higher substrate concentration and a raised risk of toxicity
    Show answerHide answer

    Correct answer: Higher substrate concentration and a raised risk of toxicity

    A strong CYP3A4 inhibitor slows the metabolism of drugs that depend on that enzyme, so their clearance falls and they accumulate: Higher substrate concentration and a raised risk of toxicity (clarithromycin with simvastatin, for example). Lower substrate levels and a likely loss of therapeutic effect is what an inducer such as rifampin produces. Higher substrate clearance and a shorter elimination half-life is also the pattern of induction; inhibition lowers clearance and lengthens half-life. Lower substrate absorption and a delayed peak plasma effect describes an absorption interaction such as binding by antacids, and inhibiting intestinal CYP3A4 tends to raise, not lower, the amount absorbed intact.

  57. A pharmacist evaluates a study reporting a number needed to harm (NNH) of 50 for a serious adverse event. How is this interpreted?

    • A.Treating 50 patients prevents one adverse event on average
    • B.The adverse event is 50 times as likely in patients treated
    • C.One additional adverse event occurs per 50 patients treated
    • D.The adverse event rate rises by 50% in the patients treated
    Show answerHide answer

    Correct answer: One additional adverse event occurs per 50 patients treated

    Number needed to harm is the reciprocal of the absolute risk increase, so an NNH of 50 means One additional adverse event occurs per 50 patients treated, an absolute increase of 2 percentage points over the comparison group. Treating 50 patients prevents one adverse event on average describes a number needed to treat, the mirror-image measure used for benefits. The adverse event is 50 times as likely in patients treated mistakes the figure for a relative risk; the NNH says nothing about how many times more likely the event is. The adverse event rate rises by 50% in the patients treated mistakes it for a percentage increase, when 1 / 50 corresponds to 2%.

  58. A drug exhibits Michaelis-Menten (capacity-limited) elimination. As the dose increases beyond enzyme saturation, what happens to the apparent half-life?

    • A.It falls as elimination shifts toward zero-order kinetics
    • B.It rises as elimination shifts toward first-order kinetics
    • C.It falls as elimination shifts toward first-order kinetics
    • D.It rises as elimination shifts toward zero-order kinetics
    Show answerHide answer

    Correct answer: It rises as elimination shifts toward zero-order kinetics

    Once the metabolizing enzymes are saturated, a fixed amount of drug, not a fixed fraction, is removed per unit time, so the higher the concentration the longer it takes to fall by half: It rises as elimination shifts toward zero-order kinetics. Phenytoin behaves this way. It falls as elimination shifts toward zero-order kinetics names the right kinetic shift but the wrong direction, since saturated clearance cannot keep pace with rising concentrations. It rises as elimination shifts toward first-order kinetics has the direction right and the kinetics wrong: saturation moves the drug away from first-order behavior, in which half-life would be constant. It falls as elimination shifts toward first-order kinetics is wrong on both counts.

  59. USP 797 requires media-fill testing of compounding personnel. What is the primary purpose of this test?

    • A.To verify garbing practice by sampling the gloved fingertips of compounding staff
    • B.To verify final sterility by incubating samples of each compounding batch
    • C.To verify room cleanliness by plating samples from compounding surfaces
    • D.To verify aseptic technique by simulating compounding with growth medium
    Show answerHide answer

    Correct answer: To verify aseptic technique by simulating compounding with growth medium

    A media-fill test is done To verify aseptic technique by simulating compounding with growth medium: the compounder carries out representative manipulations using a sterile medium such as soybean-casein digest in place of drug, the units are incubated, and any turbidity shows that the technique introduced contamination. To verify garbing practice by sampling the gloved fingertips of compounding staff describes gloved fingertip and thumb sampling, a separate personnel test. To verify final sterility by incubating samples of each compounding batch describes sterility testing of finished preparations under USP 71. To verify room cleanliness by plating samples from compounding surfaces describes environmental surface sampling, which monitors the facility and not the person.

  60. A formulation scientist increases the particle surface area of a poorly soluble drug by micronization. What is the most likely effect on absorption?

    • A.Slower dissolution and possibly impaired absorption
    • B.Faster dissolution and possibly greater absorption
    • C.Higher gut permeability and possibly greater absorption
    • D.Lower gut permeability and possibly impaired absorption
    Show answerHide answer

    Correct answer: Faster dissolution and possibly greater absorption

    Dissolution rate is proportional to the surface area exposed to the fluid (the Noyes-Whitney relationship), so micronizing a poorly soluble drug gives Faster dissolution and possibly greater absorption; griseofulvin is the standard example, and the gain appears when dissolution is the step that limits absorption. Slower dissolution and possibly impaired absorption reverses the effect of a larger surface area. Higher gut permeability and possibly greater absorption credits the wrong property, because permeability depends on the molecule and the membrane, not on particle size. Lower gut permeability and possibly impaired absorption is wrong for the same reason and in the opposite direction.

  61. A study reports that a drug reduces mortality with a relative risk reduction of 30%, but the baseline event rate is only 2%. What does this reveal about the absolute benefit?

    • A.An absolute reduction of about 1.4%, small despite the large relative reduction
    • B.An absolute reduction of about 28%, large to match the large relative reduction
    • C.An absolute reduction of about 30%, large to match the large relative reduction
    • D.An absolute reduction of about 0.6%, small despite the large relative reduction
    Show answerHide answer

    Correct answer: An absolute reduction of about 0.6%, small despite the large relative reduction

    Absolute risk reduction is the baseline risk multiplied by the relative risk reduction: 2% x 0.30 gives An absolute reduction of about 0.6%, small despite the large relative reduction, which means roughly 167 patients treated to prevent one death. An absolute reduction of about 1.4%, small despite the large relative reduction mistakes the event rate left in the treated group (2% - 0.6% = 1.4%) for the reduction itself. An absolute reduction of about 28%, large to match the large relative reduction comes from subtracting the baseline rate from the relative figure (30 - 2), which mixes two different scales. An absolute reduction of about 30%, large to match the large relative reduction treats relative and absolute reduction as the same number, which a 2% baseline risk makes impossible.

  62. A pharmacist must calculate the loading dose of a drug for a 70 kg patient. The target concentration is 20 mg/L, the volume of distribution is 0.5 L/kg, and bioavailability is 1. What is the loading dose?

    • A.2800 mg
    • B.1400 mg
    • C.35 mg
    • D.700 mg
    Show answerHide answer

    Correct answer: 700 mg

    Loading dose = target concentration x volume of distribution / bioavailability. The volume is 0.5 L/kg×70 kg=35 L0.5\ \text{L/kg} \times 70\ \text{kg} = 35\ \text{L}, and 20 mg/L×35 L/1=700 mg20\ \text{mg/L} \times 35\ \text{L} / 1 = 700\ \text{mg}. 2800 mg comes from dividing by 0.5 instead of multiplying (70×20/0.570 \times 20 / 0.5). 1400 mg multiplies the weight by the concentration (70×2070 \times 20) and leaves out the 0.5 L/kg. 35 mg stops at the volume of distribution, 35 L, and reports that number as the dose.

  63. Which describes the half-life of a drug?

    • A.The time needed for the plasma concentration to reach its peak value
    • B.The time needed for the plasma concentration to reach a steady state
    • C.The time needed for the plasma concentration to drop below detection
    • D.The time needed for the plasma concentration to decrease by one half
    Show answerHide answer

    Correct answer: The time needed for the plasma concentration to decrease by one half

    Half-life is The time needed for the plasma concentration to decrease by one half; it equals 0.693 x volume of distribution / clearance and guides the choice of dosing interval. The time needed for the plasma concentration to reach its peak value is Tmax, which reflects the rate of absorption. The time needed for the plasma concentration to reach a steady state is about four to five half-lives, a multiple of the half-life and not the half-life itself. The time needed for the plasma concentration to drop below detection likewise spans several half-lives and depends on the dose and on the sensitivity of the assay.

  64. A 0.9% sodium chloride solution is referred to as normal saline. What is the concentration expressed in mg/mL?

    • A.9 mg/mL
    • B.0.9 mg/mL
    • C.900 mg/mL
    • D.154 mg/mL
    Show answerHide answer

    Correct answer: 9 mg/mL

    A percent weight-in-volume strength is grams per 100 mL, so 0.9% is 0.9 g in 100 mL, which is 900 mg in 100 mL, or 9 mg/mL. 0.9 mg/mL reads the percentage directly as milligrams per milliliter. 900 mg/mL converts 0.9 g to 900 mg but forgets to divide by the 100 mL. 154 mg/mL borrows the familiar figure for normal saline's sodium content, 154 mEq/L, which is a different quantity in different units.

  65. A drug's free fraction increases due to displacement from plasma proteins by a second drug. For a high-extraction-ratio drug given orally, what is the most relevant pharmacokinetic consideration?

    • A.Total concentration rises while free concentration may rise transiently
    • B.Total concentration falls while free concentration may rise transiently
    • C.Total concentration falls while free concentration may fall persistently
    • D.Total concentration rises while free concentration may fall persistently
    Show answerHide answer

    Correct answer: Total concentration falls while free concentration may rise transiently

    Displacement frees drug from its binding sites, and the freed drug is then available to distribute and to be eliminated, so Total concentration falls while free concentration may rise transiently until a new equilibrium is reached. This is why a total drug level can mislead after displacement: a lower total may accompany an unchanged or briefly higher free, active concentration. Total concentration rises while free concentration may rise transiently is wrong because the bound pool shrinks, which lowers the total. Total concentration falls while free concentration may fall persistently is wrong because displacement adds to the free pool and does not deplete it. Total concentration rises while free concentration may fall persistently reverses both changes.

  66. Under USP 800, what is the recommended primary engineering control for compounding sterile hazardous drugs?

    • A.A filtered-exhaust Class I biological safety cabinet
    • B.A HEPA-filtered horizontal laminar airflow workbench
    • C.A suitably vented Class II biological safety cabinet
    • D.A HEPA-filtered vertical laminar airflow workbench
    Show answerHide answer

    Correct answer: A suitably vented Class II biological safety cabinet

    Sterile hazardous drugs need a device that protects the product and the worker at once, and USP 800 names A suitably vented Class II biological safety cabinet (or a compounding aseptic containment isolator): HEPA-filtered downward air keeps the preparation sterile while the inward air curtain and exhaust carry drug away from the operator. A filtered-exhaust Class I biological safety cabinet protects the worker but passes unfiltered room air over the work, so it is limited to nonsterile hazardous compounding. A HEPA-filtered horizontal laminar airflow workbench blows air across the work surface straight at the compounder. A HEPA-filtered vertical laminar airflow workbench also protects only the product; it has no containment and lets contaminated air spill into the room.

  67. A study comparing two antihypertensives reports a hazard ratio of 0.75 with a 95% confidence interval of 0.60 to 0.94. How should this be interpreted regarding the primary outcome?

    • A.A statistically significant relative hazard reduction of 75%
    • B.A statistically significant relative hazard reduction of 25%
    • C.A statistically nonsignificant relative hazard reduction of 25%
    • D.A statistically nonsignificant relative hazard reduction of 75%
    Show answerHide answer

    Correct answer: A statistically significant relative hazard reduction of 25%

    A hazard ratio of 0.75 means the hazard in one group is 75% of that in the other, a 25% relative reduction, and a 95% confidence interval of 0.60 to 0.94 lies wholly below 1, so the finding is A statistically significant relative hazard reduction of 25%. A statistically significant relative hazard reduction of 75% reads the hazard ratio itself as the size of the reduction; the reduction is 1 minus the ratio. A statistically nonsignificant relative hazard reduction of 25% misreads the interval, which would have to include 1 to be nonsignificant. A statistically nonsignificant relative hazard reduction of 75% makes both mistakes.

  68. A drug with a volume of distribution of 0.07 L/kg is most likely confined to which body compartment?

    • A.The plasma compartment
    • B.The extracellular fluid compartment
    • C.The intracellular fluid compartment
    • D.The total body water compartment
    Show answerHide answer

    Correct answer: The plasma compartment

    A volume of distribution near 0.07 L/kg is about 5 L in a 70 kg adult, close to the volume of blood plasma, so the drug is essentially held in The plasma compartment; large or highly protein-bound molecules such as heparin behave this way. The extracellular fluid compartment, plasma plus interstitial fluid, corresponds to about 0.2 L/kg, as with aminoglycosides. The intracellular fluid compartment would require a still larger volume, about 0.4 L/kg, and a drug able to cross cell membranes. The total body water compartment corresponds to about 0.6 L/kg, as with ethanol.

  69. Which calculation is used to convert a drug amount in milligrams to milliequivalents for an electrolyte?

    • A.Multiply the amount in mg by the equivalent weight in mg/mEq
    • B.Divide the amount in mg by the equivalent weight in mg/mEq
    • C.Divide the amount in mg by the molecular weight in mg/mmol
    • D.Multiply the amount in mg by the molecular weight in mg/mmol
    Show answerHide answer

    Correct answer: Divide the amount in mg by the equivalent weight in mg/mEq

    Milliequivalents count charge, and the equivalent weight (molecular weight divided by valence) is the number of milligrams in one milliequivalent, so the conversion is: Divide the amount in mg by the equivalent weight in mg/mEq. For example, 745 mg of potassium chloride / 74.5 mg/mEq = 10 mEq. Multiply the amount in mg by the equivalent weight in mg/mEq uses the right factor with the wrong operation, and the units do not cancel. Divide the amount in mg by the molecular weight in mg/mmol gives millimoles, which equal milliequivalents only for a monovalent ion; for calcium or magnesium the answer would be half the true value. Multiply the amount in mg by the molecular weight in mg/mmol is wrong in both the factor and the operation.

  70. A pharmacist evaluates a meta-analysis. Which statistical concept describes the probability of correctly rejecting a false null hypothesis?

    • A.Alpha
    • B.Power
    • C.Beta
    • D.P value
    Show answerHide answer

    Correct answer: Power

    Power is the probability that a study rejects the null hypothesis when the null hypothesis is in fact false, that is, the chance of detecting an effect that really exists; it equals 1 minus beta and rises with sample size and effect size. Alpha is the probability of rejecting a null hypothesis that is true, a type I error. Beta is the probability of failing to reject a false null hypothesis, a type II error, and is the complement of power. P value is the probability, calculated from the data after the study, of a result at least as extreme as the one observed if the null hypothesis were true; it is not a property of the study design.

  71. A drug is administered as a continuous IV infusion. Which parameter primarily determines the steady-state concentration achieved?

    • A.The infusion rate divided by the volume of distribution
    • B.The infusion rate divided by the half-life
    • C.The infusion rate divided by the clearance
    • D.The volume of distribution divided by the infusion rate
    Show answerHide answer

    Correct answer: The infusion rate divided by the clearance

    At steady state the rate of drug going in equals the rate being eliminated, and elimination rate is clearance times concentration, so the steady-state concentration is The infusion rate divided by the clearance. The infusion rate divided by the volume of distribution gives only how fast the concentration starts to climb when the infusion begins; volume affects the time to reach the plateau, not its height. The infusion rate divided by the half-life is not a concentration at all, and half-life, like volume, governs how soon steady state is reached. The volume of distribution divided by the infusion rate turns that relationship upside down and would make the concentration fall as more drug is infused.

  72. A poorly water-soluble drug is reformulated as a salt to improve dissolution. This pharmaceutic strategy most directly aims to improve which property?

    • A.Bioavailability
    • B.Permeability
    • C.Lipid solubility
    • D.Plasma half-life
    Show answerHide answer

    Correct answer: Bioavailability

    A salt form dissolves faster in gastrointestinal fluid, and for a poorly soluble drug dissolution is the step that limits how much is absorbed, so the strategy is aimed at Bioavailability. Permeability is the other main determinant of absorption but belongs to the drug molecule and the gut wall; an ionized salt does not cross membranes more readily. Lipid solubility is, if anything, lower for the ionized salt than for the free acid or base; the salt is chosen for its solubility in water. Plasma half-life is set by clearance and volume of distribution once the drug is in the body and is the same whichever salt delivered it.

  73. A pharmacist reviews a forest plot from a meta-analysis. A confidence interval for an individual study's relative risk that is very wide most likely reflects which characteristic of that study?

    • A.A large effect and high significance
    • B.A heavy study weight and low variance
    • C.A small sample and low precision
    • D.A high event rate and little uncertainty
    Show answerHide answer

    Correct answer: A small sample and low precision

    The width of a confidence interval tracks the standard error, which grows as the number of participants and events shrinks, so a very wide interval points to A small sample and low precision. A large effect and high significance is about where the estimate sits, not how wide its interval is, and a wide interval is more likely to cross 1. A heavy study weight and low variance is the reverse of the truth: meta-analysis weights studies by the inverse of their variance, so wide-interval studies carry little weight. A high event rate and little uncertainty would narrow the interval, because more events mean a more stable estimate.

  74. A pharmacist must prepare 1 liter of a 0.45% sodium chloride solution from a 23.4% concentrated sodium chloride stock. Approximately how many milliliters of the concentrated stock are needed?

    • A.About 38.5 mL
    • B.About 52.0 mL
    • C.About 19.2 mL
    • D.About 10.5 mL
    Show answerHide answer

    Correct answer: About 19.2 mL

    Use the dilution equation, stock strength x stock volume = final strength x final volume: 23.4% x stock volume = 0.45% x 1000 mL, so the stock volume is 45023.4\frac{450}{23.4}, or About 19.2 mL, which is then diluted to 1000 mL. About 38.5 mL is the volume for 0.9% sodium chloride (90023.4\frac{900}{23.4}), the result of preparing normal saline instead of half-normal saline. About 52.0 mL comes from dividing the stock strength by the target strength (23.40.45\frac{23.4}{0.45}), which is the dilution factor and not a volume. About 10.5 mL comes from multiplying the two percentages (0.45×23.40.45 \times 23.4) instead of setting up the proportion.

  75. A patient receives a drug that displays first-order absorption and first-order elimination. After a single oral dose, what describes the shape of the plasma concentration-time curve?

    • A.An immediate peak (Cmax) followed by an exponential decline
    • B.A climb to a peak (Cmax) followed by an exponential decline
    • C.A climb to a peak (Cmax) followed by a straight-line decline
    • D.An immediate peak (Cmax) followed by a straight-line decline
    Show answerHide answer

    Correct answer: A climb to a peak (Cmax) followed by an exponential decline

    After an oral dose absorption at first outpaces elimination and the concentration climbs; when the two rates are equal the curve reaches its maximum at Tmax, and afterwards first-order elimination dominates: A climb to a peak (Cmax) followed by an exponential decline. An immediate peak (Cmax) followed by an exponential decline is the curve for an intravenous bolus, which has no absorption phase. A climb to a peak (Cmax) followed by a straight-line decline would mean zero-order elimination, a constant amount removed per hour, not the constant fraction that first-order elimination removes. An immediate peak (Cmax) followed by a straight-line decline has neither the absorption phase nor first-order elimination.

  76. A pharmacogenomic guideline recommends genotyping HLA-B*57:01 before initiating a specific drug. What is the primary purpose of this test?

    • A.To identify patients at higher risk of severe bone marrow suppression
    • B.To identify patients who metabolize the drug poorly and need lower doses
    • C.To identify patients at higher risk of severe hypersensitivity reactions
    • D.To identify patients who activate a prodrug poorly and gain less benefit
    Show answerHide answer

    Correct answer: To identify patients at higher risk of severe hypersensitivity reactions

    HLA-B*57:01 is screened before abacavir is started To identify patients at higher risk of severe hypersensitivity reactions; carriers must not receive the drug, and the test is about immune-mediated toxicity, not dose. To identify patients at higher risk of severe bone marrow suppression is the purpose of TPMT and NUDT15 testing before thiopurines. To identify patients who metabolize the drug poorly and need lower doses describes testing of metabolizing enzymes such as CYP2D6 or CYP2C19; HLA genes code for immune proteins, not enzymes. To identify patients who activate a prodrug poorly and gain less benefit describes CYP2C19 testing for the prodrug clopidogrel.

  77. Which of the following is the correct definition of first-pass metabolism?

    • A.Metabolism of an oral drug by the gut wall and liver before reaching the systemic circulation
    • B.Metabolism of a circulating drug by oxidative enzymes before a conjugation reaction takes place
    • C.Metabolism of a first dose at a faster rate than later doses after the enzymes become saturated
    • D.Excretion of an absorbed drug into bile and its reabsorption from the intestine into blood
    Show answerHide answer

    Correct answer: Metabolism of an oral drug by the gut wall and liver before reaching the systemic circulation

    First-pass metabolism is Metabolism of an oral drug by the gut wall and liver before reaching the systemic circulation: drug absorbed from the intestine drains through the portal vein to the liver, and whatever is metabolized on the way never becomes bioavailable. Metabolism of a circulating drug by oxidative enzymes before a conjugation reaction takes place describes phase I metabolism, where the word first refers to the order of reactions and not to a passage through the liver. Metabolism of a first dose at a faster rate than later doses after the enzymes become saturated mixes up the first pass with the first dose and describes saturable kinetics. Excretion of an absorbed drug into bile and its reabsorption from the intestine into blood describes enterohepatic recirculation.

  78. A compounding pharmacist must decide between a Category 1 and Category 2 designation under USP 797 for a sterile preparation. What primarily differentiates these categories?

    • A.The complexity of the compounding steps and the sterility of the starting ingredients
    • B.The hazard class of the compounding ingredients and the required containment controls
    • C.The conditions of the compounding environment and the assigned beyond-use date limits
    • D.The size of the compounding batch and the release testing each batch receives
    Show answerHide answer

    Correct answer: The conditions of the compounding environment and the assigned beyond-use date limits

    Under the current USP 797, what separates the categories is The conditions of the compounding environment and the assigned beyond-use date limits: a Category 1 preparation may be made in a segregated compounding area and receives short dating (12 hours at room temperature, 24 hours refrigerated), while a Category 2 preparation is made in a cleanroom suite and may be dated longer. The complexity of the compounding steps and the sterility of the starting ingredients was the basis of the former low-, medium- and high-risk levels, which the categories replaced. The hazard class of the compounding ingredients and the required containment controls is the subject of USP 800 and applies in either category. The size of the compounding batch and the release testing each batch receives affects how long a preparation may be dated within a category but does not define Category 1 against Category 2.

  79. A pharmacist calculates that an absolute risk reduction is 0.05. What is the corresponding number needed to treat?

    • A.200
    • B.5
    • C.20
    • D.95
    Show answerHide answer

    Correct answer: 20

    The number needed to treat is 20. It is the reciprocal of the absolute risk reduction: 10.05=20\frac{1}{0.05} = 20, so twenty patients must be treated to prevent one additional event. 200 comes from a decimal slip, dividing 1 by 0.005. 5 comes from reading 0.05 as 5% and reporting the percentage itself rather than its reciprocal. 95 is the complement of the reduction (100−5100 - 5), which describes the patients who gain no benefit and is not a number needed to treat.

  80. A drug undergoes glucuronidation as a major metabolic pathway. This reaction is an example of which type of drug metabolism?

    • A.Phase II conjugation
    • B.Phase I conjugation
    • C.Phase I functionalization
    • D.Phase II functionalization
    Show answerHide answer

    Correct answer: Phase II conjugation

    Phase II conjugation is correct: glucuronidation attaches glucuronic acid, an endogenous molecule, to the drug or its metabolite through UDP-glucuronosyltransferases, which makes the product more water soluble for excretion in urine or bile. Phase I conjugation names the right reaction type but the wrong phase, because conjugation reactions make up Phase II. Phase I functionalization describes oxidation, reduction and hydrolysis, which introduce or unmask a functional group rather than attach an endogenous molecule. Phase II functionalization pairs the right phase with the wrong reaction type, since functionalization reactions belong to Phase I.

  81. A new drug application includes data from a Phase II trial. What is the primary purpose of this phase?

    • A.To establish initial safety and tolerated dosing in healthy volunteers
    • B.To assess early efficacy and set optimal dosing in affected patients
    • C.To confirm efficacy and monitor safety in large comparative trials
    • D.To detect rare adverse effects and delayed risks in postmarketing use
    Show answerHide answer

    Correct answer: To assess early efficacy and set optimal dosing in affected patients

    To assess early efficacy and set optimal dosing in affected patients is correct: Phase II studies enroll a few hundred patients who have the target condition to give the first evidence that the drug works and to settle the dose carried into larger trials, while safety continues to be monitored. To establish initial safety and tolerated dosing in healthy volunteers describes Phase I, the first-in-human studies of safety, tolerability and pharmacokinetics. To confirm efficacy and monitor safety in large comparative trials describes Phase III, the large confirmatory trials that support approval. To detect rare adverse effects and delayed risks in postmarketing use describes Phase IV, the surveillance that follows approval.

  82. A pharmacist must prepare a 2 L parenteral nutrition bag and ensure the dextrose-related osmolarity is acceptable. Why is the final osmolarity calculation critical before dispensing?

    • A.It shows whether the formula needs peripheral or central venous administration
    • B.It shows whether the calcium and phosphate will stay dissolved or precipitate
    • C.It shows whether the lipid emulsion separates or stays stable
    • D.It shows whether the glucose load will stay within or exceed oxidative capacity
    Show answerHide answer

    Correct answer: It shows whether the formula needs peripheral or central venous administration

    It shows whether the formula needs peripheral or central venous administration is correct: peripheral veins tolerate only about 900 mOsm/L, so a more hypertonic parenteral nutrition formula must be infused through a central line to avoid phlebitis and vein damage. It shows whether the calcium and phosphate will stay dissolved or precipitate is wrong because precipitation risk is judged from the calcium and phosphate concentrations, the pH and the amino acid content, not from the osmolarity. It shows whether the lipid emulsion separates or stays stable is wrong because emulsion stability depends on the final concentrations of amino acids, dextrose, lipid and cations, which is a separate check. It shows whether the glucose load will stay within or exceed oxidative capacity is wrong because the glucose infusion rate is worked out in mg/kg/min from the dextrose dose and the body weight, not from the osmolarity.

  83. A drug's bioavailability after oral administration is found to be greater following a high-fat meal. This indicates the drug's absorption is most likely affected by which factor?

    • A.Improved gut solubilization caused by dietary fat
    • B.Accelerated gastric emptying caused by dietary fat
    • C.Reduced bile salt secretion caused by dietary fat
    • D.Increased hepatic extraction caused by dietary fat
    Show answerHide answer

    Correct answer: Improved gut solubilization caused by dietary fat

    Improved gut solubilization caused by dietary fat is correct: a high-fat meal stimulates bile flow, and the bile salt micelles and the fat itself dissolve a lipophilic, poorly water-soluble drug, so a larger fraction of the dose is absorbed. Accelerated gastric emptying caused by dietary fat is wrong because fat slows gastric emptying rather than speeding it. Reduced bile salt secretion caused by dietary fat is wrong because fat in the duodenum releases cholecystokinin, which increases bile secretion. Increased hepatic extraction caused by dietary fat is wrong because greater first-pass extraction by the liver would lower bioavailability, the opposite of what was observed.

  84. In hypothesis testing, what is the consequence of conducting multiple comparisons without statistical adjustment?

    • A.A higher overall chance of a type II error
    • B.A higher overall chance of a type I error
    • C.A lower statistical power in each comparison
    • D.A wider confidence interval for each comparison
    Show answerHide answer

    Correct answer: A higher overall chance of a type I error

    A higher overall chance of a type I error is correct: each test carries its own alpha, so across many unadjusted tests the probability that at least one is falsely significant rises well above 5%; corrections such as Bonferroni control this familywise error. A higher overall chance of a type II error is wrong because a type II error is a missed true effect, and running more unadjusted tests does not make missed effects more likely. A lower statistical power in each comparison is wrong because power falls when an adjustment tightens the significance threshold, not when the adjustment is omitted. A wider confidence interval for each comparison is wrong because the interval for a comparison widens only when an adjustment is applied.

  85. A pharmacist prepares a hazardous drug and must protect against environmental contamination after spills. Under USP 800, what must a facility maintain to address hazardous drug spills?

    • A.A spill kit and informal guidance for managing spills
    • B.A spill kit and written procedures for managing spills
    • C.A first-aid kit and written procedures for managing spills
    • D.A first-aid kit and informal guidance for managing spills
    Show answerHide answer

    Correct answer: A spill kit and written procedures for managing spills

    A spill kit and written procedures for managing spills is correct: USP 800 requires spill kits to be readily available wherever hazardous drugs are handled, together with standard operating procedures that cover containment, cleanup, personal protective equipment, disposal and documentation, and staff must be trained on them. A spill kit and informal guidance for managing spills is wrong because spill management must be set out in documented procedures rather than passed on informally. A first-aid kit and written procedures for managing spills is wrong because a first-aid kit holds none of the absorbent materials, protective garb and waste containers needed to contain a hazardous drug spill. A first-aid kit and informal guidance for managing spills is wrong on both counts.

  86. A pharmacist mixes equal weights of a 1% and a 5% hydrocortisone cream. What is the resulting concentration?

    • A.5.5%
    • B.3%
    • C.3.5%
    • D.4%
    Show answerHide answer

    Correct answer: 3%

    The resulting concentration is 3%. With equal weights the final strength is the simple average of the two: 1%+5%2=3%\frac{1\% + 5\%}{2} = 3\%, which alligation with equal parts confirms. 5.5% comes from keying the sum in the wrong order so that only the 1% is halved (12+5\frac{1}{2} + 5); it is also impossible, because a mixture cannot be stronger than its strongest component. 3.5% comes from the same slip the other way round, halving only the 5% (1+521 + \frac{5}{2}). 4% is the difference between the two strengths, a figure used to find alligation parts and not the strength of the mixture.

  87. A relative risk of exactly 1.0 in a cohort study indicates which of the following?

    • A.No confounding between exposure and outcome
    • B.A causal link between exposure and outcome
    • C.A protective link between exposure and outcome
    • D.No association between exposure and outcome
    Show answerHide answer

    Correct answer: No association between exposure and outcome

    No association between exposure and outcome is correct: relative risk is the incidence in the exposed group divided by the incidence in the unexposed group, so a value of exactly 1.0 means the two groups have the same incidence and the exposure neither raises nor lowers risk. No confounding between exposure and outcome is wrong because the size of a relative risk says nothing about whether a third factor has distorted it; a confounded study can still report 1.0. A causal link between exposure and outcome is wrong because a harmful effect would give a value above 1.0. A protective link between exposure and outcome is wrong because a protective effect would give a value below 1.0.

  88. A drug is given orally and its bioavailability is calculated using the formula F=AUCoralAUCIV×DoseIVDoseoralF = \frac{\text{AUC}_\text{oral}}{\text{AUC}_\text{IV}} \times \frac{\text{Dose}_\text{IV}}{\text{Dose}_\text{oral}}. This calculation specifically yields which type of bioavailability?

    • A.Absolute bioavailability
    • B.Relative bioavailability
    • C.Average bioequivalence
    • D.Population bioequivalence
    Show answerHide answer

    Correct answer: Absolute bioavailability

    Absolute bioavailability is correct: the dose-corrected oral AUC is divided by the AUC of an intravenous dose, which is completely available, so the result is the true fraction of the oral dose that reaches the systemic circulation. Relative bioavailability is wrong because it compares one non-intravenous product with another non-intravenous reference, with no intravenous dose involved. Average bioequivalence is wrong because it is a statistical comparison of the mean AUC and peak concentration of a test product and a reference product against set limits. Population bioequivalence is wrong because it extends that comparison to the variability of the two products across a population.

  89. A pharmacist must prepare a compounded sterile preparation in a cleanroom. What is the function of the anteroom, which is typically maintained at ISO Class 8 or cleaner?

    • A.To give staff a critical area for needle entries, transfers, and sterile mixing
    • B.To give staff a buffer area for the hoods, mixing carts, and final checks
    • C.To give staff a transition area for hand hygiene, garbing, and supply staging
    • D.To give staff a receiving area for unpacking, storing, and returning stock
    Show answerHide answer

    Correct answer: To give staff a transition area for hand hygiene, garbing, and supply staging

    To give staff a transition area for hand hygiene, garbing, and supply staging is correct: the anteroom separates the general pharmacy from the cleaner buffer room and is where personnel wash their hands, put on garb and stage wiped-down supplies before entering. To give staff a critical area for needle entries, transfers, and sterile mixing describes the direct compounding area inside the ISO Class 5 primary engineering control, where the sterile manipulations themselves take place. To give staff a buffer area for the hoods, mixing carts, and final checks describes the buffer room, the ISO Class 7 space that houses the primary engineering controls. To give staff a receiving area for unpacking, storing, and returning stock describes general receiving and storage, which sit outside the classified area because shipping cartons shed particles.

  90. A 10-year-old patient requires a dose based on body surface area. Which information is essential to calculate body surface area using a standard nomogram or formula?

    • A.The patient's age and weight
    • B.The patient's age and serum creatinine
    • C.The patient's height and serum creatinine
    • D.The patient's height and weight
    Show answerHide answer

    Correct answer: The patient's height and weight

    The patient's height and weight is correct: body surface area formulas such as Mosteller, the square root of (height in cm x weight in kg / 3600), and the standard nomograms need only these two measurements. The patient's age and weight gives the inputs of the older age-based and weight-based pediatric dosing rules, such as Young's and Clark's rules, not of a surface area formula. The patient's age and serum creatinine gives inputs used to estimate kidney function in adults. The patient's height and serum creatinine gives the inputs of the bedside Schwartz equation, which estimates glomerular filtration rate in children rather than body surface area.

  91. A study reports its results as statistically significant with a very small p value but a confidence interval for the effect that is extremely narrow and close to no clinical difference. What does this illustrate?

    • A.Statistical significance with a clinically important effect
    • B.Statistical nonsignificance with a clinically trivial effect
    • C.Statistical nonsignificance with a clinically important effect
    • D.Statistical significance with a clinically trivial effect
    Show answerHide answer

    Correct answer: Statistical significance with a clinically trivial effect

    Statistical significance with a clinically trivial effect is correct: a very large sample can produce a very small p value for a difference too small to matter to patients, and the narrow confidence interval sitting close to no difference shows that the true effect is precisely estimated and tiny. Statistical significance with a clinically important effect is wrong because the interval lies close to no clinical difference, so the effect is not important. Statistical nonsignificance with a clinically trivial effect is wrong because the very small p value makes the result statistically significant. Statistical nonsignificance with a clinically important effect is wrong on both counts.

  92. A drug that is a substrate of P-glycoprotein efflux transporters in the intestine may have which characteristic absorption profile?

    • A.Reduced oral absorption, as drug is pumped back into the gut lumen
    • B.Increased oral absorption, as drug is carried into the portal blood
    • C.Unchanged oral absorption, as drug is pumped out at the kidney
    • D.Increased oral absorption, as drug is shielded from enzymes in the gut wall
    Show answerHide answer

    Correct answer: Reduced oral absorption, as drug is pumped back into the gut lumen

    Reduced oral absorption, as drug is pumped back into the gut lumen is correct: P-glycoprotein sits on the luminal membrane of enterocytes and returns absorbed substrate to the lumen, which lowers oral bioavailability; inhibitors of the transporter raise exposure and inducers lower it. Increased oral absorption, as drug is carried into the portal blood is wrong because it treats an efflux transporter as an uptake transporter. Unchanged oral absorption, as drug is pumped out at the kidney is wrong because the question concerns the intestinal transporter, which acts on the drug before it ever reaches the kidney. Increased oral absorption, as drug is shielded from enzymes in the gut wall is wrong because efflux back into the lumen gives gut wall enzymes such as CYP3A4 repeated access to the drug, which adds to presystemic loss rather than preventing it.

  93. A drug reaches steady state during multiple dosing. At steady state, what is true about the relationship between the rate of drug administration and the rate of elimination?

    • A.Administration rate still exceeds elimination rate
    • B.Administration rate steadily trails elimination rate
    • C.Administration rate fully saturates elimination rate
    • D.Administration rate roughly equals elimination rate
    Show answerHide answer

    Correct answer: Administration rate roughly equals elimination rate

    Administration rate roughly equals elimination rate is correct: at steady state the amount of drug entering the body over a dosing interval matches the amount removed, so the average plasma concentration stays constant; this takes about four to five half-lives. Administration rate still exceeds elimination rate describes the accumulation period before steady state, when concentrations are still rising. Administration rate steadily trails elimination rate describes the period after dosing is reduced or stopped, when concentrations are falling. Administration rate fully saturates elimination rate is wrong because saturation of elimination is a feature of capacity-limited (Michaelis-Menten) drugs at high concentrations, not a definition of steady state.

  94. A pharmacogenomics report indicates a patient carries a reduced-function allele for a thiopurine-metabolizing enzyme. What dosing consideration is most appropriate for a thiopurine drug?

    • A.Give a smaller dose to limit the risk of severe myelosuppression
    • B.Give a larger dose to offset the faster clearance of the drug
    • C.Give the standard dose with allopurinol to boost active metabolites
    • D.Give the standard dose and rely on monthly liver enzyme tests to monitor safety
    Show answerHide answer

    Correct answer: Give a smaller dose to limit the risk of severe myelosuppression

    Give a smaller dose to limit the risk of severe myelosuppression is correct: reduced thiopurine methyltransferase (or NUDT15) activity shunts azathioprine, mercaptopurine or thioguanine toward thioguanine nucleotides, which accumulate and suppress the bone marrow, so genotype-guided dosing starts lower and titrates against blood counts. Give a larger dose to offset the faster clearance of the drug is wrong because a reduced-function allele slows inactivation of the drug; it does not speed clearance. Give the standard dose with allopurinol to boost active metabolites is wrong because allopurinol blocks xanthine oxidase, another inactivating pathway, and would raise the toxic metabolites further. Give the standard dose and rely on monthly liver enzyme tests to monitor safety is wrong because the standard dose is the hazard here and the toxicity to watch for is in the blood count, not the liver enzymes.

  95. A pharmacist must calculate how many grams of dextrose are in 1 liter of a 50% dextrose solution. What is the answer?

    • A.50 grams
    • B.2000 grams
    • C.20 grams
    • D.500 grams
    Show answerHide answer

    Correct answer: 500 grams

    The answer is 500 grams. A 50% weight-in-volume solution contains 50 g in every 100 mL, and 1 liter is ten times 100 mL, so 50 g x 10 = 500 g. 50 grams is the amount in 100 mL, the result of stopping before scaling up to 1000 mL. 2000 grams comes from dividing 1000 mL by 0.5 instead of multiplying by it. 20 grams comes from dividing 1000 by 50, which inverts the percentage.

  96. A pharmacist reviews a study with a relative risk reduction of 50% and a control event rate of 10%. What is the number needed to treat?

    • A.20
    • B.50
    • C.40
    • D.5
    Show answerHide answer

    Correct answer: 20

    The number needed to treat is 20. The absolute risk reduction is the relative risk reduction applied to the control event rate, 0.50×10%=5%0.50 \times 10\% = 5\%, and the number needed to treat is its reciprocal, 10.05=20\frac{1}{0.05} = 20. 50 is the relative risk reduction itself, read from the stem as a percentage; it is not a count of patients and it ignores the baseline risk. 40 comes from applying the 50% reduction a second time, to the 5% rate in the treated group, which gives 2.5% and 10.025\frac{1}{0.025}. 5 is the absolute risk reduction expressed as a percentage, reported without taking the reciprocal.

  97. Which dosage form characteristic would most likely result in the highest and fastest bioavailability for a given drug?

    • A.Intramuscular solution
    • B.Intravenous solution
    • C.Oral suspension
    • D.Subcutaneous suspension
    Show answerHide answer

    Correct answer: Intravenous solution

    Intravenous solution is correct: the drug is placed directly and completely into the systemic circulation, with no absorption step and no first-pass loss, so bioavailability is 100% by definition and onset is immediate. Intramuscular solution is wrong because the drug must still be absorbed from the muscle, which takes time and depends on local blood flow. Oral suspension is wrong because the drug must dissolve, cross the gut wall and survive first-pass metabolism. Subcutaneous suspension is wrong because the drug is absorbed slowly from poorly perfused tissue, and its particles must dissolve first.

  98. USP 797 specifies environmental monitoring of compounding areas. What does viable air sampling primarily assess?

    • A.Surface microbial contamination
    • B.Airborne nonviable particle counts
    • C.Airborne microbial contamination
    • D.Surface nonviable particle counts
    Show answerHide answer

    Correct answer: Airborne microbial contamination

    Airborne microbial contamination is correct: viable air sampling draws a measured volume of air onto growth media, which is incubated and read in colony-forming units to detect bacteria and fungi in the classified areas. Surface microbial contamination is wrong because it is assessed separately by surface sampling with contact plates or swabs. Airborne nonviable particle counts is wrong because total particle counts, taken with an electronic particle counter, are what establish the ISO classification of the air and say nothing about whether the particles are living. Surface nonviable particle counts is wrong on both counts and is not a test in the standard.

  99. A drug that is weakly acidic (low pKa) will be predominantly nonionized in which environment, favoring its absorption there?

    • A.The duodenum, at a pH of about 6
    • B.The stomach, at a pH of about 2
    • C.The ileum, at a pH of about 7.5
    • D.The colon, at a pH of about 6.5
    Show answerHide answer

    Correct answer: The stomach, at a pH of about 2

    The stomach, at a pH of about 2 is correct: by the Henderson-Hasselbalch relationship a weak acid is mostly protonated, and therefore nonionized, when the pH is below its pKa, and only the strongly acidic gastric contents meet that condition; the nonionized form is the lipid-soluble one that crosses membranes. The duodenum, at a pH of about 6 is wrong because that pH is already above the pKa of such an acid, so most of it is ionized. The ileum, at a pH of about 7.5 is wrong because a mildly alkaline pH leaves the acid almost completely ionized. The colon, at a pH of about 6.5 is wrong for the same reason as the duodenum. In practice the large surface area of the small intestine still allows substantial absorption of weak acids, but that is not because they are nonionized there.

  100. A pharmacist evaluates a trial reporting both a p value of 0.04 and a confidence interval that barely excludes the null value. What is the relationship between these two statistics?

    • A.They agree, as a p value below 0.05 matches a 95% interval that excludes the null
    • B.They conflict, as a 95% interval that excludes the null needs a p value over 0.05
    • C.They agree, as a p value of 0.04 means a 96% chance that the 95% interval excludes the null
    • D.They conflict, as a 95% interval that excludes the null needs a p value below 0.025
    Show answerHide answer

    Correct answer: They agree, as a p value below 0.05 matches a 95% interval that excludes the null

    They agree, as a p value below 0.05 matches a 95% interval that excludes the null is correct: a two-sided test at an alpha of 0.05 and a 95% confidence interval are built from the same standard error, so a p value just under 0.05 goes with an interval that just excludes the null value; the interval adds the size and precision of the effect. They conflict, as a 95% interval that excludes the null needs a p value over 0.05 is wrong because a p value above 0.05 goes with an interval that includes the null. They agree, as a p value of 0.04 means a 96% chance that the 95% interval excludes the null is wrong because a p value is the probability of data this extreme if the null hypothesis were true; it is not the probability that an interval is right, and the confidence level stays 95%. They conflict, as a 95% interval that excludes the null needs a p value below 0.025 is wrong because the 0.025 in each tail of a two-sided test adds up to the same 0.05 threshold.

  101. A drug has a volume of distribution of 42 L in a 70 kg adult. This value most closely approximates which physiologic space?

    • A.Total blood volume
    • B.Extracellular fluid
    • C.Total body water
    • D.Intracellular fluid
    Show answerHide answer

    Correct answer: Total body water

    Total body water is correct: it is about 0.6 L/kg, or 42 L in a 70 kg adult, so a volume of distribution of 42 L suggests a drug that spreads evenly through body water without marked tissue binding, as ethanol does. Total blood volume is only about 5 L, the value approached by drugs confined to the bloodstream. Extracellular fluid is about one third of body water, roughly 14 L. Intracellular fluid is about two thirds of body water, roughly 28 L.

  102. A pharmacist reviews two oral tablet formulations of the same drug and finds their AUCs differ. This comparison between two non-intravenous products measures which property?

    • A.Absolute bioavailability
    • B.Pharmaceutical equivalence
    • C.Relative bioavailability
    • D.Therapeutic equivalence
    Show answerHide answer

    Correct answer: Relative bioavailability

    Relative bioavailability is correct: comparing the AUC of one non-intravenous product with that of another gives the extent of absorption of the test product relative to the reference, the measurement that underlies bioequivalence testing. Absolute bioavailability is wrong because it requires an intravenous dose as the reference. Pharmaceutical equivalence is wrong because it is a matter of the products having the same active ingredient, strength, dosage form and route, and is not measured from the AUC. Therapeutic equivalence is wrong because it is the regulatory conclusion that pharmaceutically equivalent products are also bioequivalent, not the property the AUC comparison itself measures.

  103. A drug with a long half-life is dosed once daily. A clinician wants to reach therapeutic concentrations on the first day rather than waiting several days. What strategy achieves this?

    • A.Give each dose at a shorter interval
    • B.Reduce the maintenance dose
    • C.Administer a loading dose
    • D.Divide the daily dose
    Show answerHide answer

    Correct answer: Administer a loading dose

    Administer a loading dose is correct: a single larger first dose, sized as the target concentration multiplied by the volume of distribution, fills that volume at once, and the usual maintenance doses then hold the level. Give each dose at a shorter interval is wrong because it changes the steady-state level and the peak-to-trough swing, while the time to reach steady state still depends on the half-life. Reduce the maintenance dose is wrong because a smaller maintenance dose lowers the steady-state concentration and does nothing to shorten the four to five half-lives needed to reach it. Divide the daily dose is wrong because it smooths the fluctuation without changing the average concentration or the time needed to reach it.

  104. USP 800 requires assessment of risk for hazardous drugs that are handled only in their final, intact dosage forms (for example, counting tablets). What does this allow a facility to potentially implement?

    • A.Alternative containment strategies supported by a documented assessment of risk
    • B.Alternative containment strategies allowed without a documented assessment of risk
    • C.Full exemption from the chapter supported by a documented assessment of risk
    • D.Full exemption from the chapter allowed without a documented assessment of risk
    Show answerHide answer

    Correct answer: Alternative containment strategies supported by a documented assessment of risk

    Alternative containment strategies supported by a documented assessment of risk is correct: for final dosage forms that need no manipulation beyond counting or repackaging, USP 800 lets an entity adopt alternative containment strategies and work practices, provided the assessment considers the drug, the dosage form, the risk of exposure, the packaging and the manipulation, and is documented and reviewed at least every 12 months. Alternative containment strategies allowed without a documented assessment of risk is wrong because without the documented assessment every containment requirement of the chapter applies. Full exemption from the chapter supported by a documented assessment of risk is wrong because the assessment changes how such drugs are contained; it does not take them out of the chapter. Full exemption from the chapter allowed without a documented assessment of risk is wrong on both counts.

  105. A pharmacist reviews a study and notes the confidence interval for the mean difference is reported at the 99% level rather than 95%. Compared with a 95% interval from the same data, the 99% interval will be:

    • A.Narrower
    • B.Wider
    • C.Unchanged
    • D.Shifted
    Show answerHide answer

    Correct answer: Wider

    Wider is correct: a higher confidence level uses a larger critical value (about 2.58 standard errors instead of 1.96), so the interval must cover a broader range of plausible values. Narrower reverses the relationship; it is the lower confidence level, such as 90%, that gives a tighter interval. Unchanged is wrong because the margin of error changes with the confidence level even though the data do not. Shifted is wrong because both intervals are centered on the same point estimate.

  106. A pharmacist needs to determine the equivalent weight of magnesium sulfate where magnesium has a valence of 2 and the molecular weight is about 120. What is the equivalent weight used for milliequivalent conversions?

    • A.12 mg/mEq
    • B.120 mg/mEq
    • C.24 mg/mEq
    • D.60 mg/mEq
    Show answerHide answer

    Correct answer: 60 mg/mEq

    The equivalent weight is 60 mg/mEq. It is the molecular weight of the salt divided by the valence: 1202=60\frac{120}{2} = 60, and this figure converts between milligrams and milliequivalents of magnesium sulfate. 12 mg/mEq is the equivalent weight of elemental magnesium alone (atomic weight 24 divided by 2), not of the salt that is being weighed. 120 mg/mEq leaves out the division by the valence and would be right only for a monovalent salt. 24 mg/mEq is the atomic weight of magnesium, with neither the sulfate nor the valence accounted for.

  107. A pharmacist explains alligation to a student. What type of pharmacy problem is the alligation method primarily designed to solve?

    • A.Finding the amount of sodium chloride that must be added to make a solution isotonic with tears
    • B.Finding the proportions in which two strengths are mixed to obtain an intermediate strength
    • C.Finding the milliequivalents of an electrolyte that are supplied by an ordered salt dose
    • D.Finding the drops per minute at which a set volume is delivered in the ordered time
    Show answerHide answer

    Correct answer: Finding the proportions in which two strengths are mixed to obtain an intermediate strength

    Finding the proportions in which two strengths are mixed to obtain an intermediate strength is correct: alligation alternate sets the higher and lower strengths against the desired strength, and the differences give the relative parts of each to combine; it is used in compounding when neither stock strength matches the one prescribed. Finding the amount of sodium chloride that must be added to make a solution isotonic with tears is an isotonicity problem, solved with sodium chloride equivalents (E values) or freezing point depression. Finding the milliequivalents of an electrolyte that are supplied by an ordered salt dose is a milliequivalent conversion, which uses the molecular weight and the valence. Finding the drops per minute at which a set volume is delivered in the ordered time is a flow rate problem, which uses the drop factor of the administration set.

  108. A drug undergoes enterohepatic recirculation. What effect does this process most likely have on the drug's duration of action?

    • A.It shortens the half-life and the duration of action
    • B.It extends the half-life but not the duration of action
    • C.It shortens the half-life but not the duration of action
    • D.It extends the half-life and the duration of action
    Show answerHide answer

    Correct answer: It extends the half-life and the duration of action

    It extends the half-life and the duration of action is correct: drug or its conjugate is excreted in bile, the conjugate is cleaved by gut bacteria, and the drug is reabsorbed and returned to the circulation, which delays final elimination and can produce secondary peaks. It shortens the half-life and the duration of action is wrong because recycling returns drug to the body rather than removing it faster. It extends the half-life but not the duration of action is wrong because the drug that keeps returning to the plasma also keeps producing its effect, so the duration of action lengthens with the half-life. It shortens the half-life but not the duration of action is wrong on both counts.

  109. A pharmacist reviewing a clinical study notes the trial was double-blinded. What is the primary purpose of blinding in a clinical trial?

    • A.To give each patient an equal and unpredictable chance of drug or placebo
    • B.To keep each patient in the randomized group and count dropouts or crossovers
    • C.To limit bias in outcome assessment and patient or investigator behavior
    • D.To protect patient identity and records from sponsors or outside parties
    Show answerHide answer

    Correct answer: To limit bias in outcome assessment and patient or investigator behavior

    To limit bias in outcome assessment and patient or investigator behavior is correct: when participants, clinicians and assessors do not know the assignment, expectations cannot change how patients report symptoms, how they are managed or how outcomes are judged, which protects internal validity. To give each patient an equal and unpredictable chance of drug or placebo describes randomization, which balances known and unknown confounders between groups. To keep each patient in the randomized group and count dropouts or crossovers describes intention-to-treat analysis, which keeps the benefit of randomization when patients deviate from the protocol. To protect patient identity and records from sponsors or outside parties describes confidentiality protections, which concern privacy rather than knowledge of the treatment assignment.

  110. A pharmacist calculates a beyond-use date for a compounded sterile preparation stored under refrigeration rather than at room temperature. How does refrigeration typically affect the permissible beyond-use date?

    • A.It generally forces a shorter beyond-use date
    • B.It generally permits a longer beyond-use date
    • C.It generally leaves the beyond-use date unchanged
    • D.It generally allows the beyond-use date for frozen storage
    Show answerHide answer

    Correct answer: It generally permits a longer beyond-use date

    It generally permits a longer beyond-use date is correct: cold slows both chemical degradation and microbial growth, so the USP 797 limits for each compounding category are longer for refrigerated storage than for controlled room temperature; a Category 1 preparation, for example, moves from 12 hours to 24 hours. It generally forces a shorter beyond-use date reverses the effect of temperature. It generally leaves the beyond-use date unchanged is wrong because storage temperature is one of the factors that set the limit. It generally allows the beyond-use date for frozen storage is wrong because frozen storage carries its own, longer limits, and they do not apply to a refrigerated preparation.

  111. A drug's clearance is reduced by half in a patient with hepatic impairment, while volume of distribution is unchanged. What is the expected effect on the drug's half-life?

    • A.The half-life is roughly halved
    • B.The half-life is roughly unchanged
    • C.The half-life is roughly doubled
    • D.The half-life is roughly quadrupled
    Show answerHide answer

    Correct answer: The half-life is roughly doubled

    The half-life is roughly doubled is correct: half-life equals 0.693 x volume of distribution / clearance, so with the volume fixed, cutting clearance to one half doubles the half-life, and the dose or interval usually needs adjusting. The half-life is roughly halved treats half-life as directly proportional to clearance when it is inversely proportional. The half-life is roughly unchanged would hold only if the volume of distribution had fallen by half as well. The half-life is roughly quadrupled would need clearance to fall to one quarter; it applies the halving twice.

  112. Which biostatistical measure expresses the proportion of a disease or outcome in an exposed group divided by the proportion in an unexposed group, and is most appropriate for cohort studies?

    • A.Odds ratio
    • B.Relative risk
    • C.Hazard ratio
    • D.Attributable risk
    Show answerHide answer

    Correct answer: Relative risk

    Relative risk is correct: it is the incidence of the outcome in the exposed group divided by the incidence in the unexposed group, and a cohort study follows both groups forward so that incidence can be measured directly. Odds ratio compares the odds of exposure in cases and controls and is the measure for case-control studies, where incidence cannot be measured. Hazard ratio compares instantaneous event rates over time in a survival analysis. Attributable risk is the difference between the two incidences, not their quotient.

  113. A pharmacist prepares an admixture and must select an appropriate beyond-use date. Under USP 797, which factor does NOT contribute to assigning the beyond-use date of a compounded sterile preparation?

    • A.The retail markup applied to the final preparation
    • B.The storage temperature used for the preparation
    • C.The compounding category assigned to the preparation
    • D.The sterility testing performed on the preparation
    Show answerHide answer

    Correct answer: The retail markup applied to the final preparation

    The retail markup applied to the final preparation is the factor that plays no part: pricing has no bearing on how long a preparation stays sterile and stable. The storage temperature used for the preparation does count, because limits differ for room temperature, refrigerator and freezer storage. The compounding category assigned to the preparation does count, because Category 1, 2 and 3 preparations are made under different environmental and quality controls and carry different maximum dates. The sterility testing performed on the preparation does count, because a preparation that passes sterility testing may be given a longer date within its category.

  114. A pharmacist must understand why intravenous drugs are assigned a bioavailability of 1 (or 100%). What is the correct rationale?

    • A.The whole dose stays in the plasma compartment with no distribution into tissue
    • B.The whole dose is excreted by the kidney with no prior metabolism in the liver
    • C.The whole dose enters the systemic circulation directly with no absorption loss
    • D.The whole dose reaches its receptors at once with no binding to plasma proteins
    Show answerHide answer

    Correct answer: The whole dose enters the systemic circulation directly with no absorption loss

    The whole dose enters the systemic circulation directly with no absorption loss is correct: bioavailability is the fraction of a dose that reaches the systemic circulation unchanged, and an intravenous dose has no membrane to cross and no first-pass metabolism on the way, which makes it the reference for absolute bioavailability. The whole dose stays in the plasma compartment with no distribution into tissue is wrong because it describes a small volume of distribution, a separate property that the route does not determine. The whole dose is excreted by the kidney with no prior metabolism in the liver is wrong because it describes the route of elimination, which follows entry into the circulation. The whole dose reaches its receptors at once with no binding to plasma proteins is wrong because protein binding and receptor access are distribution and pharmacodynamic matters, and intravenous drugs bind plasma proteins like any others.

  115. A drug's absorption is described as dissolution-rate limited. Which property of the dosage form would most improve the rate of absorption?

    • A.Raising the membrane permeability of the drug
    • B.Raising the mean particle size of the drug
    • C.Raising the lipid solubility of the drug
    • D.Raising the dissolution rate of the drug
    Show answerHide answer

    Correct answer: Raising the dissolution rate of the drug

    Raising the dissolution rate of the drug is correct: when dissolution is the slow step, drug crosses the gut wall only as fast as it goes into solution, so micronizing the particles, choosing a more soluble salt or using an amorphous form speeds absorption. Raising the membrane permeability of the drug is wrong because permeation is already faster than dissolution for such a drug, so improving it does not relieve the bottleneck. Raising the mean particle size of the drug is wrong because larger particles have less surface area and dissolve more slowly. Raising the lipid solubility of the drug is wrong because a more lipophilic drug is less soluble in the aqueous gut fluids and dissolves more slowly still.

Medication Use Process (115)

  1. A biosimilar product has been approved by the FDA for the reference biologic adalimumab. Which statement best describes what 'biosimilar' status legally requires of that product?

    • A.It is structurally identical to the reference product, with no variation in amino acid sequence, glycosylation, and folding
    • B.It is bioequivalent to the reference product, with the same active ingredient, dosage form, and route of administration
    • C.It is interchangeable with the reference product, with no added risk in efficacy, immunogenicity, and repeated switching
    • D.It is highly similar to the reference product, with no clinically meaningful differences in safety, purity, and potency
    Show answerHide answer

    Correct answer: It is highly similar to the reference product, with no clinically meaningful differences in safety, purity, and potency

    It is highly similar to the reference product, with no clinically meaningful differences in safety, purity, and potency is correct: this is the standard in the Public Health Service Act, which allows minor differences in clinically inactive components because a large, cell-derived protein cannot be copied exactly. It is structurally identical to the reference product, with no variation in amino acid sequence, glycosylation, and folding is wrong because an identical structure is neither achievable nor required; small differences in features such as glycosylation are expected even between lots of the reference product. It is bioequivalent to the reference product, with the same active ingredient, dosage form, and route of administration is wrong because it states the standard for a small-molecule generic drug under an abbreviated new drug application. It is interchangeable with the reference product, with no added risk in efficacy, immunogenicity, and repeated switching is wrong because interchangeability is a further designation that only some biosimilars hold.

  2. During dispensing, a pharmacist must decide whether a biosimilar may be substituted for its reference biologic without prescriber authorization. Which additional FDA designation is required for that substitution at the pharmacy level?

    • A.Therapeutic equivalence designation
    • B.Fast track designation
    • C.Interchangeability designation
    • D.Priority review designation
    Show answerHide answer

    Correct answer: Interchangeability designation

    Interchangeability designation is correct: a biosimilar that FDA has also found interchangeable may be substituted for its reference product at the pharmacy without the prescriber intervening, subject to state pharmacy law, and such products are listed in the Purple Book. Therapeutic equivalence designation is wrong because therapeutic equivalence codes such as AB are Orange Book ratings for small-molecule generic drugs, not for biologics. Fast track designation is wrong because it speeds the development and review of drugs for serious conditions with unmet need. Priority review designation is wrong because it shortens the FDA review clock for an application; neither has anything to do with substitution.

  3. A patient asks why their insulin glargine 'follow-on' product was allowed to be dispensed in place of the originator product at the pharmacy without calling the doctor. The most accurate explanation is that the product carries which status?

    • A.An authorized generic
    • B.An orphan-designated biosimilar
    • C.An interchangeable biosimilar
    • D.An AB-rated generic
    Show answerHide answer

    Correct answer: An interchangeable biosimilar

    The status is an interchangeable biosimilar. Insulins are regulated as biologics, and a pharmacist may substitute for the prescribed reference biologic without contacting the prescriber only when FDA has found the follow-on product interchangeable, as listed in the Purple Book, and state law allows it. An orphan-designated biosimilar is wrong because orphan designation is an incentive for developing drugs for rare diseases and says nothing about substitution. An AB-rated generic is wrong because AB ratings come from the Orange Book and apply to small-molecule generics, not to biologics such as insulin glargine. An authorized generic is wrong because an authorized generic is the brand company's own small-molecule drug sold without the brand name, which is not the pathway that follow-on insulins use.

  4. Which feature of biosimilar naming is intended to help with tracking and pharmacovigilance during the medication-use process?

    • A.A four-letter prefix added to the core nonproprietary name
    • B.A four-letter suffix added to the core nonproprietary name
    • C.A four-letter suffix added to the assigned proprietary name
    • D.A four-letter prefix added to the assigned proprietary name
    Show answerHide answer

    Correct answer: A four-letter suffix added to the core nonproprietary name

    The feature is a four-letter suffix added to the core nonproprietary name. FDA gives each biological product a proper name made of the shared core name plus a hyphen and four lowercase letters with no meaning, as in infliximab-dyyb, so that a prescription, a dispensing record or an adverse-event report can be tied to one specific product. A four-letter prefix added to the core nonproprietary name is wrong because the distinguishing letters follow the core name; they do not come before it. A four-letter suffix added to the assigned proprietary name is wrong because the suffix belongs to the nonproprietary name, and the brand name is a separate identifier chosen by the company. A four-letter prefix added to the assigned proprietary name is wrong on both counts: the letters are a suffix, and they are attached to the nonproprietary name.

  5. What is a biosimilar?

    • A.A biologic structurally identical to its reference product, with no detectable molecular variation
    • B.A biologic engineered to outperform its reference product, with no added safety concerns
    • C.A biologic highly similar to its reference product, with no clinically meaningful differences
    • D.A biologic compounded to match its reference product, with no premarket approval needed
    Show answerHide answer

    Correct answer: A biologic highly similar to its reference product, with no clinically meaningful differences

    A biosimilar is a biologic highly similar to its reference product, with no clinically meaningful differences in safety, purity and potency; that is the definition in the Biologics Price Competition and Innovation Act. "A biologic structurally identical to its reference product, with no detectable molecular variation" is wrong because large proteins made in living cells cannot be copied exactly; identity of the active ingredient is the standard for small-molecule generics, while biosimilars are allowed minor differences in clinically inactive components. "A biologic engineered to outperform its reference product, with no added safety concerns" is wrong because it describes what is often called a biobetter, which is a new product needing its own full application, not a biosimilar. "A biologic compounded to match its reference product, with no premarket approval needed" is wrong because a biosimilar is an FDA-licensed manufactured product approved through the abbreviated 351(k) pathway, not something prepared in a pharmacy.

  6. A pharmacy receives a biosimilar that is NOT designated interchangeable, but the prescription is written for the reference biologic. What is the appropriate action in the medication-use process?

    • A.Obtain prescriber approval before dispensing the biosimilar
    • B.Obtain patient consent before dispensing the biosimilar
    • C.Confirm formulary coverage before dispensing the biosimilar
    • D.Confirm matching strength before dispensing the biosimilar
    Show answerHide answer

    Correct answer: Obtain prescriber approval before dispensing the biosimilar

    The pharmacist should obtain prescriber approval before dispensing the biosimilar. Only a product that FDA has designated interchangeable may be substituted for the prescribed reference biologic at the pharmacy, so a biosimilar without that designation needs the prescriber to authorize the change or write a new prescription for it. To obtain patient consent before dispensing the biosimilar is not enough, because the patient's agreement does not replace the prescriber's order. To confirm formulary coverage before dispensing the biosimilar is not enough, because a plan's preference for the biosimilar is a payment matter and gives no legal authority to substitute. To confirm matching strength before dispensing the biosimilar is not enough either: the same strength and dosage form do not make a non-interchangeable biosimilar substitutable.

  7. Which of the following is an accurate distinction between a biosimilar and a generic drug as it affects substitution decisions?

    • A.Biosimilars need analytical, nonclinical and often clinical comparison with a reference product, while generics need proof of bioequivalence for an identical active ingredient
    • B.Generics need analytical, nonclinical and often clinical comparison with a reference product, while biosimilars need proof of bioequivalence for an identical active ingredient
    • C.Biosimilars and generics both need analytical, nonclinical and often clinical comparison with a reference product
    • D.Biosimilars and generics both need proof of bioequivalence for an identical active ingredient
    Show answerHide answer

    Correct answer: Biosimilars need analytical, nonclinical and often clinical comparison with a reference product, while generics need proof of bioequivalence for an identical active ingredient

    The accurate statement is "Biosimilars need analytical, nonclinical and often clinical comparison with a reference product, while generics need proof of bioequivalence for an identical active ingredient". A biosimilar is a large, complex protein that cannot be copied exactly, so its sponsor builds a stepwise case of high similarity to the reference product, whereas a generic contains the same small-molecule active ingredient and is approved on bioequivalence. "Generics need analytical, nonclinical and often clinical comparison with a reference product, while biosimilars need proof of bioequivalence for an identical active ingredient" reverses the two pathways. "Biosimilars and generics both need analytical, nonclinical and often clinical comparison with a reference product" is wrong because generics are not put through that comparability program; an abbreviated new drug application rests on pharmaceutical equivalence and bioequivalence. "Biosimilars and generics both need proof of bioequivalence for an identical active ingredient" is wrong because a biosimilar's active ingredient is highly similar, not identical, so bioequivalence alone cannot support its approval. This is why a generic is substituted under its Orange Book rating, while a biosimilar is substituted at the pharmacy only when it is also designated interchangeable.

  8. A hospital's pharmacy and therapeutics committee approves dispensing pantoprazole whenever esomeprazole is ordered, based on equivalent therapeutic outcomes within the proton pump inhibitor class. This practice is best described as which element of the medication-use process?

    • A.Therapeutic equivalence
    • B.Therapeutic duplication
    • C.Therapeutic drug monitoring
    • D.Therapeutic interchange
    Show answerHide answer

    Correct answer: Therapeutic interchange

    This is therapeutic interchange: dispensing a chemically different drug from the same class in place of the one ordered, under a protocol the pharmacy and therapeutics committee has approved in advance. Therapeutic equivalence is wrong because it is the Orange Book finding that two products with the same active ingredient, strength, dosage form and route can be substituted for each other, which is the basis of generic substitution; pantoprazole and esomeprazole are different active ingredients. Therapeutic duplication is wrong because it is a drug-utilization problem in which a patient receives two agents from the same class at the same time. Therapeutic drug monitoring is wrong because it means measuring drug concentrations to adjust a dose.

  9. Which requirement most distinguishes therapeutic interchange from ordinary generic substitution?

    • A.An Orange Book rating or state formulary listing, because a bioequivalent generic is dispensed
    • B.A Purple Book listing or interchangeable designation, because a licensed biosimilar is dispensed
    • C.A prior authorization or step-therapy edit, because a non-formulary drug is dispensed
    • D.An approved protocol or prescriber agreement, because a chemically distinct drug is dispensed
    Show answerHide answer

    Correct answer: An approved protocol or prescriber agreement, because a chemically distinct drug is dispensed

    What sets therapeutic interchange apart is the need for an approved protocol or prescriber agreement, because a chemically distinct drug is dispensed. The patient receives a different active ingredient from the one prescribed, so the exchange has to be authorized in advance, usually by a pharmacy and therapeutics committee protocol, or agreed by the prescriber. "An Orange Book rating or state formulary listing, because a bioequivalent generic is dispensed" describes ordinary generic substitution, in which the same active ingredient is supplied. "A Purple Book listing or interchangeable designation, because a licensed biosimilar is dispensed" describes substitution of an interchangeable biological product, which is a separate legal mechanism. "A prior authorization or step-therapy edit, because a non-formulary drug is dispensed" describes insurance utilization management, which decides what a plan will pay for and does not authorize a pharmacist to change the drug.

  10. A formulary therapeutic-interchange protocol converts all ordered histamine-2 antagonists to famotidine. Before dispensing famotidine for an ordered ranitidine, the pharmacist should primarily verify that:

    • A.The protocol covers the order and the dose is copied from ranitidine
    • B.The protocol covers the order and the dose is converted for famotidine
    • C.The Orange Book rates the drugs AB and the dose is converted for famotidine
    • D.The Orange Book rates the drugs AB and the dose is copied from ranitidine
    Show answerHide answer

    Correct answer: The protocol covers the order and the dose is converted for famotidine

    The pharmacist should verify that "the protocol covers the order and the dose is converted for famotidine". Therapeutic interchange is lawful only inside the approved protocol, and drugs in one class are not equal milligram for milligram: ranitidine 150 mg corresponds to about famotidine 20 mg, so the dose has to be converted, with attention to renal function. "The protocol covers the order and the dose is copied from ranitidine" is wrong because carrying the ranitidine milligram dose over to famotidine would be a large overdose. "The Orange Book rates the drugs AB and the dose is converted for famotidine" is wrong because AB ratings apply only to products with the same active ingredient, so the Orange Book never rates ranitidine against famotidine. "The Orange Book rates the drugs AB and the dose is copied from ranitidine" is wrong for both reasons: it relies on a rating that does not exist and skips the dose conversion.

  11. A prescription is presented for a drug with a high potential for abuse and currently NO accepted medical use in the United States. Into which controlled-substance schedule does this drug fall, and how should the pharmacy handle the prescription?

    • A.Schedule II; it cannot be dispensed on a telephoned prescription
    • B.Schedule III; it can be refilled on a written prescription
    • C.Schedule V; it can be refilled on a telephoned prescription
    • D.Schedule I; it cannot be dispensed on a regular prescription
    Show answerHide answer

    Correct answer: Schedule I; it cannot be dispensed on a regular prescription

    The answer is "Schedule I; it cannot be dispensed on a regular prescription". High abuse potential with no currently accepted medical use in the United States defines Schedule I, and those substances may be used only in registered research, so a prescription for one cannot be filled. "Schedule II; it cannot be dispensed on a telephoned prescription" is wrong because Schedule II drugs also have high abuse potential but do have an accepted medical use. "Schedule III; it can be refilled on a written prescription" and "Schedule V; it can be refilled on a telephoned prescription" are wrong because Schedules III and V cover drugs with accepted medical uses and lower abuse potential; the prescription rules they quote belong to those schedules and not to the drug described.

  12. Under federal controlled-substance rules, which schedule of prescription may NOT be refilled at all?

    • A.Schedule III
    • B.Schedule IV
    • C.Schedule V
    • D.Schedule II
    Show answerHide answer

    Correct answer: Schedule II

    Schedule II is the answer: federal law prohibits refilling a Schedule II prescription, so every fill needs a new prescription, although a prescriber may issue several prescriptions at once for up to a 90-day supply, each with its own earliest fill date. Schedule III and Schedule IV prescriptions may be refilled up to five times within six months of the date of issue, and Schedule V prescriptions may be refilled as the prescriber authorizes.

  13. A Schedule III or IV controlled-substance prescription that authorizes refills may be refilled a maximum of how many times and within what period under federal law?

    • A.Up to five refills within twelve months of the date issued
    • B.Up to five refills within six months of the date issued
    • C.Up to eleven refills within six months of the date issued
    • D.Up to eleven refills within twelve months of the date issued
    Show answerHide answer

    Correct answer: Up to five refills within six months of the date issued

    The federal limit is "up to five refills within six months of the date issued", whichever comes first; after that a new prescription is required. "Up to five refills within twelve months of the date issued" has the right number of refills but doubles the period. "Up to eleven refills within six months of the date issued" keeps the six-month period but borrows the refill count commonly written on a year's supply of a non-controlled drug. "Up to eleven refills within twelve months of the date issued" describes that typical one-year non-controlled prescription and is wrong on both the number and the time limit.

  14. Pregabalin, an agent with lower abuse potential than benzodiazepines but still federally controlled, is classified in which schedule, affecting how the pharmacy stores and tracks it?

    • A.Schedule I
    • B.Schedule II
    • C.Schedule V
    • D.Schedule IV
    Show answerHide answer

    Correct answer: Schedule V

    Pregabalin is in Schedule V, the least restrictive federal schedule, so it still has to be inventoried and recorded as a controlled substance. Schedule IV is where the benzodiazepines themselves sit, and the question places pregabalin below them in abuse potential. Schedule II holds the drugs with the highest abuse potential that still have a medical use, such as oxycodone and methylphenidate. Schedule I is reserved for substances with no accepted medical use, and pregabalin is an approved medicine.

  15. Which factor primarily determines the controlled-substance schedule assigned to a drug during regulatory classification?

    • A.Its overdose and toxicity risk, weighed against its clinical benefit
    • B.Its pharmacologic class and mechanism, weighed against its existing alternatives
    • C.Its street price and diversion rate, weighed against its legitimate sales
    • D.Its abuse and dependence potential, weighed against its accepted medical use
    Show answerHide answer

    Correct answer: Its abuse and dependence potential, weighed against its accepted medical use

    A drug is scheduled mainly on its abuse and dependence potential, weighed against its accepted medical use. The Controlled Substances Act sorts drugs by how likely they are to be abused, how severe the physical or psychological dependence can be, and whether there is a currently accepted medical use in the United States. "Its overdose and toxicity risk, weighed against its clinical benefit" is wrong because a drug can be very toxic in overdose and still be unscheduled, as acetaminophen and digoxin are. "Its pharmacologic class and mechanism, weighed against its existing alternatives" is wrong because members of one class can sit in different schedules; opioids are found in Schedules II through V. "Its street price and diversion rate, weighed against its legitimate sales" is wrong because market figures are not the statutory test, even though evidence of actual abuse is considered.

  16. A patient brings a prescription for a Schedule II opioid that the prescriber transmitted as a paper prescription. Which handling requirement applies during the dispensing process?

    • A.A written or electronic prescription, with five refills permitted
    • B.A written or electronic prescription, with no refills permitted
    • C.A written or telephoned prescription, with no refills permitted
    • D.A written or telephoned prescription, with five refills permitted
    Show answerHide answer

    Correct answer: A written or electronic prescription, with no refills permitted

    The requirement is "a written or electronic prescription, with no refills permitted". A Schedule II drug may be dispensed only on a signed written prescription or a compliant electronic one, and each fill needs a new prescription. "A written or electronic prescription, with five refills permitted" is wrong because the five-refills-in-six-months allowance belongs to Schedules III and IV. "A written or telephoned prescription, with no refills permitted" is wrong because an oral order for a Schedule II drug is accepted only in a true emergency, for the amount needed to cover the emergency and with a written prescription to follow within seven days; it is not a routine way to prescribe. "A written or telephoned prescription, with five refills permitted" is wrong on both points.

  17. How does the federal refill limit for Schedule V controlled substances generally compare with that for Schedule II substances?

    • A.Schedule II allows authorized refills and Schedule V bars refills
    • B.Schedule II and Schedule V both allow authorized refills
    • C.Schedule V allows authorized refills and Schedule II bars refills
    • D.Schedule V and Schedule II both bar authorized refills
    Show answerHide answer

    Correct answer: Schedule V allows authorized refills and Schedule II bars refills

    The correct comparison is "Schedule V allows authorized refills and Schedule II bars refills". A Schedule V prescription may be refilled as the prescriber authorizes, while federal law prohibits any refill of a Schedule II prescription, reflecting the fall in abuse potential from Schedule II to Schedule V. "Schedule II allows authorized refills and Schedule V bars refills" turns the two rules around. "Schedule II and Schedule V both allow authorized refills" is wrong because a Schedule II prescription can never carry refills. "Schedule V and Schedule II both bar authorized refills" is wrong because it applies the Schedule II prohibition to the least restrictive schedule.

  18. Before administering an intramuscular influenza vaccine to an adult in the deltoid, which needle and site technique is most appropriate for a typical-weight adult?

    • A.A 1-inch to 1.5-inch needle at a 45-degree angle
    • B.A 1/2-inch to 5/8-inch needle at a 90-degree angle
    • C.A 1/2-inch to 5/8-inch needle at a 45-degree angle
    • D.A 1-inch to 1.5-inch needle at a 90-degree angle
    Show answerHide answer

    Correct answer: A 1-inch to 1.5-inch needle at a 90-degree angle

    The right technique is "a 1-inch to 1.5-inch needle at a 90-degree angle": an intramuscular injection goes straight into the deltoid, and a typical-weight adult needs a needle of about that length to pass through the subcutaneous fat and reach the muscle. "A 1-inch to 1.5-inch needle at a 45-degree angle" is wrong because a 45-degree angle is used for subcutaneous injections. "A 1/2-inch to 5/8-inch needle at a 90-degree angle" is wrong because so short a needle is likely to leave the vaccine in the subcutaneous tissue of an adult of typical weight. "A 1/2-inch to 5/8-inch needle at a 45-degree angle" describes subcutaneous technique as a whole, which is used for vaccines such as MMR and varicella and not for an intramuscular influenza vaccine.

  19. A pharmacist is preparing to vaccinate a patient and must confirm appropriateness. Which screening element is most directly part of safe immunization administration?

    • A.Recording temperature and pulse, including a repeat set of vital signs for the visibly anxious or flushed patient
    • B.Reviewing contraindications and precautions, including a severe allergic reaction to the vaccine or a component
    • C.Ordering titers and serology, including a urine or serum pregnancy test before each dose in a series
    • D.Deferring for illness and antibiotics, including a patient with a low-grade fever or a mild cold
    Show answerHide answer

    Correct answer: Reviewing contraindications and precautions, including a severe allergic reaction to the vaccine or a component

    The screening step is "reviewing contraindications and precautions, including a severe allergic reaction to the vaccine or a component". A standard screening questionnaire is used before every dose to find contraindications and precautions, and a severe allergic reaction such as anaphylaxis after an earlier dose or to a component is a contraindication to that vaccine. "Recording temperature and pulse, including a repeat set of vital signs for the visibly anxious or flushed patient" is wrong because routine vital signs are not required before vaccination. "Ordering titers and serology, including a urine or serum pregnancy test before each dose in a series" is wrong because laboratory testing is not a routine part of screening; the vaccinator asks about pregnancy and immune status and does not test for them. "Deferring for illness and antibiotics, including a patient with a low-grade fever or a mild cold" is wrong because mild illness, with or without low-grade fever, and current antibiotic therapy are not reasons to withhold a vaccine, and treating them as such leads to missed doses.

  20. Which preparedness measure should be immediately available wherever vaccines are administered in a pharmacy to manage a possible anaphylactic reaction?

    • A.Epinephrine for intramuscular injection
    • B.Diphenhydramine for intramuscular injection
    • C.Epinephrine for intravenous injection
    • D.Diphenhydramine for intravenous injection
    Show answerHide answer

    Correct answer: Epinephrine for intramuscular injection

    Epinephrine for intramuscular injection is the answer: it is the first-line treatment for anaphylaxis and is given promptly into the outer thigh, so it must be on hand wherever vaccines are given. Diphenhydramine for intramuscular injection and diphenhydramine for intravenous injection are wrong because an antihistamine eases hives and itching but does not reverse airway swelling or low blood pressure, so it is at most an add-on after epinephrine. Epinephrine for intravenous injection is wrong because the intravenous route carries a risk of dangerous arrhythmias and dosing errors and is kept for monitored settings; the intramuscular route is the standard for first response.

  21. After administering a vaccine, what observation practice is recommended to detect an immediate hypersensitivity reaction such as syncope or anaphylaxis?

    • A.Keep the patient supine for about 60 minutes
    • B.Observe the patient onsite for about 15 minutes
    • C.Telephone the patient once after about 2 hours
    • D.Reassess the patient again after about 48 hours
    Show answerHide answer

    Correct answer: Observe the patient onsite for about 15 minutes

    The recommended practice is to observe the patient onsite for about 15 minutes. Fainting and most immediate allergic reactions happen within minutes of an injection, so the patient stays seated or lying down where staff can see them for roughly a quarter of an hour, and for 30 minutes if there is a history of a serious reaction. "Keep the patient supine for about 60 minutes" is wrong because nobody is routinely kept flat for an hour. "Telephone the patient once after about 2 hours" is wrong because a call two hours later would miss a reaction that occurs in the first few minutes. "Reassess the patient again after about 48 hours" is wrong because a return visit at 48 hours is how a tuberculin skin test is read; it does nothing to detect an immediate reaction.

  22. A pharmacy receives a shipment of a vaccine labeled for refrigerated storage at 2 to 8 degrees Celsius. Which medication-handling practice best preserves its stability before dispensing?

    • A.Keep it in a refrigerator door bin within easy reach and rotate the stock weekly
    • B.Keep it in a dormitory-style refrigerator under the freezer shelf and check the thermometer weekly
    • C.Keep it in a refrigerator set below the stated range and extend the expiry date
    • D.Keep it in a monitored refrigerator within the stated range and log the temperature excursions
    Show answerHide answer

    Correct answer: Keep it in a monitored refrigerator within the stated range and log the temperature excursions

    The best practice is "keep it in a monitored refrigerator within the stated range and log the temperature excursions". A refrigerated vaccine stays potent only between 2 and 8 degrees Celsius, so the unit needs continuous temperature monitoring, and any reading outside the range is documented and acted on before the product is used. "Keep it in a refrigerator door bin within easy reach and rotate the stock weekly" is wrong because door shelves have the least stable temperatures in a refrigerator. "Keep it in a dormitory-style refrigerator under the freezer shelf and check the thermometer weekly" is wrong because dormitory-style units, with a freezer compartment inside the refrigerator, are not acceptable for vaccine storage, and a weekly check is far too infrequent. "Keep it in a refrigerator set below the stated range and extend the expiry date" is wrong because colder is not safer: many refrigerated vaccines are ruined by freezing, and storage conditions never extend the manufacturer's expiration date.

  23. A reconstituted oral antibiotic suspension is labeled stable for 14 days when refrigerated. Which counseling and handling point reflects proper attention to its stability?

    • A.Finish the remaining suspension after the labeled period, even if it takes longer
    • B.Freeze the suspension before the labeled period ends, in case the infection returns
    • C.Discard the remaining suspension after the labeled period, even if doses remain
    • D.Leave the suspension unrefrigerated for the labeled period, in case it thickens when cold
    Show answerHide answer

    Correct answer: Discard the remaining suspension after the labeled period, even if doses remain

    The right counseling point is "discard the remaining suspension after the labeled period, even if doses remain". Once water is added the antibiotic begins to break down, and potency is assured only for the 14 refrigerated days on the label, so whatever is left is thrown away at that point. "Finish the remaining suspension after the labeled period, even if it takes longer" is wrong because it stretches the advice to complete a course into using a product that may no longer be potent. "Freeze the suspension before the labeled period ends, in case the infection returns" is wrong because freezing is not a labeled storage condition and leftover antibiotic should not be saved for a later illness. "Leave the suspension unrefrigerated for the labeled period, in case it thickens when cold" is wrong because the 14-day period applies only under refrigeration; at room temperature the suspension degrades sooner.

  24. Nitroglycerin sublingual tablets are sensitive to which handling factor, requiring storage in their original tightly closed container?

    • A.Risk of explosion from exposure to shock, impact, sparks and static
    • B.Hardening of tablets from exposure to cold, dark, glass and silica
    • C.Loss of potency from exposure to light, heat, air and moisture
    • D.Growth of microbes from exposure to hands, dust, saliva and damp
    Show answerHide answer

    Correct answer: Loss of potency from exposure to light, heat, air and moisture

    The concern is loss of potency from exposure to light, heat, air and moisture. Nitroglycerin is volatile and unstable, so the tablets are kept in the manufacturer's small amber glass bottle with the cap tightly closed and are not moved to a pill organizer or a plastic vial. "Risk of explosion from exposure to shock, impact, sparks and static" is wrong because the nitroglycerin in tablets is diluted and stabilized and is not an explosive hazard. "Hardening of tablets from exposure to cold, dark, glass and silica" is wrong because glass is the proper container and the tablets are not harmed by the dark. "Growth of microbes from exposure to hands, dust, saliva and damp" is wrong because the storage instruction protects potency; it is not an infection-control measure.

  25. Insulin that is currently in use is generally kept at room temperature for a limited number of days, while unopened supply is refrigerated. What is the rationale for this medication-handling approach?

    • A.Room-temperature in-use storage reduces injection-site discomfort while limiting time to preserve potency, and refrigeration preserves unopened stock
    • B.Room-temperature in-use storage speeds subcutaneous absorption while making its effect more predictable, and refrigeration keeps unopened stock from clumping
    • C.Room-temperature in-use storage spares a punctured vial the damage of repeated rewarming, and refrigeration lets unopened stock survive freezing
    • D.Room-temperature in-use storage keeps a punctured vial from contamination, and refrigeration keeps the preservative of unopened stock active
    Show answerHide answer

    Correct answer: Room-temperature in-use storage reduces injection-site discomfort while limiting time to preserve potency, and refrigeration preserves unopened stock

    The rationale is "room-temperature in-use storage reduces injection-site discomfort while limiting time to preserve potency, and refrigeration preserves unopened stock". Cold insulin is more uncomfortable to inject, and most products remain potent for about 28 days at room temperature once in use, so the in-use vial or pen may be kept out for that limited time while the reserve supply stays at 2 to 8 degrees Celsius until its expiration date. "Room-temperature in-use storage speeds subcutaneous absorption while making its effect more predictable, and refrigeration keeps unopened stock from clumping" is wrong because storage temperature is not used to change how insulin is absorbed. "Room-temperature in-use storage spares a punctured vial the damage of repeated rewarming, and refrigeration lets unopened stock survive freezing" is wrong because an in-use vial may go back into the refrigerator, and insulin that has been frozen must be discarded. "Room-temperature in-use storage keeps a punctured vial from contamination, and refrigeration keeps the preservative of unopened stock active" is wrong because a vial is no more sterile at room temperature than in the refrigerator, and the preservative does not depend on cold.

  26. A drug product label states 'protect from light.' Which dispensing practice supports this stability requirement?

    • A.Dispense it in an amber, light-resistant container and advise keeping it out of direct sunlight
    • B.Dispense it in a clear, child-resistant vial and advise keeping it out of reach in a locked cabinet
    • C.Dispense it in a tight, moisture-proof container and advise keeping the desiccant inside
    • D.Dispense it in an insulated, cold-chain pouch and advise keeping it in the refrigerator
    Show answerHide answer

    Correct answer: Dispense it in an amber, light-resistant container and advise keeping it out of direct sunlight

    The practice is to dispense it in an amber, light-resistant container and advise keeping it out of direct sunlight. Amber containers filter the wavelengths that drive photodegradation, and the counseling carries that protection into the home. "Dispense it in a clear, child-resistant vial and advise keeping it out of reach in a locked cabinet" is wrong because a clear vial is not light-resistant, so the product is unprotected whenever it is out of the cabinet. "Dispense it in a tight, moisture-proof container and advise keeping the desiccant inside" is wrong because it answers a different instruction, protect from moisture. "Dispense it in an insulated, cold-chain pouch and advise keeping it in the refrigerator" is wrong because it answers a refrigerated-storage requirement, and cold storage is not what the label asks for.

  27. When dispensing intact, final-dosage-form hazardous drug tablets that do not require manipulation, USP 800 generally permits which approach to handling?

    • A.An externally vented containment primary engineering control for the activity
    • B.An enclosed negative pressure containment secondary engineering control for the activity
    • C.An added containment layer of closed-system drug-transfer devices for the activity
    • D.An assessment of risk allowing alternative containment strategies for the activity
    Show answerHide answer

    Correct answer: An assessment of risk allowing alternative containment strategies for the activity

    USP 800 permits an assessment of risk allowing alternative containment strategies for the activity. For final dosage forms that only need to be counted or repackaged, the entity may document an assessment of risk covering the drug, its dosage form, the risk of exposure, the packaging and the manipulation, and from it set alternative containment strategies and work practices; the assessment is reviewed at least every 12 months. "An externally vented containment primary engineering control for the activity" and "An enclosed negative pressure containment secondary engineering control for the activity" are wrong because the ventilated hood and the negative-pressure room are the controls required for manipulating hazardous drugs, such as compounding, and not for every activity involving intact tablets. "An added containment layer of closed-system drug-transfer devices for the activity" is wrong because closed-system drug-transfer devices are used when compounding and administering injectable hazardous drugs.

  28. A technician counting hazardous drug tablets at the dispensing bench should follow which USP 800-aligned practice?

    • A.Count hazardous drugs with dedicated tools and wear personal protective equipment
    • B.Count hazardous drugs in the automated machine and wear chemotherapy-tested gloves
    • C.Count hazardous drugs with shared trays and wear a standard lab coat
    • D.Count hazardous drugs in the horizontal laminar-flow hood and wear a surgical mask
    Show answerHide answer

    Correct answer: Count hazardous drugs with dedicated tools and wear personal protective equipment

    The practice is "count hazardous drugs with dedicated tools and wear personal protective equipment". Counting trays and spatulas used for hazardous drugs are kept for that purpose and decontaminated after use, and the technician wears the protective equipment the entity specifies, such as chemotherapy-tested gloves. "Count hazardous drugs in the automated machine and wear chemotherapy-tested gloves" is wrong because automated counting machines stress the tablets and spread drug powder; antineoplastic tablets and capsules must not be placed in them. "Count hazardous drugs with shared trays and wear a standard lab coat" is wrong because a shared tray carries residue to other patients' medications and a cloth lab coat is not protective equipment for hazardous drugs. "Count hazardous drugs in the horizontal laminar-flow hood and wear a surgical mask" is wrong because a horizontal laminar-flow hood blows air toward the worker and a surgical mask gives no respiratory protection against drug particles.

  29. Which document does USP 800 require an organization to maintain that lists the hazardous drugs it handles and informs the controls used during the medication-use process?

    • A.An entity-maintained list of hazardous drugs drawn from the EPA waste list
    • B.An entity-maintained list of hazardous drugs drawn from the ISMP high-alert list
    • C.An entity-maintained list of hazardous drugs drawn from the DEA schedules
    • D.An entity-maintained list of hazardous drugs drawn from the NIOSH list
    Show answerHide answer

    Correct answer: An entity-maintained list of hazardous drugs drawn from the NIOSH list

    USP 800 requires "an entity-maintained list of hazardous drugs drawn from the NIOSH list": the entity identifies which drugs on the current NIOSH list of hazardous drugs in healthcare settings it actually handles, keeps that list, and reviews it at least every 12 months and whenever a new drug or dosage form is added. "An entity-maintained list of hazardous drugs drawn from the EPA waste list" is wrong because the EPA lists of hazardous wastes govern how pharmaceutical waste is discarded, not which drugs are an occupational hazard to staff. "An entity-maintained list of hazardous drugs drawn from the ISMP high-alert list" is wrong because high-alert medications are those that cause serious patient harm when used in error, a different concept from occupational hazard. "An entity-maintained list of hazardous drugs drawn from the DEA schedules" is wrong because controlled-substance scheduling is based on abuse potential.

  30. During prescription validation, a pharmacist notices that a written prescription lacks the patient's date of birth and the drug strength. What is the most appropriate next step in the medication-use process?

    • A.Confirm the missing elements with the patient before dispensing
    • B.Clarify the missing elements with the prescriber before dispensing
    • C.Dispense the lowest marketed strength and document the gap afterward
    • D.Dispense the strength last filled on the profile and document the gap afterward
    Show answerHide answer

    Correct answer: Clarify the missing elements with the prescriber before dispensing

    The next step is to clarify the missing elements with the prescriber before dispensing. A prescription must identify the patient and state the drug and its strength, and the pharmacist cannot supply a missing strength by inference, so the prescriber is contacted and the clarification is documented. To confirm the missing elements with the patient before dispensing is wrong because the patient can give a date of birth but cannot authorize a drug strength. To dispense the lowest marketed strength and document the gap afterward is wrong because it is a guess, and the lowest strength may underdose the patient or be multiplied wrongly by the directions. To dispense the strength last filled on the profile and document the gap afterward is wrong because the prescriber may have meant to change the dose, so an old fill is not evidence of the current order.

  31. A pharmacist performing the final verification (check) step of dispensing is primarily responsible for confirming which of the following?

    • A.The product, strength, quantity and label match the verified prescription
    • B.The payer, copay, days supply and refill count match the adjudicated claim
    • C.The lot, expiry, wholesaler and case count match the receiving invoice
    • D.The name, address, birthdate and signature match the photo identification
    Show answerHide answer

    Correct answer: The product, strength, quantity and label match the verified prescription

    At final verification the pharmacist confirms that "the product, strength, quantity and label match the verified prescription"; this product check is the last safeguard before the medication reaches the patient. "The payer, copay, days supply and refill count match the adjudicated claim" is wrong because it describes billing reconciliation, which does not establish that the right medication is in the container. "The lot, expiry, wholesaler and case count match the receiving invoice" is wrong because it describes checking in a wholesaler delivery. "The name, address, birthdate and signature match the photo identification" is wrong because it describes an identity check at pickup, which comes after the pharmacist's verification of the filled prescription.

  32. A community pharmacy uses barcode scanning at the point of dispensing. Which medication-use error does this technology most directly help prevent?

    • A.Pulling the wrong product from the shelf
    • B.Typing the wrong directions from the script
    • C.Counting the wrong quantity from the bottle
    • D.Calculating the wrong dose from the weight
    Show answerHide answer

    Correct answer: Pulling the wrong product from the shelf

    Barcode scanning most directly prevents pulling the wrong product from the shelf: the scanner compares the National Drug Code on the stock bottle with the product chosen for the prescription and stops the fill when they do not match. Typing the wrong directions from the script is a data-entry error, which a scan of the stock bottle cannot detect. Counting the wrong quantity from the bottle is a counting error, since the barcode identifies the product and not how many units were dispensed. Calculating the wrong dose from the weight is a prescribing or dose-checking error that is caught by clinical review.

  33. Tall man lettering, such as writing predniSONE and prednisoLONE, is used in the dispensing process primarily to reduce which type of error?

    • A.Trailing-zero and leading-zero decimal dose errors
    • B.Look-alike and sound-alike drug selection errors
    • C.Wrong-route and wrong-time dose administration errors
    • D.Wrong-patient and wrong-bag prescription pickup errors
    Show answerHide answer

    Correct answer: Look-alike and sound-alike drug selection errors

    Tall man lettering targets look-alike and sound-alike drug selection errors: capitalizing the letters that differ, as in predniSONE and prednisoLONE, makes two similar names easier to tell apart on shelf labels, computer screens and prescription labels. Trailing-zero and leading-zero decimal dose errors are prevented by writing a zero before a decimal point and never after a whole number. Wrong-route and wrong-time dose administration errors are prevented by clear directions and checks at administration. Wrong-patient and wrong-bag prescription pickup errors are prevented by confirming two patient identifiers at the point of sale.

  34. A prescription order reads 'metoprolol 25 mg, take 1 tablet QD.' Before dispensing, the pharmacist should be alert that the abbreviation 'QD' appears on error-prone abbreviation lists because it may be misread as which of the following?

    • A.TID (three times daily)
    • B.QID (four times daily)
    • C.Q8H (every eight hours)
    • D.Q12H (every twelve hours)
    Show answerHide answer

    Correct answer: QID (four times daily)

    The abbreviation can be read as QID (four times daily): a period or a stray pen stroke after the Q looks like an I, and the patient then receives four times the intended daily dose. TID (three times daily) is wrong because nothing in a handwritten QD resembles a T, and Q8H (every eight hours) and Q12H (every twelve hours) are wrong because each needs a numeral that QD does not contain. Writing out the word daily removes the risk.

  35. Which independent double-check is most appropriate during the dispensing of high-alert medications such as concentrated insulin or anticoagulants?

    • A.A second qualified person simply countersigns the drug, dose and calculation
    • B.A second qualified person separately verifies the drug, dose and calculation
    • C.The same dispensing pharmacist separately rechecks the drug, dose and calculation
    • D.The same dispensing pharmacist later rechecks the drug, dose and calculation
    Show answerHide answer

    Correct answer: A second qualified person separately verifies the drug, dose and calculation

    The appropriate check is "a second qualified person separately verifies the drug, dose and calculation". The second person works without being told the first person's result, so the two are unlikely to make the same mistake. "A second qualified person simply countersigns the drug, dose and calculation" is wrong because a checker who signs off on the answer shown tends to confirm it, which is confirmation bias and not an independent check. "The same dispensing pharmacist separately rechecks the drug, dose and calculation" and "The same dispensing pharmacist later rechecks the drug, dose and calculation" are wrong because someone rechecking their own work tends to repeat the same error, however carefully or however much later it is done.

  36. A patient's electronic prescription is transmitted with a directions field reading 'take as directed.' Why is this a concern during the medication-use process?

    • A.Vague directions raise the risk of misunderstanding and administration errors
    • B.Vague directions void the prescription under federal and state rules
    • C.Vague directions shift the burden of dosing decisions and liability to the pharmacist
    • D.Vague directions are required for all controlled substances under the federal and state rules
    Show answerHide answer

    Correct answer: Vague directions raise the risk of misunderstanding and administration errors

    The concern is that "vague directions raise the risk of misunderstanding and administration errors". The label is the patient's main reference at home, and 'take as directed' leaves the dose, frequency and duration to memory; the pharmacist also cannot fully check the dose or counsel on it. "Vague directions void the prescription under federal and state rules" is wrong because the wording of the directions does not by itself make a prescription void. "Vague directions shift the burden of dosing decisions and liability to the pharmacist" is wrong because the prescriber and the pharmacist each keep their own responsibility for safe use. "Vague directions are required for all controlled substances under the federal and state rules" is wrong because no rule requires this wording for controlled substances; clear directions for use are expected on every prescription.

  37. A patient asks how to safely dispose of unused controlled-substance tablets. Which option best reflects current recommended medication-disposal practice?

    • A.Return them to a local pharmacy counter or an authorized prescriber when unopened
    • B.Crush them to a powder and rinse it down the sink or the toilet
    • C.Take them to a drug take-back program or an authorized collector when available
    • D.Mail them to the manufacturer or the DEA field office in a padded envelope
    Show answerHide answer

    Correct answer: Take them to a drug take-back program or an authorized collector when available

    The recommended practice is to take them to a drug take-back program or an authorized collector when available. Take-back events, and collection receptacles or mail-back packages run by collectors registered with the DEA, remove the tablets from the home without risk of diversion or environmental release. "Return them to a local pharmacy counter or an authorized prescriber when unopened" is wrong because only a pharmacy registered as an authorized collector may accept controlled substances from patients, prescribers do not take them back, and returned drugs are never dispensed again. "Crush them to a powder and rinse it down the sink or the toilet" is wrong because crushing is not advised, and flushing is kept for the specific drugs on the FDA flush list when no take-back option is available. "Mail them to the manufacturer or the DEA field office in a padded envelope" is wrong because neither manufacturers nor DEA offices accept patients' leftover tablets by ordinary mail.

  38. Certain hazardous medications carry specific FDA flush-list disposal instructions when no take-back option is available. The rationale for this targeted instruction is primarily to:

    • A.Prevent landfill or groundwater pollution from slow breakdown or leaching of unusually persistent drugs
    • B.Prevent civil or criminal liability from improper storage or transfer of patient-held controlled drugs
    • C.Prevent death or serious harm from accidental ingestion or misuse of especially dangerous drugs
    • D.Prevent skin or inhalation exposure from torn bags or spills of discarded hazardous drugs
    Show answerHide answer

    Correct answer: Prevent death or serious harm from accidental ingestion or misuse of especially dangerous drugs

    The purpose is to prevent death or serious harm from accidental ingestion or misuse of especially dangerous drugs. The flush list is short and consists mostly of potent opioids, such as fentanyl patches, where a single dose can kill a child, a pet or someone who takes it by mistake; for those drugs FDA judges the risk of keeping them in the home to outweigh the small environmental effect of flushing. "Prevent landfill or groundwater pollution from slow breakdown or leaching of unusually persistent drugs" is wrong because flushing does not protect the environment; it is accepted in spite of the environmental concern. "Prevent civil or criminal liability from improper storage or transfer of patient-held controlled drugs" is wrong because the list is a safety measure and has nothing to do with a patient's legal liability. "Prevent skin or inhalation exposure from torn bags or spills of discarded hazardous drugs" is wrong because exposure of waste handlers is not the basis of the list.

  39. A formulary committee evaluates switching all patients from a reference infliximab product to an interchangeable biosimilar. Which is the most accurate statement about the clinical evidence standard supporting interchangeability?

    • A.Switching studies may be needed to show that alternating with the biosimilar gives better outcomes than the reference product alone
    • B.Switching patients off the reference product for a year converts biosimilar approval into interchangeable status
    • C.Switching studies may be needed to show that alternating with the biosimilar adds no risk beyond the reference product alone
    • D.Switching patients from the reference product is supported by the biosimilar approval itself, needing no further evidence
    Show answerHide answer

    Correct answer: Switching studies may be needed to show that alternating with the biosimilar adds no risk beyond the reference product alone

    The accurate statement is "switching studies may be needed to show that alternating with the biosimilar adds no risk beyond the reference product alone". For a product given more than once, the interchangeability standard is that the risk in safety or reduced efficacy of alternating or switching between the biosimilar and the reference product is no greater than the risk of using the reference product without switching, and sponsors have often addressed this with dedicated switching studies. "Switching studies may be needed to show that alternating with the biosimilar gives better outcomes than the reference product alone" is wrong because the standard is no added risk, not superiority. "Switching patients off the reference product for a year converts biosimilar approval into interchangeable status" is wrong because time on the market does not confer the designation; FDA grants it on review of the sponsor's data. "Switching patients from the reference product is supported by the biosimilar approval itself, needing no further evidence" is wrong because interchangeability is an additional finding beyond biosimilarity.

  40. Which statement about the medication-use handling of biosimilars is correct regarding their indications?

    • A.A biosimilar is approved for all indications of the reference product at launch, with no need for any extrapolation data
    • B.A biosimilar may be approved for just the trial-tested indications of the reference product, with extrapolation barred by statute
    • C.A biosimilar may be approved for some or all indications of the reference product, with extrapolation backed by scientific justification
    • D.A biosimilar is approved for some indications of the reference product at launch, with extrapolation added after one or two postmarketing studies
    Show answerHide answer

    Correct answer: A biosimilar may be approved for some or all indications of the reference product, with extrapolation backed by scientific justification

    The correct statement is "a biosimilar may be approved for some or all indications of the reference product, with extrapolation backed by scientific justification". A sponsor may seek fewer indications than the reference product has, for example because of patents or exclusivity, and FDA may approve an indication that was not studied directly when the sponsor justifies it scientifically, for instance from the mechanism of action, pharmacokinetics and immunogenicity in each condition. "A biosimilar is approved for all indications of the reference product at launch, with no need for any extrapolation data" is wrong because extrapolation is not automatic. "A biosimilar may be approved for just the trial-tested indications of the reference product, with extrapolation barred by statute" is wrong because the law allows extrapolation, which spares the sponsor a trial in every indication. "A biosimilar is approved for some indications of the reference product at launch, with extrapolation added after one or two postmarketing studies" is wrong because no rule holds back indications at first approval or ties extrapolation to postmarketing studies.

  41. A pharmacy must store Schedule II controlled substances. Which storage approach satisfies federal security requirements?

    • A.In a securely locked, substantially constructed cabinet or safe, or dispersed among the noncontrolled stock
    • B.In a clearly labeled, separately shelved bay or bin, or left on an open shelf at the front counter
    • C.In a sturdy, substantially constructed cabinet left unlocked, or grouped on one shelf near the pharmacist station
    • D.In a closed, clearly labeled tote among the will-call bags, or kept in one drawer under the counter
    Show answerHide answer

    Correct answer: In a securely locked, substantially constructed cabinet or safe, or dispersed among the noncontrolled stock

    Federal rules are met by storing them "in a securely locked, substantially constructed cabinet or safe, or dispersed among the noncontrolled stock". A pharmacy may lock its controlled substances away or spread them through the other stock in a way that obstructs theft and diversion. "In a clearly labeled, separately shelved bay or bin, or left on an open shelf at the front counter" is wrong because gathering the Schedule II drugs in a marked, unlocked place makes them easier to find and steal, and an open shelf at the front counter is not secured at all. "In a sturdy, substantially constructed cabinet left unlocked, or grouped on one shelf near the pharmacist station" is wrong because a cabinet has to be locked, and grouping the drugs on one shelf is the opposite of dispersal. "In a closed, clearly labeled tote among the will-call bags, or kept in one drawer under the counter" is wrong because a tote or a drawer is neither a locked, substantially constructed cabinet nor dispersal through the stock.

  42. When transferring a controlled-substance prescription record between pharmacies that share a real-time online database, which controlled schedules are eligible for refill transfer (one time) under federal rules for schedules permitting refills?

    • A.Schedules II, III and V
    • B.Schedules III and IV
    • C.Schedules III, IV and V
    • D.Schedules I, II and III
    Show answerHide answer

    Correct answer: Schedules III, IV and V

    The answer is "Schedules III, IV and V". Under 21 CFR 1306.25, refill information for a controlled-substance prescription may be transferred once between pharmacies, and pharmacies sharing a real-time online database may transfer up to the refills remaining; the rule covers only the schedules that can carry refills. "Schedules II, III and V" is wrong because a Schedule II prescription can never be refilled, so there is no refill to transfer. "Schedules I, II and III" is wrong for the same reason and because Schedule I substances have no accepted medical use and are not prescribed at all. "Schedules III and IV" is incomplete, because a Schedule V prescription that authorizes refills can be transferred in the same way.

  43. A pharmacist receives an emergency oral order for a Schedule II opioid. Which condition applies to lawfully dispensing it?

    • A.The quantity is limited to a thirty-day emergency supply and a written prescription must follow within the required time frame
    • B.The quantity is limited to the emergency period and a pharmacy memo may then stand in for the written prescription
    • C.The quantity is limited to a thirty-day emergency supply and a pharmacy memo may then stand in for the written prescription
    • D.The quantity is limited to the emergency period and a written prescription must follow within the required time frame
    Show answerHide answer

    Correct answer: The quantity is limited to the emergency period and a written prescription must follow within the required time frame

    Federal rules (21 CFR 1306.11) let a pharmacist dispense a Schedule II drug on an emergency oral order under two conditions, so the answer is "The quantity is limited to the emergency period and a written prescription must follow within the required time frame": the amount is limited to what is needed for the emergency, and the prescriber must deliver a written prescription for it within 7 days. "The quantity is limited to a thirty-day emergency supply and a written prescription must follow within the required time frame" gets the follow-up right but the amount wrong, because a routine month of therapy goes beyond the emergency. "The quantity is limited to the emergency period and a pharmacy memo may then stand in for the written prescription" gets the amount right, but the pharmacist's own written record of the call does not stand in for the prescriber's prescription. "The quantity is limited to a thirty-day emergency supply and a pharmacy memo may then stand in for the written prescription" makes both mistakes.

  44. A pharmacist administering vaccines must follow cold-chain requirements. A 'cold-chain break' during vaccine handling most directly threatens which attribute of the product?

    • A.Potency and effectiveness
    • B.Sterility and vial seals
    • C.Identity and traceability
    • D.Fill volume and tonicity
    Show answerHide answer

    Correct answer: Potency and effectiveness

    A cold-chain break most directly threatens potency and effectiveness: heat or freezing can damage the antigen or the adjuvant, so a vaccine that looks unchanged may no longer protect the patient. "Sterility and vial seals" is the tempting choice, but a temperature excursion does not open the container or introduce organisms. "Identity and traceability" depend on the label, lot number and records, which temperature does not alter. "Fill volume and tonicity" are fixed at manufacture and are not what an excursion puts at risk.

  45. Which immunization-administration practice helps prevent a wrong-site or wrong-route error when giving a subcutaneous vaccine?

    • A.Flattening the skin and inserting a long needle at a 90-degree angle into the deltoid muscle
    • B.Holding the forearm skin taut and inserting a fine needle at a 15-degree angle into dermal tissue
    • C.Spreading the thigh skin and inserting a long needle at a 90-degree angle into the muscle
    • D.Pinching the skin and inserting a short needle at a 45-degree angle into subcutaneous tissue
    Show answerHide answer

    Correct answer: Pinching the skin and inserting a short needle at a 45-degree angle into subcutaneous tissue

    For a subcutaneous vaccine the technique is "Pinching the skin and inserting a short needle at a 45-degree angle into subcutaneous tissue": lifting the fatty layer and entering at 45 degrees with a short (5/8-inch) needle keeps the dose out of the muscle beneath. "Flattening the skin and inserting a long needle at a 90-degree angle into the deltoid muscle" and "Spreading the thigh skin and inserting a long needle at a 90-degree angle into the muscle" both describe intramuscular technique, which would deliver the dose by the wrong route. "Holding the forearm skin taut and inserting a fine needle at a 15-degree angle into dermal tissue" is intradermal technique, which places the dose in the skin instead of the tissue under it.

  46. A pharmacy technician enters a new order into the dispensing system. The pharmacist's verification of this entry primarily guards against which step-specific error type?

    • A.Prescribing errors, as the order is generated
    • B.Administration errors, as the order is carried out
    • C.Transcription errors, as the order is entered
    • D.Monitoring errors, as the order is evaluated later
    Show answerHide answer

    Correct answer: Transcription errors, as the order is entered

    Each step of the medication-use process has its own error type, and checking a technician's data entry against the original prescription targets "Transcription errors, as the order is entered": a wrong drug, strength, quantity or set of directions typed in so that the record no longer matches what the prescriber intended. "Prescribing errors, as the order is generated" arise earlier, when the prescriber chooses and writes the therapy; the pharmacist's clinical review addresses those, not the comparison of the entry with the order. "Administration errors, as the order is carried out" happen later, when the ordered dose is given to the patient. "Monitoring errors, as the order is evaluated later" happen later still, when the response to therapy is followed up.

  47. During dispensing, a computerized clinical decision support system fires an alert. To avoid alert fatigue while maintaining safety, the most appropriate professional response is to:

    • A.Click past each alert for a familiar drug and document the reasoning for any override
    • B.Evaluate each clinically significant alert and document the reasoning for any override
    • C.Evaluate each clinically significant alert and treat the notes for any override as optional
    • D.Click past each alert for a familiar drug and treat the notes for any override as optional
    Show answerHide answer

    Correct answer: Evaluate each clinically significant alert and document the reasoning for any override

    The professional response is "Evaluate each clinically significant alert and document the reasoning for any override": the pharmacist weighs the alerts that matter for this patient and, when one is overridden, documents why. "Click past each alert for a familiar drug and document the reasoning for any override" is the habit alert fatigue produces; a reason typed in after the alert was never weighed protects no one. "Evaluate each clinically significant alert and treat the notes for any override as optional" drops the documentation that lets the next pharmacist and any later review see why the alert was set aside. "Click past each alert for a familiar drug and treat the notes for any override as optional" fails on both counts.

  48. A leading-zero/trailing-zero convention recommends writing '0.5 mg' and avoiding '5.0 mg' during order processing. The purpose is to prevent which dispensing error?

    • A.Thousandfold errors from an unclear unit symbol
    • B.Tenfold errors from an overlooked decimal point
    • C.Wrong-drug errors from look-alike product names
    • D.Wrong-frequency errors from Latin abbreviations
    Show answerHide answer

    Correct answer: Tenfold errors from an overlooked decimal point

    The zero conventions prevent "Tenfold errors from an overlooked decimal point": without a leading zero, .5 mg can be read as 5 mg, and with a trailing zero, 5.0 mg can be read as 50 mg. "Thousandfold errors from an unclear unit symbol" are a different problem, addressed by writing mcg instead of the Greek-letter symbol that can be read as mg. "Wrong-drug errors from look-alike product names" are addressed by tall man lettering and separated storage. "Wrong-frequency errors from Latin abbreviations" are addressed by writing 'daily' in place of abbreviations such as QD.

  49. A state's generic-substitution law allows a pharmacist to dispense an AB-rated generic for a brand prescription unless the prescriber indicates otherwise. This authority is best categorized within the medication-use process as:

    • A.Generic substitution with the identical active ingredient
    • B.Therapeutic interchange with the generic of a related drug
    • C.Pharmaceutical alternative with an ester of the generic
    • D.Step therapy with a generic trial under the plan formulary
    Show answerHide answer

    Correct answer: Generic substitution with the identical active ingredient

    This is "Generic substitution with the identical active ingredient": an AB rating in the FDA Orange Book means the generic is therapeutically equivalent to the brand, with the same active ingredient, strength, dosage form and route. "Therapeutic interchange with the generic of a related drug" would mean dispensing a different drug molecule, which needs a protocol or the prescriber's approval and is not what a substitution law permits. "Pharmaceutical alternative with an ester of the generic" describes a product that is not AB-rated to the brand, because a different salt, ester or dosage form is not a pharmaceutical equivalent. "Step therapy with a generic trial under the plan formulary" is a payer coverage rule, not a pharmacist's dispensing authority.

  50. A prescriber writes 'dispense as written' (DAW) on a prescription for a brand-name drug. How should this affect the dispensing decision in a state with generic-substitution allowance?

    • A.Dispense the brand product as specified and do not substitute a generic
    • B.Dispense a generic of the brand product because the written note is not binding
    • C.Dispense the brand product as specified unless the patient picks a generic
    • D.Dispense a generic of the brand product and give written notice later
    Show answerHide answer

    Correct answer: Dispense the brand product as specified and do not substitute a generic

    A valid 'dispense as written' instruction removes the pharmacist's substitution authority, so the answer is "Dispense the brand product as specified and do not substitute a generic". "Dispense a generic of the brand product because the written note is not binding" is wrong because substitution laws apply only when the prescriber has not prohibited substitution. "Dispense the brand product as specified unless the patient picks a generic" starts correctly, but a patient's request does not override the prescriber's instruction; the prescriber would have to change the order. "Dispense a generic of the brand product and give written notice later" is wrong because telling the prescriber later does not make a prohibited substitution lawful.

  51. A small hazardous drug spill occurs at the dispensing area. Which immediate medication-handling response aligns with USP 800 principles?

    • A.Use towels and exam gloves to wipe up the spill, then seal the waste as hazardous
    • B.Use the spill kit and PPE to contain the spread, then seal the waste as hazardous
    • C.Use the spill kit and PPE to contain the spread, then flush hazardous traces away
    • D.Use towels and exam gloves to wipe up the spill, then flush hazardous traces away
    Show answerHide answer

    Correct answer: Use the spill kit and PPE to contain the spread, then seal the waste as hazardous

    USP 800 calls for "Use the spill kit and PPE to contain the spread, then seal the waste as hazardous": the spill is contained and cleaned at once by trained staff using the spill kit and its protective equipment, and everything used goes into hazardous-waste containers. "Use towels and exam gloves to wipe up the spill, then seal the waste as hazardous" gets disposal right but exposes the worker, because ordinary exam gloves and towels are not tested against hazardous drugs. "Use the spill kit and PPE to contain the spread, then flush hazardous traces away" starts correctly but spreads the drug into the drain and onto nearby surfaces. "Use towels and exam gloves to wipe up the spill, then flush hazardous traces away" makes both mistakes.

  52. When wearing chemotherapy gloves for hazardous drug handling, USP 800 supports which practice regarding glove use during the activity?

    • A.Gloves of routine exam-grade latex, changed at set intervals or when contaminated
    • B.Gloves tested to the ASTM standard, wiped with alcohol and worn for a whole shift
    • C.Gloves tested to the ASTM standard, changed at set intervals or when contaminated
    • D.Gloves of routine exam-grade latex, wiped with alcohol and worn for a whole shift
    Show answerHide answer

    Correct answer: Gloves tested to the ASTM standard, changed at set intervals or when contaminated

    USP 800 supports "Gloves tested to the ASTM standard, changed at set intervals or when contaminated": chemotherapy gloves must meet ASTM D6978, and because drug permeation increases with wear time they are changed every 30 minutes unless the manufacturer states otherwise, and whenever torn, punctured or contaminated. "Gloves of routine exam-grade latex, changed at set intervals or when contaminated" has the right schedule but the wrong glove, since ordinary exam gloves are not tested against chemotherapy permeation. "Gloves tested to the ASTM standard, wiped with alcohol and worn for a whole shift" has the right glove, but wiping does not reverse permeation and alcohol can weaken the glove material. "Gloves of routine exam-grade latex, wiped with alcohol and worn for a whole shift" makes both mistakes.

  53. Which vaccine-administration error is most directly prevented by checking the vaccine vial against the order and verifying the diluent (when required) before reconstitution?

    • A.Giving the vaccine by the wrong route or in the wrong site
    • B.Giving the vaccine early or at the wrong age per schedule
    • C.Giving the wrong vaccine or mixing in the wrong diluent
    • D.Giving the vaccine to the wrong patient or recording it on the wrong chart
    Show answerHide answer

    Correct answer: Giving the wrong vaccine or mixing in the wrong diluent

    Comparing the vial with the order and confirming the manufacturer's diluent before reconstitution targets "Giving the wrong vaccine or mixing in the wrong diluent": look-alike vaccine names and packaging, and diluents that are not interchangeable, are caught at exactly this check. "Giving the vaccine by the wrong route or in the wrong site" is prevented by confirming route, needle and site at the time of injection. "Giving the vaccine early or at the wrong age per schedule" is prevented by reviewing the patient's immunization record against the schedule. "Giving the vaccine to the wrong patient or recording it on the wrong chart" is prevented by confirming two patient identifiers.

  54. Cough preparations containing limited amounts of codeine that may, in some states, be sold under specific recordkeeping without a prescription are typically classified in which schedule?

    • A.Schedule III
    • B.Schedule IV
    • C.Schedule II
    • D.Schedule V
    Show answerHide answer

    Correct answer: Schedule V

    The answer is "Schedule V". The Controlled Substances Act places preparations with no more than 200 mg of codeine per 100 mL in the lowest schedule, and some states allow a pharmacist to sell limited quantities without a prescription if the sale is recorded in a bound log. "Schedule III" is the usual trap: it covers the more concentrated codeine combination products, such as tablets with acetaminophen. "Schedule IV" is wrong because it holds drugs such as benzodiazepines and tramadol, not codeine preparations. "Schedule II" is wrong because it covers codeine as a single-entity product.

  55. A pharmacist must decide how many days a Schedule III prescription remains valid for refills. Refills of a Schedule III prescription are limited to a maximum total based on which two constraints?

    • A.Five refills or six months from issue, whichever comes first
    • B.Five refills or one year from issue, whichever comes first
    • C.Eleven refills or six months from issue, whichever comes first
    • D.Eleven refills or one year from issue, whichever comes first
    Show answerHide answer

    Correct answer: Five refills or six months from issue, whichever comes first

    For Schedule III and IV prescriptions, 21 CFR 1306.22 sets the limit at "Five refills or six months from issue, whichever comes first"; once either limit is reached a new prescription is needed. "Five refills or one year from issue, whichever comes first" has the right refill count but borrows the one-year period that many states apply to non-controlled prescriptions. "Eleven refills or six months from issue, whichever comes first" has the right period but the wrong count; eleven refills is a common pattern for a year of a non-controlled maintenance drug. "Eleven refills or one year from issue, whichever comes first" is wrong on both the count and the period.

  56. A vial of reconstituted intravenous antibiotic carries a labeled stability of 24 hours refrigerated. After 30 hours in the refrigerator, what is the correct medication-handling decision?

    • A.Dispense it because clarity shows the labeled stability period still holds
    • B.Freeze it because freezing restarts the labeled stability period
    • C.Discard it because the labeled stability period has been exceeded
    • D.Infuse it because the labeled stability period is not a hard limit
    Show answerHide answer

    Correct answer: Discard it because the labeled stability period has been exceeded

    The decision is "Discard it because the labeled stability period has been exceeded": the label supports 24 hours under refrigeration, and at 30 hours neither potency nor safety can be assured. "Dispense it because clarity shows the labeled stability period still holds" is wrong because chemical degradation is usually invisible, so a clear solution proves nothing. "Freeze it because freezing restarts the labeled stability period" is wrong because freezing cannot recover time already exceeded and is not a labeled storage condition for this vial. "Infuse it because the labeled stability period is not a hard limit" is wrong because the labeled period is the tested limit and carries no grace margin.

  57. Why are many monoclonal antibody and protein-based products required to avoid vigorous shaking during handling?

    • A.Agitation can hydrolyze or oxidize the protein, forming toxic or pyrogenic chain fragments
    • B.Agitation can dissolve or disperse the protein, speeding absorption or lifting peak levels
    • C.Agitation can ionize or neutralize the protein, shifting formulation pH or final tonicity
    • D.Agitation can denature or aggregate the protein, cutting potency or raising immunogenicity
    Show answerHide answer

    Correct answer: Agitation can denature or aggregate the protein, cutting potency or raising immunogenicity

    The reason is "Agitation can denature or aggregate the protein, cutting potency or raising immunogenicity": shear and air-liquid contact unfold these large molecules and make them clump, and aggregates are less active and more likely to trigger an immune response. "Agitation can hydrolyze or oxidize the protein, forming toxic or pyrogenic chain fragments" confuses physical with chemical instability; shaking does not break peptide bonds or produce pyrogens. "Agitation can dissolve or disperse the protein, speeding absorption or lifting peak levels" is wrong because these products are already in solution and shaking does not change their absorption. "Agitation can ionize or neutralize the protein, shifting formulation pH or final tonicity" is wrong because mechanical stress does not alter a buffered solution's pH or tonicity.

  58. At the point of dispensing, an offer to counsel is extended to the patient. From a medication-use-process standpoint, the primary purpose of patient counseling at dispensing is to:

    • A.Promote safe and effective use, including how to take the medication and what to monitor
    • B.Limit legal and regulatory liability, including how and when to document the offer to counsel
    • C.Confirm the diagnosis, including whether the drug and dose chosen suit the condition treated
    • D.Finish product verification, including whether the vial and the label match the order
    Show answerHide answer

    Correct answer: Promote safe and effective use, including how to take the medication and what to monitor

    The primary purpose is "Promote safe and effective use, including how to take the medication and what to monitor"; counseling is the last chance to make sure the patient knows how to use the medication, what effects to expect and what to watch for. "Limit legal and regulatory liability, including how and when to document the offer to counsel" describes documentation of the offer, which is a legal requirement but not the reason counseling exists. "Confirm the diagnosis, including whether the drug and dose chosen suit the condition treated" is wrong because diagnosis belongs to the prescriber, and the pharmacist's review of appropriateness happens before the prescription is filled. "Finish product verification, including whether the vial and the label match the order" describes the final product check, a separate step completed before the patient is counseled.

  59. A pharmacist identifies that a dispensed prescription label lists the wrong directions after the patient has left. Which action best follows safe medication-use-process and error-management principles?

    • A.Contact the patient promptly to rectify the directions, then document the event for error review
    • B.Hand the patient amended directions at the next refill, then document the event for error review
    • C.Contact the patient promptly to rectify the directions, then keep the error off the incident log
    • D.Hand the patient amended directions at the next refill, then keep the error off the incident log
    Show answerHide answer

    Correct answer: Contact the patient promptly to rectify the directions, then document the event for error review

    Sound error management calls for "Contact the patient promptly to rectify the directions, then document the event for error review": the patient may already be taking the medication incorrectly, and reporting the event lets the pharmacy find and fix the cause. "Hand the patient amended directions at the next refill, then document the event for error review" reports the event but leaves the patient following wrong directions for weeks. "Contact the patient promptly to rectify the directions, then keep the error off the incident log" protects this patient but hides the event from the review that prevents a repeat. "Hand the patient amended directions at the next refill, then keep the error off the incident log" fails on both counts.

  60. A medication is dispensed in a unit-dose packaging system in a hospital. A primary medication-use-process advantage of unit-dose distribution is that it:

    • A.Cuts pharmacy workload by assigning dose preparation to nursing units
    • B.Cuts errors and waste by supplying single labeled patient-ready doses
    • C.Cuts product costs by extending repackaged doses to bulk expiry dates
    • D.Cuts delays and calls by keeping multi-day bulk supply at the bedside
    Show answerHide answer

    Correct answer: Cuts errors and waste by supplying single labeled patient-ready doses

    Unit-dose distribution "Cuts errors and waste by supplying single labeled patient-ready doses": each dose arrives identified and ready for administration, so nurses do not measure from bulk containers and unused doses can be returned. "Cuts pharmacy workload by assigning dose preparation to nursing units" is backward, because unit-dose systems move preparation into the pharmacy. "Cuts product costs by extending repackaged doses to bulk expiry dates" is wrong because repackaged doses receive a shorter beyond-use date, not the bulk container's date. "Cuts delays and calls by keeping multi-day bulk supply at the bedside" describes floor stock, the older system that unit dose replaced.

  61. Two products contain the same opioid, but one is combined with acetaminophen and the other is a single-entity formulation. The single-entity opioid is Schedule II while the combination may be Schedule III in some cases. What general principle explains a lower schedule for certain combination products?

    • A.A limited opioid dose combined with non-controlled ingredients can lower the abuse-potential classification
    • B.A second ingredient combined with the opioid dose can interfere with opioid receptors and end the dependence liability
    • C.A combination tablet can take on the schedule of whichever ingredient outweighs the opioid contained in it
    • D.A combination product can acquire an accepted medical use that the opioid lacks as a single-entity product
    Show answerHide answer

    Correct answer: A limited opioid dose combined with non-controlled ingredients can lower the abuse-potential classification

    The principle is "A limited opioid dose combined with non-controlled ingredients can lower the abuse-potential classification": the Controlled Substances Act places certain products with a capped amount of opioid per dosage unit, combined with a therapeutic amount of a non-controlled drug, in a lower schedule because they are judged less liable to abuse. "A second ingredient combined with the opioid dose can interfere with opioid receptors and end the dependence liability" is wrong because acetaminophen has no action at opioid receptors and these products still cause dependence. "A combination tablet can take on the schedule of whichever ingredient outweighs the opioid contained in it" is wrong because scheduling follows the amount and concentration of the controlled drug, not the tablet's bulk. "A combination product can acquire an accepted medical use that the opioid lacks as a single-entity product" is wrong because Schedule II drugs also have an accepted medical use.

  62. A pharmacist counsels a patient being switched to an interchangeable biosimilar. Which counseling point accurately reflects the expected clinical relationship to the reference product?

    • A.No molecular difference from the reference product, as with small-molecule generics
    • B.A weaker or slower response than the reference product as the dosage is titrated upward
    • C.No clinically meaningful difference from the reference product in safety or efficacy
    • D.A gentler side-effect profile than the reference product, at some cost in effectiveness
    Show answerHide answer

    Correct answer: No clinically meaningful difference from the reference product in safety or efficacy

    The accurate counseling point is "No clinically meaningful difference from the reference product in safety or efficacy"; that is the standard a biosimilar must meet for licensure, and an interchangeable product has also been shown to give the same result in any given patient. "No molecular difference from the reference product, as with small-molecule generics" overstates the case: a biosimilar is highly similar to its reference, not an identical copy, because biologics are made in living cells. "A weaker or slower response than the reference product as the dosage is titrated upward" is wrong because the biosimilar is given at the same dose and schedule, with no re-titration. "A gentler side-effect profile than the reference product, at some cost in effectiveness" is wrong because neither safety nor efficacy is expected to differ in a meaningful way.

  63. When repackaging tablets from a bulk bottle into unit-dose blisters, which beyond-use consideration applies to the handling of the repackaged product?

    • A.A beyond-use date set from packaging stability data, capped at the original expiration
    • B.A beyond-use date taken from the original expiration, as the tablets themselves stay intact
    • C.A beyond-use date one year from repackaging, as a sealed blister outlasts the bulk bottle
    • D.A beyond-use date thirty days from dispensing, with blister stock dated at the point of use
    Show answerHide answer

    Correct answer: A beyond-use date set from packaging stability data, capped at the original expiration

    Repackaged tablets need "A beyond-use date set from packaging stability data, capped at the original expiration": the new container protects the drug differently from the manufacturer's bottle, so the date reflects both the original expiration and what is known about the new packaging, and it can never run later than the manufacturer's expiration. "A beyond-use date taken from the original expiration, as the tablets themselves stay intact" ignores that the manufacturer's date applies only in the original container. "A beyond-use date one year from repackaging, as a sealed blister outlasts the bulk bottle" is wrong because a fixed year could run past the manufacturer's expiration, and unit-dose blisters usually protect less well than the original bottle. "A beyond-use date thirty days from dispensing, with blister stock dated at the point of use" is wrong because the date is assigned and labeled when the product is repackaged, not when it is dispensed.

  64. A 65-year-old presents for a pneumococcal vaccine. Which standing-order or screening element is part of the immunization medication-use process before administration?

    • A.Measuring antibody titers by serology and vaccinating those found susceptible
    • B.Requesting a patient-specific prescription and withholding the dose meanwhile
    • C.Taking a temperature reading and postponing the dose for a mild cough or cold
    • D.Confirming age or risk eligibility and ruling out protocol contraindications
    Show answerHide answer

    Correct answer: Confirming age or risk eligibility and ruling out protocol contraindications

    Under a standing order the pharmacist screens by "Confirming age or risk eligibility and ruling out protocol contraindications", for example age 65 and no severe allergic reaction to an earlier dose or a vaccine component. "Measuring antibody titers by serology and vaccinating those found susceptible" is not part of pneumococcal screening; vaccination is based on age and risk, not on a titer. "Requesting a patient-specific prescription and withholding the dose meanwhile" defeats the purpose of a standing order, which authorizes vaccination of anyone who meets its criteria. "Taking a temperature reading and postponing the dose for a mild cough or cold" is wrong because a mild illness, with or without low-grade fever, is not a reason to withhold a vaccine.

  65. In the medication-use process, the term 'therapeutic interchange' most precisely refers to:

    • A.A chemically distinct, therapeutically equivalent drug, dispensed under an approved policy
    • B.A chemically identical, bioequivalent multisource drug, dispensed under an approved policy
    • C.A chemically distinct, therapeutically equivalent drug, dispensed at individual discretion
    • D.A chemically identical, bioequivalent multisource drug, dispensed at individual discretion
    Show answerHide answer

    Correct answer: A chemically distinct, therapeutically equivalent drug, dispensed under an approved policy

    Therapeutic interchange means "A chemically distinct, therapeutically equivalent drug, dispensed under an approved policy": one drug is exchanged for a different drug expected to give the same clinical result, under a protocol approved in advance, typically by a pharmacy and therapeutics committee. "A chemically identical, bioequivalent multisource drug, dispensed under an approved policy" describes generic substitution, in which the active ingredient does not change. "A chemically distinct, therapeutically equivalent drug, dispensed at individual discretion" leaves out the approved policy; switching the molecule on a pharmacist's own judgment is unauthorized substitution, not interchange. "A chemically identical, bioequivalent multisource drug, dispensed at individual discretion" is wrong on both the product and the authority.

  66. Which statement correctly defines a Schedule II controlled substance?

    • A.High abuse potential with no accepted medical use and undetermined clinical safety
    • B.Moderate abuse potential with accepted medical use and refills on the prescription
    • C.Low abuse potential with accepted medical use and sales without a prescription
    • D.High abuse potential with accepted medical use and a severe dependence liability
    Show answerHide answer

    Correct answer: High abuse potential with accepted medical use and a severe dependence liability

    The Controlled Substances Act defines Schedule II as "High abuse potential with accepted medical use and a severe dependence liability", either psychological or physical. "High abuse potential with no accepted medical use and undetermined clinical safety" defines Schedule I. "Moderate abuse potential with accepted medical use and refills on the prescription" fits Schedule III, whose abuse potential is lower than that of Schedules I and II and whose prescriptions can be refilled. "Low abuse potential with accepted medical use and sales without a prescription" fits Schedule V.

  67. A prescriber wants a Schedule II stimulant continued for a patient on a chronic basis. Which method allows the prescriber to provide for up to a 90-day supply without violating the no-refill rule?

    • A.Listing extra refills, each marked with its earliest allowable fill date
    • B.Issuing sequential prescriptions, each marked with its earliest fill date
    • C.Allowing partial fills of one prescription, spaced monthly over ninety days
    • D.Phoning in later fills of one prescription, spaced monthly over ninety days
    Show answerHide answer

    Correct answer: Issuing sequential prescriptions, each marked with its earliest fill date

    Under 21 CFR 1306.12 the lawful method is "Issuing sequential prescriptions, each marked with its earliest fill date": the prescriber may write multiple Schedule II prescriptions on the same day, together covering up to 90 days, with written 'do not fill until' instructions on each. "Listing extra refills, each marked with its earliest allowable fill date" is wrong because a Schedule II prescription cannot be refilled, however the refills are dated. "Allowing partial fills of one prescription, spaced monthly over ninety days" is wrong because the remaining portions of a partially filled Schedule II prescription must be dispensed within 30 days of the date it was written. "Phoning in later fills of one prescription, spaced monthly over ninety days" is wrong because oral Schedule II orders are limited to emergencies and cannot serve as refills.

  68. Which is an accurate statement about Schedule IV controlled substances relative to Schedule II?

    • A.Higher addiction risk, with up to five refills within six months
    • B.Lower abuse potential, with up to five refills within six months
    • C.Lower abuse potential, with refills prohibited under federal law
    • D.Higher addiction risk, with refills prohibited under federal law
    Show answerHide answer

    Correct answer: Lower abuse potential, with up to five refills within six months

    The accurate comparison is "Lower abuse potential, with up to five refills within six months": Schedule IV drugs have less potential for abuse and dependence than Schedule II drugs, and their prescriptions may be refilled as authorized up to five times in the six months after issue. "Higher addiction risk, with up to five refills within six months" has the refill rule right but reverses the ranking, since Schedule II carries the greater risk. "Lower abuse potential, with refills prohibited under federal law" has the ranking right but applies the Schedule II no-refill rule to Schedule IV. "Higher addiction risk, with refills prohibited under federal law" is wrong on both points.

  69. A pharmacy maintains a perpetual inventory for Schedule II substances. The primary medication-handling purpose of this record is to:

    • A.Replace the biennial and initial inventories that federal law requires
    • B.Submit the dispensing records to state and federal monitoring programs
    • C.Record supply orders and receipts in place of the official order form
    • D.Reconcile the controlled-substance count to detect and deter diversion
    Show answerHide answer

    Correct answer: Reconcile the controlled-substance count to detect and deter diversion

    The purpose of a perpetual inventory is to "Reconcile the controlled-substance count to detect and deter diversion": every receipt and every dose dispensed is tracked against the stock on hand, so a discrepancy is seen and investigated quickly. "Replace the biennial and initial inventories that federal law requires" is wrong because those inventories are still required of every registrant. "Submit the dispensing records to state and federal monitoring programs" describes prescription drug monitoring program reporting, a separate submission made to the state. "Record supply orders and receipts in place of the official order form" is wrong because Schedule II drugs must still be ordered with DEA Form 222 or its electronic equivalent.

  70. A pharmacist explains why a biosimilar cannot be approved through the same abbreviated pathway used for small-molecule generics. The best rationale is that:

    • A.Biologics are injected, sterile and preservative-free, so blood levels cannot be compared and outcome data are needed
    • B.Biologics are potent, scarce and donor-derived, so production cannot be scaled up and fresh safety data are needed
    • C.Biologics are large, complex and process-sensitive, so exact copies cannot be assured and comparative data are needed
    • D.Biologics are dosed by weight, age and indication, so strengths cannot be matched up and dose-ranging data are needed
    Show answerHide answer

    Correct answer: Biologics are large, complex and process-sensitive, so exact copies cannot be assured and comparative data are needed

    The rationale is "Biologics are large, complex and process-sensitive, so exact copies cannot be assured and comparative data are needed": a protein made in living cells varies with the manufacturing process, so a biosimilar sponsor must show through analytical and, where needed, clinical comparison that the product is highly similar to its reference. "Biologics are injected, sterile and preservative-free, so blood levels cannot be compared and outcome data are needed" is wrong because blood levels of injected drugs can be compared, and biosimilar programs do include pharmacokinetic studies. "Biologics are potent, scarce and donor-derived, so production cannot be scaled up and fresh safety data are needed" is wrong because most biologics are made by recombinant technology and supply has nothing to do with the approval pathway. "Biologics are dosed by weight, age and indication, so strengths cannot be matched up and dose-ranging data are needed" is wrong because a biosimilar is licensed at the same strength and dosing as its reference.

  71. A pharmacy inventory contains both the reference product and a non-interchangeable biosimilar for the same biologic. When a prescription specifies the reference product by brand, the default dispensing action is to:

    • A.Substitute the biosimilar for the reference product and send the prescriber the notice state law requires
    • B.Substitute the biosimilar for the reference product because biosimilarity alone permits the switch
    • C.Dispense the reference product as written unless the prescriber authorizes the biosimilar
    • D.Dispense the biosimilar in place of the reference product if the patient consents
    Show answerHide answer

    Correct answer: Dispense the reference product as written unless the prescriber authorizes the biosimilar

    The default is "Dispense the reference product as written unless the prescriber authorizes the biosimilar", because only a biosimilar that the FDA has designated interchangeable may be substituted by the pharmacist. "Substitute the biosimilar for the reference product and send the prescriber the notice state law requires" describes the notice rule many states attach to interchangeable products; it does not extend to this one. "Substitute the biosimilar for the reference product because biosimilarity alone permits the switch" is wrong because biosimilar licensure and the interchangeable designation are separate determinations. "Dispense the biosimilar in place of the reference product if the patient consents" is wrong because a patient's preference cannot replace the prescriber's order.

  72. Which route is correct for a varicella (chickenpox) vaccine, affecting needle selection during administration?

    • A.Intradermal, into the skin layer of the inner forearm or the upper back
    • B.Intranasal, as mist sprayed into the left or the right nostril in turn
    • C.Subcutaneous, into fatty tissue of the triceps or anterolateral thigh
    • D.Oral, as liquid drops squeezed into the cheek pouch or under the tongue
    Show answerHide answer

    Correct answer: Subcutaneous, into fatty tissue of the triceps or anterolateral thigh

    The standard route for varicella vaccine is "Subcutaneous, into fatty tissue of the triceps or anterolateral thigh", using a 5/8-inch needle at a 45-degree angle. "Intradermal, into the skin layer of the inner forearm or the upper back" is not a route for any varicella product; intradermal injection uses a much finer needle at a shallow angle. "Intranasal, as mist sprayed into the left or the right nostril in turn" is the route for the live attenuated influenza vaccine. "Oral, as liquid drops squeezed into the cheek pouch or under the tongue" describes how rotavirus vaccine is given to infants.

  73. A patient reports a prior anaphylactic reaction to a previous dose of the same vaccine. During immunization screening, this finding represents:

    • A.A contraindication to the live vaccine, so an inactivated one is given
    • B.A contraindication, so the vaccine is not given
    • C.A precaution, so the vaccine is still given with extended observation
    • D.A precaution, so the vaccine is given after oral antihistamines
    Show answerHide answer

    Correct answer: A contraindication, so the vaccine is not given

    Anaphylaxis after an earlier dose is "A contraindication, so the vaccine is not given"; a severe allergic reaction to a previous dose or to a vaccine component is a contraindication for every vaccine. "A contraindication to the live vaccine, so an inactivated one is given" is wrong because the rule applies to the vaccine that caused the reaction, whether live or inactivated. "A precaution, so the vaccine is still given with extended observation" is wrong because a precaution is a condition that might raise risk and can be weighed against benefit; prior anaphylaxis to the same vaccine is not in that category. "A precaution, so the vaccine is given after oral antihistamines" is wrong for the same reason, and premedication does not reliably prevent anaphylaxis.

  74. A multi-dose vial of injectable medication has been opened for use. Which handling practice supports safe stability and infection control?

    • A.Date the vial at first puncture, then leave it in service through the printed expiry
    • B.Date the vial at first puncture, then discard it when the labeled in-use period ends
    • C.Pool the vial with older stock, then discard it when the labeled in-use period ends
    • D.Pool the vial with older stock, then leave it in service through the printed expiry
    Show answerHide answer

    Correct answer: Date the vial at first puncture, then discard it when the labeled in-use period ends

    The safe practice is "Date the vial at first puncture, then discard it when the labeled in-use period ends": once the stopper is entered, the clock runs from that date, and the vial is discarded at the in-use limit, commonly 28 days unless the manufacturer states otherwise. "Date the vial at first puncture, then leave it in service through the printed expiry" is wrong because the manufacturer's expiration date applies only to an unopened vial. "Pool the vial with older stock, then discard it when the labeled in-use period ends" is wrong because combining the contents of vials spreads any contamination and mixes lots and dates. "Pool the vial with older stock, then leave it in service through the printed expiry" makes both mistakes.

  75. A patient stores their levothyroxine tablets in a humid bathroom cabinet. The pharmacist should advise relocating storage primarily because:

    • A.Heat and humidity can concentrate the tablets, risking overdose
    • B.Heat and humidity can contaminate the tablets, seeding bacteria
    • C.Heat and humidity can degrade the tablets, reducing potency
    • D.Heat and humidity can soften the tablets, speeding absorption
    Show answerHide answer

    Correct answer: Heat and humidity can degrade the tablets, reducing potency

    The reason to move them is that "Heat and humidity can degrade the tablets, reducing potency"; levothyroxine is unstable in the presence of moisture and heat, and its labeling calls for storage in a dry place at controlled room temperature. "Heat and humidity can concentrate the tablets, risking overdose" has the direction backward, because degradation lowers the amount of active drug. "Heat and humidity can contaminate the tablets, seeding bacteria" is wrong because microbial growth is not the concern with a dry solid dosage form in a closed vial. "Heat and humidity can soften the tablets, speeding absorption" is wrong because moisture and heat break down the drug itself; they do not make it absorb faster.

  76. A high-alert medication such as a concentrated electrolyte (for example, concentrated potassium chloride) is best managed in the dispensing process by:

    • A.Restricting it to critical care units and dispensing vials on request
    • B.Restricting it to the pharmacy and dispensing diluted or premixed forms
    • C.Stocking it on nursing units and keeping the vials locked or well marked
    • D.Stocking it in unit cabinets and requiring a cosigned check before it is diluted
    Show answerHide answer

    Correct answer: Restricting it to the pharmacy and dispensing diluted or premixed forms

    The safest handling is "Restricting it to the pharmacy and dispensing diluted or premixed forms": removing concentrated electrolytes from patient-care areas makes it impossible to give the concentrate directly by mistake. "Restricting it to critical care units and dispensing vials on request" still leaves vials of concentrate where a fatal undiluted injection can occur. "Stocking it on nursing units and keeping the vials locked or well marked" relies on labels and a lock, which are weaker safeguards than removing the product. "Stocking it in unit cabinets and requiring a cosigned check before it is diluted" adds a check but keeps the hazard on the unit and leaves dilution to be done at the bedside.

  77. During the verification step, the pharmacist confirms the days' supply on a prescription for a 30-tablet, once-daily medication is entered as 30 days. This check most directly prevents which downstream problem?

    • A.Mislabeled directions, with wrong doses or dosing times
    • B.Miscounted tablets, with short fills or stock shortages
    • C.Misfiled records, with wrong prescriber or patient profiles
    • D.Mistimed refills, with early requests or insurer rejections
    Show answerHide answer

    Correct answer: Mistimed refills, with early requests or insurer rejections

    An accurate days' supply most directly prevents "Mistimed refills, with early requests or insurer rejections": the pharmacy system and the insurer both use this field to calculate when the next fill is due, so a wrong value makes a refill look too early or lets one go through too soon. "Mislabeled directions, with wrong doses or dosing times" comes from an error in the directions field, which is verified separately. "Miscounted tablets, with short fills or stock shortages" comes from the quantity dispensed, which is checked at product verification. "Misfiled records, with wrong prescriber or patient profiles" comes from selecting the wrong patient or prescriber at data entry.

  78. Which practice during dispensing helps prevent a wrong-patient error when two patients share the same last name?

    • A.Confirming two unique patient identifiers, full name plus date of birth, at pickup
    • B.Confirming two unique label details, patient surname plus drug name, at pickup
    • C.Confirming two unique order details, patient surname plus name of the prescriber, at pickup
    • D.Confirming two unique bin tags, patient name initial plus shelf location, at pickup
    Show answerHide answer

    Correct answer: Confirming two unique patient identifiers, full name plus date of birth, at pickup

    The safeguard is "Confirming two unique patient identifiers, full name plus date of birth, at pickup": two details that belong only to the person, ideally stated by the patient, separate people who share a surname. "Confirming two unique label details, patient surname plus drug name, at pickup" is wrong because the drug name is not a patient identifier, and relatives are often prescribed the same medication. "Confirming two unique order details, patient surname plus name of the prescriber, at pickup" is wrong because family members commonly see the same prescriber. "Confirming two unique bin tags, patient name initial plus shelf location, at pickup" is wrong because it identifies where the bag was stored, not who the patient is.

  79. A pharmacist receives an electronic prescription that auto-populated an unusual directions string due to a software default. The most appropriate response in the medication-use process is to:

    • A.Assess the directions clinically, then convert apparent errors to the usual dosing
    • B.Assess the directions clinically, then clarify apparent errors with the prescriber
    • C.Transcribe the directions as sent, then settle patient queries with the prescriber
    • D.Transcribe the directions as sent, then counsel the patient on the usual dosing
    Show answerHide answer

    Correct answer: Assess the directions clinically, then clarify apparent errors with the prescriber

    The right response is "Assess the directions clinically, then clarify apparent errors with the prescriber": electronic prescriptions can carry default or mis-selected directions, so the pharmacist judges whether they make sense and resolves doubts with the person who wrote the order. "Assess the directions clinically, then convert apparent errors to the usual dosing" is wrong because the pharmacist cannot change the directions on an assumption about what was meant. "Transcribe the directions as sent, then settle patient queries with the prescriber" is wrong because it passes an unreviewed order through and leaves the patient to find the problem. "Transcribe the directions as sent, then counsel the patient on the usual dosing" is wrong because the label and the counseling would then disagree, and neither has been confirmed.

  80. Narrow therapeutic index drugs, such as certain antiepileptics, are often excluded from automatic substitution policies. The rationale in the medication-use process is that:

    • A.Generics skip bioequivalence or assay testing, which could leave blood levels in doubt
    • B.A product switch returns kinetics to baseline, so a second loading dose could be needed
    • C.A product switch alters the active metabolite and could void older serum targets
    • D.Small differences in blood levels between products could affect efficacy or toxicity
    Show answerHide answer

    Correct answer: Small differences in blood levels between products could affect efficacy or toxicity

    The rationale is "Small differences in blood levels between products could affect efficacy or toxicity": with a narrow therapeutic index the gap between an effective and a toxic concentration is small, so even the variation allowed between bioequivalent products could matter for a given patient. "Generics skip bioequivalence or assay testing, which could leave blood levels in doubt" is wrong because every approved generic must demonstrate bioequivalence, and the limits are tighter for some narrow therapeutic index drugs. "A product switch returns kinetics to baseline, so a second loading dose could be needed" is wrong because the same drug at the same dose continues at steady state. "A product switch alters the active metabolite and could void older serum targets" is wrong because a generic contains the same active ingredient and is metabolized the same way.

  81. A hospital protocol permits IV-to-oral (IV-to-PO) conversion of a highly bioavailable antibiotic once the patient can take oral medication. Categorize this within the medication-use process:

    • A.A protocol-driven substitution of the generic form
    • B.A protocol-driven adjustment of the dose for renal function
    • C.A protocol-driven reconciliation of the home medication list
    • D.A protocol-driven switch of the route of administration
    Show answerHide answer

    Correct answer: A protocol-driven switch of the route of administration

    Moving a patient from the intravenous to the oral form of a well-absorbed antibiotic is A protocol-driven switch of the route of administration: the drug stays the same, only the route changes, and the protocol lets the pharmacist act once the patient can swallow, which cuts line infections and cost and so optimizes the medication-use process. A protocol-driven substitution of the generic form would mean dispensing another manufacturer's version of the same dosage form, and an oral tablet is not a generic of an injection. A protocol-driven adjustment of the dose for renal function changes how much drug is given because the kidneys clear it more slowly, which is not what happened here. A protocol-driven reconciliation of the home medication list compares the drugs taken before admission with the inpatient orders and does not change a route.

  82. USP 800 requires that hazardous drug receiving and unpacking from external shipping containers occur where, to limit contamination spread?

    • A.In an area at positive pressure to nearby rooms or corridors
    • B.In the sterile compounding buffer room or its anteroom
    • C.In the sterile compounding hood or the compounding isolator
    • D.In an area at neutral or negative pressure to nearby rooms
    Show answerHide answer

    Correct answer: In an area at neutral or negative pressure to nearby rooms

    USP 800 says hazardous drugs are unpacked In an area at neutral or negative pressure to nearby rooms, so that any powder or vapor released from a damaged container is held in or drawn away instead of being pushed outward. Unpacking In an area at positive pressure to nearby rooms or corridors does the opposite, because air flows out of a positive-pressure space and carries contamination into the surrounding rooms. Unpacking In the sterile compounding buffer room or its anteroom is ruled out because shipping cartons shed particles and may carry drug residue, and USP 800 forbids opening external shipping containers in sterile compounding areas. Unpacking In the sterile compounding hood or the compounding isolator brings the outer carton into the cleanest workspace in the pharmacy, which is reserved for compounding itself.

  83. Which personal protective measure is appropriate when administering an oral hazardous drug to a patient if the drug must be manipulated (for example, an oral liquid that requires measuring)?

    • A.Wear a surgical mask and reserve gloves as protective equipment for injectable drugs
    • B.Wear sterile gloves and a sterile gown as the protective equipment for aseptic compounding
    • C.Wear suitable gloves and add other protective equipment as called for by a risk assessment
    • D.Wear a respirator and coveralls over double gloves as the protective equipment for a large spill
    Show answerHide answer

    Correct answer: Wear suitable gloves and add other protective equipment as called for by a risk assessment

    Measuring an oral liquid can put a hazardous drug on the skin, so the person giving it should Wear suitable gloves and add other protective equipment as called for by a risk assessment; USP 800 ties anything beyond gloves, such as a gown or eye protection, to the facility's assessment of risk for that drug and dosage form. The advice to Wear a surgical mask and reserve gloves as protective equipment for injectable drugs leaves the hands bare, and a surgical mask does not protect against drug contact, while gloves are needed for any hazardous drug that is handled, not only injections. The advice to Wear sterile gloves and a sterile gown as the protective equipment for aseptic compounding confuses protecting the product from microbes with protecting the worker from the drug, and sterility is not the concern at the bedside. The advice to Wear a respirator and coveralls over double gloves as the protective equipment for a large spill applies spill-response equipment to a routine dose, which the risk-based approach does not call for.

  84. Sharps generated during immunization or injectable dispensing should be disposed of in:

    • A.An approved puncture-resistant sharps container
    • B.A red biohazard bag used for sharps and gauze
    • C.A drug take-back kiosk that also accepts used sharps
    • D.An empty stock bottle with the sharps recapped
    Show answerHide answer

    Correct answer: An approved puncture-resistant sharps container

    Used needles and syringes go straight into An approved puncture-resistant sharps container, which is rigid, leak-proof on the sides and bottom, closable and labeled, and is kept within reach of where the injection is given. A red biohazard bag used for sharps and gauze is wrong because a bag can be pierced by a needle, so soft biohazard bags are for items such as gauze and never for sharps. A drug take-back kiosk that also accepts used sharps is wrong because take-back kiosks collect unwanted medicines and are not built or permitted to receive needles. An empty stock bottle with the sharps recapped is wrong on two counts: a stock bottle is not an approved, labeled container for a pharmacy to use, and recapping a used needle is itself a leading cause of needlestick injury.

  85. Which of the following best characterizes the relationship between an interchangeable biosimilar and its reference product at the pharmacy level?

    • A.It may be substituted only after the prescriber has approved the switch in writing
    • B.It may be substituted as an AB-rated generic under the Orange Book
    • C.It may be substituted only for patients new to the reference product
    • D.It may be substituted without approval from the prescriber where state law allows
    Show answerHide answer

    Correct answer: It may be substituted without approval from the prescriber where state law allows

    An interchangeable designation means the product has met the added FDA standard for switching, so It may be substituted without approval from the prescriber where state law allows; the state pharmacy act then sets details such as patient notice and record keeping. The statement that It may be substituted only after the prescriber has approved the switch in writing describes a biosimilar that lacks the interchangeable designation. The statement that It may be substituted as an AB-rated generic under the Orange Book applies small-molecule rules to a biologic: biologics are listed in the Purple Book and carry no AB rating. The statement that It may be substituted only for patients new to the reference product is not a condition of interchangeability, which specifically covers switching a patient who is already taking the reference product.

  86. Records of receipt and disposition for controlled substances must generally be maintained and readily retrievable for what minimum period under federal requirements?

    • A.At least three years
    • B.At least five years
    • C.At least seven years
    • D.At least two years
    Show answerHide answer

    Correct answer: At least two years

    Federal regulations require controlled-substance records such as invoices, executed order forms, inventories and dispensing records to be kept and readily retrievable for At least two years from the date of the record. At least three years and At least five years are longer periods that some states set for pharmacy records, and a pharmacy in those states follows the stricter rule, but they are not the federal minimum. At least seven years is a period often used for tax and business records, which is not the controlled-substance rule.

  87. A DEA Form 222 (or its electronic CSOS equivalent) is required during the medication-handling process for ordering which controlled substances?

    • A.Schedule II and III substances
    • B.Schedule I and II substances
    • C.Schedule III and IV substances
    • D.Schedule IV and V substances
    Show answerHide answer

    Correct answer: Schedule I and II substances

    The official order form, DEA Form 222, or an electronic order through the Controlled Substance Ordering System, is required to order or transfer Schedule I and II substances, the schedules with the highest potential for abuse. Schedule II and III substances is half right: Schedule II needs the form, but Schedule III does not. Schedule III and IV substances and Schedule IV and V substances are ordered on an ordinary invoice or purchase order, and the pharmacy simply keeps the dated invoice as its record of receipt.

  88. After administering a vaccine, which documentation must be recorded as part of the immunization medication-use process?

    • A.The vaccine name, claim number, date billed, payer and copay, and billing provider
    • B.The vaccine name, invoice number, date received, quantity and wholesaler, and ordering provider
    • C.The vaccine name, lot number, date administered, site and route, and administering provider
    • D.The vaccine name, storage unit number, date stocked, high and low temperature, and supervising provider
    Show answerHide answer

    Correct answer: The vaccine name, lot number, date administered, site and route, and administering provider

    The administration record must show The vaccine name, lot number, date administered, site and route, and administering provider, together with the manufacturer and the edition date of the information statement that was provided; these details let a dose be traced if a lot is recalled or an adverse event is reported. The vaccine name, claim number, date billed, payer and copay, and billing provider describes the insurance claim, which matters for payment but does not record how the dose was given. The vaccine name, invoice number, date received, quantity and wholesaler, and ordering provider describes the receiving record kept when stock arrives from the supplier. The vaccine name, storage unit number, date stocked, high and low temperature, and supervising provider describes the storage and temperature log, which protects the cold chain but says nothing about the dose a patient received.

  89. Reconstituted amoxicillin oral suspension should be stored under which condition to preserve stability over its labeled use period?

    • A.Kept in the freezer, thawed before each dose, and thrown out once the labeled period ends
    • B.Kept in the refrigerator, shaken well before each dose, and thrown out once the labeled period ends
    • C.Kept in the refrigerator, shaken well before each dose, and used past the labeled period until the bottle is empty
    • D.Kept in the freezer, thawed before each dose, and used past the labeled period until the bottle is empty
    Show answerHide answer

    Correct answer: Kept in the refrigerator, shaken well before each dose, and thrown out once the labeled period ends

    Once water is added, amoxicillin suspension is best Kept in the refrigerator, shaken well before each dose, and thrown out once the labeled period ends, which for this product is 14 days: cold slows hydrolysis, shaking redistributes the settled drug so each dose is even, and the short discard date reflects how quickly the drug breaks down in water. Kept in the freezer, thawed before each dose, and thrown out once the labeled period ends gets the discard date right but freezing and thawing a suspension can change its texture and dosing uniformity, and it is not a labeled storage condition. Kept in the refrigerator, shaken well before each dose, and used past the labeled period until the bottle is empty gets the storage right but ignores the discard date, and suspension kept beyond it may have lost potency even though some remains in the bottle. Kept in the freezer, thawed before each dose, and used past the labeled period until the bottle is empty combines both errors.

  90. Which storage practice is appropriate for a medication labeled 'store at controlled room temperature'?

    • A.Keep it within the refrigerator range if possible, since controlled room temperature and humidity shorten shelf life
    • B.Keep it within the cool range, just below controlled room temperature and above refrigeration
    • C.Keep it within the controlled room temperature range, away from extreme heat and cold
    • D.Keep it within the warm range, just above controlled room temperature and below excessive heat
    Show answerHide answer

    Correct answer: Keep it within the controlled room temperature range, away from extreme heat and cold

    The label means what it says: Keep it within the controlled room temperature range, away from extreme heat and cold. USP defines that range as 20 to 25 degrees Celsius, with brief excursions between 15 and 30 degrees allowed. The advice to Keep it within the refrigerator range if possible, since controlled room temperature and humidity shorten shelf life is wrong because refrigeration is 2 to 8 degrees, a separate labeled condition, and cold can harm some products by causing precipitation or condensation. The advice to Keep it within the cool range, just below controlled room temperature and above refrigeration describes 8 to 15 degrees, which is a different USP storage term. The advice to Keep it within the warm range, just above controlled room temperature and below excessive heat describes 30 to 40 degrees, which is above the labeled range and speeds degradation.

  91. Look-alike/sound-alike (LASA) medications are best managed in the dispensing area by:

    • A.Separating them on shelves, posting shelf alerts, and applying tall man lettering
    • B.Shelving them side by side, matching labels on bins, and applying uniform lowercase lettering
    • C.Pooling them in one bin, posting both names, and relying on final verification
    • D.Abbreviating them on labels, shortening shelf tags, and relying on staff familiarity
    Show answerHide answer

    Correct answer: Separating them on shelves, posting shelf alerts, and applying tall man lettering

    Confusable names are best handled by Separating them on shelves, posting shelf alerts, and applying tall man lettering, three measures that make the two products look and sit differently at the moment a bottle is picked. Shelving them side by side, matching labels on bins, and applying uniform lowercase lettering is wrong because it removes every visual difference between the pair, which is how the wrong bottle gets picked. Pooling them in one bin, posting both names, and relying on final verification is wrong because it guarantees the two products are mixed and leaves a single downstream check to catch every error. Abbreviating them on labels, shortening shelf tags, and relying on staff familiarity is wrong because abbreviations make similar names more alike, and familiarity is exactly what lets a reader see the name they expect.

  92. A pharmacist notices that an automated dispensing cabinet override was used to obtain a high-alert medication before pharmacist review. The safest system response is to:

    • A.Restrict overrides to charge nurses and require pharmacist review of high-alert drugs by the next day
    • B.Limit overrides to defined emergencies and require pharmacist review of high-alert drugs whenever feasible
    • C.Allow overrides for any urgent order and require pharmacist review of high-alert drugs in a monthly audit
    • D.Reserve overrides for high-alert drugs and require pharmacist review of lower-risk drugs before each removal
    Show answerHide answer

    Correct answer: Limit overrides to defined emergencies and require pharmacist review of high-alert drugs whenever feasible

    The safest response is to Limit overrides to defined emergencies and require pharmacist review of high-alert drugs whenever feasible: an override skips the independent check of the order, so it should be confined to situations where waiting would harm the patient, and the drugs most able to cause harm should get that check first. The plan to Restrict overrides to charge nurses and require pharmacist review of high-alert drugs by the next day changes who may override without limiting when, and a review the next day comes after the dose has been given. The plan to Allow overrides for any urgent order and require pharmacist review of high-alert drugs in a monthly audit lets the word urgent stand in for a true emergency and turns review into a look back at errors that have already reached patients. The plan to Reserve overrides for high-alert drugs and require pharmacist review of lower-risk drugs before each removal reverses the priorities by leaving the most dangerous drugs with the least oversight.

  93. A prescription for a Schedule II drug is presented 10 months after it was written. How should the pharmacist evaluate its validity for dispensing?

    • A.State law often limits fill time for a Schedule II prescription, so this one needs prescriber verification before it is filled
    • B.Federal law voids a Schedule II prescription six months after issuance, so this one must be refused for being out of date
    • C.Federal law sets no expiration date for a Schedule II prescription, so this one should be filled as written without further inquiry
    • D.State law usually treats a Schedule II prescription like a noncontrolled one, so this one stays valid for a full year after issuance
    Show answerHide answer

    Correct answer: State law often limits fill time for a Schedule II prescription, so this one needs prescriber verification before it is filled

    State law often limits fill time for a Schedule II prescription, so this one needs prescriber verification before it is filled. Federal law sets no fixed expiration, but many states do, and a pharmacist's corresponding responsibility means a prescription for a potent opioid or stimulant that surfaces ten months late has to be confirmed as still needed and legitimate. The statement that Federal law voids a Schedule II prescription six months after issuance, so this one must be refused for being out of date borrows the six-month limit that federal law places on Schedule III and IV prescriptions. The statement that Federal law sets no expiration date for a Schedule II prescription, so this one should be filled as written without further inquiry starts from a true premise and reaches the wrong conclusion, because the absence of a federal deadline does not remove state limits or the duty to question a stale order. The statement that State law usually treats a Schedule II prescription like a noncontrolled one, so this one stays valid for a full year after issuance is not how states regulate these drugs; where a state sets a limit for Schedule II, it is shorter than for other prescriptions, not the same.

  94. A formulary lists an interchangeable biosimilar as the preferred agent over its reference biologic. When a clinician orders the reference product, the formulary system supports dispensing the biosimilar because:

    • A.FDA has rated the interchangeable biosimilar as a generic, which permits substitution by its Orange Book code
    • B.FDA has designated the biosimilar interchangeable, which permits substitution under policy and law
    • C.FDA has licensed the biosimilar, which permits substitution whether or not it is interchangeable
    • D.The formulary has listed the biosimilar, which permits substitution because formulary status overrides FDA designations, interchangeable or not
    Show answerHide answer

    Correct answer: FDA has designated the biosimilar interchangeable, which permits substitution under policy and law

    The substitution rests on the product's regulatory status: FDA has designated the biosimilar interchangeable, which permits substitution under policy and law. Interchangeability is an added standard showing that switching between the two products carries no greater risk than staying on the reference product, and state pharmacy acts and hospital policy build on that designation. The claim that FDA has rated the interchangeable biosimilar as a generic, which permits substitution by its Orange Book code misplaces the product, because biologics are listed in the Purple Book and are never rated as generics. The claim that FDA has licensed the biosimilar, which permits substitution whether or not it is interchangeable skips the step that matters, since licensure as a biosimilar does not by itself let a pharmacist substitute the product for the reference biologic. The claim that The formulary has listed the biosimilar, which permits substitution because formulary status overrides FDA designations, interchangeable or not gives a committee decision a power it does not have; a formulary chooses among lawful options and cannot create interchangeability.

  95. Which site is preferred for intramuscular vaccine administration in most adults?

    • A.The deltoid muscle of the upper arm
    • B.The dorsogluteal muscle of the buttock
    • C.The vastus lateralis muscle of the thigh
    • D.The ventrogluteal muscle of the hip
    Show answerHide answer

    Correct answer: The deltoid muscle of the upper arm

    For most adults the preferred intramuscular vaccine site is The deltoid muscle of the upper arm, which is easy to reach, has enough muscle mass for the usual volumes, and gives a reliable immune response. The dorsogluteal muscle of the buttock is avoided for vaccines because the thick fat layer there can keep the dose out of the muscle, which has reduced the response to vaccines such as hepatitis B, and because the sciatic nerve runs nearby. The vastus lateralis muscle of the thigh is the preferred site in infants and young children and only an alternative in adults. The ventrogluteal muscle of the hip is used for larger-volume intramuscular drugs and is not a routine vaccine site.

  96. When a tablet labeled 'protect from moisture' is repackaged, which handling step best preserves stability?

    • A.Using moisture-resistant packaging, an optional desiccant, and a suitable beyond-use date for the container
    • B.Using light-resistant packaging, cotton to absorb moisture instead of a desiccant, and the original expiration date
    • C.Using moisture-permeable packaging, the desiccant removed, and a suitable beyond-use date
    • D.Using sealed packaging in a refrigerator to keep moisture out, the desiccant removed, and the original expiration date
    Show answerHide answer

    Correct answer: Using moisture-resistant packaging, an optional desiccant, and a suitable beyond-use date for the container

    The step that preserves stability is Using moisture-resistant packaging, an optional desiccant, and a suitable beyond-use date for the container: a tight container keeps water vapor out, a desiccant takes up what does get in, and a shorter date reflects that the tablets have left the manufacturer's tested container. Using light-resistant packaging, cotton to absorb moisture instead of a desiccant, and the original expiration date guards against light, which is not the stated hazard, and cotton holds moisture against the tablets; the manufacturer's date also no longer applies once the product is repackaged. Using moisture-permeable packaging, the desiccant removed, and a suitable beyond-use date lets room humidity pass through the container wall to the tablets, and taking out the desiccant removes the one thing that would absorb it. Using sealed packaging in a refrigerator to keep moisture out, the desiccant removed, and the original expiration date is a common mistake, because a refrigerator is humid and condensation forms each time the container is opened.

  97. A near-miss is caught at the final verification step before a wrong-strength tablet reaches the patient. From a medication-use-process safety perspective, this near-miss should be:

    • A.Filed and used to retrain and discipline the individual involved
    • B.Classified as a sentinel event and reported to the board and accrediting body
    • C.Recorded and analyzed to find and fix the underlying cause
    • D.Disclosed and logged as a dispensing error to the patient and prescriber
    Show answerHide answer

    Correct answer: Recorded and analyzed to find and fix the underlying cause

    An error caught before it reaches the patient is free information about a weak point in the process, so it should be Recorded and analyzed to find and fix the underlying cause, for example look-alike packaging or adjacent shelf locations for two strengths. Being Filed and used to retrain and discipline the individual involved treats a system problem as one person's failing and teaches staff not to report. Being Classified as a sentinel event and reported to the board and accrediting body misuses a term reserved for events that cause death or serious harm. Being Disclosed and logged as a dispensing error to the patient and prescriber overstates what happened, because the wrong tablet never left the pharmacy; disclosure applies to errors that reach the patient.

  98. Federal law permits partial filling of a Schedule II prescription under certain conditions. Which scenario is a recognized basis for a partial fill?

    • A.The pharmacist doubts the prescription is legitimate, and the remainder is dispensed after it is verified
    • B.The pharmacy cannot supply the full quantity, and the remainder is dispensed within the time allowed
    • C.The prescriber has not signed the prescription, and the remainder is dispensed once the prescriber signs
    • D.The patient cannot show identification, and the remainder is dispensed when it is presented
    Show answerHide answer

    Correct answer: The pharmacy cannot supply the full quantity, and the remainder is dispensed within the time allowed

    A recognized basis is this one: The pharmacy cannot supply the full quantity, and the remainder is dispensed within the time allowed, which federal rules set at 72 hours, after which a new prescription is needed for the rest. The other recognized bases are a request by the patient or prescriber and a patient who is terminally ill or in a long-term care facility. The scenario in which The pharmacist doubts the prescription is legitimate, and the remainder is dispensed after it is verified is wrong because a prescription of doubtful legitimacy should not be dispensed at all until the doubt is resolved. The scenario in which The prescriber has not signed the prescription, and the remainder is dispensed once the prescriber signs is wrong because an unsigned Schedule II prescription is not valid, so nothing may be dispensed from it. The scenario in which The patient cannot show identification, and the remainder is dispensed when it is presented is wrong because identification is a matter for pharmacy policy or state law and is not a ground for splitting the quantity.

  99. A patient with a moderate acute illness and fever presents for a routine, non-urgent vaccine. According to immunization screening principles, moderate acute illness is generally considered a:

    • A.Contraindication that rules out the remaining doses of that vaccine series
    • B.Precaution that can justify postponing vaccination while the symptoms last
    • C.Precaution that applies to live vaccines, while inactivated vaccines can proceed on schedule
    • D.Condition that is incorrectly perceived as a contraindication, so vaccination should proceed as with mild illness
    Show answerHide answer

    Correct answer: Precaution that can justify postponing vaccination while the symptoms last

    Moderate or severe acute illness, with or without fever, is a Precaution that can justify postponing vaccination while the symptoms last; waiting avoids confusing symptoms of the illness with a vaccine reaction, and the decision weighs how urgent the vaccine is. It is not a Contraindication that rules out the remaining doses of that vaccine series, a description that fits a severe allergic reaction to a previous dose. It is not a Precaution that applies to live vaccines, while inactivated vaccines can proceed on schedule, because the precaution covers every vaccine type. It is not a Condition that is incorrectly perceived as a contraindication, so vaccination should proceed as with mild illness; that reasoning applies to a mild illness such as a cold or low-grade fever, which should not delay vaccination, but this patient's illness is moderate.

  100. A refrigerator storing vaccines should be equipped with which tool to support proper medication handling?

    • A.A factory-set thermostat dial with a weekly check of its setting
    • B.A door-ajar alarm with a monthly check of its backup battery
    • C.A calibrated temperature monitoring device with a log of the readings
    • D.An infrared surface thermometer gun with a spot reading of the vial cartons
    Show answerHide answer

    Correct answer: A calibrated temperature monitoring device with a log of the readings

    Vaccine storage calls for A calibrated temperature monitoring device with a log of the readings, ideally a digital data logger with a buffered probe and a current calibration certificate, so that staff can see the minimum and maximum temperatures and prove the cold chain held. A factory-set thermostat dial with a weekly check of its setting controls the compressor but does not measure or record the temperature inside the unit. A door-ajar alarm with a monthly check of its backup battery warns about one cause of a temperature excursion and reports nothing about the temperature itself. An infrared surface thermometer gun with a spot reading of the vial cartons gives a surface reading at a single moment, which misses excursions overnight and does not reflect the temperature of the vaccine in the vial.

  101. After performing an approved therapeutic interchange, which documentation supports continuity of care in the medication-use process?

    • A.Recording the agent dispensed and its dose as though they were the original order, so the chart shows one drug
    • B.Recording the original order with the agent dispensed and its dose conversion, so other clinicians stay informed
    • C.Recording the original order unchanged, so the protocol itself tells clinicians which agent was dispensed
    • D.Recording why the original order was changed in the pharmacy file alone, so the chart lists just the agent dispensed
    Show answerHide answer

    Correct answer: Recording the original order with the agent dispensed and its dose conversion, so other clinicians stay informed

    Continuity depends on Recording the original order with the agent dispensed and its dose conversion, so other clinicians stay informed: anyone reading the chart can then see what was prescribed, what the patient actually received, and how the doses compare, which matters at discharge when the original drug is usually resumed. Recording the agent dispensed and its dose as though they were the original order, so the chart shows one drug erases the prescriber's order and hides the fact that a substitution took place. Recording the original order unchanged, so the protocol itself tells clinicians which agent was dispensed leaves the chart showing a drug the patient never received and expects every reader to know the protocol. Recording why the original order was changed in the pharmacy file alone, so the chart lists just the agent dispensed keeps the explanation where nurses, prescribers and the next pharmacist cannot see it.

  102. USP 800 describes cleaning surfaces that contact hazardous drugs using which sequence to limit residue?

    • A.Disinfection, cleaning, decontamination, then deactivation, as applicable
    • B.Deactivation, decontamination, cleaning, then disinfection, as applicable
    • C.Cleaning, disinfection, deactivation, then decontamination, as applicable
    • D.Decontamination, deactivation, disinfection, then cleaning, as applicable
    Show answerHide answer

    Correct answer: Deactivation, decontamination, cleaning, then disinfection, as applicable

    USP 800 gives the order as Deactivation, decontamination, cleaning, then disinfection, as applicable: the drug is first made inert where an agent can do that, the residue is then removed from the surface, a germicidal detergent takes off remaining soil, and a disinfectant is applied last in areas used for sterile compounding. Disinfection, cleaning, decontamination, then deactivation, as applicable runs the sequence backward, so the disinfectant is applied to a surface still carrying drug residue and soil. Cleaning, disinfection, deactivation, then decontamination, as applicable cleans and disinfects before the hazardous residue has been dealt with, which spreads it. Decontamination, deactivation, disinfection, then cleaning, as applicable removes residue before inactivating it and cleans after disinfecting, which leaves the surface recontaminated.

  103. Which phrase most accurately completes the statement: 'A biosimilar is approved based on demonstrating it is ___ to the reference product.'?

    • A.Highly similar, with no clinically meaningful differences
    • B.Bioequivalent, with the same rate and extent of absorption
    • C.Structurally identical, with the same inactive components
    • D.Therapeutically equivalent, with an AB rating for substitution
    Show answerHide answer

    Correct answer: Highly similar, with no clinically meaningful differences

    The licensure standard for a biosimilar is that it is Highly similar, with no clinically meaningful differences in safety, purity and potency; minor differences in clinically inactive components are allowed. Bioequivalent, with the same rate and extent of absorption is the standard for a generic small-molecule drug, shown in pharmacokinetic studies. Structurally identical, with the same inactive components cannot be the test, because large proteins made in living cells vary slightly from lot to lot even within the reference product. Therapeutically equivalent, with an AB rating for substitution is Orange Book language for generic drugs, and biologics are listed in the Purple Book without such ratings.

  104. Which credential is generally required for a practitioner to prescribe controlled substances that a pharmacy must verify during processing?

    • A.A valid DEA registration number (or institutional equivalent)
    • B.A valid NPI provider number (or group practice equivalent)
    • C.A valid REMS certification number (or program-specific equivalent)
    • D.A valid PTAN enrollment number (or state plan equivalent)
    Show answerHide answer

    Correct answer: A valid DEA registration number (or institutional equivalent)

    Controlled-substance prescriptions must carry A valid DEA registration number (or institutional equivalent); a resident or staff physician may prescribe under a hospital's registration with an assigned suffix, and the pharmacist checks that the number is plausible for the prescriber. A valid NPI provider number (or group practice equivalent) identifies a clinician for billing and electronic transactions and conveys no authority over controlled substances. A valid REMS certification number (or program-specific equivalent) applies only to a few specific drugs with restricted distribution programs. A valid PTAN enrollment number (or state plan equivalent) is a Medicare billing identifier and has nothing to do with prescribing authority.

  105. During stock rotation, a technician finds an expired bottle on the dispensing shelf. The correct medication-handling action is to:

    • A.Flag it on the shelf with an expired sticker and leave it for the next count or audit
    • B.Pull it from the shelf and discard it in the regular pharmacy trash or drain for safety
    • C.Move it to the front of the shelf and mark it for first use to clear old or short-dated bottles
    • D.Take it off the shelf and set it aside in quarantine for return or disposal
    Show answerHide answer

    Correct answer: Take it off the shelf and set it aside in quarantine for return or disposal

    The technician should Take it off the shelf and set it aside in quarantine for return or disposal, typically in a marked area or bin until a reverse distributor collects it. The plan to Flag it on the shelf with an expired sticker and leave it for the next count or audit leaves an outdated product within reach, where it can still be picked during a busy fill. The plan to Pull it from the shelf and discard it in the regular pharmacy trash or drain for safety gets it away from patients but uses disposal routes that are not permitted for pharmacy drug waste. The plan to Move it to the front of the shelf and mark it for first use to clear old or short-dated bottles misapplies stock rotation, which puts the shortest-dated product in front only while it is still in date; an expired drug may not be dispensed.

  106. Two different inactivated vaccines are indicated at the same visit. Proper administration technique includes:

    • A.Giving them at separate anatomic sites, both from one syringe with a new needle
    • B.Giving them at a single injection point, each from a syringe of its own
    • C.Giving them at a single injection point, both mixed and given from one syringe
    • D.Giving them at separate anatomic sites, each from a syringe of its own
    Show answerHide answer

    Correct answer: Giving them at separate anatomic sites, each from a syringe of its own

    Vaccines given at one visit are handled by Giving them at separate anatomic sites, each from a syringe of its own; different limbs are preferred, and two injections in one limb are spaced at least an inch apart so that any local reaction can be traced to the right product. Giving them at separate anatomic sites, both from one syringe with a new needle lets the first vaccine contaminate the second inside the syringe, and changing the needle does not prevent that. Giving them at a single injection point, each from a syringe of its own keeps the products apart in the syringe but deposits them in the same tissue, where local reactions cannot be told apart. Giving them at a single injection point, both mixed and given from one syringe is allowed only for products licensed to be combined, since mixing others can reduce the response to each.

  107. A pharmacist consults the state prescription drug monitoring program (PDMP) before dispensing a controlled substance. The primary purpose of this step in the medication-use process is to:

    • A.Verify the federal registration, state license, or prescribing scope of the prescriber
    • B.Screen for known allergies, interactions, or contraindications in the pharmacy profile
    • C.Confirm the formulary tier, quantity limit, or prior authorization for the claim
    • D.Identify signs of misuse, duplicate therapy, or doctor shopping to guide the fill
    Show answerHide answer

    Correct answer: Identify signs of misuse, duplicate therapy, or doctor shopping to guide the fill

    The monitoring program shows controlled-substance fills from every pharmacy and prescriber that reports to it, so the pharmacist checks it to Identify signs of misuse, duplicate therapy, or doctor shopping to guide the fill; overlapping opioid and benzodiazepine fills or several prescribers in a short period are the usual warning signs. To Verify the federal registration, state license, or prescribing scope of the prescriber is a separate check made against licensing and registration records, not the monitoring program. To Screen for known allergies, interactions, or contraindications in the pharmacy profile is the prospective drug review done from the pharmacy's own records, which the program supplements but does not perform. To Confirm the formulary tier, quantity limit, or prior authorization for the claim is a billing task handled through the insurer's claim system.

  108. A lyophilized (freeze-dried) injectable is reconstituted just before administration. Why is it often supplied in this powdered form rather than as a ready solution?

    • A.Because the drug can be sterilized as a dry powder and cannot be filtered once it is in solution
    • B.Because the drug is better absorbed as a dry powder and has a slower onset once it is in solution
    • C.Because the drug is more stable as a dry powder and breaks down faster once it is in solution
    • D.Because the drug is free of pyrogens as a dry powder and picks up endotoxin once it is in solution
    Show answerHide answer

    Correct answer: Because the drug is more stable as a dry powder and breaks down faster once it is in solution

    Freeze-drying is used Because the drug is more stable as a dry powder and breaks down faster once it is in solution: water drives hydrolysis and other degradation, so removing it gives a practical shelf life, and the product is reconstituted shortly before the dose. The reason is not Because the drug can be sterilized as a dry powder and cannot be filtered once it is in solution, since these products are sterilized by filtering the solution before it is freeze-dried. The reason is not Because the drug is better absorbed as a dry powder and has a slower onset once it is in solution, as the powder is dissolved before injection and the patient receives a solution either way. The reason is not Because the drug is free of pyrogens as a dry powder and picks up endotoxin once it is in solution, as endotoxin limits apply to every injectable form and water for injection adds none.

  109. Before applying a therapeutic interchange protocol to an individual patient, the pharmacist should still assess:

    • A.Clinical factors such as drug allergies, past intolerances, and contraindications to the substituted agent
    • B.Purchasing factors such as contract price, wholesaler supply, and manufacturer rebate level of the substituted agent
    • C.Prescriber factors such as specialty, practice site, and stated preference for the original agent
    • D.Coverage factors such as formulary tier, copay level, and prior authorization for the original agent
    Show answerHide answer

    Correct answer: Clinical factors such as drug allergies, past intolerances, and contraindications to the substituted agent

    A protocol authorizes the switch in general, but the pharmacist must still check, for this patient, Clinical factors such as drug allergies, past intolerances, and contraindications to the substituted agent; a patient who reacted to the preferred drug, or who has a condition or interacting therapy that rules it out, should stay on the drug ordered. Purchasing factors such as contract price, wholesaler supply, and manufacturer rebate level of the substituted agent were weighed by the committee when it wrote the protocol and say nothing about one patient's safety. Prescriber factors such as specialty, practice site, and stated preference for the original agent do not decide the matter, since an approved protocol already carries the medical staff's agreement, with an opt-out for a documented clinical reason. Coverage factors such as formulary tier, copay level, and prior authorization for the original agent belong to outpatient billing and are not a safety check on the substituted drug.

  110. Some vaccines require frozen storage. A pharmacist handling such a product should:

    • A.Keep it frozen within the labeled range and follow the specific thawing instructions
    • B.Keep it frozen during shipment and then stock it in the refrigerator until its expiration date
    • C.Keep it frozen in the freezer door and thaw each vial in warm water before use
    • D.Keep it frozen on dry ice as the coldest option and refreeze the thawed vials left unused
    Show answerHide answer

    Correct answer: Keep it frozen within the labeled range and follow the specific thawing instructions

    The pharmacist should Keep it frozen within the labeled range and follow the specific thawing instructions, because both the storage range and the time allowed after thawing are set by stability testing. The plan to Keep it frozen during shipment and then stock it in the refrigerator until its expiration date shortens the product's life sharply, since a frozen vaccine moved to the refrigerator must be used within the short period its labeling allows, not by the printed date. The plan to Keep it frozen in the freezer door and thaw each vial in warm water before use exposes vials to the warmest and least stable part of the unit and thaws them by a method the labeling does not permit. The plan to Keep it frozen on dry ice as the coldest option and refreeze the thawed vials left unused can take the product below its labeled range, and a vaccine that has thawed must not be frozen again.

  111. A pharmacist receives a controlled-substance prescription from a mid-level practitioner. Before dispensing, the pharmacist should confirm that:

    • A.The practitioner has authority to prescribe every schedule under federal law and holds any state license
    • B.The practitioner uses the registration of the supervising physician, since state law bars a separate one
    • C.The practitioner has authority to prescribe this schedule under state law and holds a valid registration
    • D.The practitioner has a countersignature from the supervising physician, as federal law requires for each order
    Show answerHide answer

    Correct answer: The practitioner has authority to prescribe this schedule under state law and holds a valid registration

    Two things must be true: The practitioner has authority to prescribe this schedule under state law and holds a valid registration. Each state decides which schedules nurse practitioners, physician assistants and similar prescribers may order, and the DEA registers them only within those limits. The belief that The practitioner has authority to prescribe every schedule under federal law and holds any state license has it backward, because federal registration follows state authority and cannot widen it. The belief that The practitioner uses the registration of the supervising physician, since state law bars a separate one is wrong because a mid-level practitioner prescribes under a registration of their own and may not borrow a supervising physician's. The belief that The practitioner has a countersignature from the supervising physician, as federal law requires for each order is wrong because federal law has no countersignature rule; where one exists, it comes from the state.

  112. Which of the following is the central function of the pharmacist's final verification ('product verification') step before a medication is released to the patient?

    • A.Counseling the patient on correct use for the length of therapy
    • B.Screening the profile for interactions before the label prints
    • C.Entering the prescribed directions for the label into the pharmacy system
    • D.Checking the filled prescription for accuracy against the order
    Show answerHide answer

    Correct answer: Checking the filled prescription for accuracy against the order

    Final verification means Checking the filled prescription for accuracy against the order: the right drug, strength, dosage form, quantity and label for the right patient, which is the last chance to catch a filling error. Counseling the patient on correct use for the length of therapy happens after the product has been verified and serves a different purpose. Screening the profile for interactions before the label prints is the clinical review carried out earlier, when the prescription is entered. Entering the prescribed directions for the label into the pharmacy system is data entry, the first step, whose result the final check compares the product against.

  113. Before administering a vaccine, providing the patient with the appropriate Vaccine Information Statement (VIS) serves which purpose in the medication-use process?

    • A.Documenting the signed consent of the patient and a witness to the vaccine before the dose is given
    • B.Screening the patient for known contraindications and precautions to the vaccine before the dose is given
    • C.Informing the patient of the benefits and risks of the vaccine before the dose is given
    • D.Recording for the patient the lot number and manufacturer of the vaccine after the dose is given
    Show answerHide answer

    Correct answer: Informing the patient of the benefits and risks of the vaccine before the dose is given

    The statement exists for Informing the patient of the benefits and risks of the vaccine before the dose is given, and federal law requires that the current edition be offered before each dose of a covered vaccine. It is not a means of Documenting the signed consent of the patient and a witness to the vaccine before the dose is given, because the statement is an information sheet and federal law does not require a signature. It is not a means of Screening the patient for known contraindications and precautions to the vaccine before the dose is given, which is done with a separate screening questionnaire and the patient's history. It is not a means of Recording for the patient the lot number and manufacturer of the vaccine after the dose is given, as those details go in the administration record or on the patient's vaccination card.

  114. Like the reference biologic, a biosimilar protein product generally requires which storage consideration during handling?

    • A.Frozen storage that avoids thawing and light, as its labeling directs
    • B.Room temperature storage that avoids humidity and direct sunlight, as its labeling directs
    • C.Refrigeration that avoids light and includes shaking before each dose, as its labeling directs
    • D.Refrigeration that avoids freezing and vigorous shaking, as its labeling directs
    Show answerHide answer

    Correct answer: Refrigeration that avoids freezing and vigorous shaking, as its labeling directs

    Protein drugs keep their folded structure only within narrow conditions, so the usual requirement is Refrigeration that avoids freezing and vigorous shaking, as its labeling directs: ice crystals and the shear and foaming caused by agitation both denature and aggregate proteins. Frozen storage that avoids thawing and light, as its labeling directs is wrong because a single freeze can damage most protein products. Room temperature storage that avoids humidity and direct sunlight, as its labeling directs is wrong because these products are generally allowed only brief, labeled periods outside the refrigerator. Refrigeration that avoids light and includes shaking before each dose, as its labeling directs is wrong because protein solutions are swirled gently if they are mixed at all, and shaking is the kind of agitation that causes aggregation.

  115. A pharmacist must process a prescription containing a drug abbreviation 'U' written for insulin units. Why is writing 'U' for 'units' discouraged in the medication-use process?

    • A.'U' can be mistaken for a V or an IV, leading to wrong-route errors
    • B.'U' can be mistaken for a micro sign or a small m, leading to thousandfold errors
    • C.'U' can be mistaken for a zero or a four, leading to large dosing errors
    • D.'U' can be mistaken for a daily or a nightly direction, leading to wrong-time errors
    Show answerHide answer

    Correct answer: 'U' can be mistaken for a zero or a four, leading to large dosing errors

    The danger is that 'U' can be mistaken for a zero or a four, leading to large dosing errors: a handwritten 10U can be read as 100, giving ten times the intended insulin dose, which is why the word units is written out. The idea that 'U' can be mistaken for a V or an IV, leading to wrong-route errors describes the problem with the separate abbreviation for international units. The idea that 'U' can be mistaken for a micro sign or a small m, leading to thousandfold errors describes the microgram abbreviation, which is confused with milligrams. The idea that 'U' can be mistaken for a daily or a nightly direction, leading to wrong-time errors describes the Latin frequency abbreviations, another entry on the error-prone list but not the reason for avoiding this one.

Person-Centered Assessment and Treatment Planning (184)

  1. A 68 kg patient with normal renal function is started on intravenous vancomycin for a serious gram-positive infection. Using contemporary weight-based dosing, which initial regimen is most consistent with current guideline recommendations of approximately 15 to 20 mg/kg per dose?

    • A.1250 mg every 8 to 12 hours
    • B.500 mg every 8 to 12 hours
    • C.1750 mg every 8 to 12 hours
    • D.2750 mg every 8 to 12 hours
    Show answerHide answer

    Correct answer: 1250 mg every 8 to 12 hours

    Multiply the actual body weight by the dose range: 68 kg x 15 mg/kg = 1020 mg and 68 kg x 20 mg/kg = 1360 mg, so each dose should fall between 1020 and 1360 mg, and 1250 mg every 8 to 12 hours fits. 500 mg every 8 to 12 hours comes from treating 68 as pounds and dividing by 2.2, which gives about 31 kg and a dose near 465 to 620 mg. 1750 mg every 8 to 12 hours matches a loading dose of about 25 mg/kg, not the maintenance range in the question. 2750 mg every 8 to 12 hours comes from multiplying 68 by 2.2 before dosing, which gives about 150 kg and a dose near 2250 to 3000 mg.

  2. Current consensus guidelines recommend monitoring vancomycin therapy for serious MRSA infections primarily by which pharmacokinetic target rather than relying solely on a trough concentration?

    • A.Peak serum drug concentration to minimum inhibitory concentration ratio
    • B.Area under the curve to minimum inhibitory concentration ratio
    • C.Trough level to minimum inhibitory concentration ratio
    • D.Time above minimum inhibitory concentration to dosing interval ratio
    Show answerHide answer

    Correct answer: Area under the curve to minimum inhibitory concentration ratio

    For serious MRSA infections the 2020 consensus guideline targets the Area under the curve to minimum inhibitory concentration ratio, written AUC/MIC, with a goal of 400 to 600 assuming an MIC of 1 mg/L, because total daily exposure predicts both efficacy and kidney injury better than a single level. The Peak serum drug concentration to minimum inhibitory concentration ratio is the index that predicts the effect of concentration-dependent drugs such as aminoglycosides. The Trough level to minimum inhibitory concentration ratio is a trough-based measure, the approach the guideline moved away from because troughs of 15 to 20 mg/L often overshoot the exposure needed. The Time above minimum inhibitory concentration to dosing interval ratio is the index for time-dependent drugs such as beta-lactams.

  3. A patient receiving vancomycin has a measured trough of 25 mg/L and a rising serum creatinine over three days. What is the most appropriate interpretation and action?

    • A.The high trough with rising creatinine suggests a mistimed sample and mild dehydration, so keep the regimen and repeat the level in a week
    • B.The high trough with rising creatinine suggests injury from another drug and good vancomycin exposure, so keep the regimen and add fluids
    • C.The high trough with rising creatinine suggests accumulation and possible nephrotoxicity, so reduce the dose or extend the interval
    • D.The high trough with rising creatinine suggests sepsis and poor penetration, so raise the dose or shorten the interval
    Show answerHide answer

    Correct answer: The high trough with rising creatinine suggests accumulation and possible nephrotoxicity, so reduce the dose or extend the interval

    The high trough with rising creatinine suggests accumulation and possible nephrotoxicity, so reduce the dose or extend the interval. Vancomycin is cleared by the kidneys, so falling renal function raises the level, and troughs above 20 mg/L are themselves linked to kidney injury; exposure has to come down while levels and creatinine are followed closely. The reading that The high trough with rising creatinine suggests a mistimed sample and mild dehydration, so keep the regimen and repeat the level in a week explains away two findings that point the same way and leaves the patient on a toxic regimen for another week. The reading that The high trough with rising creatinine suggests injury from another drug and good vancomycin exposure, so keep the regimen and add fluids ignores that a trough of 25 mg/L is above target and that the drug may be the cause of the injury. The reading that The high trough with rising creatinine suggests sepsis and poor penetration, so raise the dose or shorten the interval would increase exposure in a patient who is already accumulating the drug.

  4. When is a vancomycin trough concentration most appropriately drawn during the dosing cycle?

    • A.In the 30 minutes after the infusion ends, once steady state is reached
    • B.In the 30 minutes before the next dose, once steady state is reached
    • C.In the 30 minutes before the second dose, ahead of steady state
    • D.In the 30 minutes after the first infusion ends, ahead of steady state
    Show answerHide answer

    Correct answer: In the 30 minutes before the next dose, once steady state is reached

    A trough is the lowest concentration of the dosing interval, so it is drawn In the 30 minutes before the next dose, once steady state is reached, which for vancomycin usually means before the fourth dose. A sample taken In the 30 minutes after the infusion ends, once steady state is reached is at steady state but is close to the peak, before distribution is even complete. A sample taken In the 30 minutes before the second dose, ahead of steady state is timed correctly within the interval but comes before the drug has accumulated to steady state, so it underestimates later troughs. A sample taken In the 30 minutes after the first infusion ends, ahead of steady state is wrong on both counts.

  5. A patient is started on warfarin for atrial fibrillation. Which laboratory value, standardized as the international normalized ratio, is used to monitor and adjust the dose?

    • A.Activated partial thromboplastin time
    • B.Activated clotting time
    • C.Prothrombin time
    • D.Thrombin time
    Show answerHide answer

    Correct answer: Prothrombin time

    Warfarin is monitored with the prothrombin time, reported as the international normalized ratio so that results are comparable between laboratories. The prothrombin time is sensitive to the vitamin K-dependent factors II, VII and X that warfarin depletes. The activated partial thromboplastin time is the usual test for unfractionated heparin infusions. The activated clotting time is a point-of-care test for high-dose heparin during procedures such as cardiopulmonary bypass, and the thrombin time measures the conversion of fibrinogen to fibrin and is used to detect heparin or dabigatran effect, not to adjust warfarin.

  6. A patient on warfarin for nonvalvular atrial fibrillation has a target INR range that is most consistent with which of the following?

    • A.1.5 to 2.0
    • B.2.5 to 3.5
    • C.3.0 to 4.0
    • D.2.0 to 3.0
    Show answerHide answer

    Correct answer: 2.0 to 3.0

    For nonvalvular atrial fibrillation, as for most warfarin indications, the target INR is 2.0 to 3.0, which balances stroke prevention against bleeding. A range of 1.5 to 2.0 is a lower-intensity target that leaves most patients with atrial fibrillation underprotected. A range of 2.5 to 3.5 is the higher-intensity target used for a mechanical mitral valve, and 3.0 to 4.0 exceeds any routine target and adds bleeding risk without added benefit for this indication.

  7. A patient stabilized on warfarin presents with an INR of 6.5 but no signs of bleeding. Which management approach is most appropriate?

    • A.Hold warfarin and reassess while considering low-dose oral vitamin K based on bleeding risk
    • B.Hold warfarin and give intravenous vitamin K plus prothrombin complex concentrate to prevent bleeding
    • C.Continue warfarin on a lower weekly dose and recheck the INR in one week if no bleeding has developed
    • D.Continue warfarin while giving fresh frozen plasma to control the INR and the bleeding risk
    Show answerHide answer

    Correct answer: Hold warfarin and reassess while considering low-dose oral vitamin K based on bleeding risk

    An INR of 6.5 without bleeding is managed conservatively: hold warfarin and reassess while considering low-dose oral vitamin K based on bleeding risk. The choice to hold warfarin and give intravenous vitamin K plus prothrombin complex concentrate to prevent bleeding applies the treatment for major or life-threatening bleeding to a patient who is not bleeding. The plan to continue warfarin on a lower weekly dose and recheck the INR in one week if no bleeding has developed suits an INR only slightly above range; at 6.5 the doses must be held, not merely reduced. The plan to continue warfarin while giving fresh frozen plasma to control the INR and the bleeding risk keeps giving the drug that caused the problem and uses a blood product reserved for serious bleeding.

  8. A patient taking warfarin substantially increases their intake of leafy green vegetables. What is the most likely effect on anticoagulation control?

    • A.The INR falls because the added vitamin K counteracts warfarin
    • B.The INR climbs because the added vitamin K reinforces warfarin
    • C.The INR rises because leafy greens inhibit warfarin metabolism
    • D.The INR is steady because leafy greens do not affect warfarin
    Show answerHide answer

    Correct answer: The INR falls because the added vitamin K counteracts warfarin

    Warfarin works by blocking the recycling of vitamin K needed to make clotting factors, and leafy greens are rich in vitamin K, so the INR falls because the added vitamin K counteracts warfarin. The statement that the INR climbs because the added vitamin K reinforces warfarin reverses the relationship: vitamin K is the antidote to warfarin, not an enhancer. The statement that the INR rises because leafy greens inhibit warfarin metabolism describes an enzyme-inhibition interaction of the kind seen with azole antifungals, which these vegetables do not cause. The statement that the INR is steady because leafy greens do not affect warfarin is wrong because a change in diet is a well-known cause of INR variability, which is why patients are counseled to keep vitamin K intake consistent.

  9. A patient with nonvalvular atrial fibrillation and adequate renal function asks why a direct oral anticoagulant such as apixaban may be chosen instead of warfarin. Which feature most accurately distinguishes DOACs?

    • A.A long elimination half-life that usually makes a missed dose far less important than with warfarin
    • B.A hepatic route of clearance that usually makes dosing adjustments for renal impairment unnecessary
    • C.A proven safety record that usually makes them preferable for patients with mechanical heart valves
    • D.A predictable pharmacokinetic profile that usually makes routine coagulation monitoring unnecessary
    Show answerHide answer

    Correct answer: A predictable pharmacokinetic profile that usually makes routine coagulation monitoring unnecessary

    The feature that sets direct oral anticoagulants apart from warfarin is a predictable pharmacokinetic profile that usually makes routine coagulation monitoring unnecessary, so fixed doses can be used without INR checks. They do not have a long elimination half-life that usually makes a missed dose far less important than with warfarin: their half-lives are much shorter than the duration of warfarin's effect, so protection fades quickly after a missed dose. They do not have a hepatic route of clearance that usually makes dosing adjustments for renal impairment unnecessary, because dabigatran, rivaroxaban, apixaban and edoxaban all have some renal elimination and renal dosing criteria. They do not have a proven safety record that usually makes them preferable for patients with mechanical heart valves; warfarin remains the anticoagulant for mechanical valves.

  10. A direct oral anticoagulant that is a direct factor Xa inhibitor is being selected for a patient. Which of the following agents acts by directly inhibiting factor Xa?

    • A.Dabigatran
    • B.Apixaban
    • C.Fondaparinux
    • D.Argatroban
    Show answerHide answer

    Correct answer: Apixaban

    Apixaban binds directly to the active site of factor Xa, as do rivaroxaban and edoxaban. Dabigatran is an oral direct thrombin (factor IIa) inhibitor. Fondaparinux does inhibit factor Xa, but indirectly, by binding antithrombin, and it is injected rather than taken by mouth. Argatroban is an intravenous direct thrombin inhibitor used in heparin-induced thrombocytopenia.

  11. A patient on dabigatran develops life-threatening bleeding. Which specific reversal agent directly targets dabigatran?

    • A.Andexanet alfa
    • B.Tranexamic acid
    • C.Idarucizumab
    • D.Phytonadione
    Show answerHide answer

    Correct answer: Idarucizumab

    Idarucizumab is a monoclonal antibody fragment that binds dabigatran with very high affinity and neutralizes it within minutes. Andexanet alfa is a decoy factor Xa that reverses apixaban and rivaroxaban, not a thrombin inhibitor. Tranexamic acid is an antifibrinolytic that slows clot breakdown; it does not bind or neutralize any anticoagulant. Phytonadione (vitamin K) restores synthesis of clotting factors in patients taking warfarin and has no effect on dabigatran.

  12. A patient taking apixaban for atrial fibrillation has declining renal function. Why does renal function matter for many direct oral anticoagulants?

    • A.Several are activated by the kidney, so impairment lowers drug levels and raises clotting risk
    • B.Several are cleared by the kidney, so impairment raises drug levels and bleeding risk
    • C.Several are toxic to the kidney, so impairment worsens with any continued anticoagulant dosing
    • D.Several are active within the kidney, so impairment blunts their anticoagulant effect
    Show answerHide answer

    Correct answer: Several are cleared by the kidney, so impairment raises drug levels and bleeding risk

    Renal function matters for direct oral anticoagulants because several are cleared by the kidney, so impairment raises drug levels and bleeding risk; dabigatran is the most dependent on renal elimination, and apixaban, rivaroxaban and edoxaban all carry renal dosing criteria. It is not true that several are activated by the kidney, so impairment lowers drug levels and raises clotting risk: dabigatran etexilate is a prodrug, but it is activated by esterases in the gut, plasma and liver. It is not true that several are toxic to the kidney, so impairment worsens with any continued anticoagulant dosing; the concern is accumulation of the drug, not injury caused by it. Nor is it true that several are active within the kidney, so impairment blunts their anticoagulant effect, since these drugs act on clotting factors in the blood.

  13. A patient taking simvastatin is prescribed clarithromycin, a strong CYP3A4 inhibitor. What is the primary clinical concern with this drug-drug interaction?

    • A.Lower simvastatin levels with a risk of treatment failure and plaque growth
    • B.Higher simvastatin levels with a risk of myopathy and rhabdomyolysis
    • C.Lower clarithromycin levels with a risk of treatment failure and resistance
    • D.Higher clarithromycin levels with a risk of arrhythmia and hepatitis
    Show answerHide answer

    Correct answer: Higher simvastatin levels with a risk of myopathy and rhabdomyolysis

    Simvastatin is extensively metabolized by CYP3A4, and clarithromycin strongly inhibits that enzyme, so the result is higher simvastatin levels with a risk of myopathy and rhabdomyolysis; the combination is contraindicated in simvastatin labeling. Lower simvastatin levels with a risk of treatment failure and plaque growth would follow an enzyme inducer such as rifampin, not an inhibitor. Lower clarithromycin levels with a risk of treatment failure and resistance mistakes both the affected drug and the direction of the change. Higher clarithromycin levels with a risk of arrhythmia and hepatitis mistakes which drug is affected: simvastatin does not inhibit the metabolism of clarithromycin.

  14. A patient on a monoamine oxidase inhibitor is at risk of serotonin syndrome if which class of medication is added?

    • A.A norepinephrine-dopamine reuptake inhibitor
    • B.A selective serotonin reuptake inhibitor
    • C.A serotonin-dopamine receptor antagonist
    • D.A benzodiazepine receptor agonist
    Show answerHide answer

    Correct answer: A selective serotonin reuptake inhibitor

    A monoamine oxidase inhibitor slows the breakdown of serotonin, and a selective serotonin reuptake inhibitor blocks its reuptake, so together they can raise synaptic serotonin to toxic levels; the combination is contraindicated and needs a washout period. A norepinephrine-dopamine reuptake inhibitor such as bupropion has no meaningful serotonergic action; its interaction with a monoamine oxidase inhibitor is a hypertensive reaction. A serotonin-dopamine receptor antagonist (a second-generation antipsychotic) blocks serotonin receptors rather than increasing serotonin. A benzodiazepine receptor agonist such as zolpidem acts at GABA-A receptors and does not raise serotonin; benzodiazepines are in fact used to treat the agitation of serotonin syndrome.

  15. A patient taking warfarin is started on a course of an azole antifungal. Which interaction outcome is most likely?

    • A.Slower warfarin metabolism, a higher INR and more bleeding risk
    • B.Rapid warfarin metabolism, a lower INR and added clotting risk
    • C.Slower warfarin metabolism, a lower INR and more clotting risk
    • D.Rapid warfarin metabolism, a higher INR and added bleeding risk
    Show answerHide answer

    Correct answer: Slower warfarin metabolism, a higher INR and more bleeding risk

    Azole antifungals such as fluconazole inhibit CYP2C9 and CYP3A4, the enzymes that clear warfarin, so the expected result is slower warfarin metabolism, a higher INR and more bleeding risk; the INR should be checked more often and the dose often reduced. Rapid warfarin metabolism, a lower INR and added clotting risk is the pattern produced by an enzyme inducer such as rifampin. Slower warfarin metabolism, a lower INR and more clotting risk is inconsistent, because warfarin is given as the active drug and slower clearance increases its effect. Rapid warfarin metabolism, a higher INR and added bleeding risk is also inconsistent, and azoles do not speed warfarin clearance.

  16. A patient on an oral contraceptive is prescribed rifampin, a potent enzyme inducer. What counseling point is most appropriate?

    • A.Rifampin can weaken the contraceptive effect, so an additional method is advised
    • B.Rifampin can increase the contraceptive level, so a lower-dose tablet is advised
    • C.Rifampin can bind the contraceptive in the gut, so taking the doses apart is advised
    • D.Rifampin can lose efficacy with the contraceptive, so an extra antibiotic is advised
    Show answerHide answer

    Correct answer: Rifampin can weaken the contraceptive effect, so an additional method is advised

    Rifampin strongly induces CYP3A4 and other enzymes, which speeds the metabolism of ethinyl estradiol and progestins. Rifampin can weaken the contraceptive effect, so an additional method is advised during treatment and for about a month afterward. The statement that rifampin can increase the contraceptive level, so a lower-dose tablet is advised has the direction backward: induction lowers hormone exposure. The statement that rifampin can bind the contraceptive in the gut, so taking the doses apart is advised treats this as a binding interaction; enzyme induction lasts all day and cannot be avoided by timing. The statement that rifampin can lose efficacy with the contraceptive, so an extra antibiotic is advised mistakes which drug is affected, since the contraceptive does not alter rifampin.

  17. A patient takes a tetracycline antibiotic with a calcium-containing antacid. What is the most likely consequence of this drug-food or drug-drug interaction?

    • A.Higher gastric pH that raises tetracycline absorption and toxicity
    • B.Cation chelation that reduces tetracycline absorption and efficacy
    • C.Enzyme induction that boosts tetracycline clearance and resistance
    • D.Albumin displacement that raises unbound tetracycline and toxicity
    Show answerHide answer

    Correct answer: Cation chelation that reduces tetracycline absorption and efficacy

    Tetracyclines bind polyvalent cations such as calcium, magnesium, aluminum and iron in the gut to form insoluble complexes, so the consequence is cation chelation that reduces tetracycline absorption and efficacy; the doses should be separated by several hours. Higher gastric pH that raises tetracycline absorption and toxicity gets the direction wrong, because antacids lower rather than raise the amount absorbed. Enzyme induction that boosts tetracycline clearance and resistance is not involved, since antacids do not induce drug-metabolizing enzymes. Albumin displacement that raises unbound tetracycline and toxicity is not involved either, because the interaction takes place in the gut before the antibiotic is absorbed.

  18. A patient taking levothyroxine is counseled about administration timing. Which instruction reflects an important drug-food interaction?

    • A.Take it on an empty stomach, apart from meals, calcium, and iron
    • B.Take it at breakfast, apart from coffee, calcium, and iron
    • C.Take it on an empty stomach, along with calcium, iron, and fiber
    • D.Take it at breakfast, along with calcium, iron, and coffee
    Show answerHide answer

    Correct answer: Take it on an empty stomach, apart from meals, calcium, and iron

    Food, coffee and polyvalent cations all reduce levothyroxine absorption, so the instruction is: take it on an empty stomach, apart from meals, calcium, and iron, usually 30 to 60 minutes before breakfast and about 4 hours away from calcium or iron products. The instruction to take it at breakfast, apart from coffee, calcium, and iron separates the supplements correctly but still lets the meal reduce absorption. The instruction to take it on an empty stomach, along with calcium, iron, and fiber gets the timing with meals right, but the minerals and fiber bind the drug in the gut. The instruction to take it at breakfast, along with calcium, iron, and coffee combines both errors.

  19. A patient prescribed an oral bisphosphonate such as alendronate should be counseled to take it how, reflecting a key drug-food interaction?

    • A.With a full glass of plain water on an empty stomach, then remaining upright
    • B.With a full glass of fruit juice on an empty stomach, then lying down
    • C.With a full glass of plain water after a light snack, then lying down
    • D.With a full glass of fruit juice after a light snack, then remaining upright
    Show answerHide answer

    Correct answer: With a full glass of plain water on an empty stomach, then remaining upright

    Oral bisphosphonates are very poorly absorbed and can injure the esophagus, so alendronate is taken with a full glass of plain water on an empty stomach, then remaining upright for at least 30 minutes and until the first food of the day. Taking it with a full glass of fruit juice on an empty stomach, then lying down fails twice: juice sharply reduces absorption, and lying down lets the tablet irritate the esophagus. Taking it with a full glass of plain water after a light snack, then lying down uses the right fluid, but any food blocks absorption and the posture risks esophagitis. Taking it with a full glass of fruit juice after a light snack, then remaining upright protects the esophagus, but both the juice and the food prevent the dose from being absorbed.

  20. A patient taking a statin asks about grapefruit juice. Which explanation reflects the relevant drug-food interaction?

    • A.Grapefruit juice can induce intestinal CYP3A4 and reduce levels of certain statins, weakening the lipid response
    • B.Grapefruit juice can inhibit hepatic CYP2C9 and raise levels of certain statins, calling for a dose decrease
    • C.Grapefruit juice can inhibit intestinal CYP3A4 and raise levels of certain statins, increasing the toxicity risk
    • D.Grapefruit juice can induce hepatic CYP2C9 and reduce levels of certain statins, calling for a dose increase
    Show answerHide answer

    Correct answer: Grapefruit juice can inhibit intestinal CYP3A4 and raise levels of certain statins, increasing the toxicity risk

    Furanocoumarins in grapefruit irreversibly inactivate CYP3A4 in the wall of the small intestine, which reduces first-pass metabolism. Grapefruit juice can inhibit intestinal CYP3A4 and raise levels of certain statins, increasing the toxicity risk; simvastatin and lovastatin are affected most, atorvastatin less, and the concern is myopathy. The statement that grapefruit juice can induce intestinal CYP3A4 and reduce levels of certain statins, weakening the lipid response names the right enzyme but the wrong direction. The statement that grapefruit juice can inhibit hepatic CYP2C9 and raise levels of certain statins, calling for a dose decrease names the wrong enzyme and site; CYP2C9 handles fluvastatin and is not the target of grapefruit. The statement that grapefruit juice can induce hepatic CYP2C9 and reduce levels of certain statins, calling for a dose increase is wrong on both counts.

  21. A patient on an MAO inhibitor must avoid tyramine-rich foods such as aged cheeses and cured meats. What is the rationale for this drug-food restriction?

    • A.Tyramine can build up and trigger a disulfiram-like reaction
    • B.Tyramine can build up and trigger a hypertensive crisis
    • C.Tyramine can build up and trigger serotonin syndrome
    • D.Tyramine can build up and trigger orthostatic hypotension
    Show answerHide answer

    Correct answer: Tyramine can build up and trigger a hypertensive crisis

    Monoamine oxidase in the gut and liver normally destroys dietary tyramine. When the enzyme is inhibited, tyramine can build up and trigger a hypertensive crisis by releasing stored norepinephrine from nerve endings, with severe headache and very high blood pressure. The idea that tyramine can build up and trigger a disulfiram-like reaction confuses this with the flushing and vomiting caused by alcohol taken with drugs such as metronidazole. The idea that tyramine can build up and trigger serotonin syndrome confuses the food interaction with the drug interaction between these antidepressants and serotonergic medicines. The idea that tyramine can build up and trigger orthostatic hypotension is wrong because a fall in blood pressure on standing is a side effect of the antidepressant itself, while tyramine raises blood pressure.

  22. A patient develops a maculopapular rash, eosinophilia, fever, and organ involvement several weeks after starting a new anticonvulsant. This presentation is most consistent with which type of adverse drug reaction?

    • A.Stevens-Johnson syndrome / toxic epidermal necrolysis spectrum (SJS/TEN)
    • B.Serum sickness-like reaction (SSLR)
    • C.Drug reaction with eosinophilia and systemic symptoms (DRESS)
    • D.Drug-induced lupus syndrome (DIL)
    Show answerHide answer

    Correct answer: Drug reaction with eosinophilia and systemic symptoms (DRESS)

    A widespread rash with fever, eosinophilia and internal organ involvement that begins 2 to 8 weeks after starting an aromatic anticonvulsant is drug reaction with eosinophilia and systemic symptoms (DRESS), a delayed, idiosyncratic hypersensitivity reaction that requires stopping the drug at once. The Stevens-Johnson syndrome / toxic epidermal necrolysis spectrum (SJS/TEN) is marked by painful blistering, skin detachment and mucosal erosions rather than eosinophilia with organ involvement. A serum sickness-like reaction (SSLR) causes fever, rash and joint pain one to three weeks after a drug such as cefaclor, without eosinophilia or organ damage. Drug-induced lupus syndrome (DIL) develops after months of drugs such as hydralazine or procainamide, with joint pain, serositis and antihistone antibodies.

  23. Which of the following best describes a type A (augmented) adverse drug reaction?

    • A.An unpredictable, dose-independent response of the adaptive immune system
    • B.A predictable, dose-dependent extension of the known pharmacologic effect
    • C.A cumulative, dose-related effect of continuous treatment over the long term
    • D.A delayed, time-related effect appearing several years after the exposure
    Show answerHide answer

    Correct answer: A predictable, dose-dependent extension of the known pharmacologic effect

    A type A (augmented) reaction is a predictable, dose-dependent extension of the known pharmacologic effect, such as bleeding with an anticoagulant or hypoglycemia with insulin; these reactions are common and usually respond to a dose reduction. An unpredictable, dose-independent response of the adaptive immune system describes a type B (bizarre) reaction, such as anaphylaxis. A cumulative, dose-related effect of continuous treatment over the long term describes a type C (chronic) reaction, such as adrenal suppression from corticosteroids. A delayed, time-related effect appearing several years after the exposure describes a type D (delayed) reaction, such as a secondary cancer after chemotherapy.

  24. A patient reports a new dry, persistent cough after starting an ACE inhibitor. What is the most appropriate assessment of this finding?

    • A.It is a shared effect of ACE inhibitors and ARBs that may warrant moving to a thiazide
    • B.It is a dose-related effect of ACE inhibitors that may warrant reducing the daily dose
    • C.It is a side effect of ACE inhibitors that may warrant switching the therapy to an ARB
    • D.It is a fluid-related effect of ACE inhibitors that may warrant an extra diuretic dose
    Show answerHide answer

    Correct answer: It is a side effect of ACE inhibitors that may warrant switching the therapy to an ARB

    ACE inhibitors block the breakdown of bradykinin, and its accumulation in the airway causes a dry, persistent cough in a minority of patients. It is a side effect of ACE inhibitors that may warrant switching the therapy to an ARB, because angiotensin receptor blockers do not raise bradykinin. The statement that it is a shared effect of ACE inhibitors and ARBs that may warrant moving to a thiazide is wrong because ARBs do not cause the cough, so there is no need to leave the renin-angiotensin drugs. The statement that it is a dose-related effect of ACE inhibitors that may warrant reducing the daily dose is wrong because the cough is not dose-dependent and persists until the drug is stopped. The statement that it is a fluid-related effect of ACE inhibitors that may warrant an extra diuretic dose is wrong because these drugs do not cause fluid retention and the cough is dry rather than congestive.

  25. A patient who took an antibiotic develops facial swelling, urticaria, and difficulty breathing within minutes. This is best classified as which type of adverse drug reaction?

    • A.A cytotoxic type II (antibody-mediated) hypersensitivity reaction
    • B.An immune-complex type III (serum sickness) hypersensitivity reaction
    • C.An immediate type I (anaphylactic) hypersensitivity reaction
    • D.A delayed type IV (cell-mediated) hypersensitivity reaction
    Show answerHide answer

    Correct answer: An immediate type I (anaphylactic) hypersensitivity reaction

    Facial swelling, hives and breathing difficulty within minutes of a dose is an immediate type I (anaphylactic) hypersensitivity reaction in the Gell and Coombs classification: the drug cross-links preformed IgE on mast cells, histamine is released, and epinephrine is the treatment. It is unpredictable and not related to dose. A cytotoxic type II (antibody-mediated) hypersensitivity reaction involves IgG or IgM directed at cell-surface antigens, as in drug-induced hemolytic anemia. An immune-complex type III (serum sickness) hypersensitivity reaction appears one to three weeks after exposure with fever, rash and joint pain. A delayed type IV (cell-mediated) hypersensitivity reaction is driven by T cells and takes days to develop, as in contact dermatitis.

  26. A patient with an estimated creatinine clearance of 25 mL/min is prescribed a renally eliminated antibiotic. What is the most appropriate prescribing principle?

    • A.Keep the dose and interval as usual until the serum creatinine level rises further
    • B.Reduce just the loading dose and leave the maintenance dose and interval unchanged
    • C.Adjust the dose or interval to the reduced renal clearance to prevent accumulation
    • D.Shorten the usual interval or raise the dose to offset the reduced renal clearance
    Show answerHide answer

    Correct answer: Adjust the dose or interval to the reduced renal clearance to prevent accumulation

    With a creatinine clearance of 25 mL/min, a renally eliminated antibiotic is cleared much more slowly, so the principle is to adjust the dose or interval to the reduced renal clearance to prevent accumulation and toxicity. The choice to keep the dose and interval as usual until the serum creatinine level rises further ignores impairment that is already present. The choice to reduce just the loading dose and leave the maintenance dose and interval unchanged has it backward: the loading dose depends on the volume of distribution and is usually kept, while the maintenance regimen is what clearance determines. The choice to shorten the usual interval or raise the dose to offset the reduced renal clearance moves in the wrong direction, because either change increases accumulation.

  27. Which equation is commonly used to estimate creatinine clearance for renal drug dosing adjustments?

    • A.The MDRD study equation
    • B.The CKD-EPI equation
    • C.The Cockcroft-Gault equation
    • D.The Harris-Benedict equation
    Show answerHide answer

    Correct answer: The Cockcroft-Gault equation

    The Cockcroft-Gault equation estimates creatinine clearance from age, weight, sex and serum creatinine, and most drug labeling bases renal dose adjustments on it. The MDRD study equation and the CKD-EPI equation estimate glomerular filtration rate normalized to body surface area; they are used to detect and stage chronic kidney disease rather than to calculate creatinine clearance. The Harris-Benedict equation estimates basal energy expenditure for nutrition support.

  28. A patient with end-stage renal disease on hemodialysis is prescribed a medication that is significantly removed by dialysis. What dosing consideration is most appropriate?

    • A.Time the daily dose just before dialysis to remove the excess
    • B.Hold the daily dose on dialysis days and resume the day after
    • C.Administer a supplemental dose after dialysis when indicated
    • D.Keep the usual dose and timing when dialysis is done routinely
    Show answerHide answer

    Correct answer: Administer a supplemental dose after dialysis when indicated

    A drug that is significantly removed by hemodialysis can fall below therapeutic concentrations during a session, so the usual approach is to administer a supplemental dose after dialysis when indicated, or simply to schedule the regular dose after the session. To time the daily dose just before dialysis to remove the excess wastes the dose, because much of it is cleared before it can act. To hold the daily dose on dialysis days and resume the day after leaves the patient without effective drug for a day or more. To keep the usual dose and timing when dialysis is done routinely is wrong because intermittent dialysis provides only a fraction of normal renal clearance, and a dose given before a session is partly removed.

  29. Metformin carries dosing and use restrictions tied to renal function primarily because of the risk of which adverse outcome?

    • A.Fluid retention
    • B.Hypoglycemia
    • C.Ketoacidosis
    • D.Lactic acidosis
    Show answerHide answer

    Correct answer: Lactic acidosis

    Metformin is cleared unchanged by the kidney, and when it accumulates in significant renal impairment it can cause lactic acidosis, which is rare but often fatal. For that reason it is contraindicated when the estimated glomerular filtration rate is below 30 and should not be started between 30 and 45. Fluid retention is the concern with thiazolidinediones. Hypoglycemia is the renal concern with sulfonylureas such as glyburide and with insulin; metformin alone rarely causes it. Ketoacidosis, sometimes with near-normal glucose, is associated with SGLT2 inhibitors.

  30. Therapeutic drug monitoring is most clearly indicated for which type of medication?

    • A.A drug with a broad therapeutic index and a clinical response that varies little among patients
    • B.A drug with a narrow therapeutic index and serum levels that track efficacy and toxicity
    • C.A drug with a narrow therapeutic index and a clinical response that is easy to measure directly
    • D.A drug with a broad therapeutic index and serum levels that bear no relation to outcomes
    Show answerHide answer

    Correct answer: A drug with a narrow therapeutic index and serum levels that track efficacy and toxicity

    Measuring concentrations is worthwhile for a drug with a narrow therapeutic index and serum levels that track efficacy and toxicity, such as digoxin, lithium, phenytoin, vancomycin and the aminoglycosides, especially when the response cannot easily be judged at the bedside. A drug with a broad therapeutic index and a clinical response that varies little among patients can be given at standard doses without measuring levels. A drug with a narrow therapeutic index and a clinical response that is easy to measure directly is adjusted by that response instead, as warfarin is by the INR and insulin is by blood glucose. A drug with a broad therapeutic index and serum levels that bear no relation to outcomes gains nothing from measurement, because a level is useful only when it predicts effect.

  31. What is therapeutic drug monitoring?

    • A.Reviewing the drug list of a patient to identify and resolve medication therapy problems
    • B.Collecting adverse-event reports to uncover signals and communicate drug safety concerns
    • C.Auditing drug use by predefined criteria to improve prescribing and treatment outcomes
    • D.Measuring drug concentrations to optimize dosing and balance efficacy against toxicity
    Show answerHide answer

    Correct answer: Measuring drug concentrations to optimize dosing and balance efficacy against toxicity

    Therapeutic drug monitoring means measuring drug concentrations to optimize dosing and balance efficacy against toxicity, usually in serum or plasma and at defined times such as a trough. It is most valuable for drugs with a narrow therapeutic range and variable pharmacokinetics. Reviewing the drug list of a patient to identify and resolve medication therapy problems describes a comprehensive medication review within medication therapy management. Collecting adverse-event reports to uncover signals and communicate drug safety concerns describes pharmacovigilance. Auditing drug use by predefined criteria to improve prescribing and treatment outcomes describes drug utilization review.

  32. A patient on digoxin develops nausea, visual disturbances, and a new arrhythmia. Therapeutic drug monitoring would most appropriately be used to assess which possibility?

    • A.Digoxin toxicity with an elevated serum concentration
    • B.Digoxin underdosing with a subtherapeutic serum concentration
    • C.Digoxin allergy with an unchanged serum concentration
    • D.Digoxin nonadherence with a nondetectable serum concentration
    Show answerHide answer

    Correct answer: Digoxin toxicity with an elevated serum concentration

    Nausea, visual disturbances such as yellow-green halos, and a new arrhythmia are the classic picture of digoxin toxicity with an elevated serum concentration, and a level drawn at least 6 hours after the last dose helps confirm it; potassium, magnesium and renal function should be checked as well. Digoxin underdosing with a subtherapeutic serum concentration would show as uncontrolled heart rate or heart failure symptoms, not as this triad, and raising the dose here could be dangerous. Digoxin allergy with an unchanged serum concentration would present with rash or other hypersensitivity signs. Digoxin nonadherence with a nondetectable serum concentration would bring back the original symptoms rather than new gastrointestinal and visual complaints.

  33. For aminoglycoside therapy using traditional dosing, which monitoring strategy reflects appropriate therapeutic drug monitoring?

    • A.Peak and trough levels to confirm efficacy while limiting nephrotoxicity and ototoxicity
    • B.A single random level and a nomogram to guide the interval while limiting nephrotoxicity
    • C.Trough levels alone to keep exposure high while limiting resistance and treatment failure
    • D.Serum creatinine and urea to guide each dose while reserving levels for apparent toxicity
    Show answerHide answer

    Correct answer: Peak and trough levels to confirm efficacy while limiting nephrotoxicity and ototoxicity

    With traditional dosing, in which an aminoglycoside is given several times a day, the standard approach is peak and trough levels to confirm efficacy while limiting nephrotoxicity and ototoxicity: the peak shows that the concentration-dependent killing target is reached, and a low trough shows that the drug is clearing between doses. A single random level and a nomogram to guide the interval while limiting nephrotoxicity is the method for extended-interval, once-daily dosing, not for traditional dosing. Trough levels alone to keep exposure high while limiting resistance and treatment failure reverses the goal, since aminoglycoside troughs are kept low and a trough says nothing about the peak. Serum creatinine and urea to guide each dose while reserving levels for apparent toxicity is inadequate, because creatinine rises only after kidney injury has occurred.

  34. A patient is diagnosed with a serious methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infection. Which intravenous agent is a recommended first-line option?

    • A.Vancomycin
    • B.Gentamicin
    • C.Clindamycin
    • D.Ceftriaxone
    Show answerHide answer

    Correct answer: Vancomycin

    Vancomycin is a first-line intravenous agent for serious MRSA infections, including bacteremia, with daptomycin as the main alternative. Gentamicin is not reliable as single-agent therapy for staphylococcal bacteremia, and adding it mainly adds nephrotoxicity. Clindamycin is bacteriostatic and is an option for some MRSA skin infections, not for bloodstream infection. Ceftriaxone, like other conventional beta-lactams, cannot bind the altered penicillin-binding protein (PBP2a) that defines MRSA.

  35. A patient with an uncomplicated skin and soft tissue MRSA infection suitable for oral outpatient therapy could appropriately receive which of the following?

    • A.Amoxicillin-clavulanate or cefpodoxime proxetil
    • B.Cephalexin or dicloxacillin
    • C.Azithromycin or levofloxacin
    • D.Doxycycline or trimethoprim-sulfamethoxazole
    Show answerHide answer

    Correct answer: Doxycycline or trimethoprim-sulfamethoxazole

    Oral agents with reliable activity against community-associated MRSA include doxycycline or trimethoprim-sulfamethoxazole, with clindamycin and linezolid as other choices. Amoxicillin-clavulanate or cefpodoxime proxetil would not work, because the resistance comes from an altered penicillin-binding protein, not a beta-lactamase, so a beta-lactamase inhibitor or a later-generation oral cephalosporin does not restore activity. Cephalexin or dicloxacillin are the standard oral drugs for methicillin-susceptible staphylococci and streptococci and are inactive against MRSA. Azithromycin or levofloxacin are not recommended, since macrolide resistance is common in MRSA and fluoroquinolone resistance emerges readily.

  36. A patient with MRSA bacteremia cannot tolerate vancomycin. Which alternative agent is appropriate for MRSA bloodstream infection?

    • A.Nafcillin
    • B.Meropenem
    • C.Tobramycin
    • D.Daptomycin
    Show answerHide answer

    Correct answer: Daptomycin

    Daptomycin is the recommended alternative to vancomycin for MRSA bacteremia; it is rapidly bactericidal, and creatine kinase should be monitored during therapy. Nafcillin is a drug of choice for methicillin-susceptible Staphylococcus aureus but is inactive against MRSA. Meropenem has a very broad spectrum, yet like nearly all beta-lactams it does not cover MRSA. Tobramycin is an aminoglycoside used mainly for gram-negative organisms such as Pseudomonas and is not a treatment for staphylococcal bacteremia.

  37. Why is daptomycin inappropriate for treating MRSA pneumonia despite its activity against MRSA?

    • A.Eosinophilic pneumonia appears with daptomycin, worsening injury in the lungs
    • B.High plasma protein binding traps daptomycin, keeping levels low in the lungs
    • C.Pulmonary surfactant inactivates daptomycin, abolishing efficacy in the lungs
    • D.Bacteriostatic activity constrains daptomycin, allowing regrowth in the lungs
    Show answerHide answer

    Correct answer: Pulmonary surfactant inactivates daptomycin, abolishing efficacy in the lungs

    Pulmonary surfactant inactivates daptomycin, abolishing efficacy in the lungs: the drug inserts into surfactant lipids and is sequestered, and it failed in pneumonia trials for that reason. Vancomycin or linezolid is used for MRSA pneumonia. The claim that eosinophilic pneumonia appears with daptomycin, worsening injury in the lungs points to a real but uncommon adverse effect, which is not why the drug fails in pneumonia. The claim that high plasma protein binding traps daptomycin, keeping levels low in the lungs is not the accepted explanation; the drug reaches the alveoli but is inactivated there. The claim that bacteriostatic activity constrains daptomycin, allowing regrowth in the lungs is false because daptomycin is rapidly bactericidal.

  38. According to current major hypertension guidelines, a recommended first-line antihypertensive class for a patient without compelling comorbidities is which of the following?

    • A.A loop diuretic
    • B.A beta-adrenergic blocker
    • C.A selective alpha-1 blocker
    • D.A thiazide-type diuretic
    Show answerHide answer

    Correct answer: A thiazide-type diuretic

    The first-line classes for hypertension without a compelling indication are thiazide-type diuretics, calcium channel blockers, ACE inhibitors and angiotensin receptor blockers, so a thiazide-type diuretic is the answer here. A loop diuretic lowers blood pressure less reliably and is kept for patients with heart failure or advanced kidney disease. A beta-adrenergic blocker is no longer first-line unless the patient has ischemic heart disease or heart failure, because it protects less well against stroke. A selective alpha-1 blocker is an add-on agent; doxazosin was associated with more heart failure than chlorthalidone in ALLHAT.

  39. A 55-year-old Black patient without heart failure or chronic kidney disease needs initial hypertension therapy. Which initial regimen is most consistent with guideline recommendations for this population?

    • A.An ACE inhibitor or angiotensin II receptor blocker
    • B.A direct renin inhibitor or beta-adrenergic blocker
    • C.A loop diuretic or centrally acting alpha-2 agonist
    • D.A calcium channel blocker or thiazide-type diuretic
    Show answerHide answer

    Correct answer: A calcium channel blocker or thiazide-type diuretic

    For Black adults with hypertension who do not have heart failure or chronic kidney disease, the 2017 ACC/AHA guideline recommends that initial therapy include a calcium channel blocker or thiazide-type diuretic, which lower blood pressure and prevent stroke more effectively in this group than renin-angiotensin blockade used alone. An ACE inhibitor or angiotensin II receptor blocker is less effective as initial monotherapy here, although it becomes the preferred choice when chronic kidney disease with albuminuria or heart failure is present. A direct renin inhibitor or beta-adrenergic blocker is not a first-line choice for uncomplicated hypertension. A loop diuretic or centrally acting alpha-2 agonist is kept for specific situations such as volume overload or resistant hypertension.

  40. A patient with hypertension and concurrent chronic kidney disease with albuminuria would most appropriately receive which class as a compelling indication?

    • A.A long-acting dihydropyridine calcium channel blocker or thiazide-type diuretic
    • B.An alpha-1 adrenergic antagonist or centrally acting alpha-2 agonist
    • C.A loop diuretic or potassium-sparing diuretic such as triamterene
    • D.An angiotensin-converting enzyme inhibitor or angiotensin receptor blocker
    Show answerHide answer

    Correct answer: An angiotensin-converting enzyme inhibitor or angiotensin receptor blocker

    In hypertension with chronic kidney disease and albuminuria, an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker is the compelling-indication choice, because blocking the renin-angiotensin system lowers intraglomerular pressure, reduces proteinuria and slows the decline in kidney function. A long-acting dihydropyridine calcium channel blocker or thiazide-type diuretic lowers blood pressure but does not reduce albuminuria in the same way and is added afterward if needed. An alpha-1 adrenergic antagonist or centrally acting alpha-2 agonist offers no specific kidney protection. A loop diuretic or potassium-sparing diuretic such as triamterene may help with volume or potassium balance but does not slow the progression of proteinuric kidney disease.

  41. A patient is found to have a blood pressure of 150/95 mmHg confirmed on repeat readings. Under current guideline thresholds defining stage 2 hypertension, this reading is best categorized as which stage?

    • A.Elevated blood pressure
    • B.Stage 2 hypertension
    • C.Stage 1 hypertension
    • D.Normal blood pressure
    Show answerHide answer

    Correct answer: Stage 2 hypertension

    Under the ACC/AHA classification, stage 2 hypertension is a systolic pressure of 140 mmHg or higher or a diastolic pressure of 90 mmHg or higher, so a confirmed 150/95 mmHg meets both criteria. Elevated blood pressure is 120 to 129 systolic with a diastolic below 80. Stage 1 hypertension is 130 to 139 systolic or 80 to 89 diastolic. Normal blood pressure is below 120 systolic and below 80 diastolic.

  42. A patient with heart failure with reduced ejection fraction is being optimized on guideline-directed medical therapy. Which combination represents foundational pillars of this therapy?

    • A.A loop diuretic plus a low-dose digitalis glycoside plus an intravenous phosphodiesterase-3 inhibitor
    • B.A renin-angiotensin system inhibitor plus a beta-blocker plus a mineralocorticoid receptor antagonist
    • C.A beta-blocker plus a nondihydropyridine calcium channel blocker plus a peripheral alpha-1 antagonist
    • D.A renin-angiotensin system inhibitor plus a low-dose thiazide diuretic plus a calcium channel blocker
    Show answerHide answer

    Correct answer: A renin-angiotensin system inhibitor plus a beta-blocker plus a mineralocorticoid receptor antagonist

    The therapies that reduce mortality in heart failure with reduced ejection fraction are a renin-angiotensin system inhibitor plus a beta-blocker plus a mineralocorticoid receptor antagonist, with an SGLT2 inhibitor now added as a fourth pillar and an angiotensin receptor-neprilysin inhibitor preferred as the renin-angiotensin agent. A loop diuretic plus a low-dose digitalis glycoside plus an intravenous phosphodiesterase-3 inhibitor relieves congestion and symptoms, but none of the three improves survival. A beta-blocker plus a nondihydropyridine calcium channel blocker plus a peripheral alpha-1 antagonist contains only one pillar; verapamil and diltiazem depress contractility and are avoided in this condition, and alpha-1 antagonists have shown no benefit. A renin-angiotensin system inhibitor plus a low-dose thiazide diuretic plus a calcium channel blocker is a regimen for hypertension, not the foundation of heart failure therapy.

  43. Which medication class is now recommended for heart failure with reduced ejection fraction based on demonstrated mortality and hospitalization benefit, even in patients without diabetes?

    • A.Sodium-glucose cotransporter-2 (SGLT2) inhibitors
    • B.Glucagon-like peptide-1 (GLP-1) receptor agonists
    • C.Dipeptidyl peptidase-4 (DPP-4) inhibitors
    • D.Thiazolidinediones (PPAR-gamma agonists)
    Show answerHide answer

    Correct answer: Sodium-glucose cotransporter-2 (SGLT2) inhibitors

    Sodium-glucose cotransporter-2 (SGLT2) inhibitors such as dapagliflozin and empagliflozin reduced cardiovascular death and heart failure hospitalization in patients with reduced ejection fraction whether or not they had diabetes, and they are now part of guideline-directed therapy. Glucagon-like peptide-1 (GLP-1) receptor agonists lower atherosclerotic events in type 2 diabetes but have not shown this benefit in heart failure with reduced ejection fraction. Dipeptidyl peptidase-4 (DPP-4) inhibitors have no heart failure benefit, and saxagliptin and alogliptin carry a warning about heart failure hospitalization. Thiazolidinediones (PPAR-gamma agonists) cause fluid retention and can precipitate or worsen heart failure.

  44. A patient with heart failure with reduced ejection fraction is switched from an ACE inhibitor to sacubitril-valsartan (an angiotensin receptor-neprilysin inhibitor). What washout precaution is essential?

    • A.Wait at least 24 hours after the last ACE inhibitor dose to lower the risk of angioedema
    • B.Wait at least 36 hours after the last ACE inhibitor dose to lower the risk of hyperkalemia
    • C.Wait at least 24 hours after the last ACE inhibitor dose to lower the risk of hyperkalemia
    • D.Wait at least 36 hours after the last ACE inhibitor dose to lower the risk of angioedema
    Show answerHide answer

    Correct answer: Wait at least 36 hours after the last ACE inhibitor dose to lower the risk of angioedema

    The right precaution is "Wait at least 36 hours after the last ACE inhibitor dose to lower the risk of angioedema": sacubitril blocks neprilysin, an enzyme that breaks down bradykinin, and an ACE inhibitor does the same by another route, so the two must not overlap. "Wait at least 24 hours after the last ACE inhibitor dose to lower the risk of angioedema" names the right hazard but skipping a single daily dose is too short a gap; the labeled minimum is 36 hours. "Wait at least 36 hours after the last ACE inhibitor dose to lower the risk of hyperkalemia" gives the right interval for the wrong reason, because the washout exists for bradykinin-related angioedema, and potassium is managed by monitoring, not by a washout. "Wait at least 24 hours after the last ACE inhibitor dose to lower the risk of hyperkalemia" is wrong on both the interval and the reason.

  45. A patient with symptomatic heart failure and reduced ejection fraction develops worsening fluid overload with peripheral edema and dyspnea. Which class is most appropriate to relieve these congestive symptoms?

    • A.A loop diuretic such as furosemide
    • B.An ACE inhibitor such as lisinopril
    • C.A beta-blocker such as carvedilol
    • D.An aldosterone antagonist such as spironolactone
    Show answerHide answer

    Correct answer: A loop diuretic such as furosemide

    "A loop diuretic such as furosemide" is the class that removes excess fluid quickly, so it relieves edema and dyspnea even though it has not been shown to prolong survival. "An ACE inhibitor such as lisinopril" improves survival and slows remodeling, but it does not clear congestion on its own. "A beta-blocker such as carvedilol" also improves survival, yet it is started or increased only when the patient is no longer fluid overloaded, because it can worsen congestion in the short term. "An aldosterone antagonist such as spironolactone" is used at low doses for its mortality benefit and is too weak a diuretic to treat marked fluid overload.

  46. Metformin is recommended as the typical first-line pharmacologic agent for most patients with type 2 diabetes primarily because of which combination of attributes?

    • A.It is effective, weight-neutral, inexpensive, and unlikely to cause hypoglycemia by itself
    • B.It is potent, weight-reducing, inexpensive, and safe to use at any level of kidney function
    • C.It is potent, fast-acting, well tolerated, and able to stimulate insulin release by itself
    • D.It is effective, well tolerated, convenient, and easy to take without gastrointestinal upset
    Show answerHide answer

    Correct answer: It is effective, weight-neutral, inexpensive, and unlikely to cause hypoglycemia by itself

    Metformin is the usual starting drug because "It is effective, weight-neutral, inexpensive, and unlikely to cause hypoglycemia by itself": it lowers hepatic glucose output without raising insulin levels. "It is potent, weight-reducing, inexpensive, and safe to use at any level of kidney function" fails because metformin is contraindicated when the eGFR is below 30 mL/min/1.73 m21.73\ \text{m}^{2}, owing to the risk of lactic acidosis, and it does not produce reliable weight loss. "It is potent, fast-acting, well tolerated, and able to stimulate insulin release by itself" describes an insulin secretagogue such as a sulfonylurea; metformin does not stimulate insulin release and takes weeks to reach full effect. "It is effective, well tolerated, convenient, and easy to take without gastrointestinal upset" is wrong because diarrhea, nausea and abdominal discomfort are its most common adverse effects, which is why the dose is titrated slowly and taken with meals.

  47. A patient with type 2 diabetes and established atherosclerotic cardiovascular disease would most benefit from adding which class for its proven cardiovascular benefit?

    • A.A DPP-4 inhibitor or sulfonylurea with proven cardiovascular benefit
    • B.A thiazolidinedione or alpha-glucosidase inhibitor with proven cardiovascular benefit
    • C.A GLP-1 receptor agonist or SGLT2 inhibitor with proven cardiovascular benefit
    • D.A premixed 70/30 insulin or DPP-4 inhibitor with proven cardiovascular benefit
    Show answerHide answer

    Correct answer: A GLP-1 receptor agonist or SGLT2 inhibitor with proven cardiovascular benefit

    For type 2 diabetes with established atherosclerotic cardiovascular disease, guidelines recommend "A GLP-1 receptor agonist or SGLT2 inhibitor with proven cardiovascular benefit", whatever the A1c, because agents in these two classes reduced major cardiovascular events in outcome trials. "A DPP-4 inhibitor or sulfonylurea with proven cardiovascular benefit" does not exist: DPP-4 inhibitors were neutral in their trials and sulfonylureas have no outcome benefit. "A thiazolidinedione or alpha-glucosidase inhibitor with proven cardiovascular benefit" is also wrong, since thiazolidinediones cause fluid retention and heart failure and acarbose did not reduce events. "A premixed 70/30 insulin or DPP-4 inhibitor with proven cardiovascular benefit" fails for the same reason: insulin has shown no cardiovascular outcome benefit, and a premixed product adds weight gain and hypoglycemia.

  48. Which diabetes medication class carries the highest risk of hypoglycemia among oral agents and works by stimulating insulin secretion?

    • A.Meglitinides
    • B.Sulfonylureas
    • C.Thiazolidinediones
    • D.Biguanides
    Show answerHide answer

    Correct answer: Sulfonylureas

    Sulfonylureas close the ATP-sensitive potassium channel on the beta cell and release insulin whatever the glucose level, and their long duration gives them the highest hypoglycemia risk of the oral agents, especially in older adults and in renal impairment. Meglitinides also stimulate insulin secretion, but they are short acting and taken only with meals, so their hypoglycemia risk is lower. Thiazolidinediones improve insulin sensitivity and do not stimulate insulin secretion. Biguanides (metformin) reduce hepatic glucose production and rarely cause hypoglycemia when used alone.

  49. A patient starting an SGLT2 inhibitor for type 2 diabetes should be counseled about which characteristic adverse effect?

    • A.Nausea and early fullness caused by food held longer in the stomach
    • B.Peripheral edema and weight gain caused by excess fluid retained in the tissues
    • C.Abdominal bloating and flatulence caused by carbohydrate fermented in the colon
    • D.Genital and urinary tract infections caused by glucose excreted in the urine
    Show answerHide answer

    Correct answer: Genital and urinary tract infections caused by glucose excreted in the urine

    SGLT2 inhibitors block glucose reabsorption in the proximal tubule, so the characteristic adverse effect is "Genital and urinary tract infections caused by glucose excreted in the urine"; genital yeast infections are the most common. "Nausea and early fullness caused by food held longer in the stomach" describes a GLP-1 receptor agonist, which slows gastric emptying. "Peripheral edema and weight gain caused by excess fluid retained in the tissues" describes a thiazolidinedione; SGLT2 inhibitors cause a mild diuresis and modest weight loss. "Abdominal bloating and flatulence caused by carbohydrate fermented in the colon" describes an alpha-glucosidase inhibitor such as acarbose.

  50. A patient with type 2 diabetes wants an agent associated with weight loss and a low hypoglycemia risk that is given by injection. Which class best fits?

    • A.An SGLT2 inhibitor
    • B.A DPP-4 inhibitor
    • C.Premixed 70/30 human insulin
    • D.A GLP-1 receptor agonist
    Show answerHide answer

    Correct answer: A GLP-1 receptor agonist

    "A GLP-1 receptor agonist" matches all three requirements: it promotes weight loss, releases insulin only when glucose is raised, so hypoglycemia is uncommon, and most products are injected under the skin. "An SGLT2 inhibitor" gives weight loss with a low hypoglycemia risk, but it is an oral tablet. "A DPP-4 inhibitor" has a low hypoglycemia risk, but it is oral and weight-neutral. "Premixed 70/30 human insulin" is injected, but it causes weight gain and carries a clear hypoglycemia risk.

  51. During admission, a pharmacist compares the patient's home medication list to the inpatient orders and resolves discrepancies. This process is best described as which person-centered assessment activity?

    • A.Medication therapy management
    • B.Drug utilization review
    • C.Drug regimen review
    • D.Medication reconciliation
    Show answerHide answer

    Correct answer: Medication reconciliation

    Comparing the home list with the current orders and resolving every discrepancy at a transition of care is "Medication reconciliation"; it catches omissions, duplications and dose errors when a patient is admitted, transferred or discharged. "Medication therapy management" is a broader, ongoing service that optimizes therapy and adherence for a patient with complex regimens and is not tied to comparing two lists at admission. "Drug utilization review" screens a prescription against the patient profile for interactions, duplication and dose problems at the time of dispensing. "Drug regimen review" is the periodic review a consultant pharmacist performs for residents of long-term care facilities.

  52. What is the primary patient-safety goal of performing medication reconciliation at transitions of care?

    • A.To lower medication costs through generic prescribing, formulary switches, and discount programs
    • B.To document medication allergies such as rashes, anaphylaxis, and drug intolerances
    • C.To prevent medication errors such as omissions, duplicate therapy, and dosing discrepancies
    • D.To improve medication adherence through pill organizers, refill reminders, and simpler regimens
    Show answerHide answer

    Correct answer: To prevent medication errors such as omissions, duplicate therapy, and dosing discrepancies

    Transitions of care are where lists diverge, so the goal of reconciliation is "To prevent medication errors such as omissions, duplicate therapy, and dosing discrepancies". "To lower medication costs through generic prescribing, formulary switches, and discount programs" describes formulary management, which is a cost aim and not the safety purpose of reconciling two lists. "To document medication allergies such as rashes, anaphylaxis, and drug intolerances" is part of taking an admission history, but recording allergies does not compare what the patient was taking with what is now ordered. "To improve medication adherence through pill organizers, refill reminders, and simpler regimens" describes adherence support, a separate service that assumes the list is already accurate.

  53. While taking a medication history, a pharmacist learns the patient also uses an over-the-counter NSAID and an herbal supplement. Why is capturing these during reconciliation important?

    • A.These products meet the same standards as an approved drug, so they need no separate review
    • B.These products rarely alter prescription drug levels and effects, so they need no place on the list
    • C.These products can cause drug interactions and adverse effects, so they need to be assessed
    • D.These products can cause rashes more often than a prescription drug, so they need to be entered as allergies
    Show answerHide answer

    Correct answer: These products can cause drug interactions and adverse effects, so they need to be assessed

    The reason is that "These products can cause drug interactions and adverse effects, so they need to be assessed": an NSAID can raise blood pressure, impair renal function and add to bleeding risk, and herbal products such as St. John's wort induce drug-metabolizing enzymes. "These products meet the same standards as an approved drug, so they need no separate review" is false because dietary supplements are marketed without FDA review of safety or efficacy, and even an approved nonprescription drug still has to be checked against the rest of the regimen. "These products rarely alter prescription drug levels and effects, so they need no place on the list" is false because clinically important interactions with nonprescription and herbal products are well documented. "These products can cause rashes more often than a prescription drug, so they need to be entered as allergies" is false; they belong on the medication list, and most documented drug allergies involve prescription drugs such as antibiotics.

  54. A patient is discharged with several medication changes. Which reconciliation step most directly reduces post-discharge confusion and readmission risk?

    • A.Sending the physician a full, signed summary of medication changes and booking a clinic visit
    • B.Taking a complete, verified medication history and noting the recent changes on admission
    • C.Providing a clear, updated medication list and counseling the patient on the changes
    • D.Filing a complete, signed medication record in the chart and reviewing the changes with nurses
    Show answerHide answer

    Correct answer: Providing a clear, updated medication list and counseling the patient on the changes

    The step that speaks directly to the patient is "Providing a clear, updated medication list and counseling the patient on the changes": the patient leaves knowing what was started, stopped and adjusted, which is what prevents mix-ups at home. "Sending the physician a full, signed summary of medication changes and booking a clinic visit" keeps the next prescriber informed, but it leaves the patient without the new list in the days before that visit. "Taking a complete, verified medication history and noting the recent changes on admission" builds the starting list and does nothing to explain what was changed by discharge. "Filing a complete, signed medication record in the chart and reviewing the changes with nurses" documents the regimen for staff, but the patient, who has to manage the drugs at home, is told nothing.

  55. A patient receiving an aminoglycoside has a measured trough above the target range. Beyond efficacy, which toxicity does an elevated aminoglycoside trough specifically raise concern for?

    • A.Hepatotoxicity and neurotoxicity
    • B.Nephrotoxicity and ototoxicity
    • C.Cardiotoxicity and myelosuppression
    • D.Phototoxicity and tendinopathy
    Show answerHide answer

    Correct answer: Nephrotoxicity and ototoxicity

    Aminoglycosides accumulate in the renal proximal tubule and in the inner ear when the drug is not allowed to clear between doses, so a high trough raises concern for "Nephrotoxicity and ototoxicity". "Hepatotoxicity and neurotoxicity" is the pattern watched for with isoniazid; aminoglycosides are not metabolized by the liver and do not injure it. "Cardiotoxicity and myelosuppression" is the pattern of an anthracycline such as doxorubicin. "Phototoxicity and tendinopathy" is the pattern of a fluoroquinolone and has no link to aminoglycoside trough concentrations.

  56. A patient on phenytoin has a low albumin level. Why must total phenytoin concentrations be interpreted carefully in this setting during therapeutic drug monitoring?

    • A.The total level can read high while the free, active fraction is relatively lower
    • B.The total level can read low while the free, active fraction is relatively higher
    • C.The total level can read low while the free, active fraction is relatively lower
    • D.The total level can read high while the free, active fraction is relatively higher
    Show answerHide answer

    Correct answer: The total level can read low while the free, active fraction is relatively higher

    Phenytoin is about 90% bound to albumin. With less albumin there is less bound drug, so "The total level can read low while the free, active fraction is relatively higher"; a free phenytoin level, or a total level corrected for albumin, should guide the dose. "The total level can read high while the free, active fraction is relatively lower" reverses both effects. "The total level can read low while the free, active fraction is relatively lower" gets the total right but the free fraction wrong, and acting on it by raising the dose is how toxicity occurs. "The total level can read high while the free, active fraction is relatively higher" gets the free fraction right but the total wrong: fewer binding sites lower the total concentration.

  57. A patient with type 1 diabetes requires basal-bolus insulin therapy. Which statement best describes the role of basal insulin?

    • A.It supplies a rapid burst of insulin at meals and snacks to cover carbohydrate
    • B.It supplies a corrective dose of insulin for high readings between meals and at bedtime
    • C.It supplies a single daily dose of insulin that covers both fasting needs and meals
    • D.It supplies a steady background of insulin between meals and overnight
    Show answerHide answer

    Correct answer: It supplies a steady background of insulin between meals and overnight

    Basal insulin suppresses hepatic glucose output in the fasting state, so "It supplies a steady background of insulin between meals and overnight". "It supplies a rapid burst of insulin at meals and snacks to cover carbohydrate" describes bolus (prandial) insulin, the other half of the regimen. "It supplies a corrective dose of insulin for high readings between meals and at bedtime" describes correction insulin, which is rapid-acting insulin added for a high reading. "It supplies a single daily dose of insulin that covers both fasting needs and meals" is wrong because basal insulin has no mealtime peak; in type 1 diabetes rapid-acting insulin is still required with food.

  58. A patient with heart failure with reduced ejection fraction is started on spironolactone. Which monitoring parameter is most important to assess for a key adverse effect?

    • A.Serum transaminases and bilirubin
    • B.Serum calcium and uric acid
    • C.Serum potassium and renal function
    • D.Serum glucose and cholesterol levels
    Show answerHide answer

    Correct answer: Serum potassium and renal function

    Spironolactone blocks the mineralocorticoid receptor and reduces potassium excretion, so the tests to follow are "Serum potassium and renal function"; hyperkalemia is most likely when kidney function falls or when an ACE inhibitor, ARB or ARNI is also taken. "Serum transaminases and bilirubin" monitor for liver injury, which is not a characteristic effect of spironolactone. "Serum calcium and uric acid" are the values a thiazide diuretic can raise. "Serum glucose and cholesterol levels" are metabolic values affected by thiazides and some beta-blockers, not by spironolactone.

  59. A patient taking lithium is also prescribed a thiazide diuretic. What is the primary clinical concern with this drug-drug interaction?

    • A.Lithium excretion rises, lowering serum levels and the control of mood symptoms
    • B.Lithium reabsorption rises, raising serum levels and the risk of toxicity
    • C.Thiazide excretion falls, raising diuretic exposure and the risk of hypokalemia
    • D.Thiazide response falls, lowering sodium loss and the control of blood pressure
    Show answerHide answer

    Correct answer: Lithium reabsorption rises, raising serum levels and the risk of toxicity

    A thiazide causes sodium loss, and the proximal tubule responds by reabsorbing more sodium and, with it, more lithium. The concern is therefore "Lithium reabsorption rises, raising serum levels and the risk of toxicity"; lithium has a narrow therapeutic index, so levels are checked and the dose is often reduced. "Lithium excretion rises, lowering serum levels and the control of mood symptoms" is the opposite direction; that pattern is seen with osmotic diuretics, caffeine and theophylline. "Thiazide excretion falls, raising diuretic exposure and the risk of hypokalemia" is wrong because lithium does not impair thiazide elimination. "Thiazide response falls, lowering sodium loss and the control of blood pressure" is wrong because lithium does not blunt the thiazide's diuretic or antihypertensive effect.

  60. A patient with hypertension and a history of gout should generally avoid which antihypertensive due to its potential to worsen the comorbidity?

    • A.An ACE inhibitor, because it raises serum uric acid
    • B.An angiotensin receptor blocker, because it raises serum uric acid
    • C.A thiazide diuretic, because it raises serum uric acid
    • D.A calcium channel blocker, because it raises serum uric acid
    Show answerHide answer

    Correct answer: A thiazide diuretic, because it raises serum uric acid

    The drug to avoid is "A thiazide diuretic, because it raises serum uric acid": thiazides compete with urate for secretion and increase its reabsorption, which can precipitate a gout flare. "An ACE inhibitor, because it raises serum uric acid" is wrong because ACE inhibitors do not raise urate. "An angiotensin receptor blocker, because it raises serum uric acid" is wrong, and losartan in particular lowers urate through a uricosuric effect. "A calcium channel blocker, because it raises serum uric acid" is wrong because calcium channel blockers are urate-neutral or slightly lowering and are a reasonable choice in a patient with gout.

  61. A clinician is selecting an oral anticoagulant for a patient with mechanical heart valve. Which agent is appropriate, reflecting an important DOAC limitation?

    • A.Dabigatran
    • B.Warfarin
    • C.Edoxaban
    • D.Apixaban
    Show answerHide answer

    Correct answer: Warfarin

    Warfarin, adjusted to the INR target for the valve type and position, is the oral anticoagulant for a mechanical heart valve. Dabigatran was compared with warfarin in patients with mechanical valves and caused more thromboembolic and more bleeding events, and its labeling contraindicates this use. Apixaban also proved inferior to warfarin in a mechanical aortic valve trial. Edoxaban, like the other direct oral anticoagulants, is not approved or recommended for mechanical valves.

  62. A patient on vancomycin develops flushing of the upper body and a rash during a rapid infusion. This reaction is best characterized as which of the following?

    • A.Vancomycin infusion reaction (formerly red man syndrome) related to the administration rate
    • B.Anaphylaxis to vancomycin (an IgE-mediated allergic reaction) unrelated to the infusion rate
    • C.Phlebitis from vancomycin (a local vein reaction) related to the infusion rate and site
    • D.DRESS from vancomycin (a delayed hypersensitivity reaction) unrelated to the infusion rate
    Show answerHide answer

    Correct answer: Vancomycin infusion reaction (formerly red man syndrome) related to the administration rate

    Flushing and a rash of the face, neck and upper trunk during a rapid dose is "Vancomycin infusion reaction (formerly red man syndrome) related to the administration rate": vancomycin releases histamine directly from mast cells, so giving it more slowly, with or without an antihistamine beforehand, allows the drug to be continued. "Anaphylaxis to vancomycin (an IgE-mediated allergic reaction) unrelated to the infusion rate" would bring hypotension, wheeze or angioedema and would mean avoiding the drug. "Phlebitis from vancomycin (a local vein reaction) related to the infusion rate and site" causes pain and redness along the vein, not upper-body flushing. "DRESS from vancomycin (a delayed hypersensitivity reaction) unrelated to the infusion rate" appears after weeks of therapy with fever, eosinophilia and organ involvement.

  63. A patient with diabetes is found to have an A1c that reflects average glycemia over approximately what time period, guiding treatment intensification decisions?

    • A.The previous 2 to 3 months
    • B.The previous 2 to 3 weeks
    • C.The previous 4 to 6 weeks
    • D.The previous 4 to 6 months
    Show answerHide answer

    Correct answer: The previous 2 to 3 months

    Glucose attaches to hemoglobin for the life of the red cell, about 120 days, so the A1c reflects average glycemia over "The previous 2 to 3 months" and is rechecked about every 3 months when therapy is being adjusted. "The previous 2 to 3 weeks" is the window of fructosamine or glycated albumin, not of A1c. "The previous 4 to 6 weeks" is too short for a full turnover of red cells. "The previous 4 to 6 months" is longer than a red cell survives.

  64. A patient starting amiodarone is also taking warfarin. Which adjustment is most appropriate given the interaction?

    • A.Expect the INR to fall, so raise the warfarin dose and monitor more closely
    • B.Expect the INR to rise, so reduce the warfarin dose and monitor more closely
    • C.Expect the INR to rise, so hold the warfarin dose and restart it once amiodarone is at steady state
    • D.Expect the INR to fall, so keep the warfarin dose and add a heparin bridge
    Show answerHide answer

    Correct answer: Expect the INR to rise, so reduce the warfarin dose and monitor more closely

    Amiodarone inhibits CYP2C9 and other enzymes that clear warfarin, so the right plan is "Expect the INR to rise, so reduce the warfarin dose and monitor more closely"; an empiric reduction of roughly a third to a half is common, and the effect builds over weeks. "Expect the INR to fall, so raise the warfarin dose and monitor more closely" is the response to an enzyme inducer such as rifampin and would cause bleeding here. "Expect the INR to rise, so hold the warfarin dose and restart it once amiodarone is at steady state" gets the direction right but the action wrong, because amiodarone takes months to reach steady state and the patient would be left without anticoagulation. "Expect the INR to fall, so keep the warfarin dose and add a heparin bridge" is wrong on direction and would add a second anticoagulant just as warfarin's effect increases.

  65. A patient with heart failure and reduced ejection fraction has a resting heart rate that remains elevated despite a maximally tolerated beta-blocker and is in sinus rhythm. Which agent specifically lowers heart rate in this setting?

    • A.Ivabradine
    • B.Diltiazem
    • C.Digoxin
    • D.Vericiguat
    Show answerHide answer

    Correct answer: Ivabradine

    Ivabradine blocks the funny current in the sinoatrial node and slows the heart rate without reducing contractility; it is used in heart failure with reduced ejection fraction when the patient is in sinus rhythm with a resting rate of 70 beats per minute or more despite a maximally tolerated beta-blocker. Diltiazem slows the heart rate, but nondihydropyridine calcium channel blockers are negative inotropes and are avoided when the ejection fraction is reduced. Digoxin can reduce heart failure hospitalizations and controls the ventricular rate in atrial fibrillation, but it is not the agent chosen to lower a sinus rate. Vericiguat, a soluble guanylate cyclase stimulator, is added after a recent worsening of heart failure and does not lower heart rate.

  66. A patient with type 2 diabetes and chronic kidney disease with albuminuria would gain added renal protection from which class beyond glycemic control?

    • A.An SGLT2 inhibitor
    • B.A DPP-4 inhibitor
    • C.A sulfonylurea such as glipizide
    • D.A meglitinide such as repaglinide
    Show answerHide answer

    Correct answer: An SGLT2 inhibitor

    "An SGLT2 inhibitor" slows the decline in kidney function and reduces kidney failure in chronic kidney disease with albuminuria, a benefit that does not depend on how much it lowers glucose. "A DPP-4 inhibitor" is safe in kidney disease, but it has not been shown to slow its progression. "A sulfonylurea such as glipizide" lowers glucose by stimulating insulin release and has no kidney protection of its own. "A meglitinide such as repaglinide" stimulates insulin release in the same way and likewise offers no renal benefit beyond glucose control.

  67. A patient receiving vancomycin requires a loading dose for a severe infection. What is the rationale for using a weight-based loading dose at the start of therapy?

    • A.To reach therapeutic concentrations quickly without the delay of gradual accumulation
    • B.To produce a high peak early, since the rate of bacterial killing is concentration-dependent
    • C.To saturate tissue binding sites early, allowing longer intervals between doses of the antibiotic
    • D.To shorten the total course of therapy without the added risk of kidney injury
    Show answerHide answer

    Correct answer: To reach therapeutic concentrations quickly without the delay of gradual accumulation

    Without a loading dose, steady state is reached only after several half-lives, so the load is given "To reach therapeutic concentrations quickly without the delay of gradual accumulation"; it is based on actual body weight because it has to fill the volume of distribution. "To produce a high peak early, since the rate of bacterial killing is concentration-dependent" describes aminoglycosides; vancomycin efficacy tracks the AUC to MIC ratio, not the peak. "To saturate tissue binding sites early, allowing longer intervals between doses of the antibiotic" is wrong because the maintenance interval is set by clearance, which a loading dose does not change. "To shorten the total course of therapy without the added risk of kidney injury" is wrong because the duration of therapy is set by the infection, and a loading dose does not shorten it.

  68. A patient on metformin is scheduled for a procedure using iodinated contrast. What is the appropriate medication management consideration?

    • A.Halve the metformin dose around the contrast study in at-risk patients to lower lactic acidosis risk
    • B.Hold metformin around the contrast study in fasting patients to lower hypoglycemia risk
    • C.Halve the metformin dose around the contrast study in fasting patients to lower hypoglycemia risk
    • D.Hold metformin around the contrast study in at-risk patients to lower lactic acidosis risk
    Show answerHide answer

    Correct answer: Hold metformin around the contrast study in at-risk patients to lower lactic acidosis risk

    Iodinated contrast can cause acute kidney injury, and metformin that is not cleared can accumulate, so the plan is "Hold metformin around the contrast study in at-risk patients to lower lactic acidosis risk". At-risk patients include those with an eGFR of 30 to 60 mL/min/1.73 m21.73\ \text{m}^{2}, liver disease, alcohol use disorder or heart failure, and those given intra-arterial contrast; the drug is restarted once kidney function is confirmed stable, usually after 48 hours. "Halve the metformin dose around the contrast study in at-risk patients to lower lactic acidosis risk" names the right hazard, but the labeling calls for stopping the drug, not reducing it. "Hold metformin around the contrast study in fasting patients to lower hypoglycemia risk" gives the wrong reason and the wrong patients: metformin alone rarely causes hypoglycemia, and the concern is kidney function. "Halve the metformin dose around the contrast study in fasting patients to lower hypoglycemia risk" is wrong on the action and on the reason.

  69. A patient taking a potassium-sparing diuretic is started on an ACE inhibitor. What monitoring is most important for this drug-drug interaction?

    • A.Serum potassium for hypokalemia
    • B.Serum magnesium for hypermagnesemia
    • C.Serum magnesium for hypomagnesemia
    • D.Serum potassium for hyperkalemia
    Show answerHide answer

    Correct answer: Serum potassium for hyperkalemia

    An ACE inhibitor lowers aldosterone and a potassium-sparing diuretic blocks potassium excretion in the collecting duct, so together they retain potassium and the monitoring needed is "Serum potassium for hyperkalemia", along with renal function. "Serum potassium for hypokalemia" names the right test but the wrong direction; hypokalemia is the concern with loop and thiazide diuretics. "Serum magnesium for hypermagnesemia" is not a recognized danger of this combination. "Serum magnesium for hypomagnesemia" is a concern with loop and thiazide diuretics and with proton pump inhibitors, not with these two drugs.

  70. A pharmacist evaluates a patient on digoxin who has new hypokalemia. Why does low potassium increase the concern for digoxin toxicity?

    • A.Low potassium decreases digoxin clearance in the kidney, so toxicity can follow rising serum levels
    • B.Low potassium increases digoxin binding in the myocardium, so toxicity can occur at normal levels
    • C.Low potassium increases digoxin release from the plasma proteins, so toxicity follows a rise in free drug
    • D.Low potassium decreases digoxin metabolism in the liver, so toxicity appears at normal doses
    Show answerHide answer

    Correct answer: Low potassium increases digoxin binding in the myocardium, so toxicity can occur at normal levels

    Digoxin and potassium compete for the same site on the sodium-potassium ATPase. That is why "Low potassium increases digoxin binding in the myocardium, so toxicity can occur at normal levels", and why potassium is corrected in any patient taking digoxin. "Low potassium decreases digoxin clearance in the kidney, so toxicity can follow rising serum levels" is wrong because hypokalemia does not reduce renal clearance of digoxin; the interaction is at the receptor, not in the serum concentration. "Low potassium increases digoxin release from the plasma proteins, so toxicity follows a rise in free drug" is wrong because digoxin is only about 25% protein bound and potassium does not displace it. "Low potassium decreases digoxin metabolism in the liver, so toxicity appears at normal doses" is wrong because digoxin is eliminated mostly unchanged by the kidney.

  71. A patient with hypertension and benign prostatic hyperplasia might gain dual benefit from which agent, illustrating person-centered selection?

    • A.A beta-1 blocker
    • B.An alpha-1 blocker
    • C.An alpha-2 agonist
    • D.A beta-3 agonist
    Show answerHide answer

    Correct answer: An alpha-1 blocker

    "An alpha-1 blocker" such as doxazosin or terazosin relaxes vascular smooth muscle, which lowers blood pressure, and relaxes the prostate and bladder neck, which improves urine flow; it is not a first-line antihypertensive, but the second condition can justify it. "A beta-1 blocker" lowers blood pressure and does nothing for urinary symptoms. "An alpha-2 agonist" such as clonidine lowers blood pressure centrally and has no effect on the prostate. "A beta-3 agonist" such as mirabegron treats overactive bladder and can raise blood pressure.

  72. A patient on rivaroxaban is counseled about administration with food. Which counseling point reflects an absorption-related consideration for higher doses of this DOAC?

    • A.Higher doses should be taken before food to increase absorption
    • B.Higher doses should be taken with food to speed the onset
    • C.Higher doses should be taken with food to increase absorption
    • D.Higher doses should be taken before food to speed the onset
    Show answerHide answer

    Correct answer: Higher doses should be taken with food to increase absorption

    The 15 mg and 20 mg tablets of rivaroxaban are absorbed incompletely in the fasted state, so "Higher doses should be taken with food to increase absorption"; the 2.5 mg and 10 mg tablets can be taken with or without food. "Higher doses should be taken before food to increase absorption" is the reverse, because an empty stomach lowers exposure to these doses by roughly a third. "Higher doses should be taken with food to speed the onset" gives the right instruction for the wrong reason: food raises the amount absorbed and, if anything, delays the peak. "Higher doses should be taken before food to speed the onset" is wrong on both counts.

  73. A patient with new heart failure with preserved ejection fraction (HFpEF) and hypertension is being treated. Which agent class has shown benefit in HFpEF and addresses both conditions?

    • A.A PDE-5 inhibitor
    • B.An alpha-1 blocker
    • C.An SGLT2 inhibitor
    • D.A beta-1 blocker
    Show answerHide answer

    Correct answer: An SGLT2 inhibitor

    "An SGLT2 inhibitor" (empagliflozin or dapagliflozin) reduced heart failure hospitalizations in trials of preserved ejection fraction, and its mild diuretic effect lowers blood pressure by a few points. "A PDE-5 inhibitor" such as sildenafil did not improve exercise capacity or clinical status in preserved ejection fraction. "An alpha-1 blocker" such as doxazosin lowers blood pressure, but it has no heart failure benefit and was linked to more heart failure events than a thiazide-type diuretic in a large hypertension trial. "A beta-1 blocker" lowers blood pressure and heart rate, but it has not been shown to improve outcomes in preserved ejection fraction.

  74. A patient with type 2 diabetes on insulin reports recurrent overnight hypoglycemia. Which adjustment is most appropriate to individualize therapy?

    • A.Reduce or adjust the basal insulin and review its timing and food intake
    • B.Raise the dose of basal insulin and review its timing and food intake
    • C.Reduce or adjust the breakfast bolus insulin and review its timing and food intake
    • D.Raise the dose of breakfast bolus insulin and review its timing and food intake
    Show answerHide answer

    Correct answer: Reduce or adjust the basal insulin and review its timing and food intake

    Glucose that falls during the night, when no food is being absorbed, points to too much background insulin, so the step is "Reduce or adjust the basal insulin and review its timing and food intake". "Raise the dose of basal insulin and review its timing and food intake" targets the right insulin in the wrong direction; a higher basal dose would deepen the overnight lows. "Reduce or adjust the breakfast bolus insulin and review its timing and food intake" changes the wrong component, because a rapid-acting dose given at breakfast has worn off long before the night. "Raise the dose of breakfast bolus insulin and review its timing and food intake" is wrong on both the component and the direction.

  75. A patient is taking sildenafil and is prescribed nitroglycerin for chest pain. What is the critical drug-drug interaction concern?

    • A.Profound bradycardia from additive nodal suppression
    • B.Hypertensive crisis from additive catecholamine release
    • C.Severe hypotension from additive vasodilation
    • D.Ventricular arrhythmia from additive repolarization delay
    Show answerHide answer

    Correct answer: Severe hypotension from additive vasodilation

    Nitrates raise cyclic GMP in vascular smooth muscle and sildenafil blocks its breakdown by phosphodiesterase type 5, so the danger is "Severe hypotension from additive vasodilation"; nitrates are contraindicated within 24 hours of sildenafil. "Profound bradycardia from additive nodal suppression" is the concern when a beta-blocker is combined with verapamil or diltiazem. "Hypertensive crisis from additive catecholamine release" is the concern when a monoamine oxidase inhibitor is combined with a sympathomimetic or tyramine. "Ventricular arrhythmia from additive repolarization delay" is the concern when two drugs that prolong the QT interval are combined.

  76. A patient with MRSA pneumonia who cannot receive vancomycin is being considered for linezolid. Which monitoring concern is important with prolonged linezolid use?

    • A.Myopathy, including rhabdomyolysis, during prolonged therapy
    • B.Nephrotoxicity, including acute tubular necrosis, during prolonged therapy
    • C.Ototoxicity, including hearing loss, during prolonged therapy
    • D.Myelosuppression, including thrombocytopenia, during prolonged therapy
    Show answerHide answer

    Correct answer: Myelosuppression, including thrombocytopenia, during prolonged therapy

    The concern with linezolid is "Myelosuppression, including thrombocytopenia, during prolonged therapy": it is reversible and most often seen after about two weeks, so a complete blood count is checked weekly. "Myopathy, including rhabdomyolysis, during prolonged therapy" is the concern with daptomycin, which is followed with creatine kinase levels and is not used for pneumonia. "Nephrotoxicity, including acute tubular necrosis, during prolonged therapy" is the concern with vancomycin and the aminoglycosides; linezolid needs no renal dose adjustment. "Ototoxicity, including hearing loss, during prolonged therapy" is an aminoglycoside toxicity and is not associated with linezolid.

  77. A patient on warfarin is started on trimethoprim-sulfamethoxazole for an infection. What is the most appropriate anticoagulation action?

    • A.Check the INR more often and expect the INR to fall
    • B.Keep the usual INR schedule and expect no change in the INR
    • C.Keep the usual INR schedule and expect a rise that may require a dose reduction after several weeks
    • D.Check the INR more often and expect a rise that may require a dose reduction
    Show answerHide answer

    Correct answer: Check the INR more often and expect a rise that may require a dose reduction

    Sulfamethoxazole inhibits CYP2C9, the main enzyme that clears the more active S-warfarin, so the plan is "Check the INR more often and expect a rise that may require a dose reduction"; the INR can climb within a few days, and some clinicians lower the dose in advance or choose another antibiotic. "Check the INR more often and expect the INR to fall" is the pattern with an inducer such as rifampin. "Keep the usual INR schedule and expect no change in the INR" ignores one of the most significant warfarin interactions. "Keep the usual INR schedule and expect a rise that may require a dose reduction after several weeks" gets the direction right but the timing wrong, because the effect appears during the first week of the antibiotic, well before a routine check.

  78. A patient is being assessed for an antihypertensive and has a history of asthma with bronchospasm. Which class should be used cautiously due to potential bronchoconstriction?

    • A.A nonselective beta-blocker
    • B.A dihydropyridine calcium channel blocker
    • C.An ACE inhibitor
    • D.An aldosterone antagonist
    Show answerHide answer

    Correct answer: A nonselective beta-blocker

    "A nonselective beta-blocker" such as propranolol blocks the beta-2 receptors that keep the airways open and can trigger bronchospasm in a patient with asthma. "A dihydropyridine calcium channel blocker" relaxes smooth muscle and does not narrow the airways. "An ACE inhibitor" can cause a dry cough through bradykinin, but that is not bronchoconstriction and asthma is not a reason to avoid it. "An aldosterone antagonist" such as spironolactone acts in the kidney and has no effect on airway tone.

  79. A patient on chronic high-dose corticosteroids is being assessed for adverse effects. Which finding represents a recognized long-term adverse drug reaction of systemic corticosteroids?

    • A.Hypothyroidism, pulmonary fibrosis, and corneal deposits
    • B.Osteoporosis, hyperglycemia, and adrenal suppression
    • C.Hyperkalemia, gynecomastia, and metabolic acidosis
    • D.Nephrotoxicity, gingival hyperplasia, and tremor
    Show answerHide answer

    Correct answer: Osteoporosis, hyperglycemia, and adrenal suppression

    Long-term systemic corticosteroids cause "Osteoporosis, hyperglycemia, and adrenal suppression": they reduce bone formation, raise hepatic glucose output and insulin resistance, and suppress the hypothalamic-pituitary-adrenal axis, which is why they are tapered. "Hypothyroidism, pulmonary fibrosis, and corneal deposits" is the long-term profile of amiodarone. "Hyperkalemia, gynecomastia, and metabolic acidosis" is the profile of spironolactone; corticosteroids tend to lower potassium. "Nephrotoxicity, gingival hyperplasia, and tremor" is the profile of cyclosporine.

  80. A patient with type 2 diabetes is started on pioglitazone. Which adverse effect should be assessed, particularly relevant in patients with heart failure?

    • A.Fluid retention and edema that can aggravate heart failure
    • B.Volume depletion and hypotension that can aggravate heart failure
    • C.Resting tachycardia and palpitations that can aggravate heart failure
    • D.Hyperkalemia and bradycardia that can aggravate heart failure
    Show answerHide answer

    Correct answer: Fluid retention and edema that can aggravate heart failure

    Thiazolidinediones increase sodium and water reabsorption in the collecting duct, so the effect to assess is "Fluid retention and edema that can aggravate heart failure"; the labeling carries a boxed warning, and the drug is not started in NYHA class III or IV heart failure. "Volume depletion and hypotension that can aggravate heart failure" is the opposite of what pioglitazone does and describes the diuretic effect of an SGLT2 inhibitor. "Resting tachycardia and palpitations that can aggravate heart failure" is not an effect of pioglitazone; a small rise in heart rate is seen with GLP-1 receptor agonists. "Hyperkalemia and bradycardia that can aggravate heart failure" is wrong because pioglitazone does not raise potassium or slow the heart.

  81. During medication reconciliation, a pharmacist discovers the patient has been taking two products that both contain acetaminophen. What is the primary safety concern this finding addresses?

    • A.A drug interaction that risks higher acetaminophen levels and gastric bleeding
    • B.A subtherapeutic dose that risks acetaminophen failure and uncontrolled pain
    • C.A therapeutic duplication that risks acetaminophen overdose and liver injury
    • D.A drug allergy that risks acetaminophen cross-reactivity and anaphylaxis
    Show answerHide answer

    Correct answer: A therapeutic duplication that risks acetaminophen overdose and liver injury

    Two products with the same ingredient are "A therapeutic duplication that risks acetaminophen overdose and liver injury": the combined intake can pass the 4 g daily maximum without the patient realizing it, and acetaminophen is a leading cause of acute liver failure. "A drug interaction that risks higher acetaminophen levels and gastric bleeding" is wrong because the problem is the same drug taken twice, not one drug changing another, and gastric bleeding is an NSAID effect. "A subtherapeutic dose that risks acetaminophen failure and uncontrolled pain" is the opposite problem; two sources mean too much drug, not too little. "A drug allergy that risks acetaminophen cross-reactivity and anaphylaxis" is wrong because duplicate ingredients are a dosing hazard, not an immune reaction.

  82. A patient receiving a vancomycin infusion has AUC-guided monitoring. What is the target AUC/MIC range associated with efficacy for serious MRSA infections while limiting nephrotoxicity?

    • A.Approximately 15 to 20
    • B.Approximately 400 to 600
    • C.Approximately 100 to 125
    • D.Approximately 700 to 900
    Show answerHide answer

    Correct answer: Approximately 400 to 600

    For serious MRSA infections the 2020 consensus guideline targets a 24-hour AUC to MIC ratio of "Approximately 400 to 600" mg.h/L, assuming an MIC of 1 mg/L. "Approximately 15 to 20" is the older trough target in mg/L, which is no longer recommended as a substitute for the AUC because it is linked to more kidney injury. "Approximately 100 to 125" is the AUC to MIC target quoted for fluoroquinolones against gram-negative organisms. "Approximately 700 to 900" is above the range, and exposures over about 600 raise the risk of nephrotoxicity without adding efficacy.

  83. A patient with heart failure with reduced ejection fraction is intolerant of ACE inhibitors and ARBs because of recurrent angioedema. Which alternative regimen can be used to address neurohormonal blockade and outcomes?

    • A.Diltiazem with isosorbide mononitrate
    • B.Sacubitril combined with valsartan
    • C.Hydralazine with isosorbide dinitrate
    • D.Aliskiren combined with valsartan
    Show answerHide answer

    Correct answer: Hydralazine with isosorbide dinitrate

    Hydralazine with isosorbide dinitrate is the evidence-based substitute when a patient with heart failure with reduced ejection fraction cannot take an ACE inhibitor or an ARB; the combination lowers preload and afterload and improved survival in trials. Diltiazem with isosorbide mononitrate is an antianginal pairing, and a nondihydropyridine calcium channel blocker can worsen outcomes when the ejection fraction is reduced. Sacubitril combined with valsartan is contraindicated in a patient with a history of angioedema, and it still contains an ARB. Aliskiren combined with valsartan also relies on an ARB the patient cannot take, and adding a direct renin inhibitor has shown harm rather than benefit.

  84. A patient on an SSRI is also taking an NSAID regularly. What is the primary drug-drug interaction concern?

    • A.Higher risk of gastrointestinal bleeds
    • B.Higher risk of serotonin syndrome
    • C.Higher risk of hypertensive crisis
    • D.Higher risk of ventricular arrhythmias
    Show answerHide answer

    Correct answer: Higher risk of gastrointestinal bleeds

    The main concern is a higher risk of gastrointestinal bleeds: SSRIs deplete platelet serotonin and impair platelet aggregation, while NSAIDs injure the gastric mucosa and inhibit platelet cyclooxygenase, so the two effects add together. A higher risk of serotonin syndrome applies when an SSRI is combined with another serotonergic drug such as tramadol, linezolid or a triptan, not with an NSAID. A higher risk of hypertensive crisis is the classic problem of MAO inhibitors with tyramine or sympathomimetics. A higher risk of ventricular arrhythmias relates to QT prolongation when citalopram or escitalopram is combined with other QT-prolonging drugs, which NSAIDs are not.

  85. A pharmacist assesses a patient with newly diagnosed type 2 diabetes who has obesity. Beyond metformin, which agent class would best address both glycemia and weight?

    • A.An oral DPP-4 inhibitor
    • B.An oral thiazolidinedione
    • C.A GLP-1 receptor agonist
    • D.A basal insulin injection
    Show answerHide answer

    Correct answer: A GLP-1 receptor agonist

    A GLP-1 receptor agonist lowers glucose in a glucose-dependent way and also slows gastric emptying and reduces appetite, producing meaningful weight loss, so it treats both problems in a patient with type 2 diabetes and obesity. An oral DPP-4 inhibitor works on the same incretin pathway but is weight-neutral and less potent. An oral thiazolidinedione improves insulin sensitivity but causes weight gain and fluid retention. A basal insulin injection lowers glucose effectively but promotes weight gain and carries a risk of hypoglycemia.

  86. A patient on a stable warfarin regimen begins drinking a large amount of alcohol daily. How can chronic heavy alcohol use affect anticoagulation?

    • A.It can reduce warfarin absorption and INR response, making doses ineffective
    • B.It can speed warfarin renal clearance and INR decline, making effects weaker
    • C.It can raise warfarin protein binding and INR stability, making bleeds rarer
    • D.It can change warfarin metabolism and INR control, making dosing harder
    Show answerHide answer

    Correct answer: It can change warfarin metabolism and INR control, making dosing harder

    Chronic heavy drinking affects the liver enzymes that clear warfarin and, as liver injury develops, the synthesis of clotting factors, so it can change warfarin metabolism and INR control, making dosing harder and bleeding more likely. The statement that it can reduce warfarin absorption and INR response, making doses ineffective, is wrong because warfarin is almost completely absorbed regardless of alcohol. The statement that it can speed warfarin renal clearance and INR decline, making effects weaker, is wrong because warfarin is eliminated by hepatic metabolism, not by the kidney. The statement that it can raise warfarin protein binding and INR stability, making bleeds rarer, is wrong because heavy alcohol use destabilizes the INR and adds its own bleeding risk through gastritis and falls.

  87. A patient with hypertension has a blood pressure not controlled on a single agent. According to guidelines, what is a recommended next step?

    • A.Add a second first-line drug from a complementary class
    • B.Add a second first-line drug with a duplicate mechanism
    • C.Switch to a later-line drug from a complementary class
    • D.Switch to a later-line drug with a duplicate mechanism
    Show answerHide answer

    Correct answer: Add a second first-line drug from a complementary class

    Guidelines advise the prescriber to add a second first-line drug from a complementary class, for example a calcium channel blocker or a thiazide-type diuretic on top of an ACE inhibitor or ARB, because two mechanisms at moderate doses lower blood pressure more than pushing one drug. To add a second first-line drug with a duplicate mechanism, such as an ARB on top of an ACE inhibitor, increases adverse effects without added benefit. To switch to a later-line drug from a complementary class gives up a first-line agent with outcome evidence for a drug such as an alpha blocker or a central agonist that is reserved for later steps. To switch to a later-line drug with a duplicate mechanism makes both mistakes at once.

  88. A patient receiving an aminoglycoside is being dosed using extended-interval (once-daily) dosing. What is the pharmacodynamic rationale for this strategy?

    • A.Time-dependent killing with a postantibiotic effect
    • B.Concentration-dependent killing with a prolonged half-life
    • C.Concentration-dependent killing with a postantibiotic effect
    • D.Time-dependent killing with a prolonged elimination half-life
    Show answerHide answer

    Correct answer: Concentration-dependent killing with a postantibiotic effect

    Extended-interval dosing relies on concentration-dependent killing with a postantibiotic effect: a single large dose gives a high peak relative to the MIC, bacterial suppression continues after the level falls, and the long drug-free period lets the trough drop and limits renal and cochlear uptake. Time-dependent killing with a postantibiotic effect is wrong because time above the MIC drives beta-lactams, which are dosed frequently or by prolonged infusion, whereas aminoglycoside killing depends on the peak. Concentration-dependent killing with a prolonged half-life is wrong because aminoglycosides have a half-life of only about two to three hours when renal function is normal. Time-dependent killing with a prolonged elimination half-life is wrong on both points.

  89. A patient is prescribed clopidogrel and also takes omeprazole. What is the basis for the recognized drug-drug interaction concern?

    • A.Omeprazole may inhibit CYP2C19, lowering conversion of clopidogrel to its active form
    • B.Omeprazole may induce CYP2C19, speeding conversion of clopidogrel to its inactive form
    • C.Omeprazole may raise gastric pH, limiting dissolution of clopidogrel in its tablet form
    • D.Omeprazole may induce P-glycoprotein, limiting uptake of clopidogrel in its parent form
    Show answerHide answer

    Correct answer: Omeprazole may inhibit CYP2C19, lowering conversion of clopidogrel to its active form

    Clopidogrel is a prodrug that depends on CYP2C19 for bioactivation, and omeprazole may inhibit CYP2C19, lowering conversion of clopidogrel to its active form and weakening platelet inhibition; pantoprazole is a weaker inhibitor and is often preferred. The statement that omeprazole may induce CYP2C19, speeding conversion of clopidogrel to its inactive form, reverses the effect, because omeprazole is an inhibitor of this enzyme and the enzyme activates rather than clears the drug. The statement that omeprazole may raise gastric pH, limiting dissolution of clopidogrel in its tablet form, describes the acid-dependent absorption problem seen with drugs such as itraconazole, which is not the basis of this interaction. The statement that omeprazole may induce P-glycoprotein, limiting uptake of clopidogrel in its parent form, is wrong because omeprazole is not an inducer of that transporter.

  90. A patient with heart failure with reduced ejection fraction is started on a beta-blocker. Which initiation principle is most appropriate?

    • A.Begin at a low dose and increase it slowly while the patient is still acutely congested
    • B.Begin at the target dose and hold it there while the patient is euvolemic and stable
    • C.Begin at the target dose and hold it there while the patient is still acutely congested
    • D.Begin at a low dose and increase it slowly while the patient is euvolemic and stable
    Show answerHide answer

    Correct answer: Begin at a low dose and increase it slowly while the patient is euvolemic and stable

    The rule for carvedilol, metoprolol succinate or bisoprolol is to begin at a low dose and increase it slowly while the patient is euvolemic and stable, usually doubling the dose no more often than every two weeks, because the early negative inotropic effect can worsen symptoms before the long-term survival benefit appears. To begin at a low dose and increase it slowly while the patient is still acutely congested ignores that a beta-blocker should not be started during acute decompensation. To begin at the target dose and hold it there while the patient is euvolemic and stable skips the titration that makes the drug tolerable and risks hypotension, bradycardia and fluid retention. To begin at the target dose and hold it there while the patient is still acutely congested combines both errors.

  91. A patient develops a positive Coombs test and hemolytic anemia after taking a medication. This is best classified as which type of adverse drug reaction?

    • A.A type A augmented (dose-dependent) reaction
    • B.A type B immune (idiosyncratic) reaction
    • C.A type C cumulative (long-term use) reaction
    • D.A type D delayed (time-related) reaction
    Show answerHide answer

    Correct answer: A type B immune (idiosyncratic) reaction

    Drug-induced hemolytic anemia with a positive Coombs test is a type B immune (idiosyncratic) reaction: antibodies directed against drug-coated or altered red cells destroy them, an effect that cannot be predicted from the drug's pharmacology and is not dose-related. A type A augmented (dose-dependent) reaction is an exaggeration of the expected drug action, such as bleeding with an anticoagulant. A type C cumulative (long-term use) reaction depends on total exposure over time, such as adrenal suppression with corticosteroids. A type D delayed (time-related) reaction appears long after exposure, such as a secondary malignancy or a teratogenic effect.

  92. A patient with type 2 diabetes is started on a DPP-4 inhibitor. What is a key advantage relevant to person-centered therapy?

    • A.It promotes weight loss and rarely causes hypoglycemia
    • B.It does not change weight and rarely causes hypoglycemia
    • C.It does not change weight and lowers cardiovascular risk
    • D.It promotes weight loss and lowers cardiovascular risk
    Show answerHide answer

    Correct answer: It does not change weight and rarely causes hypoglycemia

    The advantage of a DPP-4 inhibitor such as sitagliptin or linagliptin is tolerability: it does not change weight and rarely causes hypoglycemia, because it raises incretin levels only modestly and insulin release stays glucose-dependent. The claim that it promotes weight loss and rarely causes hypoglycemia describes a GLP-1 receptor agonist or an SGLT2 inhibitor. The claim that it does not change weight and lowers cardiovascular risk is wrong because the DPP-4 inhibitor outcome trials showed cardiovascular safety, not benefit. The claim that it promotes weight loss and lowers cardiovascular risk fits agents such as liraglutide or empagliflozin, not this class.

  93. A patient on dabigatran has worsening renal function with an estimated creatinine clearance now well below the labeled threshold. What is the appropriate consideration?

    • A.Dabigatran accumulates as renal function falls, so the INR or aPTT should dictate each dose
    • B.Dabigatran is cleared mainly by the liver, so the current dose or a higher one can continue
    • C.Dabigatran is cleared mainly by the liver, so the INR or aPTT should dictate each dose
    • D.Dabigatran accumulates as renal function falls, so reduce the dose or change the agent
    Show answerHide answer

    Correct answer: Dabigatran accumulates as renal function falls, so reduce the dose or change the agent

    About 80 percent of a dabigatran dose is excreted unchanged in the urine, and the correct statement is that dabigatran accumulates as renal function falls, so reduce the dose or change the agent once creatinine clearance drops below the labeled cutoffs. The statement that dabigatran accumulates as renal function falls, so the INR or aPTT should dictate each dose, has the right premise but the wrong action: neither test is calibrated for titrating dabigatran, and dosing follows creatinine clearance. The statement that dabigatran is cleared mainly by the liver, so the current dose or a higher one can continue, is false because elimination is predominantly renal and exposure rises steeply in kidney impairment. The statement that dabigatran is cleared mainly by the liver, so the INR or aPTT should dictate each dose, is wrong on both counts.

  94. A pharmacist reviews a patient on furosemide for heart failure and notes a low potassium level. Which adverse drug reaction does this finding represent?

    • A.Diuretic-induced hypokalemia from impaired potassium absorption
    • B.Diuretic-induced hypokalemia from potassium shifting into cells
    • C.Diuretic-induced hypokalemia from urinary potassium wasting
    • D.Diuretic-induced hypokalemia from potassium lost via stool
    Show answerHide answer

    Correct answer: Diuretic-induced hypokalemia from urinary potassium wasting

    The finding is diuretic-induced hypokalemia from urinary potassium wasting: furosemide blocks sodium reabsorption in the thick ascending limb, more sodium reaches the collecting duct, and potassium is secreted in exchange, helped by the rise in aldosterone that follows volume depletion. Diuretic-induced hypokalemia from impaired potassium absorption is wrong because loop diuretics do not act on intestinal uptake. Diuretic-induced hypokalemia from potassium shifting into cells describes the effect of insulin or beta-2 agonists, not of a diuretic. Diuretic-induced hypokalemia from potassium lost via stool describes diarrhea, laxative use or a cation-exchange resin, not a loop diuretic.

  95. A patient with hypertension has resistant blood pressure on three agents including a diuretic. Which add-on agent is recommended for resistant hypertension based on guidelines?

    • A.Doxazosin (a peripheral alpha-adrenergic blocking agent)
    • B.Methyldopa (a centrally acting alpha-adrenergic agonist)
    • C.Spironolactone (a mineralocorticoid receptor antagonist)
    • D.Minoxidil (a direct arteriolar vasodilator)
    Show answerHide answer

    Correct answer: Spironolactone (a mineralocorticoid receptor antagonist)

    When blood pressure stays above goal on three drugs that include a diuretic, guidelines recommend adding spironolactone (a mineralocorticoid receptor antagonist), because aldosterone excess and sodium retention commonly drive resistant hypertension and the drug outperformed other fourth-line choices in a head-to-head trial. Doxazosin (a peripheral alpha-adrenergic blocking agent) lowered pressure less than spironolactone in that comparison and is kept for later steps. Methyldopa (a centrally acting alpha-adrenergic agonist) is limited by sedation and is used mainly in pregnancy. Minoxidil (a direct arteriolar vasodilator) causes reflex tachycardia, fluid retention and hair growth and is a last-line option.

  96. A patient receiving vancomycin develops an AUC well above the target range with stable renal function. What is the most appropriate adjustment?

    • A.Split the same total daily dose into smaller doses and lower the AUC
    • B.Reduce the total daily dose and shift the AUC into the target range
    • C.Infuse the same total daily dose over more hours to lower the AUC
    • D.Hold the total daily dose until the AUC drops below the target range
    Show answerHide answer

    Correct answer: Reduce the total daily dose and shift the AUC into the target range

    AUC over 24 hours equals the total daily dose divided by clearance, so with stable renal function the fix is to reduce the total daily dose and shift the AUC into the target range, which limits the risk of kidney injury. To split the same total daily dose into smaller doses and lower the AUC does not work, because the 24-hour exposure is unchanged when the same amount is given. To infuse the same total daily dose over more hours to lower the AUC fails for the same reason: the infusion rate changes the peak, not the total exposure. To hold the total daily dose until the AUC drops below the target range overcorrects and leaves a serious infection undertreated.

  97. A patient is being treated for community-acquired MRSA skin abscess. Beyond antibiotic selection, which intervention is often essential for cure of an abscess?

    • A.Aspiration and irrigation
    • B.Compresses and elevation
    • C.Mupirocin and skin washes
    • D.Incision and drainage
    Show answerHide answer

    Correct answer: Incision and drainage

    Incision and drainage is the primary treatment of a skin abscess, because antibiotics penetrate a walled-off collection of pus poorly and source control alone cures many uncomplicated cases. Aspiration and irrigation through a needle evacuates the cavity incompletely and has a much higher failure rate than open drainage. Compresses and elevation may ease a small furuncle or cellulitis but do not empty a drainable abscess. Mupirocin and skin washes with chlorhexidine are decolonization measures used to reduce recurrences, not to cure the current infection.

  98. A patient takes oral ciprofloxacin with a multivitamin containing iron and zinc. What is the drug-food/drug-mineral interaction outcome?

    • A.Cation chelation that lowers ciprofloxacin absorption and efficacy
    • B.Higher gastric pH that lowers ciprofloxacin dissolution and efficacy
    • C.Enzyme induction that lowers ciprofloxacin exposure and efficacy
    • D.Faster bowel transit that lowers ciprofloxacin exposure and efficacy
    Show answerHide answer

    Correct answer: Cation chelation that lowers ciprofloxacin absorption and efficacy

    The outcome is cation chelation that lowers ciprofloxacin absorption and efficacy: iron, zinc, calcium, magnesium and aluminum bind the fluoroquinolone in the gut into an insoluble complex, so ciprofloxacin should be taken at least two hours before or six hours after these products. Higher gastric pH that lowers ciprofloxacin dissolution and efficacy is the kind of mechanism by which acid suppressants reduce absorption of drugs such as itraconazole, and a multivitamin does not raise gastric pH. Enzyme induction that lowers ciprofloxacin exposure and efficacy describes drugs such as rifampin acting on hepatic metabolism, which minerals do not affect. Faster bowel transit that lowers ciprofloxacin exposure and efficacy is not how polyvalent cations interact with fluoroquinolones.

  99. A patient with diabetes and hypertension is being assessed. Which antihypertensive class is particularly favored when diabetic kidney disease with albuminuria is present?

    • A.An ACE inhibitor or ARB
    • B.A dihydropyridine or nondihydropyridine CCB
    • C.A beta-blocker
    • D.An alpha-1 blocker
    Show answerHide answer

    Correct answer: An ACE inhibitor or ARB

    An ACE inhibitor or ARB is preferred when diabetic kidney disease with albuminuria is present, because blocking angiotensin II dilates the efferent arteriole, lowers intraglomerular pressure, reduces albuminuria and slows the decline in kidney function beyond the effect of blood pressure lowering alone. A dihydropyridine or nondihydropyridine CCB (calcium channel blocker) can be added for blood pressure control but is not the favored class for albuminuria. A beta-blocker lowers blood pressure without a proven benefit on the progression of diabetic kidney disease. An alpha-1 blocker, such as doxazosin, lowers vascular resistance but does not have this specific kidney-protective effect.

  100. A patient is on apixaban and develops major bleeding. Which agent is the specific reversal for factor Xa inhibitors such as apixaban?

    • A.Idarucizumab
    • B.Oral phytonadione
    • C.Andexanet alfa
    • D.Aminocaproic acid
    Show answerHide answer

    Correct answer: Andexanet alfa

    Andexanet alfa is a modified, inactive factor Xa decoy that binds apixaban and rivaroxaban and restores thrombin generation, making it the specific reversal agent for factor Xa inhibitors. Idarucizumab is a monoclonal antibody fragment that binds only dabigatran, a direct thrombin inhibitor. Oral phytonadione is vitamin K, which reverses warfarin by restoring synthesis of clotting factors and has no effect on a direct factor Xa inhibitor. Aminocaproic acid is an antifibrinolytic that stabilizes clots but does not reverse any anticoagulant.

  101. A patient on therapy with a narrow-therapeutic-index drug switches from the brand to a generic and develops altered levels. Which monitoring approach is most appropriate?

    • A.Measure drug levels and assess clinical response after the product switch
    • B.Measure drug levels and assess clinical response at the next annual visit
    • C.Reduce the dose empirically and assess clinical response after the product switch
    • D.Reduce the dose empirically and assess clinical response at the next annual visit
    Show answerHide answer

    Correct answer: Measure drug levels and assess clinical response after the product switch

    With a narrow-therapeutic-index drug, small differences in exposure between products can matter clinically, so the right approach is to measure drug levels and assess clinical response after the product switch and adjust the dose to the result. To measure drug levels and assess clinical response at the next annual visit delays action although the levels have already changed. To reduce the dose empirically and assess clinical response after the product switch guesses at the direction of the change without a measured level and may leave the patient subtherapeutic. To reduce the dose empirically and assess clinical response at the next annual visit combines the guess with the delay.

  102. A patient with MRSA bacteremia has persistent positive blood cultures despite vancomycin with a confirmed therapeutic AUC. What does this finding most appropriately prompt?

    • A.Reassessing for vancomycin failure and adding an aminoglycoside such as gentamicin
    • B.Reassessing for culture contamination and retaining a glycopeptide such as vancomycin
    • C.Reassessing for vancomycin failure and considering an alternative such as daptomycin
    • D.Reassessing for culture contamination and adding an aminoglycoside such as gentamicin
    Show answerHide answer

    Correct answer: Reassessing for vancomycin failure and considering an alternative such as daptomycin

    Blood cultures that stay positive for MRSA even though vancomycin exposure is on target point to treatment failure, so the finding should prompt reassessing for vancomycin failure and considering an alternative such as daptomycin, together with a search for an undrained focus such as endocarditis or an abscess. Reassessing for vancomycin failure and adding an aminoglycoside such as gentamicin is not recommended, because that combination in MRSA bacteremia increases kidney injury without improving outcomes. Reassessing for culture contamination and retaining a glycopeptide such as vancomycin is wrong because repeatedly positive cultures for a true pathogen such as Staphylococcus aureus are not treated as contaminants. Reassessing for culture contamination and adding an aminoglycoside such as gentamicin repeats both errors.

  103. A patient on metformin has stable but moderately reduced renal function. Which monitoring is most appropriate to continue using metformin safely?

    • A.Periodic checks of estimated glomerular filtration rate to guide continued use or a lower dose
    • B.Periodic checks of venous plasma lactate concentrations to guide continued use or a lower dose
    • C.Periodic checks of hepatic aminotransferase levels to guide continued use or a lower dose
    • D.Periodic checks of urine albumin-to-creatinine ratio to guide continued use or a lower dose
    Show answerHide answer

    Correct answer: Periodic checks of estimated glomerular filtration rate to guide continued use or a lower dose

    Metformin is cleared unchanged by the kidney, and its labeling ties use to kidney function, so the patient needs periodic checks of estimated glomerular filtration rate to guide continued use or a lower dose: the dose is reassessed as the value falls below 45 mL/min/1.73 m21.73\ \text{m}^{2} and the drug is stopped below 30. Periodic checks of venous plasma lactate concentrations to guide continued use or a lower dose are not recommended, because routine lactate levels do not predict metformin-associated lactic acidosis. Periodic checks of hepatic aminotransferase levels to guide continued use or a lower dose do not apply, because metformin is not metabolized by the liver and its dosing thresholds are renal. Periodic checks of urine albumin-to-creatinine ratio to guide continued use or a lower dose track kidney damage in diabetes, but the metformin thresholds are defined by filtration rate, not by albuminuria.

  104. A patient with heart failure with reduced ejection fraction asks which classes have actually been shown to reduce mortality. Which class has demonstrated a mortality benefit in this condition?

    • A.Thiazide-type diuretics such as chlorthalidone or metolazone
    • B.Phosphodiesterase inhibitors such as milrinone or cilostazol
    • C.Aldosterone antagonists such as spironolactone or eplerenone
    • D.Calcium channel blockers such as diltiazem or verapamil
    Show answerHide answer

    Correct answer: Aldosterone antagonists such as spironolactone or eplerenone

    Aldosterone antagonists such as spironolactone or eplerenone, also called mineralocorticoid receptor antagonists, reduced death in randomized trials of heart failure with reduced ejection fraction and are one of the foundational drug classes, alongside renin-angiotensin inhibitors, evidence-based beta-blockers and SGLT2 inhibitors. Thiazide-type diuretics such as chlorthalidone or metolazone, like loop diuretics, relieve congestion but have not been shown to prolong survival. Phosphodiesterase inhibitors such as milrinone or cilostazol increased mortality in heart failure, and cilostazol is contraindicated in this condition. Calcium channel blockers such as diltiazem or verapamil are negative inotropes that can worsen outcomes in reduced ejection fraction.

  105. A pharmacist takes a best-possible medication history for reconciliation. Which approach yields the most accurate list?

    • A.Using chart sources such as the orders, discharge summary, problem lists, and prior progress notes
    • B.Using several sources such as the patient, pill bottles, pharmacy profiles, and prescriber records
    • C.Using verbal recall for details such as drug names, strengths, routes, and times of administration
    • D.Using insurance claims for details such as fill dates, quantities, refills, and days supplied
    Show answerHide answer

    Correct answer: Using several sources such as the patient, pill bottles, pharmacy profiles, and prescriber records

    A best-possible medication history is built by using several sources such as the patient, pill bottles, pharmacy profiles, and prescriber records, so that each source can verify and fill gaps in the others, and it also asks about nonprescription and herbal products. Using chart sources such as the orders, discharge summary, problem lists, and prior progress notes leaves out the patient interview and often repeats outdated or transcribed errors. Using verbal recall for details such as drug names, strengths, routes, and times of administration depends on memory alone, which commonly misses drugs and doses. Using insurance claims for details such as fill dates, quantities, refills, and days supplied shows what was dispensed, not what the patient actually takes, and misses cash purchases, samples and over-the-counter products.

  106. A patient on warfarin with an INR of 1.4 (target 2 to 3) has been missing doses. What is the most appropriate person-centered response?

    • A.Increase the weekly dose and recheck, then raise it again to reach the target INR
    • B.Explain risks and benefits, then maintain the dose to reach the target INR
    • C.Order pharmacogenomic and laboratory testing, then adjust dosing by genotype to reach the target INR
    • D.Explore adherence and barriers, then revise the plan to reach the target INR
    Show answerHide answer

    Correct answer: Explore adherence and barriers, then revise the plan to reach the target INR

    The INR is low because doses were missed, so the person-centered response is to explore adherence and barriers, then revise the plan to reach the target INR, for example by simplifying the regimen, using a pill organizer or resolving cost and access problems. To increase the weekly dose and recheck, then raise it again to reach the target INR, treats nonadherence as a dose requirement and risks an excessive INR once the patient takes every dose. To explain risks and benefits, then maintain the dose to reach the target INR, lectures the patient without finding out why doses are missed. To order pharmacogenomic and laboratory testing, then adjust dosing by genotype to reach the target INR, looks for a metabolic cause when the history already explains the result.

  107. A patient with type 2 diabetes is at high risk of atherosclerotic cardiovascular disease. Which assessment principle should guide adding a glucose-lowering agent?

    • A.Favor an agent with proven cardiovascular benefit regardless of the baseline A1c
    • B.Favor an agent with proven cardiovascular benefit after the A1c stays above goal
    • C.Favor an agent with the greatest glucose lowering regardless of the baseline A1c
    • D.Favor an agent with the greatest glucose lowering after the A1c stays above goal
    Show answerHide answer

    Correct answer: Favor an agent with proven cardiovascular benefit regardless of the baseline A1c

    For a patient with type 2 diabetes and high atherosclerotic cardiovascular risk, current standards say to favor an agent with proven cardiovascular benefit regardless of the baseline A1c, meaning a GLP-1 receptor agonist or an SGLT2 inhibitor with outcome-trial evidence, because the benefit is independent of glucose lowering. To favor an agent with proven cardiovascular benefit after the A1c stays above goal reflects older stepwise guidance that withheld these drugs until metformin had failed. To favor an agent with the greatest glucose lowering regardless of the baseline A1c puts glycemic potency ahead of outcome evidence. To favor an agent with the greatest glucose lowering after the A1c stays above goal makes both errors.

  108. A patient develops Stevens-Johnson syndrome after starting a sulfonamide antibiotic. How should this severe cutaneous adverse reaction be managed?

    • A.Slowly taper the offending drug and provide supportive care
    • B.Stop the offending drug at once and plan a later rechallenge
    • C.Slowly taper the offending drug and plan a later rechallenge
    • D.Stop the offending drug at once and provide supportive care
    Show answerHide answer

    Correct answer: Stop the offending drug at once and provide supportive care

    Stevens-Johnson syndrome is life-threatening, and prompt withdrawal of the cause improves survival, so the pharmacist should advise the team to stop the offending drug at once and provide supportive care, including wound and eye care, fluids and pain control, usually in a burn or intensive care unit. To slowly taper the offending drug and provide supportive care prolongs exposure while the skin detachment progresses. To stop the offending drug at once and plan a later rechallenge is dangerous because re-exposure can cause a faster and more severe recurrence, so the drug is recorded as an allergy and avoided for life. To slowly taper the offending drug and plan a later rechallenge combines both mistakes.

  109. A patient with heart failure and reduced ejection fraction taking an ARNI should avoid concurrent use of which class due to additive angioedema and renal risk?

    • A.An SGLT2 inhibitor
    • B.An ACE inhibitor
    • C.A loop diuretic
    • D.A thiazide diuretic
    Show answerHide answer

    Correct answer: An ACE inhibitor

    An ACE inhibitor must not be given with sacubitril-valsartan: both the ACE inhibitor and sacubitril block the breakdown of bradykinin, which sharply raises the risk of angioedema, and dual renin-angiotensin blockade adds hyperkalemia and kidney injury, so a 36-hour washout is required when switching. An SGLT2 inhibitor is a recommended partner of an ARNI in heart failure with reduced ejection fraction. A loop diuretic is used with an ARNI to relieve congestion and has no angioedema interaction. A thiazide diuretic can be added to a loop diuretic for resistant congestion and has no angioedema interaction with an ARNI.

  110. A patient on theophylline, a drug with a narrow therapeutic range, is started on ciprofloxacin. What therapeutic drug monitoring consideration applies?

    • A.Ciprofloxacin can slow theophylline metabolism, raising levels and seizure risk, so separate dosing
    • B.Ciprofloxacin can slow theophylline metabolism, raising levels and toxicity risk, so monitor closely
    • C.Ciprofloxacin can speed theophylline metabolism, lowering levels and symptom relief, so monitor closely
    • D.Ciprofloxacin can speed theophylline metabolism, lowering levels and symptom relief, so separate dosing
    Show answerHide answer

    Correct answer: Ciprofloxacin can slow theophylline metabolism, raising levels and toxicity risk, so monitor closely

    Ciprofloxacin inhibits CYP1A2, the main enzyme that clears theophylline, so ciprofloxacin can slow theophylline metabolism, raising levels and toxicity risk, so monitor closely: check a theophylline concentration, watch for nausea, tremor, tachycardia and seizures, and consider an empiric dose reduction. The statement that ciprofloxacin can slow theophylline metabolism, raising levels and seizure risk, so separate dosing, gives the wrong remedy, because separating the two drugs does nothing for an interaction based on hepatic enzyme inhibition. The statement that ciprofloxacin can speed theophylline metabolism, lowering levels and symptom relief, so monitor closely, describes an enzyme inducer such as rifampin or tobacco smoke. The statement that ciprofloxacin can speed theophylline metabolism, lowering levels and symptom relief, so separate dosing, is wrong about both the direction and the remedy.

  111. A patient with type 2 diabetes is started on acarbose. What counseling point reflects its mechanism and a common adverse effect?

    • A.It slows carbohydrate absorption and can cause hypoglycemia and moderate weight gain
    • B.It blocks triglyceride absorption and can cause flatulence and gastrointestinal upset
    • C.It slows carbohydrate absorption and can cause flatulence and gastrointestinal upset
    • D.It blocks triglyceride absorption and can cause hypoglycemia and moderate weight gain
    Show answerHide answer

    Correct answer: It slows carbohydrate absorption and can cause flatulence and gastrointestinal upset

    Acarbose inhibits alpha-glucosidase at the intestinal brush border, so it slows carbohydrate absorption and can cause flatulence and gastrointestinal upset when undigested carbohydrate is fermented in the colon; it is taken with the first bite of each meal. The statement that it slows carbohydrate absorption and can cause hypoglycemia and moderate weight gain pairs the right mechanism with the adverse effects of a sulfonylurea or insulin, which acarbose alone does not cause. The statement that it blocks triglyceride absorption and can cause flatulence and gastrointestinal upset describes the lipase inhibitor orlistat. The statement that it blocks triglyceride absorption and can cause hypoglycemia and moderate weight gain is wrong on both mechanism and adverse effects.

  112. A patient on warfarin needs short-term coverage with low-molecular-weight heparin during a period of subtherapeutic INR. This practice is best described as which person-centered treatment plan element?

    • A.Therapeutic drug monitoring
    • B.Bridging anticoagulation
    • C.Dual antithrombotic therapy
    • D.Therapeutic duplication
    Show answerHide answer

    Correct answer: Bridging anticoagulation

    Bridging anticoagulation is the planned use of a short-acting parenteral anticoagulant, usually low-molecular-weight heparin at treatment doses, to protect a high-risk patient while the INR is below range or warfarin is interrupted. Therapeutic drug monitoring is the measurement of a drug level or effect, such as the INR itself, to adjust a dose, and does not describe adding heparin coverage. Dual antithrombotic therapy means an oral anticoagulant combined with an antiplatelet agent, for example after coronary stenting in atrial fibrillation. Therapeutic duplication is an unintended error in which two drugs of the same class or effect are given without a reason, whereas this overlap is deliberate and time-limited.

  113. A patient with hypertension is prescribed an ACE inhibitor. Which laboratory parameter should be checked shortly after initiation to monitor for an adverse effect?

    • A.Serum potassium and creatinine
    • B.Serum phosphorus and magnesium
    • C.Serum sodium and uric acid
    • D.Serum bilirubin and albumin
    Show answerHide answer

    Correct answer: Serum potassium and creatinine

    Serum potassium and creatinine should be checked within one to two weeks of starting or increasing an ACE inhibitor, because lower aldosterone raises potassium and efferent arteriolar dilation can reduce glomerular filtration, especially with kidney disease, volume depletion or renal artery stenosis. Serum phosphorus and magnesium are not altered by this class in a way that needs early monitoring. Serum sodium and uric acid are followed with thiazide diuretics, which cause hyponatremia and hyperuricemia. Serum bilirubin and albumin reflect liver function, which is not an expected early target of this class.

  114. A patient with type 2 diabetes on insulin and a sulfonylurea has frequent hypoglycemia. Which treatment-planning change reduces hypoglycemia risk while maintaining control?

    • A.Consider doubling the sulfonylurea and adjusting the insulin or prescribing a rapid-acting meglitinide before each meal
    • B.Consider retaining the sulfonylurea and intensifying the insulin or adding a fast-acting insulin dose at each meal
    • C.Consider retaining the sulfonylurea and splitting the insulin or scheduling a daily bedtime snack
    • D.Consider stopping the sulfonylurea and adjusting the insulin or substituting a drug unlikely to cause hypoglycemia
    Show answerHide answer

    Correct answer: Consider stopping the sulfonylurea and adjusting the insulin or substituting a drug unlikely to cause hypoglycemia

    Insulin plus a sulfonylurea stacks two drugs that lower glucose regardless of the glucose level, so the plan is to consider stopping the sulfonylurea and adjusting the insulin or substituting a drug unlikely to cause hypoglycemia, such as a GLP-1 receptor agonist, an SGLT2 inhibitor or a DPP-4 inhibitor. To consider doubling the sulfonylurea and adjusting the insulin or prescribing a rapid-acting meglitinide before each meal keeps or adds secretagogues, which are the source of the problem. To consider retaining the sulfonylurea and intensifying the insulin or adding a fast-acting insulin dose at each meal increases insulin exposure and makes low readings more frequent. To consider retaining the sulfonylurea and splitting the insulin or scheduling a daily bedtime snack leaves the cause in place and manages the lows with extra food.

  115. A patient on chronic warfarin is found to have a stable INR until a new antibiotic is added, after which the INR rises. What is the most likely mechanism of this drug-drug interaction?

    • A.Rapid warfarin absorption or degradation of vitamin K by antibiotics, increasing the anticoagulant effect
    • B.Impaired renal warfarin excretion or antibiotic chelation of vitamin K, increasing the anticoagulant effect
    • C.Greater warfarin protein binding or lower liver synthesis of vitamin K, increasing the anticoagulant effect
    • D.Slower warfarin metabolism or loss of gut flora producing vitamin K, increasing the anticoagulant effect
    Show answerHide answer

    Correct answer: Slower warfarin metabolism or loss of gut flora producing vitamin K, increasing the anticoagulant effect

    Antibiotics raise the INR in two main ways: slower warfarin metabolism or loss of gut flora producing vitamin K, increasing the anticoagulant effect. Agents such as sulfamethoxazole-trimethoprim, metronidazole and fluconazole inhibit CYP2C9, and broad-spectrum agents reduce the intestinal bacteria that supply vitamin K2. Rapid warfarin absorption or degradation of vitamin K by antibiotics, increasing the anticoagulant effect, is wrong because warfarin is already almost completely absorbed and antibiotics do not degrade the vitamin. Impaired renal warfarin excretion or antibiotic chelation of vitamin K, increasing the anticoagulant effect, is wrong because warfarin is cleared by hepatic metabolism and antibiotics do not chelate vitamin K. Greater warfarin protein binding or lower liver synthesis of vitamin K, increasing the anticoagulant effect, is wrong because more binding would lower the free drug and the liver uses vitamin K but does not make it.

  116. A pharmacist is monitoring a patient on lithium. Which serum range is generally considered therapeutic for maintenance, illustrating the narrow window requiring monitoring?

    • A.Approximately 0.8 to 2.0 mEq/L
    • B.Approximately 1.5 to 2.5 mEq/L
    • C.Approximately 3.5 to 5.0 mEq/L
    • D.Approximately 0.6 to 1.2 mEq/L
    Show answerHide answer

    Correct answer: Approximately 0.6 to 1.2 mEq/L

    The usual maintenance target for lithium is approximately 0.6 to 1.2 mEq/L, measured as a 12-hour trough; toxicity becomes likely above about 1.5 mEq/L, which is why levels, kidney function and interacting drugs are monitored. Approximately 0.8 to 2.0 mEq/L borrows the figures of the digoxin range in ng/mL, and its upper end would be toxic for lithium. Approximately 1.5 to 2.5 mEq/L is the range of mild to moderate lithium toxicity, and also the normal range for serum magnesium. Approximately 3.5 to 5.0 mEq/L is the normal range for serum potassium and would be life-threatening as a lithium level.

  117. A patient with heart failure with reduced ejection fraction asks whether NSAIDs are safe for occasional pain. What is the most appropriate counseling?

    • A.NSAIDs can cause salt retention and worsen heart failure, so a diuretic should generally be added
    • B.NSAIDs can cause fluid retention and worsen heart failure, so they should generally be avoided
    • C.NSAIDs can upset the stomach but spare heart failure, so they should generally be taken with food
    • D.NSAIDs can upset the stomach but spare heart failure, so an antacid dose should generally be used
    Show answerHide answer

    Correct answer: NSAIDs can cause fluid retention and worsen heart failure, so they should generally be avoided

    By blocking renal prostaglandins, NSAIDs can cause fluid retention and worsen heart failure, so they should generally be avoided; they also blunt the effect of diuretics and renin-angiotensin inhibitors, and acetaminophen or a topical agent is the usual alternative. The statement that NSAIDs can cause salt retention and worsen heart failure, so a diuretic should generally be added, accepts the harm and then tries to treat it, when the NSAID itself reduces the diuretic response. The statement that NSAIDs can upset the stomach but spare heart failure, so they should generally be taken with food, overlooks the sodium and water retention that makes these drugs a recognized trigger of decompensation. The statement that NSAIDs can upset the stomach but spare heart failure, so an antacid dose should generally be used, makes the same error about the heart and offers a remedy for the wrong problem.

  118. A patient takes phenelzine, an MAO inhibitor, and is counseled about a high-risk food interaction. Which food poses the greatest risk?

    • A.Fresh cottage cheese
    • B.Grapefruit juice
    • C.Aged cheddar cheese
    • D.Pure cranberry juice
    Show answerHide answer

    Correct answer: Aged cheddar cheese

    Aged cheddar cheese is rich in tyramine, which forms as proteins break down during aging; with monoamine oxidase blocked by phenelzine, tyramine is not degraded in the gut and liver and releases norepinephrine, causing a hypertensive crisis. Fresh cottage cheese is unaged and contains very little tyramine, so it is permitted. Grapefruit juice is known for inhibiting intestinal CYP3A4 and raising levels of drugs such as some statins and calcium channel blockers, not for tyramine. Pure cranberry juice is discussed as a possible warfarin interaction and is not a tyramine source.

  119. A patient with type 2 diabetes is being started on basal insulin. Which counseling point about hypoglycemia recognition is essential?

    • A.Sweating, tremor, confusion, and palpitations may signal low blood glucose that needs a slowly absorbed protein snack
    • B.Sweating, tremor, confusion, and palpitations may signal low blood glucose that needs fast-acting carbohydrate
    • C.Thirst, polyuria, drowsiness, and dehydration may signal low blood glucose that needs fast-acting carbohydrate
    • D.Thirst, polyuria, drowsiness, and dehydration may signal low blood glucose that needs a slowly absorbed protein snack
    Show answerHide answer

    Correct answer: Sweating, tremor, confusion, and palpitations may signal low blood glucose that needs fast-acting carbohydrate

    The essential point is that sweating, tremor, confusion, and palpitations may signal low blood glucose that needs fast-acting carbohydrate: about 15 grams of glucose tablets, juice or regular soda, with a recheck in 15 minutes. The statement that sweating, tremor, confusion, and palpitations may signal low blood glucose that needs a slowly absorbed protein snack names the right symptoms but the wrong treatment, because protein and fat raise glucose too slowly and can delay absorption of sugar. The statement that thirst, polyuria, drowsiness, and dehydration may signal low blood glucose that needs fast-acting carbohydrate lists the symptoms of high, not low, blood glucose. The statement that thirst, polyuria, drowsiness, and dehydration may signal low blood glucose that needs a slowly absorbed protein snack is wrong on both the symptoms and the treatment.

  120. A patient is admitted with an MRSA infection and has a documented severe vancomycin allergy. Which agent provides MRSA coverage as an alternative oral or IV option?

    • A.Linezolid
    • B.Nafcillin
    • C.Cefazolin
    • D.Ertapenem
    Show answerHide answer

    Correct answer: Linezolid

    Linezolid is an oxazolidinone that is active against MRSA and has essentially complete oral bioavailability, so it can be given by mouth or intravenously when vancomycin cannot be used; platelet counts and serotonergic drug interactions should be monitored. Nafcillin is an antistaphylococcal penicillin that covers methicillin-susceptible strains only and is given intravenously. Cefazolin is a first-generation cephalosporin with no activity against MRSA. Ertapenem is a carbapenem with broad gram-negative and anaerobic activity that also does not cover MRSA.

  121. A patient on warfarin is also taking a regular NSAID. Beyond the metabolic interaction, why is this combination concerning for the treatment plan?

    • A.It raises bleeding risk by adding fibrinolytic and hepatotoxic effects to warfarin
    • B.It raises bleeding risk by adding antiplatelet and gastric effects to anticoagulation
    • C.It raises bleeding risk by blocking vitamin K recycling and clotting factor production
    • D.It raises bleeding risk by blocking thrombin activity and stable fibrin clot formation
    Show answerHide answer

    Correct answer: It raises bleeding risk by adding antiplatelet and gastric effects to anticoagulation

    Apart from any change in the INR, the combination is a concern because it raises bleeding risk by adding antiplatelet and gastric effects to anticoagulation: the NSAID inhibits platelet thromboxane and erodes the gastric mucosa in a patient whose clotting is already suppressed. The statement that it raises bleeding risk by adding fibrinolytic and hepatotoxic effects to warfarin is wrong because NSAIDs do not dissolve clots and the hazard is not a liver effect. The statement that it raises bleeding risk by blocking vitamin K recycling and clotting factor production describes how warfarin itself works, not what the NSAID adds. The statement that it raises bleeding risk by blocking thrombin activity and stable fibrin clot formation describes a direct thrombin inhibitor such as dabigatran.

  122. A patient receiving an aminoglycoside also takes a loop diuretic. What is the primary additive toxicity concern of this drug-drug interaction?

    • A.Hepatotoxicity and neutropenia
    • B.Cardiotoxicity and arrhythmias
    • C.Ototoxicity and nephrotoxicity
    • D.Phototoxicity and tendinopathy
    Show answerHide answer

    Correct answer: Ototoxicity and nephrotoxicity

    Ototoxicity and nephrotoxicity is correct because aminoglycosides and loop diuretics each damage the inner ear, so giving them together raises the risk of hearing loss, and kidney injury can add up as well. Hepatotoxicity and neutropenia are not typical of either drug; they are concerns with agents such as isoniazid or linezolid. Cardiotoxicity and arrhythmias describe the additive risk of anthracyclines or of two QT-prolonging drugs, not of this pair. Phototoxicity and tendinopathy belong to the fluoroquinolones, a different antibiotic class.

  123. A patient with type 2 diabetes and heart failure with reduced ejection fraction needs a glucose-lowering agent. Which class is both glucose-lowering and beneficial for heart failure?

    • A.An SGLT2 inhibitor
    • B.A DPP-4 inhibitor
    • C.A long-acting insulin
    • D.An insulin sensitizer of the thiazolidinedione class
    Show answerHide answer

    Correct answer: An SGLT2 inhibitor

    An SGLT2 inhibitor is correct because this class lowers glucose and also reduces heart failure hospitalization and cardiovascular death in heart failure with reduced ejection fraction, so it is preferred here. A DPP-4 inhibitor lowers glucose without any heart failure benefit, and saxagliptin and alogliptin carry a warning about heart failure hospitalization. A long-acting insulin lowers glucose but promotes sodium and fluid retention and weight gain, with no heart failure benefit. An insulin sensitizer of the thiazolidinedione class, such as pioglitazone, causes fluid retention and can worsen heart failure.

  124. A pharmacist reviewing a patient's regimen identifies a prescribing cascade in which a new drug was added to treat the side effect of another. What is the best person-centered intervention?

    • A.Keep the first drug and add a third one for the new symptom
    • B.Keep the first drug and switch the second to a similar one
    • C.Lower or stop the second drug and leave the first unchanged
    • D.Reassess the first drug and change or stop it when possible
    Show answerHide answer

    Correct answer: Reassess the first drug and change or stop it when possible

    Reassess the first drug and change or stop it when possible is correct because a prescribing cascade starts with the drug that caused the adverse effect, so modifying or stopping that drug removes the root cause. Keep the first drug and add a third one for the new symptom extends the cascade and adds to the medication burden. Keep the first drug and switch the second to a similar one still treats a side effect with another drug. Lower or stop the second drug and leave the first unchanged leaves the adverse effect in place, because the drug that causes it is still being taken.

  125. A patient with newly diagnosed hypertension and a normal heart and kidneys prefers once-daily dosing and good tolerability. Which first-line option commonly fits these preferences?

    • A.A long-acting ACE inhibitor, ARB, thiazide, or calcium channel blocker
    • B.A loop diuretic, ARNI, MRA, or SGLT2 inhibitor as used in heart failure
    • C.A central alpha-2 agonist, nitrate, minoxidil, or oral hydralazine
    • D.A short-acting form of captopril, nifedipine, clonidine, or hydralazine
    Show answerHide answer

    Correct answer: A long-acting ACE inhibitor, ARB, thiazide, or calcium channel blocker

    A long-acting ACE inhibitor, ARB, thiazide, or calcium channel blocker is correct because these are the four first-line classes for uncomplicated hypertension, and long-acting agents within them are taken once daily and are well tolerated. A loop diuretic, ARNI, MRA, or SGLT2 inhibitor as used in heart failure is a regimen for a compelling indication that this patient, with a normal heart and kidneys, does not have. A central alpha-2 agonist, nitrate, minoxidil, or oral hydralazine lists later-line or non-antihypertensive agents with more sedation, reflex tachycardia, and other adverse effects. A short-acting form of captopril, nifedipine, clonidine, or hydralazine must be taken two to four times a day, which does not fit the preference for once-daily dosing.

  126. A patient on digoxin has therapeutic drug monitoring performed. When should a digoxin level ideally be drawn for accurate interpretation?

    • A.At least 1 to 2 hours after a dose, when absorption has peaked
    • B.At least 6 to 8 hours after a dose, once distribution is complete
    • C.At least 2 to 4 hours after a dose, when the peak effect has passed
    • D.At least 36 to 48 hours after a dose, once a full half-life is over
    Show answerHide answer

    Correct answer: At least 6 to 8 hours after a dose, once distribution is complete

    At least 6 to 8 hours after a dose, once distribution is complete is correct because digoxin moves slowly from serum into tissue, and a sample taken before that phase ends reads falsely high. At least 1 to 2 hours after a dose, when absorption has peaked would allow sampling at the serum peak, which overstates the concentration at the site of action. At least 2 to 4 hours after a dose, when the peak effect has passed is still inside the distribution phase, so the result would also be misleadingly high. At least 36 to 48 hours after a dose, once a full half-life is over is not needed and would mean missing doses; the level is drawn within a normal dosing interval, after distribution, at steady state.

  127. A patient with heart failure with reduced ejection fraction on guideline-directed therapy develops hyperkalemia attributed to a mineralocorticoid receptor antagonist. What is the most appropriate response?

    • A.Recheck potassium, then stop the beta-blocker and continue the antagonist unchanged
    • B.Recheck potassium, then switch the antagonist to eplerenone and keep the same dose
    • C.Recheck potassium, then reduce or hold the antagonist and address other contributors
    • D.Recheck potassium, then hold the loop diuretic and continue the antagonist unchanged
    Show answerHide answer

    Correct answer: Recheck potassium, then reduce or hold the antagonist and address other contributors

    Recheck potassium, then reduce or hold the antagonist and address other contributors is correct because the mineralocorticoid receptor antagonist is the cause, so its dose is lowered or held while renal function, potassium supplements, and other potassium-raising drugs are reviewed. Recheck potassium, then stop the beta-blocker and continue the antagonist unchanged removes a drug with a survival benefit that is not responsible and leaves the cause in place. Recheck potassium, then switch the antagonist to eplerenone and keep the same dose does not help, because eplerenone raises potassium just as spironolactone does; it only avoids the hormonal side effects. Recheck potassium, then hold the loop diuretic and continue the antagonist unchanged would raise potassium further, since loop diuretics increase potassium excretion.

  128. A patient is being assessed for a new antihypertensive and is pregnant. Which class is contraindicated due to fetal harm?

    • A.Methyldopa or labetalol tablets
    • B.An ACE inhibitor or an ARB
    • C.Nifedipine ER or IV hydralazine
    • D.A loop diuretic or a thiazide
    Show answerHide answer

    Correct answer: An ACE inhibitor or an ARB

    An ACE inhibitor or an ARB is correct because drugs acting on the renin-angiotensin system cause fetal renal damage, oligohydramnios, and other developmental harm, so both classes are contraindicated in pregnancy. Methyldopa or labetalol tablets are established choices for chronic hypertension in pregnancy. Nifedipine ER or IV hydralazine are also used in pregnancy, hydralazine mainly for acute severe hypertension. A loop diuretic or a thiazide is not a preferred choice in pregnancy, but neither is contraindicated for fetal harm in the way renin-angiotensin system blockers are.

  129. A patient with type 2 diabetes asks why a fasting glucose alone may be insufficient to guide therapy changes. What is the best explanation?

    • A.Fasting glucose reflects after-meal peaks but misses the overnight baseline
    • B.Fasting glucose reflects a three-month average but ignores after-meal peaks
    • C.A1c with glucose patterns shows both overall control and after-meal peaks
    • D.A1c with one daily test already shows after-meal peaks and glucose swings
    Show answerHide answer

    Correct answer: A1c with glucose patterns shows both overall control and after-meal peaks

    A1c with glucose patterns shows both overall control and after-meal peaks is correct because A1c reflects average glucose over about three months, while glucose patterns reveal the postprandial rises and variability that a fasting value cannot show. Fasting glucose reflects after-meal peaks but misses the overnight baseline has it backward: a fasting value reflects overnight, basal glucose and misses the peaks after meals. Fasting glucose reflects a three-month average but ignores after-meal peaks is wrong because a fasting value is a single point in time; the three-month measure is A1c. A1c with one daily test already shows after-meal peaks and glucose swings is wrong because an average plus a single reading cannot reveal postprandial rises or variability, which is why glucose patterns are added.

  130. A patient with MRSA infection is being treated, and the laboratory reports a rising vancomycin minimum inhibitory concentration over repeated isolates. What does a higher MIC most directly suggest for treatment planning?

    • A.Rising susceptibility that may call for lower exposure or an abbreviated treatment course
    • B.Falling drug clearance that may call for a lower dose or a longer dosing interval
    • C.Rising drug clearance that may call for a higher dose or a shorter dosing interval
    • D.Falling susceptibility that may call for higher exposure or an alternative agent
    Show answerHide answer

    Correct answer: Falling susceptibility that may call for higher exposure or an alternative agent

    Falling susceptibility that may call for higher exposure or an alternative agent is correct because the minimum inhibitory concentration is the lowest concentration that stops growth, so a rising value means more drug is needed to inhibit the organism; exposure may have to increase within safe limits, or an alternative such as daptomycin may be chosen. Rising susceptibility that may call for lower exposure or an abbreviated treatment course reverses the meaning, since susceptibility rises when the value falls. Falling drug clearance that may call for a lower dose or a longer dosing interval and Rising drug clearance that may call for a higher dose or a shorter dosing interval both confuse a property of the organism with the patient's pharmacokinetics, which are judged from renal function and serum levels, not from the isolate.

  131. A patient taking warfarin is started on St. John's wort, an herbal enzyme inducer. What is the expected effect on the INR?

    • A.The INR rises as warfarin metabolism is inhibited
    • B.The INR rises as warfarin is displaced from proteins
    • C.The INR is steady as warfarin bypasses these enzymes
    • D.The INR falls as warfarin clearance is accelerated
    Show answerHide answer

    Correct answer: The INR falls as warfarin clearance is accelerated

    The INR falls as warfarin clearance is accelerated is correct because St. John's wort induces the cytochrome P450 enzymes that metabolize warfarin, so anticoagulation is reduced and clot risk rises. The INR rises as warfarin metabolism is inhibited describes an enzyme inhibitor such as fluconazole or amiodarone, the opposite of an inducer. The INR rises as warfarin is displaced from proteins describes a protein-binding interaction, which is not how this herb acts. The INR is steady as warfarin bypasses these enzymes is wrong because warfarin is cleared mainly by hepatic metabolism, so induction matters and herbal products can cause clinically important interactions.

  132. A patient is being treated for heart failure and develops worsening renal function after initiating an ACE inhibitor. A small rise in creatinine after starting renin-angiotensin system therapy is best interpreted how?

    • A.An expected and tolerable change that calls for monitoring against a threshold
    • B.An early kidney injury that calls for stopping the drug and giving fluids
    • C.A sign of renal artery stenosis that calls for urgent vascular imaging
    • D.A sign of treatment failure that calls for a switch to a different type of drug
    Show answerHide answer

    Correct answer: An expected and tolerable change that calls for monitoring against a threshold

    An expected and tolerable change that calls for monitoring against a threshold is correct because blocking angiotensin II dilates the efferent arteriole and lowers filtration pressure, so a modest rise in creatinine is anticipated and is tolerated up to a defined threshold, commonly about 30 percent above baseline, while renal function and potassium are followed. An early kidney injury that calls for stopping the drug and giving fluids is wrong because automatic discontinuation would withdraw a therapy that improves outcomes; action is reserved for larger rises or hyperkalemia. A sign of renal artery stenosis that calls for urgent vascular imaging fits a large, rapid rise in creatinine, not a small one. A sign of treatment failure that calls for a switch to a different type of drug is wrong because the change reflects the drug's hemodynamic action, not a lack of effect.

  133. A patient with type 2 diabetes is started on a GLP-1 receptor agonist. Which common adverse effect should be addressed during counseling?

    • A.Genital yeast infections and frequent urination that ease with hydration
    • B.Ankle swelling and gradual weight gain that ease with a lower daily dose
    • C.Nausea and other gastrointestinal symptoms that ease with slow titration
    • D.Hypoglycemia and gradual weight gain that ease with regular mealtimes
    Show answerHide answer

    Correct answer: Nausea and other gastrointestinal symptoms that ease with slow titration

    Nausea and other gastrointestinal symptoms that ease with slow titration is correct because GLP-1 receptor agonists slow gastric emptying, so nausea, vomiting, and diarrhea are common early on and usually improve when the dose is raised gradually. Genital yeast infections and frequent urination that ease with hydration describe SGLT2 inhibitors, which act by increasing urinary glucose. Ankle swelling and gradual weight gain that ease with a lower daily dose describe thiazolidinediones, which cause fluid retention. Hypoglycemia and gradual weight gain that ease with regular mealtimes describe sulfonylureas and insulin; a GLP-1 receptor agonist used alone rarely causes hypoglycemia and tends to reduce weight.

  134. A patient receiving vancomycin with concomitant piperacillin-tazobactam should be assessed for which heightened risk noted in some studies?

    • A.A higher rate of permanent hearing loss
    • B.A higher rate of acute kidney injury
    • C.A higher rate of dose-related seizures
    • D.A higher rate of liver enzyme elevation
    Show answerHide answer

    Correct answer: A higher rate of acute kidney injury

    A higher rate of acute kidney injury is correct because several observational studies have linked vancomycin given with piperacillin-tazobactam to more acute kidney injury than vancomycin with other beta-lactams, so renal function is followed closely or another combination is considered. A higher rate of permanent hearing loss is the concern when vancomycin is combined with other ototoxic drugs such as aminoglycosides or loop diuretics. A higher rate of dose-related seizures is associated with high exposure to agents such as imipenem or cefepime, particularly in renal impairment. A higher rate of liver enzyme elevation is not the signal reported for this pair.

  135. A patient with heart failure is taking digoxin and has new bradycardia and visual halos. The pharmacist suspects digoxin toxicity. Which serum electrolyte derangement should be promptly assessed because it worsens toxicity?

    • A.Hypokalemia and hypomagnesemia
    • B.Hyperkalemia and hypermagnesemia
    • C.Hypocalcemia and hyponatremia
    • D.Hypernatremia and hyperchloremia
    Show answerHide answer

    Correct answer: Hypokalemia and hypomagnesemia

    Hypokalemia and hypomagnesemia is correct because digoxin competes with potassium for its binding site on the sodium-potassium pump, so low potassium increases digoxin binding, and low magnesium further sensitizes the myocardium to arrhythmias; both should be checked and corrected promptly. Hyperkalemia and hypermagnesemia is the reverse: a high potassium can be a result of severe acute toxicity, but it is not the derangement that makes toxicity more likely. Hypocalcemia and hyponatremia do not worsen toxicity; it is a high calcium, not a low one, that adds to the risk. Hypernatremia and hyperchloremia have no recognized effect on digoxin toxicity.

  136. A patient on warfarin is preparing for elective surgery. Which periprocedural planning step reflects appropriate management of anticoagulation?

    • A.Hold warfarin from the morning of surgery and bridge with heparin shortly afterward
    • B.Hold warfarin a set number of days before surgery and base bridging on the clot risk
    • C.Continue warfarin through the day of surgery and reverse it if a severe bleed occurs
    • D.Continue warfarin at half the usual dose that week and omit it on the day of surgery
    Show answerHide answer

    Correct answer: Hold warfarin a set number of days before surgery and base bridging on the clot risk

    Hold warfarin a set number of days before surgery and base bridging on the clot risk is correct because warfarin is usually stopped about five days ahead so the INR can normalize, and bridging with a short-acting anticoagulant is considered only for patients at high thrombotic risk. Hold warfarin from the morning of surgery and bridge with heparin shortly afterward leaves the patient fully anticoagulated during the operation, since the effect of warfarin takes days to wear off. Continue warfarin through the day of surgery and reverse it if a severe bleed occurs accepts an avoidable bleeding risk for an elective procedure. Continue warfarin at half the usual dose that week and omit it on the day of surgery does not reliably bring the INR down in time and is not a recognized approach.

  137. A patient with type 2 diabetes is initiated on insulin glargine. How does this long-acting basal insulin differ from regular insulin in its action profile?

    • A.It has a fairly flat, prolonged effect with a minimal peak
    • B.It has a faster onset, with an early peak and shorter effect
    • C.It has a slower onset, with a distinct peak at about six hours
    • D.It has a rapid early insulin peak, with a prolonged basal tail
    Show answerHide answer

    Correct answer: It has a fairly flat, prolonged effect with a minimal peak

    It has a fairly flat, prolonged effect with a minimal peak is correct because insulin glargine forms a depot that releases insulin slowly over about 24 hours, giving steady basal coverage. It has a faster onset, with an early peak and shorter effect describes a rapid-acting analog such as lispro or aspart, which is used at meals. It has a slower onset, with a distinct peak at about six hours describes NPH, an intermediate-acting insulin with a distinct peak. It has a rapid early insulin peak, with a prolonged basal tail describes a premixed insulin, not a basal analog.

  138. A patient with hypertension is started on a calcium channel blocker (dihydropyridine). Which common adverse effect should be assessed at follow-up?

    • A.Chronic cough
    • B.Peripheral edema
    • C.Hyperkalemia
    • D.Cold extremities
    Show answerHide answer

    Correct answer: Peripheral edema

    Peripheral edema is correct because dihydropyridines such as amlodipine dilate arterioles more than veins, which raises capillary pressure and causes dose-related ankle swelling. Chronic cough is the characteristic adverse effect of ACE inhibitors, caused by bradykinin accumulation. Hyperkalemia is seen with ACE inhibitors, angiotensin receptor blockers, and potassium-sparing diuretics, not with calcium channel blockers. Cold extremities are associated with beta-blockers, which reduce peripheral blood flow.

  139. A patient on chronic vancomycin therapy for osteomyelitis requires ongoing dosing. Which parameter most appropriately guides maintenance dose adjustments over the course of therapy?

    • A.Baseline body weight together with the initial loading dose
    • B.Renal function together with AUC or serum level monitoring
    • C.ESR or CRP trends together with repeat imaging of the bones
    • D.Liver enzymes together with a weekly complete blood count
    Show answerHide answer

    Correct answer: Renal function together with AUC or serum level monitoring

    Renal function together with AUC or serum level monitoring is correct because vancomycin is cleared by the kidneys, and clearance can change over a long course, so the maintenance dose is adjusted from renal function and measured exposure. Baseline body weight together with the initial loading dose sets the starting regimen but cannot capture later changes in clearance. ESR or CRP trends together with repeat imaging of the bones help judge the response of the infection, not the dose needed to reach target exposure. Liver enzymes together with a weekly complete blood count are safety checks, but vancomycin is not cleared by the liver and these do not guide its dose.

  140. A patient develops drug-induced QT prolongation after starting a new medication. Which co-prescribed agent would most increase the risk of dangerous arrhythmia through an additive drug-drug interaction?

    • A.A second CNS-depressant drug
    • B.A second antimuscarinic drug
    • C.A second anticoagulant drug
    • D.A second QT-prolonging drug
    Show answerHide answer

    Correct answer: A second QT-prolonging drug

    A second QT-prolonging drug is correct because the effects of two such agents on cardiac repolarization add together, raising the risk of torsades de pointes; a medication review should look for combinations such as a macrolide with an antipsychotic or an antiarrhythmic. A second CNS-depressant drug adds to sedation and respiratory depression, not to arrhythmia risk. A second antimuscarinic drug adds to dry mouth, constipation, urinary retention, and confusion. A second anticoagulant drug adds to the risk of bleeding, which is a different interaction from additive QT prolongation.

  141. A patient with heart failure with reduced ejection fraction is intolerant of one beta-blocker due to fatigue. What is the most appropriate person-centered approach?

    • A.Stop the beta-blocker and switch to diltiazem or verapamil
    • B.Stop the beta-blocker and switch to ivabradine or digoxin
    • C.Switch to atenolol or propranolol as the next beta-blocker
    • D.Adjust the dose or switch to another proven beta-blocker
    Show answerHide answer

    Correct answer: Adjust the dose or switch to another proven beta-blocker

    Adjust the dose or switch to another proven beta-blocker is correct because bisoprolol, carvedilol, and metoprolol succinate reduce mortality in heart failure with reduced ejection fraction, so intolerance to one is managed by slower titration, a lower dose, or a trial of another of these agents. Stop the beta-blocker and switch to diltiazem or verapamil is wrong because nondihydropyridine calcium channel blockers depress contractility and are avoided in reduced ejection fraction. Stop the beta-blocker and switch to ivabradine or digoxin gives up a mortality benefit that neither of those drugs replaces. Switch to atenolol or propranolol as the next beta-blocker is wrong because those agents have not shown a survival benefit in heart failure.

  142. A pharmacist counsels a patient taking dabigatran capsules. Which storage and handling point reflects an important characteristic of this DOAC affecting its efficacy?

    • A.Keep the capsules in a weekly pill organizer, since light reduces potency
    • B.Refrigerate the capsules soon after opening, since warmth reduces potency
    • C.Discard the capsules a week after opening, since air reduces potency
    • D.Keep the capsules in the original bottle, since moisture reduces potency
    Show answerHide answer

    Correct answer: Keep the capsules in the original bottle, since moisture reduces potency

    Keep the capsules in the original bottle, since moisture reduces potency is correct because dabigatran capsules break down when exposed to humidity, so they stay in the manufacturer's bottle with its desiccant cap, or in the blister pack, until the moment of use. Keep the capsules in a weekly pill organizer, since light reduces potency is wrong because an organizer exposes the capsules to moisture, which is the real problem, and light is not the concern. Refrigerate the capsules soon after opening, since warmth reduces potency is wrong because the product is stored at room temperature, and a refrigerator adds humidity. Discard the capsules a week after opening, since air reduces potency is wrong because an opened bottle can be used for four months when it is kept tightly closed.

  143. A patient with type 2 diabetes and a high A1c despite two oral agents may need insulin. Which finding most supports initiating insulin in the treatment plan?

    • A.A markedly raised A1c with symptomatic hyperglycemia on oral agents
    • B.An A1c just above goal with no symptoms while taking oral agents
    • C.One high fasting glucose with a stable A1c while taking oral agents
    • D.An A1c over target with obesity and coronary disease on oral agents
    Show answerHide answer

    Correct answer: A markedly raised A1c with symptomatic hyperglycemia on oral agents

    A markedly raised A1c with symptomatic hyperglycemia on oral agents is correct because a very high A1c together with polyuria, polydipsia, or weight loss shows that oral therapy is not enough, and insulin is the most effective way to regain control. An A1c just above goal with no symptoms while taking oral agents can be managed by optimizing or adding non-insulin therapy. One high fasting glucose with a stable A1c while taking oral agents is a single reading and does not show sustained loss of control. An A1c over target with obesity and coronary disease on oral agents points first to a GLP-1 receptor agonist or an SGLT2 inhibitor, which are chosen for those comorbidities.

  144. A patient on warfarin reports starting a new course of acetaminophen at high doses for several days. What is the appropriate monitoring consideration?

    • A.Repeated high doses can lower the INR, so raise the warfarin dose
    • B.Even high doses are safe with warfarin, so keep the usual checks
    • C.Sustained high doses block platelets, so check the platelet count
    • D.Prolonged high doses can raise the INR, so arrange closer checks
    Show answerHide answer

    Correct answer: Prolonged high doses can raise the INR, so arrange closer checks

    Prolonged high doses can raise the INR, so arrange closer checks is correct because several days of acetaminophen at about 2 grams a day or more can potentiate warfarin, so the INR is monitored more closely during that period. Repeated high doses can lower the INR, so raise the warfarin dose has the direction reversed and would add to the bleeding risk. Even high doses are safe with warfarin, so keep the usual checks is the common misconception; occasional standard doses are preferred over NSAIDs, but sustained high doses do interact. Sustained high doses block platelets, so check the platelet count describes aspirin and other NSAIDs, since acetaminophen has no meaningful antiplatelet effect.

  145. A patient with hypertension and a recent myocardial infarction would gain a compelling indication for which class as part of the treatment plan?

    • A.A dihydropyridine
    • B.A renin inhibitor
    • C.A beta-blocker
    • D.A loop diuretic
    Show answerHide answer

    Correct answer: A beta-blocker

    A beta-blocker is correct because, after a myocardial infarction, this class lowers blood pressure and also reduces reinfarction and death, which makes the infarction a compelling indication for it. A dihydropyridine such as amlodipine lowers blood pressure but has no post-infarction outcome benefit. A renin inhibitor such as aliskiren is not a recommended post-infarction agent; the renin-angiotensin drugs with evidence in this setting are ACE inhibitors and angiotensin receptor blockers. A loop diuretic treats volume overload and has no compelling indication after an uncomplicated infarction.

  146. A patient receiving an aminoglycoside has therapeutic drug monitoring showing an adequate peak but a higher-than-desired trough. What adjustment best addresses this while preserving efficacy?

    • A.Lengthen the dosing interval so the trough can fall
    • B.Shorten the dosing interval so the trough cannot rise
    • C.Lower each dose so the trough falls proportionally
    • D.Raise each dose so the trough is cleared more quickly
    Show answerHide answer

    Correct answer: Lengthen the dosing interval so the trough can fall

    Lengthen the dosing interval so the trough can fall is correct because a longer interval gives more time for elimination before the next dose, which lowers the trough and the risk of toxicity while the same dose keeps the peak adequate. Shorten the dosing interval so the trough cannot rise is wrong because giving doses closer together leaves less time for elimination and raises the trough. Lower each dose so the trough falls proportionally would also lower the peak, which is already adequate, and aminoglycoside killing depends on the peak. Raise each dose so the trough is cleared more quickly is wrong because a larger dose does not speed elimination; it raises both the peak and the trough.

  147. During reconciliation at discharge, a pharmacist notes the patient was on a home medication that was inadvertently omitted from the discharge orders. What is the most appropriate action?

    • A.Add it back to the discharge orders and notify the care team later
    • B.Ask the care team whether to resume it and document the decision
    • C.Tell the patient at discharge to restart it and record that advice
    • D.Take the omission to be intended and record it as discontinued
    Show answerHide answer

    Correct answer: Ask the care team whether to resume it and document the decision

    Ask the care team whether to resume it and document the decision is correct because reconciliation exists to resolve unexplained discrepancies, and only the prescriber can confirm whether the omission was intended. Add it back to the discharge orders and notify the care team later changes the orders without the prescriber's agreement, and the drug may have been stopped for a reason. Tell the patient at discharge to restart it and record that advice gives unverified instructions directly to the patient. Take the omission to be intended and record it as discontinued assumes intent without checking and may leave a needed therapy stopped.

  148. A patient with type 2 diabetes experiences euglycemic diabetic ketoacidosis. Which medication class is most associated with this presentation?

    • A.DPP-4 inhibitors
    • B.Insulin secretagogues
    • C.Basal insulin analogs
    • D.SGLT2 inhibitors
    Show answerHide answer

    Correct answer: SGLT2 inhibitors

    SGLT2 inhibitors is correct because these drugs lower glucose through urinary loss while glucagon rises and ketone production increases, so ketoacidosis can develop with a near-normal glucose, especially during illness, fasting, or surgery. DPP-4 inhibitors are not associated with ketoacidosis; their main warnings concern pancreatitis and joint pain. Insulin secretagogues such as sulfonylureas raise insulin levels, which suppresses ketone formation; their main risk is hypoglycemia. Basal insulin analogs prevent ketoacidosis and do not cause it.

  149. A patient with heart failure with reduced ejection fraction and persistent symptoms is on a foundational regimen. Which strategy best reflects guideline-directed treatment optimization?

    • A.Titrate each foundational agent to its target dose as tolerated
    • B.Limit each foundational agent to its starting dose once improved
    • C.Raise the diuretic and keep each foundational agent at its usual dose
    • D.Add digoxin and keep each foundational agent at its current daily dose
    Show answerHide answer

    Correct answer: Titrate each foundational agent to its target dose as tolerated

    Titrate each foundational agent to its target dose as tolerated is correct because the mortality and hospitalization benefits of the foundational heart failure drugs were shown at target doses, so each is increased stepwise as blood pressure, heart rate, renal function, and potassium allow. Limit each foundational agent to its starting dose once improved leaves the patient undertreated, because the benefit does not depend on symptoms alone. Raise the diuretic and keep each foundational agent at its usual dose relieves congestion but does not improve survival. Add digoxin and keep each foundational agent at its current daily dose adds a drug with no mortality benefit in place of optimizing the therapies that have one.

  150. A patient taking an oral antibiotic for MRSA reports a personal history of severe sulfonamide allergy. Which MRSA agent should be avoided due to this allergy?

    • A.Minocycline hydrochloride
    • B.Clindamycin palmitate hydrochloride
    • C.Trimethoprim-sulfamethoxazole
    • D.Tedizolid phosphate
    Show answerHide answer

    Correct answer: Trimethoprim-sulfamethoxazole

    Trimethoprim-sulfamethoxazole is correct because sulfamethoxazole is a sulfonamide antibiotic, so the combination is avoided in a patient with a severe sulfonamide allergy. Minocycline hydrochloride is a tetracycline and contains no sulfonamide group. Clindamycin palmitate hydrochloride is a lincosamide, also unrelated to the sulfonamides. Tedizolid phosphate is an oxazolidinone, so it too remains an oral option for a susceptible isolate.

  151. A patient on a beta-blocker for hypertension develops new fatigue and a heart rate in the 40s. What is the most appropriate assessment of this adverse drug reaction?

    • A.A harmless drug effect that needs no change while the pressure is at target
    • B.A symptomatic bradycardia that may need a lower dose or review of the agent
    • C.A transient effect that should fade in a week or two at the same daily dose
    • D.A sign of depression from the drug that may need an added antidepressant
    Show answerHide answer

    Correct answer: A symptomatic bradycardia that may need a lower dose or review of the agent

    A symptomatic bradycardia that may need a lower dose or review of the agent is correct because a heart rate in the 40s with new fatigue is an adverse effect of beta blockade, so the dose is reduced or the choice of drug is reassessed. A harmless drug effect that needs no change while the pressure is at target is wrong because some slowing of the heart is expected, but a rate this low with symptoms is not acceptable. A transient effect that should fade in a week or two at the same daily dose is wrong because the bradycardia is dose-related and persists while the dose is unchanged. A sign of depression from the drug that may need an added antidepressant misreads the fatigue and would start a prescribing cascade; the slow heart rate explains it.

  152. A patient with type 2 diabetes is counseled on metformin's most common adverse effects. Which effects are typical and often improve with extended-release formulation or gradual titration?

    • A.Hypoglycemic symptoms such as tremor and hunger
    • B.Vasodilatory effects such as flushing and pruritus
    • C.Neurological effects such as numbness and tingling
    • D.Gastrointestinal upset such as nausea and diarrhea
    Show answerHide answer

    Correct answer: Gastrointestinal upset such as nausea and diarrhea

    Gastrointestinal upset such as nausea and diarrhea is correct because these are the most common adverse effects of metformin, and they usually lessen when the dose is increased slowly, the drug is taken with food, or an extended-release product is used. Hypoglycemic symptoms such as tremor and hunger are typical of sulfonylureas and insulin; metformin alone rarely causes hypoglycemia. Vasodilatory effects such as flushing and pruritus are the well-known adverse effects of niacin, which are also eased by extended-release products and slow titration. Neurological effects such as numbness and tingling can follow vitamin B12 deficiency after long-term metformin use, but they are not common early effects and do not improve with a change of formulation.

  153. A patient on warfarin has a stable INR for months, then suddenly has a low INR. Besides diet and adherence, which medication change could explain a decreased INR?

    • A.Starting an enzyme inhibitor such as fluconazole
    • B.Starting an enzyme inducer such as carbamazepine
    • C.Stopping a daily supplement such as vitamin K
    • D.Stopping a long-term antibiotic such as rifampin
    Show answerHide answer

    Correct answer: Starting an enzyme inducer such as carbamazepine

    Starting an enzyme inducer such as carbamazepine is correct because induction of the enzymes that metabolize warfarin increases its clearance, so the INR falls and anticoagulation is reduced. Starting an enzyme inhibitor such as fluconazole slows warfarin metabolism and raises the INR. Stopping a daily supplement such as vitamin K removes a source of the vitamin that opposes warfarin, so the INR would rise. Stopping a long-term antibiotic such as rifampin withdraws a potent inducer, so warfarin clearance slows over the following weeks and the INR rises.

  154. A patient is being assessed for heart failure therapy and has a low blood pressure that limits up-titration. Which approach reflects appropriate individualized management?

    • A.Stop therapy until the blood pressure recovers, then restart each agent that same day at full strength
    • B.Raise and hold the agents at their full target doses, adding oral midodrine therapy for the low blood pressure
    • C.Balance and sequence the agents for tolerability, maximizing evidence-based therapy as blood pressure allows
    • D.Continue diuretic therapy alone, while stopping each agent that is known to lower the blood pressure
    Show answerHide answer

    Correct answer: Balance and sequence the agents for tolerability, maximizing evidence-based therapy as blood pressure allows

    Balance and sequence the agents for tolerability, maximizing evidence-based therapy as blood pressure allows is correct because low blood pressure without symptoms is not a reason to give up therapy; agents with little effect on blood pressure are prioritized, doses are staggered or adjusted, and each evidence-based drug is advanced as far as the patient tolerates. Stop therapy until the blood pressure recovers, then restart each agent that same day at full strength withdraws drugs that improve survival and then reintroduces them at doses the patient is unlikely to tolerate. Raise and hold the agents at their full target doses, adding oral midodrine therapy for the low blood pressure forces titration despite hypotension and adds a vasopressor to treat a drug effect. Continue diuretic therapy alone, while stopping each agent that is known to lower the blood pressure leaves only symptom relief, because diuretics do not improve survival.

  155. A patient with hypertension is also taking a nonselective NSAID chronically. How can this affect blood pressure control?

    • A.It can lower blood pressure and add to the effect of other vasodilating drugs
    • B.It leaves blood pressure unchanged but increases the serum potassium level
    • C.It can raise blood pressure and blunt the effect of several antihypertensives
    • D.It leaves blood pressure unchanged if taken well apart from the other tablets
    Show answerHide answer

    Correct answer: It can raise blood pressure and blunt the effect of several antihypertensives

    It can raise blood pressure and blunt the effect of several antihypertensives is correct because NSAIDs inhibit renal prostaglandins, which causes sodium and fluid retention and reduces the effect of diuretics, ACE inhibitors, angiotensin receptor blockers, and beta-blockers. It can lower blood pressure and add to the effect of other vasodilating drugs has the direction reversed, since prostaglandin inhibition causes vasoconstriction and fluid retention. It leaves blood pressure unchanged but increases the serum potassium level is wrong because, although NSAIDs can raise potassium, they also raise blood pressure. It leaves blood pressure unchanged if taken well apart from the other tablets is wrong because the effect comes from sustained prostaglandin inhibition, not from the timing of doses.

  156. A patient on a maintenance vancomycin regimen has obesity. Why is using actual body weight with a maximum per-dose cap important in vancomycin dosing?

    • A.Weight-based dosing lowers the infusion-reaction risk, while a cap shortens administration time
    • B.Weight-based dosing replaces the loading dose, while a cap replaces routine serum level monitoring
    • C.Weight-based dosing improves target attainment, while a cap limits excessive doses and toxicity
    • D.Weight-based dosing matches hepatic clearance, while a cap guards against liver and biliary injury
    Show answerHide answer

    Correct answer: Weight-based dosing improves target attainment, while a cap limits excessive doses and toxicity

    Weight-based dosing improves target attainment, while a cap limits excessive doses and toxicity is correct because vancomycin volume of distribution and clearance increase with body size, so doses based on actual body weight improve target attainment, but an uncapped dose in obesity can be very large and raise the risk of nephrotoxicity. Weight-based dosing lowers the infusion-reaction risk, while a cap shortens administration time is wrong because infusion reactions depend on the rate of infusion, not on how the dose was calculated. Weight-based dosing replaces the loading dose, while a cap replaces routine serum level monitoring is wrong because a loading dose may still be used and exposure is still monitored. Weight-based dosing matches hepatic clearance, while a cap guards against liver and biliary injury is wrong because vancomycin is cleared by the kidneys and its main dose-related toxicity is renal.

  157. A patient with type 2 diabetes is started on a sulfonylurea and skips a meal. What counseling addresses the resulting risk?

    • A.Skipped meals can cause hyperglycemia, so take one extra tablet with the next full meal
    • B.Skipped meals can cause ketoacidosis, so check urine ketones and drink plenty of fluids
    • C.Skipped meals can cause hypoglycemia, so eat regularly and learn to spot and treat lows
    • D.Skipped meals can cause lactic acidosis, so hold the tablet until appetite returns
    Show answerHide answer

    Correct answer: Skipped meals can cause hypoglycemia, so eat regularly and learn to spot and treat lows

    Skipped meals can cause hypoglycemia, so eat regularly and learn to spot and treat lows is correct because a sulfonylurea stimulates insulin release whether or not food is eaten, so a missed meal can lead to low blood glucose; the patient should keep meals consistent and be able to recognize and treat hypoglycemia. Skipped meals can cause hyperglycemia, so take one extra tablet with the next full meal has the risk reversed, and doubling the dose would make hypoglycemia more likely. Skipped meals can cause ketoacidosis, so check urine ketones and drink plenty of fluids describes sick-day advice for insulin deficiency or SGLT2 inhibitors, not the risk with a sulfonylurea. Skipped meals can cause lactic acidosis, so hold the tablet until appetite returns confuses the drug with metformin, and lactic acidosis is not caused by missing a meal.

  158. A patient is taking metoprolol and verapamil together. What is the primary drug-drug interaction concern of combining a beta-blocker with a nondihydropyridine calcium channel blocker?

    • A.Additive slowing of rate and conduction, leading to bradycardia or heart block
    • B.Additive dilation of arteries and veins, leading to tachycardia or ankle edema
    • C.Additive retention of potassium, leading to hyperkalemia or a sudden arrhythmia
    • D.Additive prolongation of repolarization, leading to torsades or sudden collapse
    Show answerHide answer

    Correct answer: Additive slowing of rate and conduction, leading to bradycardia or heart block

    Additive slowing of rate and conduction, leading to bradycardia or heart block is correct because beta-blockers and nondihydropyridine calcium channel blockers such as verapamil both depress the sinoatrial and atrioventricular nodes, so their negative chronotropic and dromotropic effects add together. Additive dilation of arteries and veins, leading to tachycardia or ankle edema describes combinations of vasodilators; this pair slows the heart and does not speed it. Additive retention of potassium, leading to hyperkalemia or a sudden arrhythmia describes combining drugs such as ACE inhibitors and potassium-sparing diuretics. Additive prolongation of repolarization, leading to torsades or sudden collapse describes two QT-prolonging drugs, which is not the concern with metoprolol and verapamil.

  159. A patient develops gout flare attributed to a new medication. Which agent is a recognized cause of drug-induced hyperuricemia and gout?

    • A.A proton pump inhibitor
    • B.A thiazide diuretic
    • C.A bile acid sequestrant
    • D.A long-acting nitrate
    Show answerHide answer

    Correct answer: A thiazide diuretic

    A thiazide diuretic is correct because thiazides reduce renal excretion of uric acid, which raises the serum urate and can precipitate gout flares. A proton pump inhibitor is not a recognized cause of hyperuricemia; its long-term concerns include low magnesium and vitamin B12. A bile acid sequestrant acts in the gut, is not absorbed, and does not affect urate handling; among lipid-lowering drugs, the one linked to hyperuricemia is niacin. A long-acting nitrate causes headache and hypotension and has no effect on uric acid.

  160. A patient with type 2 diabetes and established cardiovascular disease is being assessed. Which GLP-1 receptor agonist characteristic supports its use beyond glucose lowering?

    • A.Some agents in the class reduce major adverse cardiovascular events
    • B.Some agents in the class reverse established cardiovascular disease
    • C.Some agents in the class replace statins for cardiovascular benefit
    • D.Some agents in the class relieve cardiovascular symptoms of angina
    Show answerHide answer

    Correct answer: Some agents in the class reduce major adverse cardiovascular events

    Some agents in the class reduce major adverse cardiovascular events is correct because outcome trials of liraglutide, injectable semaglutide, and dulaglutide showed fewer cardiovascular deaths, myocardial infarctions, and strokes, which supports their use in type 2 diabetes with established cardiovascular disease regardless of the need for further glucose lowering. Some agents in the class reverse established cardiovascular disease overstates the evidence, which shows fewer events and not regression of existing disease. Some agents in the class replace statins for cardiovascular benefit is wrong because these drugs are added to standard preventive therapy and do not take its place. Some agents in the class relieve cardiovascular symptoms of angina is wrong because they have no antianginal effect.

  161. A patient on chronic warfarin develops a clinically significant bleed with a markedly elevated INR. Which intervention provides the most rapid reversal of warfarin's effect in serious bleeding?

    • A.Type-specific fresh frozen plasma infusions with vitamin K
    • B.Four-factor prothrombin complex concentrate with vitamin K
    • C.Dose-adjusted intravenous protamine sulfate with vitamin K
    • D.Fibrinogen-rich thawed cryoprecipitate pool with vitamin K
    Show answerHide answer

    Correct answer: Four-factor prothrombin complex concentrate with vitamin K

    Four-factor prothrombin complex concentrate with vitamin K is correct because the concentrate replaces factors II, VII, IX, and X within minutes in a small volume, while vitamin K restarts the liver's own production so the correction lasts. Type-specific fresh frozen plasma infusions with vitamin K also supply clotting factors, but plasma must be thawed and given in large volumes over hours, so it corrects the INR more slowly and is the second choice when the concentrate is unavailable. Dose-adjusted intravenous protamine sulfate with vitamin K is wrong because protamine neutralizes heparin and does nothing for warfarin. Fibrinogen-rich thawed cryoprecipitate pool with vitamin K is wrong because cryoprecipitate supplies fibrinogen, factor VIII, and von Willebrand factor rather than the vitamin K-dependent factors that warfarin depletes.

  162. A patient with heart failure with reduced ejection fraction is on an SGLT2 inhibitor. Which counseling point reflects a relevant adverse effect to monitor?

    • A.Symptoms of recurrent hypoglycemia and weight gain
    • B.Symptoms of volume depletion and genital infection
    • C.Symptoms of persistent cough and tongue angioedema
    • D.Symptoms of breast tenderness and raised potassium
    Show answerHide answer

    Correct answer: Symptoms of volume depletion and genital infection

    Symptoms of volume depletion and genital infection is correct because SGLT2 inhibitors cause glucose and sodium loss in the urine, which produces an osmotic diuresis (dizziness, lightheadedness on standing) and promotes genital yeast infections. Symptoms of recurrent hypoglycemia and weight gain fit insulin or a sulfonylurea; an SGLT2 inhibitor on its own rarely causes hypoglycemia, particularly in a patient without diabetes, and it tends to produce modest weight loss. Symptoms of persistent cough and tongue angioedema are the bradykinin-related effects of an ACE inhibitor. Symptoms of breast tenderness and raised potassium describe spironolactone, a mineralocorticoid receptor antagonist.

  163. A patient on phenytoin is started on a CYP-inducing antiepileptic. What therapeutic drug monitoring consideration applies?

    • A.Phenytoin levels can change, so monitoring guides dose adjustment
    • B.Phenytoin levels will double, so the dose is halved before monitoring
    • C.Phenytoin levels will halve, so the dose is doubled before monitoring
    • D.Phenytoin levels are unaffected, so dose adjustment and monitoring are unnecessary
    Show answerHide answer

    Correct answer: Phenytoin levels can change, so monitoring guides dose adjustment

    Phenytoin levels can change, so monitoring guides dose adjustment is correct because phenytoin has a narrow therapeutic range and saturable metabolism, so a drug that alters its metabolism can move concentrations out of proportion, and the size and even the direction of the change vary between patients. Measured levels, read together with the clinical response, direct any change. Phenytoin levels will double, so the dose is halved before monitoring is wrong because an enzyme inducer would not be expected to raise levels in that fixed way, and an empiric cut risks breakthrough seizures. Phenytoin levels will halve, so the dose is doubled before monitoring is wrong because with saturable kinetics an automatic doubling can overshoot into toxicity. Phenytoin levels are unaffected, so dose adjustment and monitoring are unnecessary is wrong because a drug that alters phenytoin metabolism can move its levels in either direction, and being an inducer itself does not protect phenytoin from that interaction.

  164. A patient with hypertension has a serum potassium that is low. Which antihypertensive choice or addition could help, illustrating individualized therapy?

    • A.An ACE inhibitor, an ARB, or a potassium-sparing diuretic
    • B.A loop diuretic, a thiazide, or an added SGLT2 inhibitor
    • C.A long-acting DHP CCB, an alpha-1 blocker, or hydralazine
    • D.An IV mannitol infusion, a non-DHP CCB, or oral methyldopa
    Show answerHide answer

    Correct answer: An ACE inhibitor, an ARB, or a potassium-sparing diuretic

    An ACE inhibitor, an ARB, or a potassium-sparing diuretic is correct because ACE inhibitors and ARBs lower aldosterone and so tend to raise serum potassium, and potassium-sparing diuretics reduce potassium loss in the collecting duct; each lowers blood pressure while helping correct the low potassium. A loop diuretic, a thiazide, or an added SGLT2 inhibitor is wrong because loop and thiazide diuretics waste potassium and would lower it further, and an SGLT2 inhibitor does not raise it. A long-acting DHP CCB, an alpha-1 blocker, or hydralazine is wrong because these lower blood pressure without a meaningful effect on potassium. An IV mannitol infusion, a non-DHP CCB, or oral methyldopa is wrong because mannitol, an osmotic diuretic, is not an antihypertensive and increases urinary potassium loss, and calcium channel blockers (CCBs), whether dihydropyridine (DHP) or not, and methyldopa are potassium-neutral.

  165. A patient with type 2 diabetes on insulin needs to adjust the bolus dose to match carbohydrate intake. This individualized strategy is best described as which approach?

    • A.Consistent carbohydrate meals with an unchanged bolus dose
    • B.Carbohydrate exchange lists with a premixed dosing schedule
    • C.Carbohydrate restriction with a basal-only glargine regimen
    • D.Carbohydrate counting with an insulin-to-carbohydrate ratio
    Show answerHide answer

    Correct answer: Carbohydrate counting with an insulin-to-carbohydrate ratio

    Carbohydrate counting with an insulin-to-carbohydrate ratio is correct because the patient estimates the grams of carbohydrate in a meal and divides by the ratio (for example, 1 unit per 10 g) to set that meal's bolus. Consistent carbohydrate meals with an unchanged bolus dose is the opposite strategy: the food is held constant so that the dose never has to change. Carbohydrate exchange lists with a premixed dosing schedule is wrong because a premixed product is given in set amounts and cannot be adjusted meal by meal. Carbohydrate restriction with a basal-only glargine regimen is wrong because it removes the mealtime dose instead of matching it to intake.

  166. A patient on therapy for MRSA endocarditis is being assessed for the appropriate duration and route. Which principle guides treatment of serious invasive MRSA infections?

    • A.Fourteen-day intravenous therapy guided by fever curve, white cell count, and blood culture results
    • B.Ten-day oral therapy guided by symptom control, tolerability, and discharge planning
    • C.Prolonged intravenous therapy guided by infection site, source control, and clinical response
    • D.Lifelong oral therapy guided by patient adherence, drug tolerability, and pharmacy cost
    Show answerHide answer

    Correct answer: Prolonged intravenous therapy guided by infection site, source control, and clinical response

    Prolonged intravenous therapy guided by infection site, source control, and clinical response is correct because invasive MRSA infections such as endocarditis need weeks of parenteral treatment (commonly about six weeks for endocarditis), with the length set by where the infection is, whether the source has been controlled, and how the patient and the blood cultures respond. Fourteen-day intravenous therapy guided by fever curve, white cell count, and blood culture results describes the minimum course for uncomplicated bacteremia, which endocarditis by definition is not. Ten-day oral therapy guided by symptom control, tolerability, and discharge planning suits a mild skin infection and would undertreat an infected valve. Lifelong oral therapy guided by patient adherence, drug tolerability, and pharmacy cost describes chronic suppression for an infected device that cannot be removed, not the general principle for treating invasive infection.

  167. A patient with hypertension and chronic stable angina would benefit from which class that addresses both conditions?

    • A.A thiazide diuretic or direct vasodilator
    • B.A nitrate or sustained-release ranolazine
    • C.A loop diuretic or aldosterone antagonist
    • D.A beta-blocker or calcium channel blocker
    Show answerHide answer

    Correct answer: A beta-blocker or calcium channel blocker

    A beta-blocker or calcium channel blocker is correct because both classes lower blood pressure and also relieve angina by reducing myocardial oxygen demand (calcium channel blockers also dilate the coronary arteries). A thiazide diuretic or direct vasodilator lowers blood pressure but has no antianginal effect, and a direct vasodilator such as hydralazine can provoke reflex tachycardia that worsens angina. A nitrate or sustained-release ranolazine treats angina but is not used to treat hypertension. A loop diuretic or aldosterone antagonist affects volume and blood pressure without relieving angina.

  168. A patient is on warfarin and the prescriber wants tighter anticoagulation control. Which monitoring tool can support more frequent assessment, including at home in selected patients?

    • A.Point-of-care ACT self-testing devices
    • B.Point-of-care PTT self-testing devices
    • C.Point-of-care INR self-testing devices
    • D.Point-of-care TEG self-testing devices
    Show answerHide answer

    Correct answer: Point-of-care INR self-testing devices

    Point-of-care INR self-testing devices is correct because warfarin is monitored with the INR, and fingerstick meters let suitable, trained patients test at home more often, which can improve time in the therapeutic range. Point-of-care ACT self-testing devices is wrong because the activated clotting time (ACT) is used for high-dose heparin during procedures such as cardiac catheterization. Point-of-care PTT self-testing devices is wrong because the partial thromboplastin time (PTT) monitors unfractionated heparin. Point-of-care TEG self-testing devices is wrong because thromboelastography (TEG) is a whole-blood test of clot formation used in surgery and trauma, not for warfarin dosing.

  169. A patient with type 2 diabetes is being assessed for the risk of hypoglycemia unawareness. Which factor most increases this risk?

    • A.Mild hypoglycemia that produces prompt tremor and sweating
    • B.Recent recurrent hypoglycemia that blunts warning symptoms
    • C.Relative hypoglycemia that arises at higher glucose levels
    • D.Occasional mild hypoglycemia that follows one skipped meal
    Show answerHide answer

    Correct answer: Recent recurrent hypoglycemia that blunts warning symptoms

    Recent recurrent hypoglycemia that blunts warning symptoms is correct because repeated low-glucose episodes lower the glucose threshold at which the counterregulatory and adrenergic responses fire, so the patient stops feeling the early signs. Mild hypoglycemia that produces prompt tremor and sweating describes intact warning symptoms, the opposite of unawareness. Relative hypoglycemia that arises at higher glucose levels occurs when chronically high glucose makes a patient feel symptoms at normal readings, so awareness is heightened, not lost. Occasional mild hypoglycemia that follows one skipped meal is an isolated event and does not reset the symptom threshold the way repeated episodes do.

  170. A patient on multiple medications is assessed for potential interactions. Which patient-specific factor most increases the clinical significance of a drug-drug interaction?

    • A.A very wide safety margin for one interacting drug
    • B.A topical-only route for one interacting drug
    • C.A narrow therapeutic index for one interacting drug
    • D.A once-daily oral schedule for one interacting drug
    Show answerHide answer

    Correct answer: A narrow therapeutic index for one interacting drug

    A narrow therapeutic index for one interacting drug is correct because when the gap between an effective and a toxic concentration is small (warfarin, digoxin, phenytoin, lithium), even a modest change in exposure can cause toxicity or treatment failure. A very wide safety margin for one interacting drug makes the same change in concentration less likely to matter. A topical-only route for one interacting drug means little systemic absorption, which limits the amount available to interact. A once-daily oral schedule for one interacting drug describes convenience of dosing and does not by itself make an interaction more significant.

  171. A patient with heart failure with reduced ejection fraction is on an ACE inhibitor and develops a persistent dry cough. What is the most appropriate substitution to maintain neurohormonal blockade?

    • A.Switch to a different daily ACE inhibitor
    • B.Switch to an oral direct renin inhibitor
    • C.Switch to oral hydralazine plus a nitrate
    • D.Switch to an angiotensin receptor blocker
    Show answerHide answer

    Correct answer: Switch to an angiotensin receptor blocker

    Switch to an angiotensin receptor blocker is correct because an ARB blocks the renin-angiotensin system at the receptor without raising bradykinin, so the cough resolves while the mortality benefit of neurohormonal blockade is kept. Switch to a different daily ACE inhibitor is wrong because cough is a class effect and returns with any ACE inhibitor. Switch to an oral direct renin inhibitor is wrong because aliskiren has not improved outcomes in heart failure and is not a guideline substitute. Switch to oral hydralazine plus a nitrate is wrong here because that combination is a vasodilator regimen held for patients who can take neither an ACE inhibitor nor an ARB, and it does not block the renin-angiotensin system.

  172. A patient receiving an aminoglycoside has fluctuating renal function. Why must therapeutic drug monitoring be repeated rather than relying on initial levels alone?

    • A.Changing renal function alters clearance, so repeat levels keep concentrations safe and effective
    • B.Changing renal function alters metabolism, so repeat levels detect hepatic induction and tolerance
    • C.Changing renal function alters protein binding, so repeat levels separate the bound and free drug
    • D.Changing renal function alters oral absorption, so repeat levels check uptake and bioavailability
    Show answerHide answer

    Correct answer: Changing renal function alters clearance, so repeat levels keep concentrations safe and effective

    Changing renal function alters clearance, so repeat levels keep concentrations safe and effective is correct because aminoglycosides are eliminated almost entirely by glomerular filtration: as kidney function moves, so do the half-life and the trough, and a level drawn earlier no longer describes the patient. Changing renal function alters metabolism, so repeat levels detect hepatic induction and tolerance is wrong because aminoglycosides are not metabolized by the liver. Changing renal function alters protein binding, so repeat levels separate the bound and free drug is wrong because aminoglycosides are minimally protein bound, so total and free concentrations are nearly the same. Changing renal function alters oral absorption, so repeat levels check uptake and bioavailability is wrong because systemic aminoglycosides are given parenterally and are poorly absorbed from the gut.

  173. A patient with type 2 diabetes and obesity on metformin needs additional therapy and has no atherosclerotic disease but wants weight reduction. Which add-on best aligns with this goal?

    • A.A DPP-4 inhibitor or an added NPH insulin dose
    • B.A GLP-1 receptor agonist or an SGLT2 inhibitor
    • C.A low-dose daily sulfonylurea or 70/30 insulin
    • D.A meglitinide or a low-dose thiazolidinedione
    Show answerHide answer

    Correct answer: A GLP-1 receptor agonist or an SGLT2 inhibitor

    A GLP-1 receptor agonist or an SGLT2 inhibitor is correct because both classes lower glucose and promote weight loss, GLP-1 receptor agonists through satiety and slowed gastric emptying and SGLT2 inhibitors through urinary glucose loss. A DPP-4 inhibitor or an added NPH insulin dose is wrong because DPP-4 inhibitors are weight-neutral and insulin causes weight gain. A low-dose daily sulfonylurea or 70/30 insulin is wrong because both raise insulin levels and cause weight gain. A meglitinide or a low-dose thiazolidinedione is wrong because a secretagogue tends to add weight and thiazolidinediones cause weight gain and fluid retention.

  174. A patient with type 2 diabetes is started on insulin and asks about injection site rotation. Why is rotating injection sites part of the care plan?

    • A.It limits lipohypertrophy that can impair insulin absorption
    • B.It limits antibody formation that can raise the insulin dose
    • C.It limits infection that can inactivate local insulin depots
    • D.It limits needle-tip blunting that can cause insulin leakage
    Show answerHide answer

    Correct answer: It limits lipohypertrophy that can impair insulin absorption

    It limits lipohypertrophy that can impair insulin absorption is correct because repeated injection into one spot produces a rubbery lump of fatty tissue, and insulin injected there is absorbed erratically, which worsens glucose control. It limits antibody formation that can raise the insulin dose is wrong because antibody formation does not depend on where the injection is given. It limits infection that can inactivate local insulin depots is wrong because infection is prevented by clean technique and a new needle, not by moving the site. It limits needle-tip blunting that can cause insulin leakage is wrong because a blunt needle comes from reusing needles, a separate counseling point.

  175. A patient on chronic vancomycin develops a slowly rising serum creatinine without other obvious causes. What does this trend most appropriately prompt in the treatment plan?

    • A.Blaming dehydration for the rise, then giving fluids and continuing vancomycin
    • B.Assessing for vancomycin nephrotoxicity, then adjusting therapy and monitoring
    • C.Assuming low vancomycin exposure, then raising the dose and increasing troughs
    • D.Adding gentamicin to vancomycin, then repeating cultures and maintaining doses
    Show answerHide answer

    Correct answer: Assessing for vancomycin nephrotoxicity, then adjusting therapy and monitoring

    Assessing for vancomycin nephrotoxicity, then adjusting therapy and monitoring is correct because a creatinine that keeps rising with no other explanation points to the drug itself; the exposure should be checked, the dose or interval adjusted (or the agent changed), and kidney function and levels followed more closely. Blaming dehydration for the rise, then giving fluids and continuing vancomycin is wrong because the stem gives no other cause, and continuing unchanged lets the injury and drug accumulation progress. Assuming low vancomycin exposure, then raising the dose and increasing troughs is wrong because falling kidney function raises exposure, and higher troughs increase nephrotoxicity. Adding gentamicin to vancomycin, then repeating cultures and maintaining doses is wrong because an aminoglycoside adds a second nephrotoxin.

  176. A patient on a DOAC is scheduled for a surgical procedure with high bleeding risk and has normal renal function. Which planning step is most appropriate?

    • A.Hold the DOAC for the five days used with warfarin before a procedure with high bleeding risk
    • B.Hold the DOAC only on the day of the procedure because a short half-life limits bleeding risk
    • C.Hold the DOAC before the procedure for a number of days based on the agent and bleeding risk
    • D.Hold the DOAC and start warfarin seven days before the procedure to lower the bleeding risk
    Show answerHide answer

    Correct answer: Hold the DOAC before the procedure for a number of days based on the agent and bleeding risk

    Hold the DOAC before the procedure for a number of days based on the agent and bleeding risk is correct because DOACs have short, predictable half-lives, so the interruption is timed from the specific drug, the kidney function, and the bleeding risk of the operation (with normal renal function, roughly two days before a high-risk procedure). Hold the DOAC for the five days used with warfarin before a procedure with high bleeding risk is wrong because the five-day rule reflects warfarin's long offset; a DOAC clears much sooner, and a longer gap only adds time without protection. Hold the DOAC only on the day of the procedure because a short half-life limits bleeding risk is wrong because skipping a single day suits low-risk procedures and leaves too much drug on board for a high-risk one. Hold the DOAC and start warfarin seven days before the procedure to lower the bleeding risk is wrong because warfarin is slower to start and stop and would itself have to be interrupted.

  177. A patient with type 2 diabetes is assessed and found to have frequent postprandial hyperglycemia despite good fasting glucose. Which therapy adjustment most directly targets post-meal glucose?

    • A.Adding a bedtime agent such as NPH insulin or an added daily dose of detemir
    • B.Titrating up a basal agent such as U-300 insulin glargine or once-daily degludec
    • C.Moving a basal agent such as NPH insulin or U-100 glargine to a morning schedule
    • D.Adding a mealtime agent such as rapid-acting insulin or a GLP-1 receptor agonist
    Show answerHide answer

    Correct answer: Adding a mealtime agent such as rapid-acting insulin or a GLP-1 receptor agonist

    Adding a mealtime agent such as rapid-acting insulin or a GLP-1 receptor agonist is correct because the fasting glucose shows that basal coverage is adequate, so the remaining problem is the rise after meals, which prandial therapy targets directly. Adding a bedtime agent such as NPH insulin or an added daily dose of detemir is wrong because it adds overnight and fasting coverage that is already sufficient. Titrating up a basal agent such as U-300 insulin glargine or once-daily degludec is wrong because more basal insulin lowers the fasting glucose further and risks hypoglycemia without covering meals. Moving a basal agent such as NPH insulin or U-100 glargine to a morning schedule is wrong because changing the timing of basal insulin does not supply a mealtime effect.

  178. A patient is being assessed for vancomycin therapy and has rapidly changing renal function in acute kidney injury. What dosing approach is most appropriate?

    • A.Schedule doses with a calculated creatinine clearance because it tracks renal function
    • B.Schedule doses with a standard dosing nomogram because clearance is at a steady state
    • C.Start with half the usual doses because clearance drops predictably in kidney injury
    • D.Individualize doses with frequent level monitoring because clearance is unpredictable
    Show answerHide answer

    Correct answer: Individualize doses with frequent level monitoring because clearance is unpredictable

    Individualize doses with frequent level monitoring because clearance is unpredictable is correct because in acute kidney injury vancomycin elimination can change from day to day, so each dose is decided from measured concentrations and reassessed often. Schedule doses with a calculated creatinine clearance because it tracks renal function is wrong because estimating equations assume a stable serum creatinine, and in acute kidney injury the creatinine lags behind the true filtration rate. Schedule doses with a standard dosing nomogram because clearance is at a steady state is wrong because nomograms assume stable renal function, which this patient does not have. Start with half the usual doses because clearance drops predictably in kidney injury is wrong because the fall in clearance is neither fixed nor predictable, so an empiric halving can underdose or overdose.

  179. A patient on a DOAC with mild renal impairment is being assessed for dose. Why might a reduced DOAC dose be selected in certain renal or other criteria?

    • A.To replace ongoing renal function labs when clearance is reduced or patient criteria are met
    • B.To match a lower chance of blood clots when clearance is reduced or patient criteria are met
    • C.To balance efficacy with bleeding risk when clearance is reduced or patient criteria are met
    • D.To allow extra margin for missed doses when clearance is reduced or patient criteria are met
    Show answerHide answer

    Correct answer: To balance efficacy with bleeding risk when clearance is reduced or patient criteria are met

    To balance efficacy with bleeding risk when clearance is reduced or patient criteria are met is correct because a reduced DOAC dose is chosen only when labeled criteria (such as renal function, age, body weight, or an interacting drug) predict higher exposure, so that stroke or clot prevention is kept while bleeding is limited. To replace ongoing renal function labs when clearance is reduced or patient criteria are met is wrong because a lower dose never removes the need to follow kidney function. To match a lower chance of blood clots when clearance is reduced or patient criteria are met is wrong because kidney disease and older age raise thrombotic risk as well as bleeding risk. To allow extra margin for missed doses when clearance is reduced or patient criteria are met is wrong because DOACs wear off quickly, so a lower dose makes a missed dose more of a problem, not less.

  180. A patient on therapy for MRSA develops a confirmed deep-seated infection. Why is achieving an adequate vancomycin AUC particularly important in such infections?

    • A.High peak levels drive concentration-dependent killing in deep sites while shortening the course of therapy
    • B.Maximal exposure replaces surgical drainage in walled-off sites while preventing later relapse
    • C.Steady trough levels keep protein binding saturated in deep sites while protecting kidney function
    • D.Adequate exposure improves the likelihood of cure in hard-to-penetrate sites while limiting toxicity
    Show answerHide answer

    Correct answer: Adequate exposure improves the likelihood of cure in hard-to-penetrate sites while limiting toxicity

    Adequate exposure improves the likelihood of cure in hard-to-penetrate sites while limiting toxicity is correct because vancomycin efficacy tracks the ratio of AUC to MIC, and keeping the AUC in the target range (about 400 to 600 mg⋅h/L\text{mg} \cdot \text{h/L}) gives enough drug to poorly penetrated tissue without the nephrotoxicity seen at higher exposures. High peak levels drive concentration-dependent killing in deep sites while shortening the course of therapy is wrong because vancomycin killing is not peak-dependent, and deep infections still need prolonged courses. Maximal exposure replaces surgical drainage in walled-off sites while preventing later relapse is wrong because no exposure substitutes for source control, and pushing exposure higher adds kidney injury. Steady trough levels keep protein binding saturated in deep sites while protecting kidney function is wrong because saturating protein binding is not the goal of dosing, and trough-only targets were replaced by AUC-guided dosing because high troughs increase nephrotoxicity.

  181. A patient with type 2 diabetes is started on insulin and has chronic kidney disease. Why might insulin requirements decrease as renal function declines?

    • A.The kidney retains toxins that boost insulin, so impairment can sensitize tissues and lower requirements
    • B.The kidney spills more sugar as filtration falls, so impairment can spare insulin and lower requirements
    • C.The kidney loses albumin that binds insulin, so impairment can raise free hormone and lower requirements
    • D.The kidney takes part in insulin clearance, so impairment can prolong drug action and lower requirements
    Show answerHide answer

    Correct answer: The kidney takes part in insulin clearance, so impairment can prolong drug action and lower requirements

    The kidney takes part in insulin clearance, so impairment can prolong drug action and lower requirements is correct because the kidney filters and degrades a substantial share of circulating insulin (and a larger share of injected insulin, which bypasses first-pass hepatic removal). As renal function falls, insulin lasts longer, so the dose must come down to avoid hypoglycemia. The kidney retains toxins that boost insulin, so impairment can sensitize tissues and lower requirements is wrong because uremia causes insulin resistance, not greater sensitivity. The kidney spills more sugar as filtration falls, so impairment can spare insulin and lower requirements is wrong because less glucose is filtered and lost in the urine as the filtration rate declines. The kidney loses albumin that binds insulin, so impairment can raise free hormone and lower requirements is wrong because human insulin does not circulate bound to albumin, so protein loss is not the mechanism.

  182. A patient on chronic vancomycin is also receiving another nephrotoxic agent. Which monitoring intensification is most appropriate to protect the patient?

    • A.More frequent checks of vancomycin peaks and audiogram thresholds to catch early ototoxicity
    • B.More frequent checks of hepatic enzymes and vancomycin troughs to catch early hepatotoxicity
    • C.More frequent checks of renal function and vancomycin exposure to catch early nephrotoxicity
    • D.More frequent checks of neutrophil counts and vancomycin troughs to catch early neutropenia
    Show answerHide answer

    Correct answer: More frequent checks of renal function and vancomycin exposure to catch early nephrotoxicity

    More frequent checks of renal function and vancomycin exposure to catch early nephrotoxicity is correct because a second nephrotoxin (for example an aminoglycoside, piperacillin-tazobactam, or contrast) raises the risk of kidney injury, and a falling clearance in turn raises vancomycin exposure, so serum creatinine and vancomycin levels or AUC are followed more closely. More frequent checks of vancomycin peaks and audiogram thresholds to catch early ototoxicity is wrong because peaks are not used to monitor vancomycin, and the added risk named in the stem is to the kidney. More frequent checks of hepatic enzymes and vancomycin troughs to catch early hepatotoxicity is wrong because vancomycin is cleared by the kidney and is not a typical cause of liver injury. More frequent checks of neutrophil counts and vancomycin troughs to catch early neutropenia is wrong because neutropenia is an uncommon effect of prolonged vancomycin and is not what a nephrotoxic combination adds.

  183. A patient is being assessed for an MRSA urinary tract infection. Which consideration is important when selecting an agent for a urinary source?

    • A.Choose an agent that avoids urinary excretion and is eliminated primarily by hepatic metabolism
    • B.Choose an agent that has the lowest measured MIC and is selected whatever its urinary excretion
    • C.Choose an agent that reaches effective urinary concentrations and is active against the isolate
    • D.Choose an agent that covers typical urinary pathogens and is active against gram-negative flora
    Show answerHide answer

    Correct answer: Choose an agent that reaches effective urinary concentrations and is active against the isolate

    Choose an agent that reaches effective urinary concentrations and is active against the isolate is correct because a drug cures a urinary infection only if enough active drug is excreted into the urine and the organism is susceptible; several MRSA-active drugs are cleared mainly by nonrenal routes and reach the urine poorly. Choose an agent that avoids urinary excretion and is eliminated primarily by hepatic metabolism is the reverse of what is needed, since little active drug would reach the site. Choose an agent that has the lowest measured MIC and is selected whatever its urinary excretion is wrong because in vitro potency does not help if the drug does not reach the urine. Choose an agent that covers typical urinary pathogens and is active against gram-negative flora is wrong because MRSA is a gram-positive organism that usual empiric urinary regimens do not cover.

  184. A patient on therapy with a narrow-therapeutic-index immunosuppressant such as tacrolimus undergoes therapeutic drug monitoring. Why is trough monitoring central to managing this drug?

    • A.Trough levels confirm adherence and absorption, so they guide patient counseling in place of dose adjustments
    • B.Trough levels correlate with efficacy and toxicity, so they guide dosing to prevent rejection and adverse effects
    • C.Trough levels mirror renal clearance and function, so they guide dose changes by serum creatinine and urine flow
    • D.Trough levels predict future infection and malignancy, so they guide when to start prophylaxis and cancer screening
    Show answerHide answer

    Correct answer: Trough levels correlate with efficacy and toxicity, so they guide dosing to prevent rejection and adverse effects

    Trough levels correlate with efficacy and toxicity, so they guide dosing to prevent rejection and adverse effects is correct because tacrolimus has a narrow therapeutic index and wide variability between and within patients; the whole-blood trough correlates reasonably with overall exposure, so levels that are too low risk rejection and levels that are too high risk nephrotoxicity and neurotoxicity. Trough levels confirm adherence and absorption, so they guide patient counseling in place of dose adjustments is wrong because the main use of the trough is to adjust the dose to a target range. Trough levels mirror renal clearance and function, so they guide dose changes by serum creatinine and urine flow is wrong because tacrolimus is cleared by hepatic and intestinal CYP3A metabolism, not by the kidney. Trough levels predict future infection and malignancy, so they guide when to start prophylaxis and cancer screening is wrong because those long-term risks reflect overall immunosuppression and are not managed from individual trough results.

Professional Practice (23)

  1. A pharmacist screening a new patient learns the patient frequently splits tablets or skips doses near the end of each month because money runs short before payday. Which social determinant of health is most directly driving this behavior?

    • A.Education access and quality
    • B.Economic stability
    • C.Neighborhood and built environment
    • D.Social and community context
    Show answerHide answer

    Correct answer: Economic stability

    Economic stability is correct because the patient is rationing medication when money runs out before payday; income, employment, and the ability to afford necessities fall under this domain of the social determinants of health. Education access and quality concerns schooling, literacy, and language, which would apply if the patient could not understand the directions. Neighborhood and built environment concerns housing, transportation, and neighborhood conditions, which would apply if the patient could not get to the pharmacy. Social and community context concerns social support and relationships, which the stem does not describe.

  2. A health-system pharmacist wants to act on the recognition that social determinants of health account for a large share of overall health outcomes. Which statement best reflects the accepted understanding of their impact?

    • A.Social and environmental conditions shape outcomes substantially, commonly outweighing medical care alone
    • B.Social and environmental conditions shape access to medical care, while outcomes rest chiefly on its quality
    • C.Clinical and genetic factors shape outcomes predominantly, leaving social and environmental conditions marginal
    • D.Individual behaviors shape outcomes predominantly, largely apart from social and environmental conditions
    Show answerHide answer

    Correct answer: Social and environmental conditions shape outcomes substantially, commonly outweighing medical care alone

    Social and environmental conditions shape outcomes substantially, commonly outweighing medical care alone is correct because population-health models attribute only a minority of the variation in outcomes to clinical care, with income, education, housing, and the physical environment accounting for a large share. Social and environmental conditions shape access to medical care, while outcomes rest chiefly on its quality is wrong because these conditions affect health directly, through exposures, nutrition, and stress, and not only by limiting access. Clinical and genetic factors shape outcomes predominantly, leaving social and environmental conditions marginal is wrong because it understates the contribution of those conditions. Individual behaviors shape outcomes predominantly, largely apart from social and environmental conditions is wrong because behaviors such as diet, activity, and adherence are themselves strongly shaped by a person's circumstances.

  3. A pharmacist counsels a patient who cannot read the directions on a prescription label well enough to dose correctly, increasing the risk of error. Which social determinant of health should the pharmacist prioritize addressing?

    • A.Education access and health literacy
    • B.Economic stability and food security
    • C.Transportation and built environment
    • D.Community context and social support
    Show answerHide answer

    Correct answer: Education access and health literacy

    Education access and health literacy is correct because the patient cannot read the label well enough to dose correctly, a literacy barrier the pharmacist can address with plain-language counseling, pictograms, and teach-back. Economic stability and food security would be the priority if cost or hunger were limiting therapy. Transportation and built environment would be the priority if the patient could not physically reach care. Community context and social support concerns relationships and help at home; it may assist but is not the barrier described.

  4. A community pharmacy team wants to connect patients facing social barriers to local resources such as food banks, housing aid, and transportation vouchers. Which role does this referral activity represent in addressing social determinants of health?

    • A.Screening patients for unmet needs using a survey tool at the community pharmacy
    • B.Counseling patients on lower-cost generic options sold at the community pharmacy
    • C.Linking patients with community and social-service programs outside the pharmacy
    • D.Advocating for patients on community health policy and costs beyond the pharmacy
    Show answerHide answer

    Correct answer: Linking patients with community and social-service programs outside the pharmacy

    Linking patients with community and social-service programs outside the pharmacy is correct because sending patients to food banks, housing aid, and transportation help is referral: connecting an identified need to an organization that can meet it. Screening patients for unmet needs using a survey tool at the community pharmacy is the step that comes before referral; it finds the need but does not address it. Counseling patients on lower-cost generic options sold at the community pharmacy is a medication-cost intervention carried out within the pharmacy. Advocating for patients on community health policy and costs beyond the pharmacy works at the system level and does not connect an individual patient to a local service.

  5. A pharmacist notices that patients in a rural area routinely miss therapy because the nearest pharmacy is an hour away and many lack a vehicle. Which intervention most directly mitigates this specific social determinant?

    • A.Setting up mail-order delivery or a local medication pickup option
    • B.Setting up copay assistance or a lower-priced generic substitution
    • C.Setting up picture-based labels or a teach-back counseling session
    • D.Setting up interpreter services or a translated prescription label
    Show answerHide answer

    Correct answer: Setting up mail-order delivery or a local medication pickup option

    Setting up mail-order delivery or a local medication pickup option is correct because the barrier is distance and lack of transportation, and bringing the medication to the patient, or close to the patient, removes it. Setting up copay assistance or a lower-priced generic substitution addresses cost, which is not the problem described. Setting up picture-based labels or a teach-back counseling session addresses health literacy. Setting up interpreter services or a translated prescription label addresses a language barrier.

  6. A parent reports to a pharmacist that their child had a high fever and a brief seizure within a day of receiving a routine childhood vaccine. After ensuring the child is now stable, where should this event be reported?

    • A.The Vaccine Adverse Event Reporting System
    • B.The National Vaccine Injury Compensation Program
    • C.The National Vaccine Errors Reporting Program
    • D.The Vaccine Safety Datalink
    Show answerHide answer

    Correct answer: The Vaccine Adverse Event Reporting System

    The Vaccine Adverse Event Reporting System is correct because VAERS, run jointly by the CDC and FDA, is the national system that accepts reports of adverse events after any U.S.-licensed vaccine, and a febrile seizure within a day of vaccination should be reported there. The National Vaccine Injury Compensation Program, administered by HRSA, pays claims for certain vaccine injuries; filing a claim is a separate legal process and is not how an event is reported. The National Vaccine Errors Reporting Program, operated by ISMP, collects vaccine errors such as a wrong dose or wrong product, not adverse reactions to a correctly given vaccine. The Vaccine Safety Datalink, a CDC collaboration with integrated health care organizations, studies vaccine safety using their medical records and does not take individual reports.

  7. A pharmacist is preparing a vaccine adverse-event report and wants to know which event types the system most wants captured. Which category is the system specifically designed to prioritize?

    • A.Events after vaccination that are serious, unexpected, or clinically significant
    • B.Events after vaccination that are confirmed, causally proven, or biopsy verified
    • C.Events after vaccination that are mild, transient, or already listed as expected
    • D.Events after vaccination that are local, self-limiting, or at the injection site
    Show answerHide answer

    Correct answer: Events after vaccination that are serious, unexpected, or clinically significant

    Events after vaccination that are serious, unexpected, or clinically significant is correct because a passive surveillance system exists to pick up safety signals, and the reports that matter most are of severe, unusual, or otherwise medically important events, whether or not the vaccine is thought to be the cause. Events after vaccination that are confirmed, causally proven, or biopsy verified is wrong because a report does not require proof of causation or laboratory or pathology confirmation; waiting for proof would defeat early signal detection. Events after vaccination that are mild, transient, or already listed as expected is wrong because common, expected reactions such as brief fatigue or a sore arm are not the priority. Events after vaccination that are local, self-limiting, or at the injection site is wrong for the same reason: minor local reactions are well characterized and rarely signal a new problem.

  8. A new pharmacist asks why some vaccine adverse events must be reported by the provider even when a causal link to the vaccine seems unlikely. What is the correct rationale for reporting in this situation?

    • A.Reporting establishes vaccine causation, and submitted events are counted as confirmed reactions
    • B.Reporting protects each provider from liability, and filed events are what start injury compensation
    • C.Reporting triggers a product recall review, and reported events are enough to put the affected lot on hold
    • D.Reporting supports broad surveillance, and certain events are reportable regardless of suspected cause
    Show answerHide answer

    Correct answer: Reporting supports broad surveillance, and certain events are reportable regardless of suspected cause

    Reporting supports broad surveillance, and certain events are reportable regardless of suspected cause is correct because the system looks for patterns across many reports, so it asks for events even when the link to the vaccine is doubtful, and federal law requires health care providers to report the events listed in the reportable events table that occur within the specified time after vaccination. Reporting establishes vaccine causation, and submitted events are counted as confirmed reactions is wrong because a report is an unverified observation and does not show that the vaccine caused the event. Reporting protects each provider from liability, and filed events are what start injury compensation is wrong because compensation is sought through a separate claim to the Vaccine Injury Compensation Program, not through an adverse-event report. Reporting triggers a product recall review, and reported events are enough to put the affected lot on hold is wrong because reports do not by themselves lead to a hold or withdrawal; action follows investigation of a signal.

  9. A pharmacy administering vaccines wants to ensure complete and useful adverse-event reports. Which set of details is most important to capture when submitting a vaccine adverse-event report?

    • A.The vaccine cost and supplier, invoice number, date given, and a description of the event
    • B.The vaccine type and manufacturer, lot number, date given, and a description of the event
    • C.The vaccine charge and insurer, policy number, date given, and a description of the event
    • D.The vaccine provider and clinic, chart number, date given, and a description of the event
    Show answerHide answer

    Correct answer: The vaccine type and manufacturer, lot number, date given, and a description of the event

    The vaccine type and manufacturer, lot number, date given, and a description of the event is correct because these details identify exactly which product and lot the patient received and when, so reviewers can relate the event to the vaccination and look for product-specific or lot-specific signals. The vaccine cost and supplier, invoice number, date given, and a description of the event adds purchasing details and leaves out the manufacturer and lot number that identify the dose. The vaccine charge and insurer, policy number, date given, and a description of the event adds billing details that have no bearing on safety review and still does not identify the product. The vaccine provider and clinic, chart number, date given, and a description of the event says who gave the dose and where, but without the vaccine type, manufacturer, and lot number the report cannot be tied to a specific product.

  10. A patient asks a pharmacist whether they personally are allowed to report a reaction they had after a vaccine, or whether only clinicians may do so. What is the accurate answer?

    • A.No; a patient or caregiver tells the vaccinating clinician, who submits the report
    • B.Yes; a patient or caregiver, like healthcare professionals, can submit a report
    • C.No; a patient or caregiver asks the vaccine manufacturer, which submits the report
    • D.Yes; a patient or caregiver, once a doctor has confirmed it, can submit a report
    Show answerHide answer

    Correct answer: Yes; a patient or caregiver, like healthcare professionals, can submit a report

    Yes; a patient or caregiver, like healthcare professionals, can submit a report is correct because the vaccine adverse-event system accepts reports from anyone, including the person vaccinated or a family member, which widens the net for detecting safety signals. No; a patient or caregiver tells the vaccinating clinician, who submits the report is wrong because, although clinicians are encouraged (and for some events required) to report, the patient does not have to go through them. No; a patient or caregiver asks the vaccine manufacturer, which submits the report is wrong because manufacturers must report events they learn of, but they are not the only route. Yes; a patient or caregiver, once a doctor has confirmed it, can submit a report is wrong because no medical confirmation or proof of causation is needed before a patient reports.

  11. A pharmacist on an inpatient antimicrobial stewardship team reviews a patient on broad empiric therapy whose blood culture now identifies a single susceptible organism. Which stewardship action does narrowing the regimen to a targeted agent represent?

    • A.De-escalation to definitive therapy
    • B.Escalation to broader empiric therapy
    • C.Oral step-down from intravenous therapy
    • D.Continuation of broad empiric therapy
    Show answerHide answer

    Correct answer: De-escalation to definitive therapy

    De-escalation to definitive therapy is correct because once the culture and susceptibility results identify the organism, replacing broad empiric coverage with a narrower agent aimed at that organism is de-escalation, a core stewardship practice. Escalation to broader empiric therapy is the opposite move, widening coverage, usually for a patient who is worsening without a diagnosis. Oral step-down from intravenous therapy changes the route once the patient is improving and can absorb oral drugs; it does not by itself narrow the spectrum. Continuation of broad empiric therapy ignores the culture result and keeps unnecessary spectrum.

  12. An antimicrobial stewardship pharmacist promotes converting eligible patients from intravenous to oral antibiotics once they meet criteria such as clinical improvement and a functioning gut. What is a primary stewardship benefit of this intervention?

    • A.It narrows spectrum, resistance, and collateral damage while preserving efficacy
    • B.It ends blood cultures, levels, and routine lab checks while preserving efficacy
    • C.It limits interactions, dose changes, and side effects while preserving efficacy
    • D.It lowers line-related risks, cost, and length of stay while preserving efficacy
    Show answerHide answer

    Correct answer: It lowers line-related risks, cost, and length of stay while preserving efficacy

    It lowers line-related risks, cost, and length of stay while preserving efficacy is correct because an oral agent with good bioavailability gives comparable exposure, so the intravenous catheter (and its risks of infection and thrombosis) can come out, drug and administration costs fall, and the patient can often go home sooner. It narrows spectrum, resistance, and collateral damage while preserving efficacy is wrong because changing the route does not change the spectrum; narrowing is de-escalation, a different intervention. It ends blood cultures, levels, and routine lab checks while preserving efficacy is wrong because the patient still needs clinical and laboratory monitoring after the switch. It limits interactions, dose changes, and side effects while preserving efficacy is wrong because the same drug carries the same adverse effects by either route, and oral dosing can add interactions such as chelation with cations.

  13. A stewardship committee wants to publish the institution's resistance patterns so prescribers can choose appropriate empiric therapy. Which tool aggregates local susceptibility data for this purpose?

    • A.A chromatogram
    • B.A pharmacopeia
    • C.An antibiogram
    • D.An immunoassay
    Show answerHide answer

    Correct answer: An antibiogram

    An antibiogram is correct because it is the periodic summary of the percentage of local isolates of each organism that are susceptible to each antibiotic, which prescribers use to choose empiric therapy. A chromatogram is the output of a chromatographic separation used to identify and quantify compounds in a sample. A pharmacopeia is a compendium of official drug standards and monographs. An immunoassay is a laboratory method that measures a substance, such as a drug level, using antibody binding; none of the three reports an institution's resistance patterns.

  14. An antimicrobial stewardship program sets a goal of reducing inappropriate fluoroquinolone use. Which outcome would best indicate the program is achieving its broader public-health purpose?

    • A.Fewer fluoroquinolone orders and a matching rise in cephalosporin use for the same infections
    • B.Fewer antibiotic purchases and lower pharmacy drug costs across the health system
    • C.Fewer resistant infections and antibiotic-associated harms such as Clostridioides difficile
    • D.Fewer restricted-agent approvals and longer review times for prior-authorization requests
    Show answerHide answer

    Correct answer: Fewer resistant infections and antibiotic-associated harms such as Clostridioides difficile

    Fewer resistant infections and antibiotic-associated harms such as Clostridioides difficile is correct because the public-health purpose of stewardship is to slow resistance and prevent the harms of unnecessary antibiotics, and fluoroquinolones are strongly linked to both. Fewer fluoroquinolone orders and a matching rise in cephalosporin use for the same infections only shifts the selective pressure from one class to another. Fewer antibiotic purchases and lower pharmacy drug costs across the health system is a financial result, welcome but secondary to patient and population outcomes. Fewer restricted-agent approvals and longer review times for prior-authorization requests measures how the program operates, not whether patients or the community are better off.

  15. A pharmacist reviews a regimen in which a patient is empirically receiving two antibiotics that both cover the same gram-negative organisms with overlapping spectra and no added benefit. From a stewardship standpoint, what is this called and the appropriate response?

    • A.Synergistic combination therapy, which should be kept at the current dose
    • B.Redundant double coverage, which should be cut back to one suitable agent
    • C.Empiric dual coverage, which should be kept until susceptibilities return
    • D.Antagonistic combination therapy, which should be changed to another pair
    Show answerHide answer

    Correct answer: Redundant double coverage, which should be cut back to one suitable agent

    Redundant double coverage, which should be cut back to one suitable agent is correct because two drugs with the same gram-negative spectrum and no added benefit expose the patient to extra toxicity, cost, and resistance pressure for nothing, so stewardship removes one. Synergistic combination therapy, which should be kept at the current dose is wrong because synergy means the pair kills better than either drug alone, which the stem rules out. Empiric dual coverage, which should be kept until susceptibilities return is wrong because the second drug adds no spectrum, so there is nothing to be gained by waiting. Antagonistic combination therapy, which should be changed to another pair is wrong because antagonism means one drug reduces the other's activity, which is not described, and the remedy here is one agent, not a different two.

  16. A community pharmacist is filling a high-dose opioid prescription for a patient also on a long-acting opioid and wants to apply opioid stewardship at the point of dispensing. Which action best fits this responsibility?

    • A.Fill the prescription as it stands and add constipation counseling
    • B.Refuse the prescription outright and report the prescriber involved
    • C.Halve the prescription quantity and inform the prescriber afterward
    • D.Check the prescription drug monitoring program and assess the risk
    Show answerHide answer

    Correct answer: Check the prescription drug monitoring program and assess the risk

    Check the prescription drug monitoring program and assess the risk is correct because stewardship at the counter means reviewing the monitoring program record for overlapping opioids, multiple prescribers or early fills and weighing overdose and misuse risk before the opioid leaves the pharmacy. Fill the prescription as it stands and add constipation counseling adds useful counseling but skips the review that a high dose combined with a long-acting opioid calls for. Refuse the prescription outright and report the prescriber involved jumps to refusal and a complaint before any facts are gathered, which abandons a patient who may have a legitimate need. Halve the prescription quantity and inform the prescriber afterward is not within the pharmacist's authority, because a change in the quantity of a controlled substance needs the prescriber's agreement first.

  17. As part of an opioid stewardship effort, a pharmacist proactively offers naloxone to a patient on chronic high-dose opioid therapy. What is the primary rationale for this co-prescribing practice?

    • A.Naloxone offers a way to relieve opioid constipation
    • B.Naloxone offers a way to reverse opioid overdose
    • C.Naloxone offers a way to discourage opioid injection
    • D.Naloxone offers a way to ease opioid withdrawal
    Show answerHide answer

    Correct answer: Naloxone offers a way to reverse opioid overdose

    Naloxone offers a way to reverse opioid overdose is correct because naloxone is an opioid antagonist that displaces the opioid from its receptor and restores breathing, so a patient on chronic high-dose therapy and the people around that patient have a rescue drug on hand. Naloxone offers a way to relieve opioid constipation describes peripherally acting antagonists such as naloxegol and methylnaltrexone, not rescue naloxone. Naloxone offers a way to discourage opioid injection is the reason naloxone is combined with buprenorphine in one product, which is a different purpose from co-prescribing a rescue dose. Naloxone offers a way to ease opioid withdrawal is the opposite of its effect, since naloxone precipitates withdrawal in a dependent patient rather than relieving it.

  18. An opioid stewardship initiative encourages prescribers to limit the quantity of opioids given after minor outpatient procedures. What is the main stewardship reasoning behind dispensing only a short, needs-based supply?

    • A.Lower counts keep the daily dose short of sedation, tolerance, and overdose limits
    • B.Federal law holds the supply for sprains, fractures, and extractions to seven days
    • C.Leftover tablets raise the risk of misuse, diversion, and accidental exposure
    • D.Short fills spare the pharmacy extra inventory checks, order forms, and audits
    Show answerHide answer

    Correct answer: Leftover tablets raise the risk of misuse, diversion, and accidental exposure

    Leftover tablets raise the risk of misuse, diversion, and accidental exposure is correct because most patients use only part of what is dispensed after a minor procedure, and the tablets left in the home are the main source of opioids that are misused, diverted or swallowed by a child. Lower counts keep the daily dose short of sedation, tolerance, and overdose limits confuses the quantity dispensed with the dose taken each day, which a smaller supply does not change. Federal law holds the supply for sprains, fractures, and extractions to seven days is not accurate, because limits on the days supplied for acute pain come from state laws and payer policies rather than a single federal cap. Short fills spare the pharmacy extra inventory checks, order forms, and audits is not the reasoning either, since Schedule II recordkeeping applies to every fill regardless of its size.

  19. A pharmacist counsels a patient on safe storage and disposal of unused opioids as part of opioid stewardship. Which recommendation best supports the stewardship goal of preventing diversion and accidental harm?

    • A.Hide them in a kitchen drawer and save the leftover doses for a later flare of pain or a new injury
    • B.Lock them in a cabinet and dispose of unused doses through a take-back program or approved method
    • C.Keep them in a nightstand and pass any spare doses along to a relative or friend who has similar pain
    • D.Shelve them in a bathroom and toss leftover doses into the household trash or an outdoor bin
    Show answerHide answer

    Correct answer: Lock them in a cabinet and dispose of unused doses through a take-back program or approved method

    Lock them in a cabinet and dispose of unused doses through a take-back program or approved method is correct because secure storage keeps the opioid away from children, visitors and anyone seeking it, and a take-back program or another approved method removes the unused doses from the home. Hide them in a kitchen drawer and save the leftover doses for a later flare of pain or a new injury is wrong on both halves, since a drawer is not secure and doses kept for later remain available for misuse or unsupervised use. Keep them in a nightstand and pass any spare doses along to a relative or friend who has similar pain leaves the supply within easy reach and hands a controlled substance to someone it was not prescribed for, which is unsafe and illegal. Shelve them in a bathroom and toss leftover doses into the household trash or an outdoor bin uses the room most visitors enter and discards tablets where a child, a pet or someone searching the trash can find them.

  20. A pharmacist suspects that a recently approved oral medication caused a serious, previously unrecognized liver injury in a patient. To contribute to national drug-safety surveillance, which submission is most appropriate?

    • A.A voluntary CDC VAERS report
    • B.A voluntary MedSun report
    • C.A voluntary MedWatch report
    • D.A voluntary ISMP MERP report
    Show answerHide answer

    Correct answer: A voluntary MedWatch report

    A voluntary MedWatch report is correct because MedWatch is the FDA program through which clinicians and patients report suspected serious adverse events from marketed drugs, and those reports feed postmarketing surveillance. A voluntary CDC VAERS report goes to the Vaccine Adverse Event Reporting System, which collects events after vaccination rather than after an oral drug. A voluntary MedSun report goes to the Medical Product Safety Network, an FDA program in which participating facilities report problems with medical devices. A voluntary ISMP MERP report goes to the Medication Errors Reporting Program run by the Institute for Safe Medication Practices, which collects medication errors and hazards rather than suspected reactions to a correctly used drug.

  21. A pharmacist wants to report a suspected serious problem not with a drug's effect but with the product itself, such as a defective inhaler device or evidence of contamination. Which statement about MedWatch is accurate for this situation?

    • A.MedWatch takes product quality and device malfunction reports that are filed by the manufacturer alone
    • B.MedWatch takes product quality and device malfunction reports after harm to a patient has been shown
    • C.MedWatch takes product quality and device malfunction reports as well as adverse drug reaction reports
    • D.MedWatch takes product quality and device malfunction reports sent through the state board of pharmacy
    Show answerHide answer

    Correct answer: MedWatch takes product quality and device malfunction reports as well as adverse drug reaction reports

    MedWatch takes product quality and device malfunction reports as well as adverse drug reaction reports is correct because the program collects reports of suspected contamination, defects and device malfunctions as well as adverse reactions, so the pharmacist can report a faulty inhaler directly. The statement that MedWatch takes product quality and device malfunction reports that are filed by the manufacturer alone is wrong, because health professionals and consumers file voluntary reports and manufacturers file mandatory ones. The statement that MedWatch takes product quality and device malfunction reports after harm to a patient has been shown is wrong, because a suspected quality problem can be reported before anyone has been injured. The statement that MedWatch takes product quality and device malfunction reports sent through the state board of pharmacy is wrong, because reports go straight to the FDA online, by mail or by telephone and not through a state board.

  22. A pharmacist explains to a student that filing a voluntary MedWatch report does not require certainty that the drug caused the event. Why is reporting still valuable in cases of uncertain causation?

    • A.Because FDA establishes causation in every report through its own investigation
    • B.Because FDA derives the true incidence of a reaction from the submitted totals
    • C.Because FDA requires a labeling change for each adverse reaction reported by clinicians
    • D.Because FDA finds safety signals in pooled reports that no single case could reveal
    Show answerHide answer

    Correct answer: Because FDA finds safety signals in pooled reports that no single case could reveal

    Because FDA finds safety signals in pooled reports that no single case could reveal is correct because spontaneous reports are pooled and screened for patterns, and a cluster of similar uncertain cases can point to a risk that one case alone would never establish. Because FDA establishes causation in every report through its own investigation is wrong, since the agency does not investigate and confirm each individual report. Because FDA derives the true incidence of a reaction from the submitted totals is wrong, since voluntary reports have no reliable count of exposed patients and are known to be incomplete, so they cannot give a true incidence. Because FDA requires a labeling change for each adverse reaction reported by clinicians is wrong, since labeling changes follow a confirmed signal after further evaluation and not each single report.

  23. A patient who experienced a serious reaction to a marketed drug worries that submitting a MedWatch report will expose their private health information publicly. How should the pharmacist accurately address this concern?

    • A.FDA withholds confidential patient identifiers from public release
    • B.FDA forwards the patient identifiers to the manufacturer
    • C.FDA lists patient identifiers in its searchable database
    • D.FDA requires consent from the patient before identifiers are recorded
    Show answerHide answer

    Correct answer: FDA withholds confidential patient identifiers from public release

    FDA withholds confidential patient identifiers from public release is correct because the identity of the patient in an adverse event report is protected by law and is not disclosed when report data are made available. The claim that FDA forwards the patient identifiers to the manufacturer is wrong, because the only identity FDA may share with the manufacturer is the reporter's, and the reporter can decline that on the form, while the patient's identity stays protected either way. The claim that FDA lists patient identifiers in its searchable database is wrong, because the data FDA makes searchable have personal identifiers removed. The claim that FDA requires consent from the patient before identifiers are recorded is wrong, because privacy rules allow disclosure to FDA for safety surveillance without written authorization.

Pharmacy Management and Leadership (23)

  1. A medication use evaluation (MUE) is best described as which kind of process within a pharmacy quality program?

    • A.A proactive, team-based method to predict and prevent failures in medication use
    • B.A retrospective, event-based method to review and correct mistakes in medication use
    • C.A continuous, criteria-based method to assess and improve how medications are used
    • D.A structured, interview-based method to compare and validate lists of medications
    Show answerHide answer

    Correct answer: A continuous, criteria-based method to assess and improve how medications are used

    A continuous, criteria-based method to assess and improve how medications are used is correct because a medication use evaluation measures prescribing, dispensing, administration and monitoring against explicit criteria on an ongoing basis and feeds the results back to improve outcomes. A proactive, team-based method to predict and prevent failures in medication use describes failure mode and effects analysis, which looks ahead at how a process could fail. A retrospective, event-based method to review and correct mistakes in medication use describes root cause analysis, which looks back at a single event to learn why it happened. A structured, interview-based method to compare and validate lists of medications describes medication reconciliation, which is done for one patient at transitions of care.

  2. A pharmacy director is selecting the very first step before launching a medication use evaluation for an antibiotic class. Which task should the team complete first?

    • A.Collect historical chart-based records and outcomes for appropriate antibiotic use
    • B.Set explicit evidence-based criteria and thresholds for appropriate antibiotic use
    • C.Deliver targeted case-based workshops and reminders for appropriate antibiotic use
    • D.Report detailed unit-based compliance and trends for appropriate antibiotic use
    Show answerHide answer

    Correct answer: Set explicit evidence-based criteria and thresholds for appropriate antibiotic use

    Set explicit evidence-based criteria and thresholds for appropriate antibiotic use is correct because an evaluation has nothing to measure against until the team has written the standards for appropriate use and the performance level that will count as acceptable. Collect historical chart-based records and outcomes for appropriate antibiotic use comes next, since data can only be judged once the criteria exist. Deliver targeted case-based workshops and reminders for appropriate antibiotic use is an intervention chosen after the data show where prescribing falls short. Report detailed unit-based compliance and trends for appropriate antibiotic use comes near the end of the cycle, when results are analyzed and shared.

  3. A pharmacy and therapeutics committee wants to study whether a newly added drug is being prescribed appropriately by reviewing the first 50 charts as orders are written, before the drug is dispensed each time. Which timing category of medication use evaluation does this describe?

    • A.Concurrent
    • B.Retrospective
    • C.Observational
    • D.Prospective
    Show answerHide answer

    Correct answer: Prospective

    Prospective is correct because each order is checked against the criteria before the drug is dispensed, so an inappropriate order can be stopped before the patient receives a dose. Concurrent evaluation reviews therapy that is already under way, after doses have been dispensed and given. Retrospective evaluation looks back at completed therapy through charts or claims data. Observational describes a type of study in which the investigator does not assign treatment, which is a research design and not a timing category defined by the point of dispensing.

  4. A pharmacy completes a medication use evaluation and finds high appropriateness with no notable problems identified. What is the most appropriate next leadership action?

    • A.Record the results and continue routine monitoring at planned intervals
    • B.Record the results and retire the evaluation at the annual quality review
    • C.Record the results and launch refresher training for every new prescriber
    • D.Record the results and tighten the formulary restriction on the drug
    Show answerHide answer

    Correct answer: Record the results and continue routine monitoring at planned intervals

    Record the results and continue routine monitoring at planned intervals is correct because medication use evaluation is a continuous cycle, so a favorable result is documented and the drug is checked again on a schedule to confirm that performance holds. Record the results and retire the evaluation at the annual quality review treats one good result as permanent and gives up the oversight that would catch later drift. Record the results and launch refresher training for every new prescriber spends an intervention on a problem the data did not find. Record the results and tighten the formulary restriction on the drug limits access to a drug that is already being prescribed appropriately.

  5. A health-system pharmacy is choosing the threshold for an antibiotic medication use evaluation. Which element makes a measurement threshold useful for quality improvement?

    • A.It is revised after data collection to match the rate that was observed
    • B.It is preset as a specific percentage that triggers action once crossed
    • C.It is stated as a qualitative judgment that reviewers apply to every case
    • D.It is derived from prescriber baselines so that targets vary by clinician
    Show answerHide answer

    Correct answer: It is preset as a specific percentage that triggers action once crossed

    It is preset as a specific percentage that triggers action once crossed is correct because a threshold works only as a numeric level of acceptable performance, chosen before the data are collected, that tells the team objectively when to intervene. It is revised after data collection to match the rate that was observed describes a target moved to fit the result, which can never signal a problem. It is stated as a qualitative judgment that reviewers apply to every case describes a judgment made case by case, which gives no objective trigger. It is derived from prescriber baselines so that targets vary by clinician gives every clinician a different target and removes the common standard the evaluation depends on.

  6. A pharmacy uses ongoing medication use evaluation data to negotiate which agents stay on the formulary and to design order sets. This illustrates that a medication use evaluation primarily serves which organizational purpose?

    • A.It informs evidence-based formulary and system decisions that improve medication use
    • B.It flags medication use that breaches formulary limits for peer review and discipline
    • C.It tracks medication use and formulary spending that determine the yearly drug budget
    • D.It writes medication use and formulary rules that replace committee deliberation
    Show answerHide answer

    Correct answer: It informs evidence-based formulary and system decisions that improve medication use

    It informs evidence-based formulary and system decisions that improve medication use is correct because the evaluation produces the appropriateness and outcome data that leadership uses to refine the formulary, order sets and protocols across the organization. It flags medication use that breaches formulary limits for peer review and discipline mistakes a system-improvement tool for a way to police individual prescribers. It tracks medication use and formulary spending that determine the yearly drug budget reduces the evaluation to cost accounting, when its purpose is appropriate use and outcomes. It writes medication use and formulary rules that replace committee deliberation is backwards, because the evaluation supplies evidence to the pharmacy and therapeutics committee, which still makes the decisions.

  7. When investigating a serious medication error, a root cause analysis team repeatedly asks why each contributing factor occurred until they reach the underlying system cause. What is the central goal of this approach?

    • A.To predict where the system is likely to fail so that safeguards go in first
    • B.To identify the latent system weaknesses so that recurrence is prevented
    • C.To rank system failures by frequency so that time is spent on the commonest
    • D.To judge whether the employee bypassed the system so that discipline is fair
    Show answerHide answer

    Correct answer: To identify the latent system weaknesses so that recurrence is prevented

    To identify the latent system weaknesses so that recurrence is prevented is correct because asking why at each level moves the team past the immediate mistake to the process and design flaws underneath it, and correcting those keeps the same error from happening again. To predict where the system is likely to fail so that safeguards go in first describes failure mode and effects analysis, which is done before an event rather than after one. To rank system failures by frequency so that time is spent on the commonest describes a Pareto analysis, which sorts problems by how often they occur rather than tracing one event to its origin. To judge whether the employee bypassed the system so that discipline is fair describes a culpability review of an individual, which root cause analysis deliberately looks beyond.

  8. A root cause analysis team is building a diagram that visually groups potential contributing causes of a dispensing error into categories such as people, equipment, environment, and process. Which tool are they most likely using?

    • A.A Pareto diagram
    • B.A fishbone diagram
    • C.A spaghetti diagram
    • D.A scatter diagram
    Show answerHide answer

    Correct answer: A fishbone diagram

    A fishbone diagram is correct because this cause-and-effect tool, also called an Ishikawa diagram, places the problem at the head and sorts possible causes onto branches for categories such as people, equipment, environment and process. A Pareto diagram, also called a Pareto chart, orders causes from most to least frequent and does not group them by category. A spaghetti diagram traces the physical path that staff or products travel through a work area. A scatter diagram plots one variable against another to show whether the two are related.

  9. A root cause analysis of a wrong-dose event reveals that a look-alike drug name and a confusing shelf layout both contributed. The team must prioritize corrective actions. Which action sits highest on the hierarchy of effectiveness?

    • A.Forcing functions, such as separating similar products and adding tall-man lettering
    • B.Independent double checks, such as having a second technician verify and sign each fill
    • C.Refresher education, such as reviewing look-alike names and doses at an in-service
    • D.Written policies, such as requiring pharmacy staff to read and confirm each label twice
    Show answerHide answer

    Correct answer: Forcing functions, such as separating similar products and adding tall-man lettering

    Forcing functions, such as separating similar products and adding tall-man lettering is correct because changes built into the storage layout and the computer system act on every fill without depending on anyone's memory, which places them at the top of the hierarchy among these choices. Independent double checks, such as having a second technician verify and sign each fill can catch errors but still relies on a second person noticing the problem, so it ranks lower. Refresher education, such as reviewing look-alike names and doses at an in-service depends on staff recalling what they were taught and is among the weakest strategies. Written policies, such as requiring pharmacy staff to read and confirm each label twice likewise depends on vigilance and on people following the rule each time.

  10. An accrediting body requires a hospital to conduct a root cause analysis after a particular category of event. Which event most clearly triggers this requirement?

    • A.A sentinel event that causes the patient unexpected serious harm or death
    • B.A near-miss event that nurses intercept before the error reaches the patient
    • C.A no-harm event that reaches the patient without causing detectable injury
    • D.An expected adverse event that the patient recovers from within a day or two
    Show answerHide answer

    Correct answer: A sentinel event that causes the patient unexpected serious harm or death

    A sentinel event that causes the patient unexpected serious harm or death is correct because accrediting bodies define a sentinel event as an unexpected occurrence involving death or serious harm and require a thorough root cause analysis in response. A near-miss event that nurses intercept before the error reaches the patient is worth analyzing to prevent future harm, but analysis is encouraged rather than required. A no-harm event that reaches the patient without causing detectable injury is handled the same way through internal reporting and review. An expected adverse event that the patient recovers from within a day or two is a known effect of therapy and not a failure of the system, so it does not meet the definition.

  11. After completing a root cause analysis, a pharmacy leader wants to confirm that the corrective actions are actually being carried out and are working. Which step accomplishes this?

    • A.Presenting the actions before executive leadership and obtaining written sign-off on the timeline
    • B.Teaching staff the actions and collecting signed attestations that the training was completed
    • C.Setting measurable outcomes and re-auditing to verify completion and effectiveness of the actions
    • D.Mapping the actions to each root cause and filing copies of the plan with an accreditation agency
    Show answerHide answer

    Correct answer: Setting measurable outcomes and re-auditing to verify completion and effectiveness of the actions

    Setting measurable outcomes and re-auditing to verify completion and effectiveness of the actions is correct because only a measure tracked after the change, checked again by audit, shows whether the fix was put in place and whether it prevented recurrence. Presenting the actions before executive leadership and obtaining written sign-off on the timeline secures approval for the plan but says nothing about what happens afterward. Teaching staff the actions and collecting signed attestations that the training was completed documents that people were told, which is not evidence that practice changed or that the change helped. Mapping the actions to each root cause and filing copies of the plan with an accreditation agency completes the paperwork of the analysis without testing the result.

  12. In a just-culture framework, a technician makes a single inadvertent slip while following a well-designed process correctly. According to root cause analysis principles, how should leadership most appropriately respond?

    • A.Coach the individual without penalty and study the risky choice made
    • B.Discipline the individual without delay and record reckless conduct
    • C.Retrain the individual without blame and retest competency afterward
    • D.Console the individual without punishment and strengthen the system
    Show answerHide answer

    Correct answer: Console the individual without punishment and strengthen the system

    Console the individual without punishment and strengthen the system is correct because a just culture answers simple human error with support for the person and a look at how the system can make the same slip less likely. Coach the individual without penalty and study the risky choice made is the response to at-risk behavior, where someone chose a shortcut, and no choice was made here. Discipline the individual without delay and record reckless conduct is reserved for reckless conduct, meaning a conscious disregard of a known and substantial risk. Retrain the individual without blame and retest competency afterward treats the slip as a gap in knowledge or skill, yet the technician knew the process and was following it correctly.

  13. An FDA drug recall is classified as Class I. Which situation matches this classification?

    • A.A reasonable probability of serious adverse health consequences or death
    • B.A chance of temporary or medically reversible adverse health consequences
    • C.A violative product not likely to cause any adverse health consequences
    • D.A minor violation lacking adverse health consequences and not subject to FDA legal action
    Show answerHide answer

    Correct answer: A reasonable probability of serious adverse health consequences or death

    A reasonable probability of serious adverse health consequences or death is correct because Class I is the most serious recall class, used when there is a reasonable probability that using or being exposed to the product will cause serious harm or death. A chance of temporary or medically reversible adverse health consequences describes Class II, in which any harm is temporary or medically reversible or the probability of serious harm is remote. A violative product not likely to cause any adverse health consequences describes Class III, the least serious class of recall. A minor violation lacking adverse health consequences and not subject to FDA legal action describes a market withdrawal, which is not classified as a recall at all.

  14. A pharmacy receives notice of a Class III drug recall. Which statement best characterizes a Class III recall?

    • A.Adverse health consequences from use are not likely
    • B.Adverse health consequences from use are temporary or reversible
    • C.Adverse health consequences from use are serious and reasonably probable
    • D.Adverse health consequences from use are serious but very improbable
    Show answerHide answer

    Correct answer: Adverse health consequences from use are not likely

    Adverse health consequences from use are not likely is correct because Class III is the least serious recall class, used when use of or exposure to a violative product is not likely to harm health. Adverse health consequences from use are temporary or reversible describes Class II. Adverse health consequences from use are serious and reasonably probable describes Class I, the most serious class. Adverse health consequences from use are serious but very improbable gives the other limb of the Class II definition, in which serious harm is possible but its probability is remote.

  15. A community pharmacy is setting up a standing procedure for handling future recalls efficiently. Which element belongs in a sound recall-management procedure?

    • A.A set process to quarantine affected lots, notify patients, and document actions taken
    • B.A set process to destroy affected lots, bill the supplier, and discard the recall notice
    • C.A set process to monitor affected lots, await complaints, and remove stock afterward
    • D.A set process to flag affected lots, dispense them with a warning, and record every sale
    Show answerHide answer

    Correct answer: A set process to quarantine affected lots, notify patients, and document actions taken

    A set process to quarantine affected lots, notify patients, and document actions taken is correct because a sound recall procedure pulls the implicated product out of dispensing stock, reaches patients who received it when the recall extends to that level, and keeps a record of what was done. A set process to destroy affected lots, bill the supplier, and discard the recall notice skips the return or disposition instructions in the recall notice and throws away the record the pharmacy needs. A set process to monitor affected lots, await complaints, and remove stock afterward leaves recalled product on the shelf until someone has already been affected and complains. A set process to flag affected lots, dispense them with a warning, and record every sale keeps dispensing a product that has been recalled, which a warning does not make acceptable.

  16. A manufacturer issues a recall to remove a minor violation that would not trigger FDA legal action, and the product poses essentially no patient risk. Which term best fits this removal?

    • A.A stock recovery
    • B.A market withdrawal
    • C.A Class III recall
    • D.A product correction
    Show answerHide answer

    Correct answer: A market withdrawal

    A market withdrawal is correct because it is a firm's removal or correction of a distributed product that involves a minor violation not subject to FDA legal action, or no violation at all. A stock recovery applies to product that has not yet left the firm's direct control, so nothing has been marketed. A Class III recall involves a violation that FDA could act on legally, even though harm to health is not likely. A product correction means repairing, relabeling or otherwise fixing a product where it is, without physically removing it.

  17. A health system wants to monitor for newly announced drug recalls in a timely, reliable way. Which source is the most authoritative for current recall information?

    • A.Recall summaries and the Quarterly Action Agenda from the ISMP
    • B.Recall notifications and the Health Alert Network from the CDC
    • C.Recall statements and the Pharmacopeial Forum from the USP
    • D.Recall announcements and the Enforcement Report from the FDA
    Show answerHide answer

    Correct answer: Recall announcements and the Enforcement Report from the FDA

    Recall announcements and the Enforcement Report from the FDA is correct because the FDA oversees drug recalls, posts the announcements and lists every classified recall with its class and affected lots in the weekly Enforcement Report. Recall summaries and the Quarterly Action Agenda from the ISMP points to a medication safety organization whose agenda summarizes error-prevention topics and is not the official record of recalls. Recall notifications and the Health Alert Network from the CDC points to the channel for urgent public health messages, such as outbreaks, and not for product recalls in general. Recall statements and the Pharmacopeial Forum from the USP points to the journal in which proposed compendial standards are published for comment.

  18. A hospital pharmacy anticipates a prolonged shortage of an injectable chemotherapy agent. Which strategy reflects ethical and sound shortage management when supply cannot meet demand?

    • A.Dispense the remaining supply in the order that requests reach the pharmacy
    • B.Reduce every dose equally so the remaining supply stretches to all patients
    • C.Let each treating oncologist ration the remaining supply one case at a time
    • D.Allocate the remaining supply using transparent clinical priority criteria
    Show answerHide answer

    Correct answer: Allocate the remaining supply using transparent clinical priority criteria

    Allocate the remaining supply using transparent clinical priority criteria is correct because fair management of a shortage directs limited stock to the patients with the greatest clinical need under rules that are written down and applied openly. Dispense the remaining supply in the order that requests reach the pharmacy rewards timing and ignores urgency and expected benefit. Reduce every dose equally so the remaining supply stretches to all patients sounds even-handed but can leave every patient with a dose too low to work. Let each treating oncologist ration the remaining supply one case at a time produces inconsistent decisions made out of view and puts individual clinicians in the position of rationing at the bedside.

  19. A pharmacy manager is developing a proactive plan to reduce the impact of future drug shortages. Which measure is a legitimate proactive shortage-mitigation strategy?

    • A.Stockpiling vulnerable drugs with larger orders once a shortage is announced
    • B.Sourcing reserve stock from secondary distributors outside normal supply channels
    • C.Keeping a vetted list of therapeutic alternatives with advance committee approval
    • D.Compounding copies of commercial sterile drug products from bulk substances ahead of time
    Show answerHide answer

    Correct answer: Keeping a vetted list of therapeutic alternatives with advance committee approval

    Keeping a vetted list of therapeutic alternatives with advance committee approval is correct because alternatives that the pharmacy and therapeutics committee has already reviewed let the pharmacy switch quickly and safely when a product becomes unavailable. Stockpiling vulnerable drugs with larger orders once a shortage is announced is a reaction to an announced shortage, and hoarding drains supply for other institutions and makes the shortage worse. Sourcing reserve stock from secondary distributors outside normal supply channels describes gray-market purchasing, which carries risks of counterfeit, mishandled or overpriced product. Compounding copies of commercial sterile drug products from bulk substances ahead of time is restricted by law and adds sterility and stability risks, so it is not a routine planning measure.

  20. During a national drug shortage, a pharmacy leader is consulting an authoritative resource to confirm shortage status, expected resolution, and management recommendations. Which source is most appropriate?

    • A.The CDC and ISMP shortage databases
    • B.The DEA and NABP shortage databases
    • C.The FDA and ASHP shortage databases
    • D.The USP and AHRQ shortage databases
    Show answerHide answer

    Correct answer: The FDA and ASHP shortage databases

    The FDA and ASHP shortage databases is correct because the FDA lists current drug shortages with supplier information and expected resolution, and ASHP adds affected products, alternatives and management guidance. The CDC and ISMP shortage databases is wrong because the CDC covers public health surveillance and ISMP covers medication error prevention, and neither maintains a shortage list. The DEA and NABP shortage databases is wrong because the DEA regulates controlled substances and NABP supports the state boards of pharmacy. The USP and AHRQ shortage databases is wrong because USP sets compendial standards and AHRQ funds research on health care quality.

  21. A pharmacy and therapeutics committee notices that a recurring shortage of a drug led to a wrong-concentration error when a substitute product was stocked. Which combined management response best addresses both the supply problem and the resulting safety risk?

    • A.Stockpile the substitute concentration and increase ordering levels while the shortage threatens supply
    • B.Post reminders about the substitute concentration and ask nurses to stay alert while the shortage lasts
    • C.Remove the substitute concentration from stock while the shortage persists and defer affected therapy
    • D.Standardize and label the substitute concentration while updating shortage protocols and training staff
    Show answerHide answer

    Correct answer: Standardize and label the substitute concentration while updating shortage protocols and training staff

    Standardize and label the substitute concentration while updating shortage protocols and training staff is correct because it deals with the supply gap through the protocol and removes the concentration hazard through a single standard strength, clear labeling and education. Stockpile the substitute concentration and increase ordering levels while the shortage threatens supply secures supply but leaves the unfamiliar concentration unmarked, so the same error can recur. Post reminders about the substitute concentration and ask nurses to stay alert while the shortage lasts relies on vigilance alone, the weakest kind of safeguard, and does nothing about supply. Remove the substitute concentration from stock while the shortage persists and defer affected therapy avoids the confusion only by denying treatment to patients who need it.

  22. A pharmacy quality program adds a measure tracking the percentage of high-alert medication orders that pass an independent double-check before administration. Within pharmacy management, this metric functions primarily as which kind of indicator?

    • A.A cost and quality performance indicator used to guide drug purchasing
    • B.A workload and quality performance indicator used to set staffing
    • C.A safety and quality performance indicator used to drive improvement
    • D.A service and quality performance indicator used to gauge satisfaction
    Show answerHide answer

    Correct answer: A safety and quality performance indicator used to drive improvement

    A safety and quality performance indicator used to drive improvement is correct because the share of high-alert orders that receive an independent double check measures how reliably a safety step is carried out, and the result is used to target improvement work. A cost and quality performance indicator used to guide drug purchasing would track what drugs cost against what they deliver, which this measure does not address. A workload and quality performance indicator used to set staffing would count the volume of work per staff member, such as orders verified per hour. A service and quality performance indicator used to gauge satisfaction would capture how patients or other customers rate the pharmacy's service.

  23. A pharmacy director reviewing medication use evaluation results across several quarters sees that prescribing improved sharply right after an intervention but drifted back toward baseline over the following year. What does this pattern most strongly indicate for management action?

    • A.The improvement was a chance fluctuation, so the intervention and audits should be abandoned
    • B.The improvement faded afterward, so reinforcement and periodic reassessment should be planned
    • C.The improvement proves the criteria were met, so the monitoring and reporting should be retired
    • D.The improvement was unrealistic, so criteria and audit thresholds should be reset near baseline
    Show answerHide answer

    Correct answer: The improvement faded afterward, so reinforcement and periodic reassessment should be planned

    The improvement faded afterward, so reinforcement and periodic reassessment should be planned is correct because a sharp gain right after the intervention followed by a slow return toward baseline shows that the change worked but was not maintained, which calls for reinforcing it and continuing to measure. The improvement was a chance fluctuation, so the intervention and audits should be abandoned ignores that the gain appeared immediately after the intervention and persisted for a time. The improvement proves the criteria were met, so the monitoring and reporting should be retired overlooks the later decline, which is exactly what continued measurement exists to catch. The improvement was unrealistic, so criteria and audit thresholds should be reset near baseline would redefine the problem away by moving the standard down to current practice.

References

  1. 1.National Association of Boards of Pharmacy. “NAPLEX Exam.” nabp.pharmacy. ↑
  2. 2.National Association of Boards of Pharmacy. “NAPLEX Content Outline (effective May 1, 2025).” nabp.pharmacy. ↑
  3. 3.National Association of Boards of Pharmacy. “Take the NAPLEX Exam.” nabp.pharmacy. ↑
  4. 4.National Association of Boards of Pharmacy. “Can I Retake the Exam If I Do Not Get a Passing Score?.” nabp.pharmacy. ↑
  5. 5.National Association of Boards of Pharmacy. “NAPLEX Results and Passing Score.” nabp.pharmacy. ↑
Career Employer

Career Employer is the ultimate resource to help you get started working the job of your dreams. We cover topics from general career information, career searching, exam preparation with free study materials, career interviewing, and becoming successful in your career of choice.

Follow Us:

All Posts

Career Employer’s Editorial Process

Here at Career Employer, we focus a lot on providing factually accurate information that is always up to date. We strive to provide correct information using strict editorial processes, article editing, and fact-checking for all of the information found on our website. We only utilize trustworthy and relevant resources. To find out more, make sure to read our full editorial process page here.